

The diagnosis and management of nonalcoholic fatty liver disease: recommendations from the American Association for the Study of Liver Disease

Hepatology

67, 328-357

DOI: [10.1002/hep.29367](https://doi.org/10.1002/hep.29367)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Mean Platelet Volume in Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus - A Marker of Cardiovascular Risk. International Journal of Biomedical and Advance Research, 2016, 7, 76.	0.1	1
2	Non-Alcoholic Steatohepatitis: Clinical and Translational Research. Journal of Pharmacy and Pharmaceutical Sciences, 2016, 19, 8.	0.9	4
3	Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease. JAMA Internal Medicine, 2016, 176, 1074.	2.6	208
4	Nonalcoholic steatohepatitis and diabetes. Endocrinología Y Nutrición (English Edition), 2016, 63, 377-379.	0.5	5
6	Overview of Clinical Treatment Trials for NASH. Current Hepatology Reports, 2017, 16, 366-373.	0.4	0
7	Role of Exercise in NAFLD/NASH: What is the Right Prescription?. Current Hepatology Reports, 2017, 16, 356-365.	0.4	0
8	Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. Current Hepatology Reports, 2017, 16, 286-292.	0.4	3
9	The future of diagnosing NASH - could a simple blood test be the key?. Expert Review of Gastroenterology and Hepatology, 2017, 11, 995-997.	1.4	7
10	Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólico. Clínica E Investigación En Arteriosclerosis, 2017, 29, 185-200.	0.4	6
11	Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide. Nutrients, 2017, 9, 1072.	1.7	255
12	Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-8.	0.8	17
13	Nonalcoholic Fatty Liver Disease in Children. Seminars in Liver Disease, 2018, 38, 001-013.	1.8	108
14	Basic Concepts in Insulin Resistance and Diabetes Treatment. , 2018, , 19-35.		3
15	Rodent models of fatty liver diseases. Liver Research, 2018, 2, 3-13.	0.5	15
16	NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?. Current HIV/AIDS Reports, 2018, 15, 212-222.	1.1	9
17	Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage. Hepatology Communications, 2018, 2, 654-665.	2.0	31
18	Tratamiento actual de la enfermedad por hígado graso no alcohólico. Revista De Gastroenterología De México, 2018, 83, 125-133.	0.4	8
19	Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis. Hepatology International, 2018, 12, 97-106.	1.9	19

#	ARTICLE	IF	CITATIONS
20	The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 491-502.	1.4	103
21	Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). <i>BMJ Open Gastroenterology</i> , 2018, 5, e000198.	1.1	25
22	Diabetes impacts prediction of cirrhosis and prognosis by noninvasive fibrosis models in nonalcoholic fatty liver disease. <i>Liver International</i> , 2018, 38, 1793-1802.	1.9	79
23	Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 107-117.	0.6	127
24	High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1138-1145.e5.	2.4	180
25	Should statins be discontinued in cirrhosis with decompensation?. <i>Hepatology</i> , 2018, 67, 2477-2478.	3.6	0
26	Abbreviated mpMRI protocol for diffuse liver disease: a practical approach for evaluation and follow-up of NAFLD. <i>Abdominal Radiology</i> , 2018, 43, 2340-2350.	1.0	23
27	Improvement of hepatic fibrosis and patient-reported outcomes in nonalcoholic steatohepatitis treated with selonsertib. <i>Liver International</i> , 2018, 38, 1849-1859.	1.9	72
28	Clinical studies investigating the effect of vitamin E therapy in patients with NASH. <i>Clinical Liver Disease</i> , 2018, 11, 16-21.	1.0	9
29	Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1012-1022.	1.9	50
30	Mouse models of nonalcoholic steatohepatitis: A reflection on recent literature. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1312-1320.	1.4	34
31	Future therapy for nonalcoholic fatty liver disease. <i>Liver International</i> , 2018, 38, 56-63.	1.9	42
32	Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 558-566.e2.	2.4	154
33	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2018, 14, 99-114.	4.3	284
34	The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. <i>Nature Medicine</i> , 2018, 24, 213-223.	15.2	104
35	Current and future pharmacological therapies for NAFLD/NASH. <i>Journal of Gastroenterology</i> , 2018, 53, 362-376.	2.3	490
36	Regulation of fatty acid trafficking in liver by thioesterase superfamily member 1. <i>Journal of Lipid Research</i> , 2018, 59, 368-379.	2.0	7
37	Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. <i>Hepatology International</i> , 2018, 12, 6-16.	1.9	24

#	ARTICLE	IF	CITATIONS
38	Recommendations for the Evaluation for Autoimmune Liver Disease in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2018, 68, 1203-1203.	3.6	1
39	Dietary carbohydrates and fatty liver disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2018, 21, 277-282.	1.3	51
40	Randomised clinical trial: a leucineâ€metforminâ€sildenafil combination (<sc>NS</sc>â€0200) vs placebo in patients with nonâ€alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1639-1651.	1.9	35
41	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 425-439.	8.2	207
42	Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Clinical Liver Disease</i> , 2018, 11, 98-104.	1.0	51
43	Nonâ€alcoholic fatty liver disease in patients with autoimmune hepatitis. <i>JGH Open</i> , 2018, 2, 54-58.	0.7	33
44	The epidemiology of nonalcoholic steatohepatitis. <i>Clinical Liver Disease</i> , 2018, 11, 92-94.	1.0	64
45	New Medications in the Treatment of Nonalcoholic Steatohepatitis. <i>Hospital Pharmacy</i> , 2018, 53, 146-147.	0.4	0
46	Prevalent Cardiovascular Disease Events and T1 Mapping Defined Hepatic Fibrosis. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007553.	1.3	5
47	The Management of Incidental Fatty Liver Found on Imaging. What Do We Need to do?. <i>American Journal of Gastroenterology</i> , 2018, 113, 1274-1276.	0.2	12
48	Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2018, 22, 1-10.	1.0	85
49	Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. <i>Journal of Gastroenterology</i> , 2018, 53, 181-196.	2.3	61
51	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 351-367.	1.4	47
52	Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions. <i>Journal of Hepatology</i> , 2018, 68, 296-304.	1.8	92
54	Thyroid Function and Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects. <i>Annals of Hepatology</i> , 2018, 17, 779-788.	0.6	43
55	The evolving role of liver biopsy in non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2018, 17, 899-902.	0.6	21
56	Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?. <i>World Journal of Hepatology</i> , 2018, 10, 790-794.	0.8	19
57	Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. <i>Annals of Hepatology</i> , 2018, 17, 11-13.	0.6	4

#	ARTICLE	IF	CITATIONS
58	New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 372-381.	0.7	20
59	Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2018, 3, 179-183.	0.5	5
60	Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 64-74.	0.7	73
61	Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity. <i>Journal of Diabetes and Metabolic Disorders</i> , 2018, 17, 381-391.	0.8	20
62	Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity. <i>World Journal of Gastroenterology</i> , 2018, 24, 1601-1615.	1.4	60
63	Non-alcoholic fatty liver disease and the risk of urolithiasis. <i>Medicine (United States)</i> , 2018, 97, e12092.	0.4	17
64	Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-7.	0.6	13
65	Management of Patients with Nonalcoholic Fatty Liver Disease with Lifestyle Modification. <i>Journal of Korean Diabetes</i> , 2018, 19, 82.	0.1	3
66	Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease. <i>Journal of Korean Diabetes</i> , 2018, 19, 88.	0.1	1
67	Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy. <i>Scientific Reports</i> , 2018, 8, 16461.	1.6	12
68	Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice. <i>Gastroenterology</i> , 2018, 155, 1971-1984.e4.	0.6	234
69	Objective Liver Fibrosis Estimation from Shear Wave Elastography. , 2018, 2018, 1-5.		13
70	Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481881150.	1.4	16
71	Diagnosis and Management of Nonalcoholic Fatty Liver Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2474.	3.8	39
72	A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2018, 2, 1467-1478.	2.0	9
74	Misconception: You Can't Have Liver Disease With Normal Liver Chemistries. <i>Clinical Liver Disease</i> , 2018, 12, 96-99.	1.0	13
75	Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. <i>Journal of the International AIDS Society</i> , 2018, 21, e25201.	1.2	46
76	Non-alcoholic fatty liver disease: a narrative review of genetics. <i>Journal of Biomedical Research</i> , 2018, 32, 389.	0.7	38

#	ARTICLE	IF	CITATIONS
77	Geniposide and Chlorogenic Acid Combination Ameliorates Non-alcoholic Steatohepatitis Involving the Protection on the Gut Barrier Function in Mouse Induced by High-Fat Diet. <i>Frontiers in Pharmacology</i> , 2018, 9, 1399.	1.6	60
78	Genetically Regulated Bilirubin and Risk of Non-alcoholic Fatty Liver Disease: A Mendelian Randomization Study. <i>Frontiers in Genetics</i> , 2018, 9, 662.	1.1	16
79	Surgical Issues in NASH: Bariatric Surgery and Liver Transplantation. <i>Current Hepatology Reports</i> , 2018, 17, 367-376.	0.4	1
80	Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in <i>Gynostemma pentaphylla</i> (Thunb.) Makino treated mice. <i>Nutrition and Metabolism</i> , 2018, 15, 86.	1.3	26
81	The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes. <i>Clinical Liver Disease</i> , 2018, 12, 39-44.	1.0	39
82	Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>Lancet, The</i> , 2018, 392, 2705-2717.	6.3	374
83	You are what you wheat: effects of a whole-wheat diet compared with a refined-wheat diet on hepatic steatosis. <i>American Journal of Clinical Nutrition</i> , 2018, 108, 1162-1163.	2.2	0
84	Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. <i>BMC Gastroenterology</i> , 2018, 18, 177.	0.8	23
85	The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis. <i>Current Hepatology Reports</i> , 2018, 17, 324-335.	0.4	8
86	Is <i>Toxoplasma gondii</i> infection correlated with nonalcoholic fatty liver disease?- a population-based study. <i>BMC Infectious Diseases</i> , 2018, 18, 629.	1.3	17
87	Apple Pomace Consumption Favorably Alters Hepatic Lipid Metabolism in Young Female Sprague-Dawley Rats Fed a Western Diet. <i>Nutrients</i> , 2018, 10, 1882.	1.7	14
88	Is There an Association of Vascular Disease and Atherosclerosis in Children and Adolescents With Obesity and Non-alcoholic Fatty Liver Disease?. <i>Frontiers in Pediatrics</i> , 2018, 6, 345.	0.9	4
89	Effect of Dachaihu decoction on non-alcoholic fatty liver disease model rats induced by a high-fat high-sugar diet. <i>Journal of Traditional Chinese Medical Sciences</i> , 2018, 5, 390-399.	0.1	1
90	Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. <i>Hepatology Communications</i> , 2018, 2, 1227-1234.	2.0	20
91	Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1166-1175.	0.4	51
92	Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 315-320.	1.2	11
93	Predictors of advanced fibrosis in non-€irrhotic non-€alcoholic fatty liver disease in Germany. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1109-1116.	1.9	88
94	Obesity and nonalcoholic fatty liver disease: current perspectives. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 533-542.	1.1	167

#	ARTICLE	IF	CITATIONS
95	Editorial: surviving your genesâ€”the role of <i>PNPLA3</i> variation in end-stage liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 773-775.	1.9	1
96	Diethylthiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress. <i>British Journal of Pharmacology</i> , 2018, 175, 4480-4495.	2.7	21
97	Treatment of NASH with Gastric Bypass. <i>Current Gastroenterology Reports</i> , 2018, 20, 49.	1.1	10
98	Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 91.	1.0	16
99	When to Initiate Weight Loss Medications in the NAFLD Population. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 91.	1.0	11
100	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1903-1914.	0.9	18
101	Liver fat scores predict liver disease mortality in the United States population. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1003-1016.	1.9	35
102	Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3064.	1.8	16
103	The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. <i>Current Hepatology Reports</i> , 2018, 17, 345-349.	0.4	3
104	Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design. <i>Contemporary Clinical Trials</i> , 2018, 75, 51-58.	0.8	6
105	Management of Nonalcoholic Fatty Liver Disease (NAFLD). , 0, , .		2
106	Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. <i>Pharmaceuticals</i> , 2018, 11, 104.	1.7	60
107	Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms. <i>Frontiers in Endocrinology</i> , 2018, 9, 588.	1.5	42
108	Differential Diagnosis of a Patient with Lysosomal Acid Lipase Deficiency: A Case Report. <i>Laboratory Medicine</i> , 2018, 49, 377-384.	0.8	2
109	Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). <i>Clinical and Experimental Hepatology</i> , 2018, 4, 153-157.	0.6	15
110	Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. <i>Postgraduate Medical Journal</i> , 2018, 94, 556-565.	0.9	15
111	Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 451-462.	2.3	58
112	Quantitative Hepatic Fat Quantification in Non-alcoholic Fatty Liver Disease Using Ultrasound-Based Techniques: A Review of Literature and Their Diagnostic Performance. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2461-2475.	0.7	80

#	ARTICLE	IF	CITATIONS
113	Editorial: being out of shape may impact more than your figure. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 582-583.	1.9	0
114	Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. <i>PLoS ONE</i> , 2018, 13, e0200656.	1.1	21
115	Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1153-1162.	0.4	96
116	Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. <i>Annals of Gastroenterology</i> , 2018, 31, 288-295.	0.4	54
117	Nutritional issues in patients with obesity and cirrhosis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3330-3346.	1.4	59
118	Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. <i>PLoS ONE</i> , 2018, 13, e0203084.	1.1	43
119	A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care. <i>Hepatology Communications</i> , 2018, 2, 897-909.	2.0	54
120	Comparison between groove carcinoma and groove pancreatitis. <i>Pancreatology</i> , 2018, 18, 805-811.	0.5	12
121	Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient Truths. <i>American Journal of Gastroenterology</i> , 2018, 113, 1437-1439.	0.2	4
123	Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 461-478.	8.2	400
124	Vitamin D status and associated genetic polymorphisms in a cohort of UK children with non-alcoholic fatty liver disease. <i>Pediatric Obesity</i> , 2018, 13, 433-441.	1.4	22
125	Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database. <i>Hepatology</i> , 2018, 68, 2230-2238.	3.6	103
126	Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2259-2266.	1.1	26
127	Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver. <i>Molecular Pharmaceutics</i> , 2018, 15, 2621-2632.	2.3	76
128	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , 2018, 155, 443-457.e17.	0.6	536
129	The association of sleep duration and sleep quality with non-alcoholic fatty liver disease in a Taiwanese population. <i>Obesity Research and Clinical Practice</i> , 2018, 12, 500-505.	0.8	13
130	Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 831-841.	1.5	20
131	Dyslipidemia and Fatty Liver Disease in Overweight and Obese Children. <i>Journal of Obesity</i> , 2018, 2018, 1-6.	1.1	29

#	ARTICLE	IF	CITATIONS
132	The Relationship between NAFLD and Sarcopenia in Elderly Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-4.	0.8	22
133	The Potential Effect of Chinese Herbal Formula Hongqijiangzhi Fang in Improving NAFLD: Focusing on NLRP3 Inflammasome and Gut Microbiota. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-12.	0.5	11
134	Inflammation and Metabolic Complications in HIV. <i>Current HIV/AIDS Reports</i> , 2018, 15, 371-381.	1.1	39
135	Effects of an exercise program on hepatic metabolism, hepatic fat, and cardiovascular health in overweight/obese adolescents from Bogotá, Colombia (the HEPAFIT study): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 330.	0.7	14
136	Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. <i>British Journal of Radiology</i> , 2018, 91, 20180345.	1.0	22
137	Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition. <i>Hepatology</i> , 2018, 68, 2405-2412.	3.6	39
138	Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-8.	0.8	85
139	Editorial: role of leucine- α -ketoglutarate-dependent methyltransferase combination in the treatment of nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 378-379.	1.9	1
140	Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2698-2706.	1.8	70
141	Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9879-9888.	2.9	15
142	Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation. <i>Journal of Physiology and Biochemistry</i> , 2018, 74, 503-510.	1.3	27
143	Future trends in the treatment of non-alcoholic steatohepatitis. <i>Pharmacological Research</i> , 2018, 134, 289-298.	3.1	54
144	New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2034.	1.8	117
145	Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 282-302.e8.	0.6	216
146	Preoperative Selection and Optimization for Liver Resection in Colorectal Cancer Liver Metastases. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 89-97.	1.0	0
147	Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. <i>BMJ: British Medical Journal</i> , 2018, 362, k2734.	2.4	81
148	Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers. <i>Scientific Reports</i> , 2018, 8, 10606.	1.6	52
149	Establishment of an ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver. <i>ACS Biomaterials Science and Engineering</i> , 2018, 4, 3016-3026.	2.6	9

#	ARTICLE	IF	CITATIONS
150	Imaging of nonalcoholic fatty liver disease and its clinical utility. <i>Hormones</i> , 2018, 17, 69-81.	0.9	37
151	Nonalcoholic Steatohepatitis. <i>Surgical Pathology Clinics</i> , 2018, 11, 267-285.	0.7	8
152	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. <i>Hepatology</i> , 2018, 68, 1646-1648.	3.6	1
153	Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. <i>Hepatology</i> , 2018, 68, 1741-1754.	3.6	138
154	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. <i>Journal of Gastroenterology</i> , 2018, 53, 1216-1224.	2.3	68
155	Sarcopenic obesity in cirrhosis—The confluence of 2 prognostic titans. <i>Liver International</i> , 2018, 38, 1706-1717.	1.9	91
156	A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2018, 9, 752.	1.6	23
157	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018, 69, 1365-1370.	1.8	51
158	Dietary Melatonin Supplementation Could Be a Promising Preventing/Therapeutic Approach for a Variety of Liver Diseases. <i>Nutrients</i> , 2018, 10, 1135.	1.7	40
159	Curative effect of arjunolic acid from <i>Terminalia arjuna</i> in non-alcoholic fatty liver disease models. <i>Biomedicine and Pharmacotherapy</i> , 2018, 107, 979-988.	2.5	24
160	Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. <i>BMC Medicine</i> , 2018, 16, 130.	2.3	177
161	Exome sequencing of an adolescent with nonalcoholic fatty liver disease identifies a clinically actionable case of Wilson disease. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a003087.	0.5	3
162	Clinicopathological investigation of steatohepatitic hepatocellular carcinoma: A multicenter study using immunohistochemical analysis of adenoma-related markers. <i>Hepatology Research</i> , 2018, 48, 947-955.	1.8	27
163	The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis. <i>Obesity Reviews</i> , 2018, 19, 1446-1459.	3.1	67
164	Simple Scores of Fibrosis and Mortality in Patients with NAFLD: A Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2018, 7, 219.	1.0	28
165	Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3361-3373.	1.4	375
166	NAFLD/NASH. <i>Acta Hepatologica Japonica</i> , 2018, 59, 83-91.	0.0	1
167	NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. <i>American Journal of Gastroenterology</i> , 2018, 113, 1649-1659.	0.2	401

#	ARTICLE	IF	CITATIONS
168	Non-alcoholic fatty liver disease and the interface between primary and secondary care. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 509-517.	3.7	106
169	Current treatment for non-alcoholic fatty liver disease. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2018, 83, 125-133.	0.1	3
170	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 241-248.	1.4	28
171	Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 124-133.	0.9	60
172	Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. <i>Medicinal Research Reviews</i> , 2019, 39, 328-348.	5.0	105
173	Lean non-alcoholic fatty liver disease. <i>Clinical Nutrition</i> , 2019, 38, 975-981.	2.3	77
174	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	2.4	559
175	Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1457-1476.e7.	2.4	33
176	The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease. <i>Internal Medicine</i> , 2019, 58, 1987-1992.	0.3	9
177	Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists. <i>Thyroid</i> , 2019, 29, 1173-1191.	2.4	148
178	Full annotation of serum virome in Chinese blood donors with elevated alanine aminotransferase levels. <i>Transfusion</i> , 2019, 59, 3177-3185.	0.8	14
179	DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2791.	1.2	11
180	Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). <i>Cells</i> , 2019, 8, 845.	1.8	92
181	Prevention Strategies for Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019, , 255-289.	0.4	2
182	Cranberry Attenuates Progression of Non-alcoholic Fatty Liver Disease Induced by High-Fat Diet in Mice. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 1295-1302.	0.6	11
183	Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 194, 105445.	1.2	24
184	Longitudinal Change of Body Mass Index Is Associated With Alanine Aminotransferase Elevation After Complete Viral Suppression in Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , 2019, 220, 1469-1476.	1.9	7
185	Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. <i>PLoS ONE</i> , 2019, 14, e0220612.	1.1	17

#	ARTICLE	IF	CITATIONS
186	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 781-793.	3.7	58
187	Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 849-866.	1.4	32
188	Evolving Management Strategies for Nonalcoholic Fatty Liver Disease—Targeting Primary Care Physicians. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 611-618.	2.4	1
189	Liver enzymes and all-cause mortality: Open issues. <i>Liver International</i> , 2019, 39, 1389-1390.	1.9	2
190	A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 11232.	1.6	78
191	Noninvasive Tests of Liver Fibrosis and Their Combination in Nonalcoholic Fatty Liver Disease: From Selected Patients to Real-Life Populations. <i>Hepatology</i> , 2019, 70, 1500-1502.	3.6	7
192	Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 497-505.	0.4	24
193	Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1087-1094.	1.1	19
194	Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-5.	0.7	45
195	Ursodeoxycholic acid is a GPCR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 1422-1437.	1.2	37
196	GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. <i>BMC Medicine</i> , 2019, 17, 135.	2.3	110
197	A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1900487.	1.5	32
198	Nonalcoholic fatty liver disease does not predict worse perioperative outcomes in bariatric surgery. <i>Obesity Research and Clinical Practice</i> , 2019, 13, 416-418.	0.8	2
199	Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 378-393.	0.3	4
200	Urinary thiodiglycolic acid is associated with increased risk of non-alcoholic fatty liver disease in children living near a petrochemical complex. <i>Environment International</i> , 2019, 131, 104978.	4.8	21
201	Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis. <i>PLoS ONE</i> , 2019, 14, e0217263.	1.1	15
202	Independent Association of Physical Activity with Nonalcoholic Fatty Liver Disease and Alanine Aminotransferase Levels. <i>Journal of Clinical Medicine</i> , 2019, 8, 1013.	1.0	13
203	Comparison between non-alcoholic fatty liver disease screening guidelines in children and adolescents. <i>JHEP Reports</i> , 2019, 1, 259-264.	2.6	20

#	ARTICLE	IF	CITATIONS
204	Development of liver surface nodularity quantification program and its clinical application in nonalcoholic fatty liver disease. Scientific Reports, 2019, 9, 9994.	1.6	13
205	Who Should Treat Fatty Liver Disease: Primary Care or Hepatology?. Clinical Liver Disease, 2019, 13, 158-161.	1.0	0
206	Daily Aspirin Use Reduces Risk of Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease, Providing New Uses for an Old Drug. Clinical Gastroenterology and Hepatology, 2019, 17, 2651-2653.	2.4	3
207	Nonalcoholic fatty liver disease with advanced fibrosis as a multi-systemic disease: proceed with caution. Hepatobiliary Surgery and Nutrition, 2019, 8, 170-172.	0.7	2
208	When Do Clinicians Follow-up Abnormal Liver Tests in Primary Care?. American Journal of the Medical Sciences, 2019, 358, 127-133.	0.4	1
209	Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2019, 17, 2570-2580.e37.	2.4	75
210	The Effect of Low Glycemic Index and Glycemic Load Diets on Hepatic Fat Mass, Insulin Resistance, and Blood Lipid Panels in Individuals with Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 2019, 17, 389-396.	0.5	21
211	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemporary Clinical Trials, 2019, 84, 105803.	0.8	105
212	Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation?. Seminars in Liver Disease, 2019, 39, 476-482.	1.8	23
213	Depression is associated with non-alcoholic fatty liver disease among adults in the United States. Alimentary Pharmacology and Therapeutics, 2019, 50, 590-598.	1.9	62
214	Obesity and Hepatocarcinogenesis. , 2019, , 87-102.		0
215	Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects. Journal of Clinical Medicine, 2019, 8, 1057.	1.0	14
216	From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Reports, 2019, 1, 312-328.	2.6	251
217	Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. Alimentary Pharmacology and Therapeutics, 2019, 50, 930-939.	1.9	67
218	Reversal of NASH fibrosis with pharmacotherapy. Hepatology International, 2019, 13, 534-545.	1.9	13
219	Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study. Journal of Internal Medicine, 2019, 286, 711-722.	2.7	51
220	Paediatric non-alcoholic fatty liver disease: a more complex disease than in the adulthood?. Hepatobiliary Surgery and Nutrition, 2019, 8, 270-273.	0.7	1
221	Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology, 2019, 9, 723-730.	0.4	46

#	ARTICLE	IF	CITATIONS
222	Validation of the chronic liver disease questionnaire for non-alcoholic steatohepatitis in patients: impact for the clinic. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 709-710.	1.4	0
223	Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease. <i>JAMA Internal Medicine</i> , 2019, 179, 1262.	2.6	159
224	Treatment of Fatty Liver Disease—Time to Implement Common Sense Measures. <i>JAMA Internal Medicine</i> , 2019, 179, 1272.	2.6	1
225	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	3.6	197
226	Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic Steatosis. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 2679-2687.	0.7	102
227	Comorbidities in inflammatory bowel disease: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 643-654.	3.7	112
228	The Effects of Hepatic Steatosis on the Natural History of HBV Infection. <i>Clinics in Liver Disease</i> , 2019, 23, 433-450.	1.0	22
229	The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 793-801.	1.8	1,253
230	NAFLD in children: new genes, new diagnostic modalities and new drugs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 517-530.	8.2	199
231	Mitochondrial Dysfunction in the Transition from NASH to HCC. <i>Metabolites</i> , 2019, 9, 233.	1.3	60
232	Individualized risk prediction of significant fibrosis in nonalcoholic fatty liver disease using a novel nomogram. <i>United European Gastroenterology Journal</i> , 2019, 7, 1124-1134.	1.6	29
233	Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5055.	1.8	140
234	Effect of alcohol consumption on nonalcoholic fatty liver disease. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 70-70.	1.5	16
235	Extrahepatic complications of non-alcoholic fatty liver disease. <i>Revista De Gastroenterología De México (English Edition)</i> , 2019, 84, 472-481.	0.1	3
236	The association between retinol-binding protein 4 and prediabetes in obese patients with nonalcoholic fatty liver disease. <i>Archives of Physiology and Biochemistry</i> , 2019, , 1-6.	1.0	14
237	Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. <i>Journal of General Internal Medicine</i> , 2019, 34, 2772-2778.	1.3	37
238	Prevalence and risk factors of non-alcoholic fatty liver disease in southwest Iran: a population-based case-control study. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 224-231.	0.6	16
239	Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol. <i>Trials</i> , 2019, 20, 580.	0.7	8

#	ARTICLE	IF	CITATIONS
240	Angiotensinogen in hepatocytes contributes to Western diet-induced liver steatosis. <i>Journal of Lipid Research</i> , 2019, 60, 1983-1995.	2.0	20
242	Hepatic steatosis in patients with acromegaly. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00090.	1.0	10
243	Using CRISPR/Cas9 to model human liver disease. <i>JHEP Reports</i> , 2019, 1, 392-402.	2.6	20
244	Personalized Management of Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 115.	1.7	10
245	Quantification of Liver Fat in NAFLD: Available Modalities and Clinical Significance. <i>Current Hepatology Reports</i> , 2019, 18, 492-502.	0.4	6
246	Relevant Features in Nonalcoholic Steatohepatitis Determined Using Machine Learning for Feature Selection. <i>Metabolic Syndrome and Related Disorders</i> , 2019, 17, 444-451.	0.5	17
247	Hepatocellular carcinoma and non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2019, 13, 688-694.	1.9	56
248	Lifestyle modification in NAFLD/NASH: Facts and figures. <i>JHEP Reports</i> , 2019, 1, 468-479.	2.6	147
249	A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 385-393.	1.3	8
250	Nutrition in Chronic Liver Disease. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 602-618.	0.3	7
251	CON: This Patient Should Have a Noninvasive Assessment of Liver Staging. <i>Clinical Liver Disease</i> , 2019, 14, 116-120.	1.0	0
252	PRO: This Patient Should Have a Liver Biopsy. <i>Clinical Liver Disease</i> , 2019, 14, 112-115.	1.0	0
253	Cost Saving or Cost Effective? Unanswered Questions in the Screening of Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2019, 3, 1293-1295.	2.0	3
254	Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2019, 394, 2012-2024.	6.3	401
255	Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. <i>Gene Expression</i> , 2019, 19, 187-198.	0.5	23
256	Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. <i>BMC Genomics</i> , 2019, 20, 862.	1.2	42
257	NAFLD Histology: a Critical Review and Comparison of Scoring Systems. <i>Current Hepatology Reports</i> , 2019, 18, 473-481.	0.4	8
258	Fibroblast growth factor 21 in non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 153994.	1.5	85

#	ARTICLE	IF	CITATIONS
259	Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats. <i>Molecules</i> , 2019, 24, 3943.	1.7	20
260	Essential phospholipids for people with non-alcoholic fatty liver disease. <i>The Cochrane Library</i> , 0, , .	1.5	6
261	Should We Screen High-Risk Populations for NAFLD?. <i>Current Hepatology Reports</i> , 2019, 18, 433-443.	0.4	6
262	Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. <i>Hepatology Communications</i> , 2019, 3, 1459-1471.	2.0	150
263	Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116524.	0.3	28
264	Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987904.	1.4	30
265	The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. <i>Nutrients</i> , 2019, 11, 2543.	1.7	51
266	Metformin lactic acidosis: Should we still be afraid?. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107879.	1.1	30
267	Incidental hepatic steatosis in radiology reports: a survey of emergency department cliniciansâ€™ perspectives and current practice. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 573-579.	0.9	4
268	Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 809-821.	1.9	77
269	Standardising the interpretation of liver biopsies in nonâ€alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1100-1111.	1.9	27
270	Non-resolution of non-alcoholic fatty liver disease (NAFLD) among urban, adult Sri Lankans in the general population: Aâ€prospective, cohort follow-up study. <i>PLoS ONE</i> , 2019, 14, e0224474.	1.1	2
271	Non-alcoholic fatty liver disease in Poland: how and at what stage is diagnosed, and how is treated. A survey study. <i>Przegląd Gastroenterologiczny</i> , 2019, 14, 173-177.	0.3	2
272	Direct comparison of the specialised blood fibrosis tests FibroMeter ^{V2G} and Enhanced Liver Fibrosis score in patients with nonâ€alcoholic fatty liver disease from tertiary care centres. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1214-1222.	1.9	38
273	RAGE is a Potential Cause of Onset and Progression of Nonalcoholic Fatty Liver Disease. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-11.	0.6	28
274	Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881987116.	1.4	11
275	Body Mass Index and Unenhanced CT as a Predictor of Hepatic Steatosis in Potential Liver Donors. <i>Transplantation Proceedings</i> , 2019, 51, 2373-2378.	0.3	5
276	Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis. <i>Biomolecules</i> , 2019, 9, 425.	1.8	34

#	ARTICLE	IF	CITATIONS
277	Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G508-G517.	1.6	12
278	Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3104.	1.2	135
279	Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 12541.	1.6	106
280	Jiang-Zhi granules decrease sensitivity to low-dose CCl4 induced liver injury in NAFLD rats through reducing endoplasmic reticulum stress. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 228.	3.7	11
281	Abnormal Liver Enzymes. <i>Journal of General Internal Medicine</i> , 2019, 34, 1676-1676.	1.3	0
282	Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 53-53.	1.5	34
283	Complicaciones extrahepáticas de la enfermedad por hígado graso no alcohólico: impacto más allá del hígado. <i>Revista De Gastroenterología De México</i> , 2019, 84, 472-481.	0.4	12
284	The Relationship of Obesity, Nutritional Status and Muscle Wasting in Patients Assessed for Liver Transplantation. <i>Nutrients</i> , 2019, 11, 2097.	1.7	25
285	SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. <i>World Journal of Diabetes</i> , 2019, 10, 114-132.	1.3	60
286	Deep Learning in Liver Biopsies using Convolutional Neural Networks. , 2019, , .		4
287	High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000315.	1.1	82
288	Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic PNPLA3 Genetic Variant: An Open-Label Study. <i>Lifestyle Genomics</i> , 2019, 12, 10-17.	0.6	4
289	Nonalcoholic steatohepatitis pharmacotherapy and predictors of response: dual role of aminotransferases as biosensors of metabolism and biomarkers of histological improvement. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 381-385.	0.7	0
290	The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance. <i>Endocrine Reviews</i> , 2019, 40, 1367-1393.	8.9	341
291	Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-14.	3.2	139
292	Serum Amyloid P and a Dendritic Cell-Specific Intercellular Adhesion Molecule-3 “Grabbing Nonintegrin Ligand Inhibit High-Fat Diet-Induced Adipose Tissue and Liver Inflammation and Steatosis in Mice. <i>American Journal of Pathology</i> , 2019, 189, 2400-2413.	1.9	7
293	Zeaxanthin Dipalmitate in the Treatment of Liver Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-14.	0.5	2
294	Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review. <i>Frontiers in Medicine</i> , 2019, 6, 202.	1.2	97

#	ARTICLE	IF	CITATIONS
295	Possible application of melatonin treatment in human diseases of the biliary tract. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G651-G660.	1.6	11
296	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2383-2384.	2.4	1
297	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2019, 2, e1912565.	2.8	230
298	Nonalcoholic Fatty Liver Disease: Evidence-Based Management and Early Recognition of Nonalcoholic Steatohepatitis. <i>Journal for Nurse Practitioners</i> , 2019, 15, 622-626.	0.4	3
299	Working hours and nonalcoholic fatty liver disease according to sleep duration. <i>Chronobiology International</i> , 2019, 36, 1671-1680.	0.9	9
300	Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 903-914.	3.1	85
301	Nr2e1 ablation impairs liver glucolipid metabolism and induces inflammation, high-fat diets amplify the damage. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109503.	2.5	11
302	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3415.	1.2	90
303	Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109258.	2.5	34
304	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 2057-2064.	6.1	113
305	Management of diabetes mellitus in patients undergoing liver transplantation. <i>Pharmacological Research</i> , 2019, 141, 556-573.	3.1	23
306	Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1266-1270.	2.2	25
307	Down-Regulation of SIRT1 Expression by mir-23b Contributes to Lipid Accumulation in HepG2 Cells. <i>Biochemical Genetics</i> , 2019, 57, 507-521.	0.8	21
308	Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. <i>Atherosclerosis</i> , 2019, 282, 110-120.	0.4	68
309	Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. <i>Laboratory Investigation</i> , 2019, 99, 749-763.	1.7	98
310	Role of Patients and Parents in Pediatric Drug Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 601-608.	0.8	18
311	Interactions between Host PPARs and Gut Microbiota in Health and Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 387.	1.8	46
312	Pilot Study to Diagnose Nonalcoholic Steatohepatitis With Dynamic ¹⁸ F-FDG PET. <i>American Journal of Roentgenology</i> , 2019, 212, 529-537.	1.0	19

#	ARTICLE	IF	CITATIONS
313	Insulin resistance and NAFLD: Relationship with intrahepatic iron and serum TNF- α using 1H MR spectroscopy and MRI. <i>Diabetes and Metabolism</i> , 2019, 45, 473-479.	1.4	15
314	Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. <i>Transplantation</i> , 2019, 103, 57-67.	0.5	64
315	Comment on: gastric bypass specifically impairs liver parameters as compared with sleeve gastrectomy, independently of evolution of metabolic disorders. <i>Surgery for Obesity and Related Diseases</i> , 2019, 15, 513.	1.0	0
316	Consenso mexicano de la enfermedad por hÃgado graso no alcohÃlico. <i>Revista De GastroenterologÃa De MÃxico</i> , 2019, 84, 69-99.	0.4	26
318	Association between nonalcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. <i>Liver International</i> , 2019, 39, 758-769.	1.9	75
319	Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease. <i>Medicina (Lithuania)</i> , 2019, 55, 166.	0.8	35
320	Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation. <i>Nutrients</i> , 2019, 11, 1132.	1.7	21
321	Iso-caloric Fructose Restriction Reduces Serum d-Lactate Concentration in Children With Obesity and Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3003-3011.	1.8	14
322	Current and future pharmacological therapies for managing cirrhosis and its complications. <i>World Journal of Gastroenterology</i> , 2019, 25, 888-908.	1.4	36
323	Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis. <i>Handbook of Experimental Pharmacology</i> , 2019, 256, 325-357.	0.9	43
324	New dual peroxisome proliferator activated receptor agonist Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. <i>Cardiovascular Diabetology</i> , 2019, 18, 80.	2.7	90
325	Evaluation of left atrial function in type 2 diabetes mellitus patients with nonalcoholic fatty liver disease by two-dimensional speckle tracking echocardiography. <i>Echocardiography</i> , 2019, 36, 1290-1297.	0.3	7
326	<p>Lysosomal acid lipase deficiency â€œ early diagnosis is the key</p>. <i>Hepatic Medicine: Evidence and Research</i> , 2019, Volume 11, 79-88.	0.9	28
327	Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. <i>Infectious Diseases</i> , 2019, 51, 593-601.	1.4	18
328	Referral pathways for NAFLD fibrosis in primary care â€œ No longer a â€œneedle in a haystackâ€™. <i>Journal of Hepatology</i> , 2019, 71, 246-248.	1.8	11
329	Low Free Sugar Diet in Adolescents With Nonalcoholic Fatty Liver Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2468.	3.8	0
330	Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-Leiden mice. <i>PLoS ONE</i> , 2019, 14, e0218459.	1.1	30
331	Low Free Sugar Diet in Adolescents With Nonalcoholic Fatty Liver Diseaseâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2469.	3.8	2

#	ARTICLE	IF	CITATIONS
332	UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications. <i>Handbook of Experimental Pharmacology</i> , 2019, 256, 237-264.	0.9	51
333	Alcohol consumption is associated with the risk of developing colorectal neoplasia: Propensity score matching analysis. <i>Scientific Reports</i> , 2019, 9, 8253.	1.6	8
334	Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2019, 3, 1050-1060.	2.0	44
335	Effects of Share 35 Policy on Liver Transplantation Outcomes for Patients With Nonalcoholic Steatohepatitis. <i>Progress in Transplantation</i> , 2019, 29, 248-253.	0.4	2
336	Adaptation of controlled attenuation parameter (CAP) measurement depth in morbidly obese patients addressed for bariatric surgery. <i>PLoS ONE</i> , 2019, 14, e0217093.	1.1	9
337	Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2776-2784.e4.	2.4	108
338	Tropifexorâ€Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. <i>Hepatology Communications</i> , 2019, 3, 1085-1097.	2.0	67
339	Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. <i>Journal of Gastroenterology</i> , 2019, 54, 1096-1105.	2.3	11
340	Engaging primary care clinicians in the assessment of NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 458-460.	8.2	5
341	Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2019, 42, 1481-1488.	4.3	202
342	Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity. <i>Current Obesity Reports</i> , 2019, 8, 243-254.	3.5	37
343	Implementation of collagen biomarkers in the clinical setting. , 2019, , 373-384.		0
344	Involvement of G-Protein-Coupled Receptor 40 in the Inhibitory Effects of Docosahexaenoic Acid on SREBP1-Mediated Lipogenic Enzyme Expression in Primary Hepatocytes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2625.	1.8	24
345	A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (<sc>NASH</sc>). <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00485.	1.1	17
346	Toward More Accurate Nomenclature for Fatty Liver Diseases. <i>Gastroenterology</i> , 2019, 157, 590-593.	0.6	75
347	Longâ€term metformin use may improve clinical outcomes in diabetic patients with nonâ€alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 317-328.	1.9	52
348	Nonâ€alcoholic fatty liver disease, liver fibrosis score and cognitive function in middleâ€aged adults: The Framingham Study. <i>Liver International</i> , 2019, 39, 1713-1721.	1.9	68
349	Association between nut consumption and nonâ€alcoholic fatty liver disease in adults. <i>Liver International</i> , 2019, 39, 1732-1741.	1.9	40

#	ARTICLE	IF	CITATIONS
350	Prevalence of Advanced Liver Fibrosis in Patients With Severe Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1028.	2.0	17
351	Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2305-2314.	2.2	13
352	NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2841.	1.8	79
353	Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity. <i>British Journal of Pharmacology</i> , 2019, 176, 2877-2893.	2.7	26
354	Dietary Carotenoids and Non-Alcoholic Fatty Liver Disease among US Adults, NHANES 2003–2014. <i>Nutrients</i> , 2019, 11, 1101.	1.7	41
355	Non-nutritive sweeteners and their association with the metabolic syndrome and non-alcoholic fatty liver disease: a review of the literature. <i>European Journal of Nutrition</i> , 2019, 58, 1785-1800.	1.8	17
356	Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. <i>Drugs</i> , 2019, 79, 903-927.	4.9	47
357	Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1365-1386.	1.8	167
358	A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). <i>Advances in Therapy</i> , 2019, 36, 1574-1594.	1.3	86
359	Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. <i>Hepatology</i> , 2019, 70, 1119-1133.	3.6	355
360	Imaging Biomarkers for Nonalcoholic Fatty Liver Disease. <i>Academic Radiology</i> , 2019, 26, 869-871.	1.3	1
361	Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2215.	1.8	42
362	SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy. <i>Obesity Facts</i> , 2019, 12, 291-306.	1.6	4
363	The association between lecithin-cholesterol acyltransferase activity and fatty liver index. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 583-592.	0.8	8
364	Impact of different ectopic fat depots on cardiovascular and metabolic diseases. <i>Journal of Cellular Physiology</i> , 2019, 234, 21630-21641.	2.0	128
365	Low serum vitamin D is independently associated with unexplained elevated ALT only among non-obese men in the general population. <i>Annals of Hepatology</i> , 2019, 18, 578-584.	0.6	6
366	Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. <i>BMC Medicine</i> , 2019, 17, 95.	2.3	192
367	Bromide alleviates fatty acid-induced lipid accumulation in mouse primary hepatocytes through the activation of <i>PPARα</i> signals. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 4464-4474.	1.6	8

#	ARTICLE	IF	CITATIONS
368	Repurposing drugs to target nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2019, 25, 1783-1796.	1.4	15
369	Patients With Chronic Liver Disease/Cirrhosis Should Not Take Statin Medications. <i>Clinical Liver Disease</i> , 2019, 13, 106-110.	1.0	11
370	The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. <i>Bioscience of Microbiota, Food and Health</i> , 2019, 38, 81-88.	0.8	52
371	Human Liver Regeneration: An Etiology Dependent Process. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2332.	1.8	31
372	Risk of atrial fibrillation in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 818-820.	1.9	0
373	Understanding Environmental Contaminantsâ€™ Direct Effects on Non-alcoholic Fatty Liver Disease Progression. <i>Current Environmental Health Reports</i> , 2019, 6, 95-104.	3.2	48
374	Cardiovascular Health Metrics in the Development and Regression of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 610.	1.0	9
375	Vitamin E Ameliorates Lipid Metabolism in Mice with Nonalcoholic Fatty Liver Disease via Nrf2/CES1 Signaling Pathway. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3182-3191.	1.1	33
376	Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1948.	1.8	127
377	Utility of ALT Concentration in Men and Women with Nonalcoholic Fatty Liver Disease: Cohort Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 445.	1.0	11
378	Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 127.	1.8	37
379	Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. <i>European Radiology</i> , 2019, 29, 6600-6610.	2.3	19
380	Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2093-2100.e3.	2.4	33
381	Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. <i>Hepatology</i> , 2019, 69, 2318-2322.	3.6	37
382	Emerging Circulating Biomarkers for The Diagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis. , 2019, , 423-448.		4
383	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2552-2560.e10.	2.4	65
384	Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. <i>Annals of Hepatology</i> , 2019, 18, 466-471.	0.6	42
385	A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. <i>Frontline Gastroenterology</i> , 2019, 10, 337-346.	0.9	48

#	ARTICLE	IF	CITATIONS
386	Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment. <i>Hepatology Communications</i> , 2019, 3, 605-613.	2.0	14
387	Association between <i>Helicobacter pylori</i> infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 56-65.	1.5	38
388	Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD). <i>Annals of Hepatology</i> , 2019, 18, 445-449.	0.6	20
389	Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 508-517.	0.2	61
390	Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 523-530.	1.4	19
391	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019, 70, 1841-1855.	3.6	64
392	Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders. , 2019, , 245-274.		0
393	Noninvasive diagnosis of liver fibrosis in NAFLD: Tips tricks. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 658-662.	0.7	2
394	Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis. <i>Liver International</i> , 2019, 39, 1535-1544.	1.9	23
395	The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke. <i>Frontiers in Neurology</i> , 2019, 10, 375.	1.1	9
396	Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1745.	1.8	39
397	Reply to “Transient Elastography in IBD Patients” <i>Inflammatory Bowel Diseases</i> , 2019, 25, e95-e95.	0.9	1
398	Alcohol use in patients with non-alcoholic fatty liver: a tangled web of causality. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 277-279.	0.7	0
399	Past, present and future perspectives in nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 377-386.	8.2	357
400	Role of Natural Phenolics in Hepatoprotection: A Mechanistic Review and Analysis of Regulatory Network of Associated Genes. <i>Frontiers in Pharmacology</i> , 2019, 10, 509.	1.6	73
401	HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1329.	1.8	74
402	Obesity-Related Genetic Variants and Hyperuricemia Risk in Chinese Men. <i>Frontiers in Endocrinology</i> , 2019, 10, 230.	1.5	14
403	Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 447-461.	1.4	67

#	ARTICLE	IF	CITATIONS
404	The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 41.	0.7	80
405	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999â€“2019: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 389-398.	3.7	616
406	Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1157-1164.e4.	2.4	62
407	Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: A separate phenotype of NAFLD?. <i>Journal of Clinical Lipidology</i> , 2019, 13, 425-431.	0.6	13
408	The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: a systematic review of clinical trials. <i>Pharmacy Practice</i> , 2019, 17, 1350.	0.8	29
409	Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. <i>Advances in Therapy</i> , 2019, 36, 1052-1074.	1.3	67
410	Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. <i>Liver International</i> , 2019, 39, 1098-1108.	1.9	59
411	Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT. <i>Radiology</i> , 2019, 291, 330-337.	3.6	45
412	Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1867-1876.e3.	2.4	31
413	Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 156, 1264-1281.e4.	0.6	882
414	Association between ADIPOQ G276T and C11377G polymorphisms and the risk of nonâ€“alcoholic fatty liver disease: An updated metaâ€“analysis. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e624.	0.6	11
415	iNOS Gene Ablation Prevents Liver Fibrosis in Leptin-Deficient ob/ob Mice. <i>Genes</i> , 2019, 10, 184.	1.0	12
416	Haptoglobin 2-2 Genotype is Associated with More Advanced Disease in Subjects with Non-Alcoholic Steatohepatitis: A Retrospective Study. <i>Advances in Therapy</i> , 2019, 36, 880-895.	1.3	7
417	MACKâ€“3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic nonâ€“alcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 1315-1324.	1.9	31
418	Dietary Sources of Fructose and Its Association with Fatty Liver in Mexican Young Adults. <i>Nutrients</i> , 2019, 11, 522.	1.7	18
419	Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108778.	2.5	32
420	Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics. <i>Seminars in Liver Disease</i> , 2019, 39, 124-140.	1.8	48
421	Association between <i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease: A systematic review and metaâ€“analysis of observational studies. <i>Helicobacter</i> , 2019, 24, e12576.	1.6	33

#	ARTICLE	IF	CITATIONS
422	Response to the letter by Sumida et al. regarding our manuscript "Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease". <i>Journal of Gastroenterology</i> , 2019, 54, 476-477.	2.3	0
423	Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters "an animal model of life style intervention in NAFLD. <i>Scientific Reports</i> , 2019, 9, 4007.	1.6	31
424	Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 506-514.	0.4	41
425	Association between the concurrence of pre-existing chronic liver disease and worse prognosis in patients with an herb-<i>Polygonum multiflorum</i> thunb. induced liver injury: a case-control study from a specialised liver disease center in China. <i>BMJ Open</i> , 2019, 9, e023567.	0.8	20
426	Collagen Formation Assessed by N-terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. <i>Hepatology</i> , 2019, 70, 127-141.	3.6	21
427	Metformin: Mechanisms in Human Obesity and Weight Loss. <i>Current Obesity Reports</i> , 2019, 8, 156-164.	3.5	188
428	Incidental hepatic steatosis on unenhanced computed tomography performed for suspected renal colic: Gaps in reporting and documentation. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 431-438.	0.9	15
429	Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. <i>Atherosclerosis</i> , 2019, 284, 66-74.	0.4	58
430	American Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Adults. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2301-2309.	2.4	23
431	Reply to the letter on "gastric bypass specifically impairs liver parameters compared with sleeve gastrectomy, independently of evolution of metabolic disorders". <i>Surgery for Obesity and Related Diseases</i> , 2019, 15, 514.	1.0	0
432	Experimental non-alcoholic steatohepatitis in Göttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes. <i>Journal of Translational Medicine</i> , 2019, 17, 110.	1.8	30
433	Introduction: Why (Another) Book on Vitamin E?. , 2019, , 1-4.		0
434	Role of exercise-induced hepatokines in metabolic disorders. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E11-E24.	1.8	40
435	Current Imaging Techniques for Noninvasive Staging of Hepatic Fibrosis. <i>American Journal of Roentgenology</i> , 2019, 213, 77-89.	1.0	27
436	Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2019, 3, 776-791.	2.0	50
437	Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz099.	0.4	14
438	Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 872-880.	1.8	19
439	Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients: A systematic review. <i>Liver International</i> , 2019, 39, 1521-1534.	1.9	24

#	ARTICLE	IF	CITATIONS
440	Accuracy of multi-echo Dixon sequence in quantification of hepatic steatosis in Chinese children and adolescents. <i>World Journal of Gastroenterology</i> , 2019, 25, 1513-1523.	1.4	24
441	Understanding lipid metabolism through hepatic steat-omics. <i>Nature Reviews Endocrinology</i> , 2019, 15, 321-322.	4.3	1
442	The Mexican consensus on nonalcoholic fatty liver disease. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2019, 84, 69-99.	0.1	6
443	Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1764-1772.	0.9	50
444	Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1092-1093.	1.9	2
445	From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. <i>Proceedings of the Nutrition Society</i> , 2019, 78, 290-304.	0.4	36
446	Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, 1392-1399.	0.4	25
447	Iron and liver fibrosis: Mechanistic and clinical aspects. <i>World Journal of Gastroenterology</i> , 2019, 25, 521-538.	1.4	167
448	Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. <i>JHEP Reports</i> , 2019, 1, 9-16.	2.6	52
449	Bone marrow-derived macrophage contributes to fibrosing steatohepatitis through activating hepatic stellate cells. <i>Journal of Pathology</i> , 2019, 248, 488-500.	2.1	36
450	Vitamin E and Mortality: A Critical Perspective of the Conflicting Meta-analysis Outcomes. , 2019, , 235-245.		2
451	Vitamin E in Nonalcoholic Fatty Liver Disease. , 2019, , 311-323.		1
452	Nonalcoholic Fatty Liver Disease and Obesity Treatment. <i>Current Obesity Reports</i> , 2019, 8, 220-228.	3.5	68
453	Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. <i>World Journal of Gastroenterology</i> , 2019, 25, 1307-1326.	1.4	146
454	Common Misconceptions in Hepatology: Nonalcoholic Fatty Liver Disease. <i>Clinical Liver Disease</i> , 2019, 13, 79-81.	1.0	1
455	Diagnostic value of MR-based texture analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). <i>Abdominal Radiology</i> , 2019, 44, 1816-1824.	1.0	17
456	Testosterone Levels in Women: Implications for Fatty Liver and Beyond. <i>Journal of Women's Health</i> , 2019, 28, 1015-1016.	1.5	3
457	The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. <i>Frontiers in Immunology</i> , 2019, 10, 82.	2.2	157

#	ARTICLE	IF	CITATIONS
458	Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 31.	1.8	109
459	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1148-1156.e4.	2.4	71
460	A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease. <i>Diabetes</i> , 2019, 68, 1073-1083.	0.3	41
461	Nonalcoholic Fatty Liver Disease and the Heart. <i>Journal of the American College of Cardiology</i> , 2019, 73, 948-963.	1.2	259
462	The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD). <i>Metabolites</i> , 2019, 9, 25.	1.3	7
463	Association between Sleep Disturbances and Liver Status in Obese Subjects with Nonalcoholic Fatty Liver Disease: A Comparison with Healthy Controls. <i>Nutrients</i> , 2019, 11, 322.	1.7	29
464	Reply. <i>Hepatology</i> , 2019, 69, 2304-2305.	3.6	0
465	Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum. <i>Proceedings of the Nutrition Society</i> , 2019, 78, 362-371.	0.4	5
466	Should Patients With NAFLD/NASH Be Surveyed for HCC?. <i>Transplantation</i> , 2019, 103, 39-44.	0.5	52
467	Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. <i>Radiologic Clinics of North America</i> , 2019, 57, 563-583.	0.9	7
468	Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 702-713.	1.9	28
469	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. <i>Translational Research</i> , 2019, 209, 22-38.	2.2	51
470	Serum ferritin as a biomarker for NAFLD: ready for prime time?. <i>Hepatology International</i> , 2019, 13, 110-112.	1.9	14
471	Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China. <i>Lipids in Health and Disease</i> , 2019, 18, 45.	1.2	10
472	Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. <i>Clinical Diabetes</i> , 2019, 37, 65-72.	1.2	77
473	Clinicopathological impact of anti-smooth muscle antibodies in patients with non-alcoholic fatty liver disease. <i>British Journal of Biomedical Science</i> , 2019, 76, 101-103.	1.2	2
474	Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study. <i>BMJ Open</i> , 2019, 9, e023597.	0.8	38
476	Dietary Manipulations for Nonalcoholic Fatty Liver Disease (NAFLD). , 2019, , 69-88.		5

#	ARTICLE	IF	CITATIONS
477	Genome-Based Nutrition in Chronic Liver Disease. , 2019, , 3-14.		1
478	Nutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease. , 2019, , 357-372.		3
479	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	2.4	107
480	Hepatoprotective effect of coffee pulp aqueous extract combined with simvastatin against hepatic steatosis in high-fat diet-induced obese rats. <i>Journal of Functional Foods</i> , 2019, 54, 568-577.	1.6	15
481	Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 551-560.	0.7	29
482	Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2019, 19, 27.	0.8	15
483	A Novel Discovery: Holistic Efficacy at the Special Organ Level of Pungent Flavored Compounds from Pungent Traditional Chinese Medicine. <i>International Journal of Molecular Sciences</i> , 2019, 20, 752.	1.8	10
484	How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?. <i>Annals of Internal Medicine</i> , 2019, 171, 199.	2.0	4
485	Obesity and metabolic outcomes in a safety-net health system. <i>Biodemography and Social Biology</i> , 2020, 65, 257-267.	0.4	2
486	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes 2019. <i>Diabetes Care</i> , 2019, 42, S34-S45.	4.3	169
487	Non-alcoholic Fatty Liver Disease and Surgery. , 2019, , .		1
488	Green tea polyphenols attenuate hepatic steatosis, and reduce insulin resistance and inflammation in high-fat diet-induced rats. <i>International Journal of Molecular Medicine</i> , 2019, 44, 1523-1530.	1.8	26
489	Sex hormone-binding globulin levels are inversely associated with nonalcoholic fatty liver disease in HIV-infected and uninfected men. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz468.	0.4	3
491	Benign and Malignant Diagnosis of Hepatocellular Carcinoma on CT Images Based on Fusion Network. , 2019, , .		0
492	Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals. <i>Disease Markers</i> , 2019, 2019, 1-13.	0.6	6
493	The dawn of a new era for nonalcoholic fatty liver disease?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 629-631.	0.7	2
494	The Burden and Clinical Care Pathways of Nonalcoholic Steatohepatitis in the Middle East. <i>Clinical Liver Disease</i> , 2019, 14, 207-211.	1.0	3
495	Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study. <i>Oncologist</i> , 2019, 24, e653-e661.	1.9	16

#	ARTICLE	IF	CITATIONS
496	Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000307.	1.1	12
497	Relationship of Physician Counseling to Weight Loss Among Patients With Nonalcoholic Fatty Liver Disease: An Observational Cohort Study Using National Health and Education Survey Data. <i>Clinical Liver Disease</i> , 2019, 14, 156-160.	1.0	3
498	Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2019, 3, 1704-1705.	2.0	0
499	Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints. <i>Hepatology Communications</i> , 2019, 3, 1563-1570.	2.0	9
500	HIV-Associated NAFLD: Disease Burden and Management. <i>Current Hepatology Reports</i> , 2019, 18, 482-491.	0.4	2
501	Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A "non-invasive alternative" to liver biopsy?. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 154010.	1.5	14
502	Association between Smoking and Liver Fibrosis among Patients with Nonalcoholic Fatty Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-5.	0.8	23
503	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 154005.	1.5	83
504	Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 283-297.	0.4	1
505	Evaluation of Dietary Approaches for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review. <i>Nutrients</i> , 2019, 11, 3064.	1.7	45
506	Sex- and Age-Related Differences in the Contribution of Ultrasound-Measured Visceral and Subcutaneous Abdominal Fat to Fatty Liver Index in Overweight and Obese Caucasian Adults. <i>Nutrients</i> , 2019, 11, 3008.	1.7	8
507	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?. <i>Nutrients</i> , 2019, 11, 3048.	1.7	29
508	Liver Disease Among Renal Transplant Recipients. , 2019, , 539-565.		0
509	Sodium fluorocitrate having inhibitory effect on fatty acid uptake ameliorates high fat diet-induced non-alcoholic fatty liver disease in C57BL/6J mice. <i>Scientific Reports</i> , 2019, 9, 17839.	1.6	4
510	Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?. <i>Nutrients</i> , 2019, 11, 2878.	1.7	47
511	Cerium Oxide Nanoparticles Protect against Oxidant Injury and Interfere with Oxidative Mediated Kinase Signaling in Human-Derived Hepatocytes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5959.	1.8	28
512	In Vitro Human Liver Model of Nonalcoholic Steatohepatitis by Coculturing Hepatocytes, Endothelial Cells, and Kupffer Cells. <i>Advanced Healthcare Materials</i> , 2019, 8, e1901379.	3.9	30
513	Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. <i>Systematic Reviews</i> , 2019, 8, 295.	2.5	47

#	ARTICLE	IF	CITATIONS
514	<p>A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis</p>. Hepatic Medicine: Evidence and Research, 2019, Volume 11, 159-178.	0.9	33
516	<p>Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways</p>. Drug Design, Development and Therapy, 2019, Volume 13, 4065-4074.	2.0	23
520	Long-term treatment with metformin in the prevention of fatty liver in Zucker diabetic fatty rats. Diabetology and Metabolic Syndrome, 2019, 11, 94.	1.2	12
521	Evaluation of Hepatic Steatosis in Rodents by Time-Domain Nuclear Magnetic Resonance. Diagnostics, 2019, 9, 198.	1.3	3
523	ABO blood group and risk of newly diagnosed nonalcoholic fatty liver disease: A case-control study in Han Chinese population. PLoS ONE, 2019, 14, e0225792.	1.1	5
524	Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports, 2019, 18, 444-454.	0.4	1
525	Dyslipidemia in nonalcoholic fatty liver disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 103-108.	1.2	33
526	Nonalcoholic Fatty Liver Disease. Gastroenterology Nursing, 2019, 42, 428-434.	0.2	16
527	The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease. Medicine (United States), 2019, 98, e16018.	0.4	16
528	Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. European Journal of Gastroenterology and Hepatology, 2019, 31, 859-864.	0.8	19
529	Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. Gastroenterology Research and Practice, 2019, 2019, 1-19.	0.7	48
530	Editorial: Systems Biology and Bioinformatics in Gastroenterology and Hepatology. Frontiers in Physiology, 2019, 10, 1438.	1.3	0
531	Is Fasting Necessary for Individuals With Nonalcoholic Fatty Liver Disease to Undergo Vibration-Controlled Transient Elastography?. American Journal of Gastroenterology, 2019, 114, 995-997.	0.2	15
532	Intragastric Balloons: An Emerging Therapy for Nonalcoholic Steatohepatitis and Fibrosis?. ACG Case Reports Journal, 2019, 6, e00142.	0.2	1
533	Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness. Clinical and Translational Gastroenterology, 2019, 10, e00066.	1.3	19
534	Diabetes and Fatty Liver. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S93-S96.	0.6	4
535	Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study. American Journal of Gastroenterology, 2019, 114, 620-629.	0.2	52
536	NAFLD in Women: Unique Pathways, Biomarkers, and Therapeutic Opportunities. Current Hepatology Reports, 2019, 18, 425-432.	0.4	8

#	ARTICLE	IF	CITATIONS
537	Natural Products: New Hope for Nonalcoholic Steatohepatitis?. <i>Journal of Medicinal Food</i> , 2019, 22, 1187-1188.	0.8	1
538	Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1121-1128.	0.8	49
539	Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Caseâ€“Control Study. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00011.	1.3	18
540	A gathering storm. <i>Aids</i> , 2019, 33, 1105-1115.	1.0	18
541	Alpha-fetoprotein to transaminase ratio is related to higher diagnostic efficacy for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, e15414.	0.4	14
542	Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery. <i>Medicine (United States)</i> , 2019, 98, e17277.	0.4	16
543	Current treatment options for nonalcoholic fatty liver disease. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 168-176.	1.0	14
544	Clinical significance of elevated liver transaminases in HIV-infected patients. <i>Aids</i> , 2019, 33, 1267-1282.	1.0	19
545	Liver Transplantation for Nonalcoholic Steatohepatitis: New Evidence of a Profound Increase Across Age Cohorts. <i>Transplantation</i> , 2019, 103, 1-2.	0.5	2
546	Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. <i>American Journal of Gastroenterology</i> , 2019, 114, 579-590.	0.2	27
547	Pancreatic Steatosis: An Emerging Clinical Entity. <i>American Journal of Gastroenterology</i> , 2019, 114, 1726-1734.	0.2	26
548	Obesity Is the Most Common Risk Factor for Chronic Liver Disease: Results From a Risk Stratification Pathway Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2019, 114, 1744-1752.	0.2	32
549	Serum Soluble Receptor for AGE (sRAGE) Levels Are Associated With Unhealthy Lifestyle and Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00040.	1.3	10
550	Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2019, 22, 103-110.	1.3	50
551	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. <i>American Journal of Gastroenterology</i> , 2019, 114, 1626-1635.	0.2	65
552	Pancreatic steatosis. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 440-447.	1.0	7
553	A 2-step fast-track elastometry service for advanced workup of nonalcoholic fatty liver disease (NAFLD) patients â€“ single-center real-world experience of outpatient clinical practice. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 1209-1217.	0.2	8
554	Chinese Herbal Medicine Formula Shenling Baizhu San Ameliorates High-Fat Diet-Induced NAFLD in Rats by Modulating Hepatic MicroRNA Expression Profiles. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-14.	0.5	6

#	ARTICLE	IF	CITATIONS
555	Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 313-324.	5.5	566
556	Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States. <i>Hepatology</i> , 2019, 69, 564-572.	3.6	142
557	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 2672-2682.	3.6	1,203
558	International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. <i>Transplantation</i> , 2019, 103, 45-56.	0.5	69
560	The effects of high intensity interval training on the levels of liver enzymes associated with non-alcoholic fatty liver and selected anthropometric indices in obese men. <i>Science and Sports</i> , 2019, 34, 59-60.	0.2	3
561	Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 296-307.	1.9	19
562	A role of peroxisome proliferator-activated receptor β in non-alcoholic fatty liver disease. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 528-537.	1.2	117
563	Association between serum liver enzymes and all-cause mortality: The Japan Public Health Center-based Prospective Study. <i>Liver International</i> , 2019, 39, 1566-1576.	1.9	14
564	Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study. <i>Advances in Therapy</i> , 2019, 36, 478-491.	1.3	29
565	Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. <i>Advanced Science</i> , 2019, 6, 1801585.	5.6	110
566	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. <i>Transplantation</i> , 2019, 103, 22-27.	0.5	296
567	Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 375-388.	1.9	45
568	Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1404-1410.	1.4	43
569	<sc>HOMA</sc>: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1390-1395.	1.4	67
570	Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. <i>Liver International</i> , 2019, 39, 748-757.	1.9	46
571	The immunity-related GTPase M rs13361189 variant does not increase the risk for prevalent or incident steatosis; results from the Framingham Heart Study. <i>Liver International</i> , 2019, 39, 1022-1026.	1.9	3
572	The role of the microbiome in <sc>NAFLD</sc> and <sc>NASH</sc>. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	368
573	Olive Oil, Palm Oil, and Hybrid Palm Oil Distinctly Modulate Liver Transcriptome and Induce NAFLD in Mice Fed a High-Fat Diet. <i>International Journal of Molecular Sciences</i> , 2019, 20, 8.	1.8	35

#	ARTICLE	IF	CITATIONS
574	Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction. <i>American Journal of Roentgenology</i> , 2019, 212, 332-341.	1.0	70
575	The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 145-159.	8.2	571
576	Non-alcoholic fatty liver disease – A global public health perspective. <i>Journal of Hepatology</i> , 2019, 70, 531-544.	1.8	1,345
577	Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 69-82.	0.9	15
578	Decreased serum neuregulin 4 levels associated with non-alcoholic fatty liver disease in children with obesity. <i>Clinical Obesity</i> , 2019, 9, e12289.	1.1	31
579	Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). <i>Journal of Digestive Diseases</i> , 2019, 20, 163-173.	0.7	111
580	Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. <i>Pharmacoeconomics</i> , 2019, 37, 267-278.	1.7	18
581	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 812-821.	2.2	117
582	The Future of Nonalcoholic Fatty Liver Disease Treatment. <i>Medical Clinics of North America</i> , 2019, 103, 57-69.	1.1	16
583	Obstructive Sleep Apnea, Hypoxia, and Nonalcoholic Fatty Liver Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 830-841.	2.5	145
584	Accuracy and precision of proton density fat fraction measurement across field strengths and scan intervals: A phantom and human study. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 305-314.	1.9	26
585	Outcomes of Bariatric Surgery in Patients with Cirrhosis. <i>Obesity Surgery</i> , 2019, 29, 585-592.	1.1	28
586	The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. <i>Hepatology International</i> , 2019, 13, 302-313.	1.9	34
587	Steatosis in Liver Transplantation: Current Limitations and Future Strategies. <i>Transplantation</i> , 2019, 103, 78-90.	0.5	71
588	A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?. <i>Infectious Diseases and Therapy</i> , 2019, 8, 33-50.	1.8	50
589	High prevalence of nonalcoholic steatohepatitis and abnormal liver stiffness in a young and obese Mexican population. <i>PLoS ONE</i> , 2019, 14, e0208926.	1.1	28
590	Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 1-3.	0.6	2
591	Designing professional program instruction to align with students'™ cognitive processing. <i>Currents in Pharmacy Teaching and Learning</i> , 2019, 11, 160-165.	0.4	6

#	ARTICLE	IF	CITATIONS
592	Postglucose Hyperinsulinemia in Black Women Is Not What We Thought. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 266-268.	1.8	1
593	Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden. <i>Hepatology Communications</i> , 2019, 3, 52-62.	2.0	29
594	Current Controversies in Metabolic Surgery for Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2019, 29, 1058-1067.	1.1	12
597	Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 2414-2426.	3.6	162
598	Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2019, 45, 347-355.	1.4	47
599	Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 342-352.	1.9	38
600	Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA. <i>Digestive Diseases and Sciences</i> , 2019, 64, 698-707.	1.1	26
601	The diagnosis and evaluation of patients with obesity. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 4, 50-57.	0.6	4
602	Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis. <i>Liver International</i> , 2019, 39, 557-567.	1.9	62
603	Lipid mediators of liver injury in nonalcoholic fatty liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G75-G81.	1.6	42
604	Night shift work and abnormal liver function: is non-alcohol fatty liver a necessary mediator?. <i>Occupational and Environmental Medicine</i> , 2019, 76, 83-89.	1.3	30
605	Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease. <i>Biochemical Pharmacology</i> , 2019, 160, 34-45.	2.0	50
606	Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 183-193.	1.9	80
607	Clinical workup of fatty liver for the primary care provider. <i>Postgraduate Medicine</i> , 2019, 131, 19-30.	0.9	4
608	Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1040-1060.e11.	2.4	235
609	Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. <i>Hepatology</i> , 2019, 69, 1135-1150.	3.6	15
610	Longitudinal Comparison of the Effect of Gastric Bypass to Sleeve Gastrectomy on Liver Function in a Bariatric Cohort: Tehran Obesity Treatment Study (TOTS). <i>Obesity Surgery</i> , 2019, 29, 511-518.	1.1	11
611	Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis. <i>FASEB Journal</i> , 2019, 33, 2809-2822.	0.2	40

#	ARTICLE	IF	CITATIONS
612	Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria. <i>European Journal of Nutrition</i> , 2019, 58, 1771-1784.	1.8	30
613	Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. <i>Journal of Hepatology</i> , 2019, 70, 133-141.	1.8	149
614	Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 924-932.	1.9	47
615	Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 107-120.	3.6	433
616	Prediction of Liver Steatosis Applying a New Score in Subjects from the Brazilian Longitudinal Study of Adult Health. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, e1-e10.	1.1	7
617	Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. <i>Hepatology</i> , 2020, 71, 495-509.	3.6	117
618	Development and relative validation of a short food frequency questionnaire for assessing dietary intakes of non-alcoholic fatty liver disease patients. <i>European Journal of Nutrition</i> , 2020, 59, 571-580.	1.8	12
619	The Role of Senescence in the Development of Nonalcoholic Fatty Liver Disease and Progression to Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 71, 363-374.	3.6	131
620	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020, 72, 14-24.	1.8	123
621	GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 135-141.	1.9	91
622	Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 117-123.	1.9	59
623	Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2020, 55, 100-112.	2.3	18
624	Impact of apolipoprotein E genetic polymorphisms on liver disease: An essential review. <i>Annals of Hepatology</i> , 2020, 19, 24-30.	0.6	20
625	Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 710-718.e4.	2.4	10
626	Volumetric Liver Fat Fraction Determines Grade of Steatosis More Accurately Than Controlled Attenuation Parameter in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 945-953.e2.	2.4	5
627	Evaluation of thrombocytopenia in patients with non-alcoholic fatty liver disease without cirrhosis. <i>Annals of Hepatology</i> , 2020, 19, 88-91.	0.6	7
628	Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1512-1519.	1.1	12
629	Association between edible mushroom intake and the prevalence of newly diagnosed non-alcoholic fatty liver disease: results from the Tianjin Chronic Low-Grade Systemic Inflammation and Health Cohort Study in China. <i>British Journal of Nutrition</i> , 2020, 123, 104-112.	1.2	17

#	ARTICLE	IF	CITATIONS
630	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. <i>Endocrine Reviews</i> , 2020, 41, 66-117.	8.9	134
631	Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. <i>Journal of Hepatology</i> , 2020, 72, 401-410.	1.8	40
632	Nonalcoholic Steatohepatitis After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 141-159.	1.3	49
633	Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 40-52.	8.2	203
634	Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort. <i>Hepatology</i> , 2020, 71, 1940-1952.	3.6	82
635	Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 255-262.	0.4	43
636	Epidemiology of chronic liver diseases in the USA in the past three decades. <i>Gut</i> , 2020, 69, 564-568.	6.1	321
637	Serum Nutritional Markers as Prognostic Factors for Hepatic and Extrahepatic Carcinogenesis in Japanese Patients with Nonalcoholic Fatty Liver Disease. <i>Nutrition and Cancer</i> , 2020, 72, 884-891.	0.9	9
638	Liver Disease, Nonalcoholic Fatty. , 2020, , 408-413.		1
639	Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-up of Population Cohorts. <i>Hepatology</i> , 2020, 71, 835-848.	3.6	96
640	Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis. <i>Hepatology</i> , 2020, 71, 861-873.	3.6	49
641	Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. <i>Translational Behavioral Medicine</i> , 2020, 10, 1016-1030.	1.2	34
642	Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. <i>Hepatology</i> , 2020, 71, 539-548.	3.6	128
643	C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3210.	1.7	18
644	Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 2266-2272.	1.3	32
645	Acromegaly and ultrasound: how, when and why?. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 279-287.	1.8	7
646	Food Insecurity May Be an Independent Risk Factor Associated with Nonalcoholic Fatty Liver Disease among Low-Income Adults in the United States. <i>Journal of Nutrition</i> , 2020, 150, 91-98.	1.3	65
647	Myosteatosis to predict inferior perioperative outcome in patients undergoing orthotopic liver transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 493-503.	2.6	62

#	ARTICLE	IF	CITATIONS
648	Association between habitual yogurt consumption and newly diagnosed non-alcoholic fatty liver disease. <i>European Journal of Clinical Nutrition</i> , 2020, 74, 491-499.	1.3	32
649	High Throughput Screening of Serum γ -Glutamyl Dipeptides for Risk Assessment of Nonalcoholic Steatohepatitis with Impaired Glutathione Salvage Pathway. <i>Journal of Proteome Research</i> , 2020, 19, 2689-2699.	1.8	15
650	Reproducibility of hepatic MR elastography across field strengths, pulse sequences, scan intervals, and readers. <i>Abdominal Radiology</i> , 2020, 45, 107-115.	1.0	8
651	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020, 88, 105889.	0.8	80
652	Alanine Aminotransferase Results Differ by Analyzer Manufacturer in a National Integrated Health Setting, 2012–2017. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 748-754.	1.2	6
653	Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population. <i>Hepatology</i> , 2020, 71, 820-834.	3.6	58
654	Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 5-16.	2.6	136
655	Effect of <i>PNPLA3</i> polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1057-1064.	1.4	27
656	Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis. <i>Hepatology Research</i> , 2020, 50, 190-198.	1.8	35
657	Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: A propensity matched analysis. <i>American Journal of Surgery</i> , 2020, 219, 504-507.	0.9	48
658	Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients. <i>HIV Medicine</i> , 2020, 21, 96-108.	1.0	12
659	Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 290-297.	4.3	113
660	Comparison of Technical Failure of MR Elastography for Measuring Liver Stiffness Between Gradient-Recalled Echo and Spin-Echo Planar Imaging: A Systematic Review and Meta-Analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1103-1104.	1.9	2
661	Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features. <i>Nutrition</i> , 2020, 71, 110620.	1.1	28
662	Decreased Physical Working Capacity in Adolescents With Nonalcoholic Fatty Liver Disease Associates With Reduced Iron Availability. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1584-1591.	2.4	3
663	The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 862-869.	1.4	37
664	Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. <i>Liver International</i> , 2020, 40, 355-359.	1.9	50
665	Training of Deep Convolutional Neural Networks to Identify Critical Liver Alterations in Histopathology Image Samples. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 42.	1.3	20

#	ARTICLE	IF	CITATIONS
666	Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. <i>Pharmacoeconomics</i> , 2020, 38, 485-497.	1.7	12
667	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5031-5073.	2.9	67
668	Outcomes of Bariatric Surgery in Chronic Liver Disease: a National Inpatient Sample Analysis. <i>Obesity Surgery</i> , 2020, 30, 941-947.	1.1	5
669	Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. <i>Cell Metabolism</i> , 2020, 31, 35-45.	7.2	130
670	Nutrition and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 63-94.	1.0	44
671	Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 125-133.	1.9	40
672	Investigating fibrosis and inflammation in an ex vivo NASH murine model. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G336-G351.	1.6	12
673	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1917-1925.	0.9	11
674	Liver stiffness measurement in non-alcoholic fatty liver disease: Two is better than one. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1404-1411.	1.4	12
675	Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality. <i>Liver International</i> , 2020, 40, 815-824.	1.9	26
676	Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. <i>Diabetes and Metabolism</i> , 2020, 46, 427-441.	1.4	81
677	Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	0.8	92
678	Why Do Lifestyle Recommendations Fail in Most Patients with Nonalcoholic Fatty Liver Disease?. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 95-104.	1.0	6
679	Relación entre el hipotiroidismo y el hígado graso no alcohólico en una población española. <i>Medicina Clínica</i> , 2020, 154, 1-6.	0.3	13
680	Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 99-101.	1.9	10
681	Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives. <i>Hepatology Research</i> , 2020, 50, 407-418.	1.8	35
682	Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 420-425.	0.8	22
683	Relationship between hypothyroidism and non-alcoholic fatty liver disease in the Spanish population. <i>Medicina Clínica (English Edition)</i> , 2020, 154, 1-6.	0.1	9

#	ARTICLE	IF	CITATIONS
684	Comparison of 2D Shear Wave Elastography, Transient Elastography, and MR Elastography for the Diagnosis of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Roentgenology</i> , 2020, 214, W20-W26.	1.0	87
685	Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway. <i>Phytomedicine</i> , 2020, 66, 153135.	2.3	29
686	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2843-2845.e2.	2.4	21
687	Drug-Induced Liver Injury from Statins. <i>Clinics in Liver Disease</i> , 2020, 24, 107-119.	1.0	18
688	Alcohol Use Is Associated With Hepatic Steatosis Among Persons With Presumed Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1831-1841.e5.	2.4	48
689	Reply:. <i>Hepatology</i> , 2020, 71, 1526-1526.	3.6	0
691	Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors?. <i>Liver International</i> , 2020, 40, 496-508.	1.9	39
692	Salidroside alleviates lipotoxicity-induced cell death through inhibition of TLR4/MAPKs pathway, and independently of AMPK and autophagy in AML-12 mouse hepatocytes. <i>Journal of Functional Foods</i> , 2020, 65, 103691.	1.6	10
693	The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 642-649.	0.8	24
694	Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals. <i>Frontline Gastroenterology</i> , 2020, 11, 478-483.	0.9	11
695	Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 205-208.	1.9	12
696	Factors Associated with Deep Vein Thrombosis in Type 2 Diabetics with Biopsy-Proven Non-alcoholic Fatty Liver Disease. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 32-41.	0.3	2
697	Active vitamin D impedes the progression of non-alcoholic fatty liver disease by inhibiting cell senescence in a rat model. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 513-523.	0.7	20
698	Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2020, 158, 1334-1345.e5.	0.6	203
699	Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 384-403.	1.4	33
700	Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 80-86.	0.8	7
701	Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 296-303.	1.4	47
702	Nonalcoholic fatty liver disease as a risk factor for <i>Clostridioides difficile</i> infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 569-574.	1.3	17

#	ARTICLE	IF	CITATIONS
703	Readiness for the epidemic: The adult nonalcoholic fatty liver disease toolkit for primary care nurse practitioners. <i>Journal of the American Association of Nurse Practitioners</i> , 2020, 32, 323-331.	0.5	6
704	Correlation of serum zinc levels with pathological and laboratory findings in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 748-753.	0.8	19
705	Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. <i>Aids</i> , 2020, 34, 237-244.	1.0	25
706	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , 2020, 69, 764-780.	6.1	112
707	Nonalcoholic Fatty Liver Disease. <i>Hypertension</i> , 2020, 75, 275-284.	1.3	121
708	Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. <i>Acta Diabetologica</i> , 2020, 57, 613-618.	1.2	41
709	Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 247-251.	0.9	7
710	Incidence, predictive factors and severity of methotrexate-related liver injury in rheumatoid arthritis: a longitudinal cohort study. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa020.	0.3	16
711	From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. <i>Chinese Medical Journal</i> , 2020, 133, 2271-2273.	0.9	79
712	Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 96-100.	0.5	5
713	PET Parametric Imaging: Past, Present, and Future. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2020, 4, 663-675.	2.7	54
714	Feasibility of a Very Low Calorie Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00231.	1.3	28
715	Bile Acids and FXR: Novel Targets for Liver Diseases. <i>Frontiers in Medicine</i> , 2020, 7, 544.	1.2	105
716	A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. <i>Microorganisms</i> , 2020, 8, 1526.	1.6	8
717	MEHP/ethanol co-exposure favors the death of steatotic hepatocytes, possibly through CYP4A and ADH involvement. <i>Food and Chemical Toxicology</i> , 2020, 146, 111798.	1.8	5
718	<p></p>Sequential Matrix Metalloproteinase-1 Expression Triggered by Infiltrating Monocytic Lineage Cells Modulates Pathophysiological Aspects of Human Nonalcoholic Steatohepatitis</p></p>. <i>Metalloproteinases in Medicine</i> , 0, Volume 7, 1-13.	1.0	0
719	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020, 97, 106174.	0.8	25
720	Microbiota, Fiber, and NAFLD: Is There Any Connection?. <i>Nutrients</i> , 2020, 12, 3100.	1.7	34

#	ARTICLE	IF	CITATIONS
721	Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 112, 154355.	1.5	23
722	Perfluorooctanesulfonic acid (PFOS) administration shifts the hepatic proteome and augments dietary outcomes related to hepatic steatosis in mice. <i>Toxicology and Applied Pharmacology</i> , 2020, 408, 115250.	1.3	31
723	Non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease : Conceptual changes for clinicians, researchers and patients. <i>Journal of Digestive Diseases</i> , 2020, 21, 604-609.	0.7	5
724	The role of the gut microbiome and exercise in non-alcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094174.	1.4	16
725	Urinary Resveratrol Metabolites Output: Differential Associations with Cardiometabolic Markers and Liver Enzymes in House-Dwelling Subjects Featuring Metabolic Syndrome. <i>Molecules</i> , 2020, 25, 4340.	1.7	6
726	Effects of a 6-month dietary-induced weight loss on erythrocyte membrane omega-3 fatty acids and hepatic status of subjects with nonalcoholic fatty liver disease: The Fatty Liver in Obesity study. <i>Journal of Clinical Lipidology</i> , 2020, 14, 837-849.e2.	0.6	6
727	The pharmacological treatment of nonalcoholic fatty liver disease in children. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1219-1227.	1.3	3
728	MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. <i>Liver International</i> , 2020, 40, 3018-3030.	1.9	274
729	Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. <i>BMC Medicine</i> , 2020, 18, 261.	2.3	66
730	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 256-268.	2.4	34
731	Dynamic Positron Emission Tomography/Computed Tomography Imaging Correlate of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2441-2443.	2.4	3
732	Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108487.	1.1	48
733	The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. <i>Journal of Trace Elements in Medicine and Biology</i> , 2020, 62, 126635.	1.5	23
734	Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients. <i>Medicina (Lithuania)</i> , 2020, 56, 544.	0.8	16
735	Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms. <i>Nutrients</i> , 2020, 12, 3166.	1.7	30
736	Hepatic steatosis is highly prevalent but is not correlated with stiffness in autoimmune hepatitis. <i>Medicine (United States)</i> , 2020, 99, e22805.	0.4	5
737	Cardiovascular risk, Metabolic disease and NASH control for Health Empowerment: Future endeavours. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 206-208.	0.1	0
738	The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults. <i>Lipids in Health and Disease</i> , 2020, 19, 218.	1.2	47

#	ARTICLE	IF	CITATIONS
739	The progress of epigenetics in the development and progression of non-alcoholic fatty liver disease. <i>Liver Research</i> , 2020, 4, 118-123.	0.5	8
740	Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. <i>Cerebrovascular Diseases</i> , 2020, 49, 474-480.	0.8	18
741	Non-alcoholic Fatty liver Disease in Patients with Psoriasis - Therapeutic Implications. <i>Postepy Dermatologii I Alergologii</i> , 2020, 37, 468-474.	0.4	9
742	A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study. <i>Contemporary Clinical Trials</i> , 2020, 98, 106170.	0.8	53
743	Weight gain during early adulthood, trajectory of body shape and the risk of nonalcoholic fatty liver disease: A prospective cohort study among women. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154398.	1.5	7
744	Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3413.	1.7	32
745	Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. <i>Current Diabetes Reports</i> , 2020, 20, 59.	1.7	39
746	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020, 14, 889-919.	1.9	422
747	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 996-1007.	3.7	22
748	Spectrum of liver diseases in patients referred for Fibroscan: A single center experience in the Middle East. <i>Annals of Medicine and Surgery</i> , 2020, 57, 166-170.	0.5	7
749	Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2606-2614.e4.	2.4	7
750	Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2274-2283.e5.	2.4	95
751	A Network-Based Approach to Explore the Mechanism and Bioactive Compounds of Erzhi Pill against Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-15.	1.0	5
752	NAFLD and cardiovascular diseases: a clinical review. <i>Clinical Research in Cardiology</i> , 2021, 110, 921-937.	1.5	285
753	Effect and mechanism of ginsenoside Rg1-regulating hepatic steatosis in HepG2 cells induced by free fatty acid. <i>Bioscience, Biotechnology and Biochemistry</i> , 2020, 84, 2228-2240.	0.6	12
754	Fish oil and chicoric acid combination protects better against palmitate-induced lipid accumulation via regulating AMPK-mediated SREBP-1/FAS and PPAR α /UCP2 pathways. <i>Archives of Physiology and Biochemistry</i> , 2020, , 1-9.	1.0	10
755	Frequently abnormal serum gamma-glutamyl transferase activity is associated with future development of fatty liver: a retrospective cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 217.	0.8	19
756	NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 60.	1.2	321

#	ARTICLE	IF	CITATIONS
757	Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. <i>Cells</i> , 2020, 9, 1638.	1.8	76
758	Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis. <i>JHEP Reports</i> , 2020, 2, 100081.	2.6	4
759	Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3719-3725.	1.1	1
760	Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. <i>Molecular Metabolism</i> , 2021, 50, 101049.	3.0	42
761	[1,2,5]Oxadiazolo[3,4- <i>b</i>]pyrazine-5,6-diamine Derivatives as Mitochondrial Uncouplers for the Potential Treatment of Nonalcoholic Steatohepatitis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2511-2526.	2.9	26
762	Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view. <i>Journal of Hepatology</i> , 2020, 73, 1507-1525.	1.8	105
763	Cerebral hemodynamics in the non-alcoholic fatty liver. <i>Annals of Hepatology</i> , 2020, 19, 668-673.	0.6	4
764	MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. <i>Liver International</i> , 2020, 40, 2242-2251.	1.9	48
765	Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00134.	1.0	11
766	Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 72, 1556-1568.	3.6	70
767	Neddylation: A Versatile Pathway Takes on Chronic Liver Diseases. <i>Frontiers in Medicine</i> , 2020, 7, 586881.	1.2	17
768	Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis—A multicentre study. <i>EBioMedicine</i> , 2020, 62, 103083.	2.7	10
769	Liver disease in the older child. <i>Journal of Paediatrics and Child Health</i> , 2020, 56, 1702-1707.	0.4	4
770	Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey. <i>BMJ Open</i> , 2020, 10, e039947.	0.8	11
771	Association Between Dietary Fiber Intake and Non-alcoholic Fatty Liver Disease in Adults. <i>Frontiers in Nutrition</i> , 2020, 7, 593735.	1.6	46
772	Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Nutrients</i> , 2020, 12, 3472.	1.7	27
773	NAFLD and liver transplantation: Disease burden, current management and future challenges. <i>JHEP Reports</i> , 2020, 2, 100192.	2.6	96
774	Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020, 12, 3531.	1.7	5

#	ARTICLE	IF	CITATIONS
775	Natural History of Cirrhosis: Changing Trends in Etiology Over the Years. <i>Digestive Diseases</i> , 2021, 39, 358-365.	0.8	10
776	Estimation of the risk of fibrosis in children with nonalcoholic fatty liver disease. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 220-227.	0.6	4
777	A Cohort Study Examining the Interaction of Alcohol Consumption and Obesity in Hepatic Steatosis and Mortality. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2612-2620.	1.4	12
778	Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. <i>Frontiers in Endocrinology</i> , 2020, 11, 597583.	1.5	42
779	The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD—A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2020, 12, 3460.	1.7	28
780	Sarcopenia in chronic liver disease: mechanisms and countermeasures. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G241-G257.	1.6	33
781	Validation of a Non-Laboratory Based Screening Tool for Predicting Non-Alcoholic Fatty Liver Disease in an Egyptian Setting. <i>American Journal of the Medical Sciences</i> , 2020, 360, 662-677.	0.4	7
782	Controlled Attenuation Parameter in Nonalcoholic Fatty Liver Disease: The Thresholds Do Matter. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1507-1508.	2.4	4
783	Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 294-302.	1.9	51
784	The Role of Histone Acetylation-/Methylation-Mediated Apoptotic Gene Regulation in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8894.	1.8	30
785	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. <i>Journal of Clinical Medicine</i> , 2020, 9, 3817.	1.0	27
786	Transient elastography through controlled attenuated parameter assisting the stratification of cardiovascular disease risk in NAFLD patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101580.	0.7	6
787	Tandem Mass Tag-based quantitative proteomics analysis of metabolic associated fatty liver disease induced by high fat diet in mice. <i>Nutrition and Metabolism</i> , 2020, 17, 97.	1.3	7
788	Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis. <i>Biomedicines</i> , 2020, 8, 546.	1.4	2
789	Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 2233-2239.	1.8	9
790	Patterns and predictors of mortality and disease progression among patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1185-1194.	1.9	37
791	SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001956.	1.2	24
792	Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: is there an association?. <i>BMC Family Practice</i> , 2020, 21, 238.	2.9	13

#	ARTICLE	IF	CITATIONS
793	Association of arterial stiffness with the histological severity of nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2020, 14, 1048-1056.	1.9	9
794	Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs. <i>Diagnostics</i> , 2020, 10, 912.	1.3	15
795	An Algorithmic Approach to NAFLD Screening: From PCP to Specialist. <i>ACG Case Reports Journal</i> , 2020, 7, e00473.	0.2	2
796	Predictive Value of Serum Ferritin in Combination with Alanine Aminotransferase and Glucose Levels for Noninvasive Assessment of NAFLD: Fatty Liver in Obesity (FLiO) Study. <i>Diagnostics</i> , 2020, 10, 917.	1.3	5
797	Resistance Exercise Regulates Hepatic Lipolytic Factors as Effective as Aerobic Exercise in Obese Mice. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8307.	1.2	7
798	On the occasion of publication of the feature on diagnosis and assessment of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis using ultrasound elastography. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 507-509.	0.6	0
799	Evaluation of NAFLD and fibrosis in obese patients – a comparison of histological and clinical scoring systems. <i>BMC Gastroenterology</i> , 2020, 20, 254.	0.8	25
800	Multiparametric MR mapping in clinical decision-making for diffuse liver disease. <i>Abdominal Radiology</i> , 2020, 45, 3507-3522.	1.0	30
801	Advances in ultrasound elastography for nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 521-533.	0.6	17
802	Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root. <i>Current Hepatology Reports</i> , 2020, 19, 302-314.	0.4	0
803	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 970-985.	3.7	142
804	Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS/TLR4 and autophagy pathways. <i>European Journal of Pharmacology</i> , 2020, 887, 173461.	1.7	23
805	Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. <i>Gastroenterology</i> , 2020, 159, 1985-1987.e4.	0.6	83
806	Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. <i>Gastroenterology</i> , 2020, 159, 1731-1751.e10.	0.6	49
807	Quercetin supplementation in non-alcoholic fatty liver disease. <i>Nutrition and Food Science</i> , 2020, 50, 1279-1293.	0.4	5
808	What You Should Know About Fatty Liver Disease. <i>ADCES in Practice</i> , 2020, 8, 34-35.	0.2	0
809	Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154318.	1.5	28
810	Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis. <i>Journal of Neuroimaging</i> , 2020, 30, 697-703.	1.0	3

#	ARTICLE	IF	CITATIONS
811	Dietary consumption and serum pattern of bioactive fatty acids in NAFLD patients. <i>Annals of Hepatology</i> , 2020, 19, 482-488.	0.6	6
812	The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154320.	1.5	68
813	Visceral adiposity and liver fat as mediators of the association between cardiorespiratory fitness and plasma glucose-insulin homeostasis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 319, E548-E556.	1.8	10
814	Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer. <i>PLoS ONE</i> , 2020, 15, e0236506.	1.1	18
815	Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development. <i>PLoS ONE</i> , 2020, 15, e0236353.	1.1	12
816	Adoptive Cell Transfer of Regulatory T Cells Exacerbates Hepatic Steatosis in High-Fat High-Fructose Diet-Fed Mice. <i>Frontiers in Immunology</i> , 2020, 11, 1711.	2.2	19
817	Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016. <i>Diabetes Research and Clinical Practice</i> , 2020, 167, 108358.	1.1	19
818	Non-alcoholic fatty liver disease and chronic kidney disease: renal benefit with liver stiffness assessment?. <i>Diabetes and Metabolism</i> , 2020, 46, 259-260.	1.4	0
819	Nature or Nurture? The Answer Is "Both" in Nonalcoholic Steatohepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 641-642.	2.3	0
820	Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents. <i>JHEP Reports</i> , 2020, 2, 100150.	2.6	20
821	Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease. <i>Alcohol</i> , 2020, 89, 1-7.	0.8	15
822	Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 251-260.	1.0	10
823	Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH. <i>Nucleic Acids Research</i> , 2020, 48, 8255-8268.	6.5	23
824	Liver disease. , 2020, , 483-502.		1
825	Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. <i>EClinicalMedicine</i> , 2020, 25, 100445.	3.2	15
827	Impact of Nonalcoholic Fatty Liver Disease on Arrhythmia Recurrence Following Atrial Fibrillation Ablation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1278-1287.	1.3	15
828	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2020, 10, 579.	1.3	21
829	Transfer Learning versus Custom CNN Architectures in NAFLD Biopsy Images. , 2020, , .		7

#	ARTICLE	IF	CITATIONS
831	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2161-2171.e5.	2.4	119
832	Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3604-3611.	1.1	30
833	Soy Food Intake Is Inversely Associated with Newly Diagnosed Nonalcoholic Fatty Liver Disease in the TCLSIH Cohort Study. <i>Journal of Nutrition</i> , 2020, 150, 3280-3287.	1.3	13
834	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: <i>Standards of Medical Care in Diabetes”2020</i>. <i>Diabetes Care</i> , 2020, 43, S37-S47.	4.3	169
835	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 511-520.	0.6	20
836	Chinese Medicinal Herbs Targeting the Gut“Liver Axis and Adipose Tissue“Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science. <i>Frontiers in Endocrinology</i> , 2020, 11, 572729.	1.5	15
837	The regulatory state of nonalcoholic steatohepatitis and metabolism. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00113.	1.0	4
838	Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1913-1919.	1.8	9
839	Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107706.	1.2	3
840	Efficacy and Mechanism of a Chinese Classic Prescription of Yueju in Treating Nonalcoholic Steatohepatitis and Protecting Hepatocytes from Apoptosis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-12.	0.5	3
841	Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 535-548.	0.6	9
842	Prophylactic and therapeutic effects of different doses of vitamin C on high-fat-diet-induced non-alcoholic fatty liver disease in mice. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110792.	2.5	20
843	Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. <i>Aids</i> , 2020, 34, 1915-1921.	1.0	11
844	Providing Care for Fatty Liver Disease Patients. <i>Gastroenterology Nursing</i> , 2020, 43, E184-E189.	0.2	4
845	Optimizing patients with non-alcoholic fatty liver disease pre-transplant. <i>Canadian Liver Journal</i> , 2020, 3, 237-250.	0.3	1
846	Involvement of the Autophagy-ER Stress Axis in High Fat/Carbohydrate Diet-Induced Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020, 12, 2626.	1.7	14
847	Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes. <i>Pharmaceuticals</i> , 2020, 13, 222.	1.7	23
848	Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study. <i>PLoS ONE</i> , 2020, 15, e0237360.	1.1	6

#	ARTICLE	IF	CITATIONS
849	An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials. <i>Diagnostics</i> , 2020, 10, 643.	1.3	12
850	Nonalcoholic Steatohepatitisâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 899.	3.8	4
851	Hepatocellular carcinoma in young morbid obese patients with non-alcoholic fatty liver disease. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 1289-1296.	0.4	1
852	Nonâ€”alcoholic fatty liver disease (NAFLD) in Asiaâ€”More efforts are needed. <i>Liver International</i> , 2020, 40, 3144-3144.	1.9	1
853	Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imagingâ€”determined proton density fat fraction. <i>Hepatology Research</i> , 2020, 50, 1319-1327.	1.8	29
854	Hepatitis C Testing and Liver Fibrosis Predictors in the Birth Cohort of a Primary Care Practice. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 384-390.	1.2	1
855	Effects of Dietary and Lifestyle Interventions on Liver, Clinical and Metabolic Parameters in Children and Adolescents with Non-Alcoholic Fatty Liver Disease: A Systematic Review. <i>Nutrients</i> , 2020, 12, 2864.	1.7	18
856	Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output. <i>Cell</i> , 2020, 183, 76-93.e22.	13.5	237
857	Effects of obesity reduction on transient elastographyâ€”based parameters in pediatric non-alcoholic fatty liver disease. <i>Obesity Research and Clinical Practice</i> , 2020, 14, 473-478.	0.8	10
858	Nonalcoholic Fatty Liver Disease: Making the Diagnosis. <i>Clinical Liver Disease</i> , 2020, 16, 53-57.	1.0	2
859	Surgical menopause may not increase the risk of nonâ€”alcoholic fatty liver disease. <i>GastroHep</i> , 2020, 2, 240-246.	0.3	0
860	Difference in lifestyle and metabolic profile of non-alcoholic fatty liver disease with raised alanine amino-transferases between obese and non-overweight subjects. <i>Scientific Reports</i> , 2020, 10, 15232.	1.6	5
861	Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00177.	1.0	10
862	Nonalcoholic Fatty Liver Disease Impairs the Liverâ€”Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis. <i>Hepatology Communications</i> , 2020, 4, 1610-1623.	2.0	22
863	Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. <i>Journal of Clinical Medicine</i> , 2020, 9, 2648.	1.0	93
864	Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. <i>PLoS ONE</i> , 2020, 15, e0237430.	1.1	15
865	Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5927.	1.8	31
866	Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 710-711.	1.9	3

#	ARTICLE	IF	CITATIONS
867	The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). <i>Journal of Diabetes Research</i> , 2020, 2020, 1-16.	1.0	196
868	Usefulness of Different Imaging Modalities in Evaluation of Patients with Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2020, 8, 298.	1.4	12
869	NAFLD and Statins. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3052-3053.	1.1	2
870	Identification of CYP46A1 as a new regulator of lipid metabolism through CRISPR-based whole-genome screening. <i>FASEB Journal</i> , 2020, 34, 13776-13791.	0.2	8
871	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2719-2731.	1.9	32
872	Si-Wu-Tang Alleviates Nonalcoholic Fatty Liver Disease via Blocking TLR4-JNK and Caspase-8-GSDMD Signaling Pathways. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-11.	0.5	5
873	Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3496-3504.	1.8	25
874	Nonalcoholic fatty liver disease and type 2 diabetes: a burgeoning problem with unclear solutions. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 514-517.	0.7	2
875	Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data. <i>Hepatic Medicine: Evidence and Research</i> , 2020, Volume 12, 115-123.	0.9	13
876	Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study. <i>Hepatology Research</i> , 2020, 50, 1328-1336.	1.8	23
877	The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2020, 4, 1302-1315.	2.0	13
878	Predicting Nonalcoholic Fatty Liver Disease through a Panel of Plasma Biomarkers and MicroRNAs in Female West Virginia Population. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6698.	1.8	21
879	Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. <i>Life</i> , 2020, 10, 198.	1.1	11
880	Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study. <i>Journal of NeuroVirology</i> , 2020, 26, 870-879.	1.0	15
882	Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with suspected non-alcoholic fatty liver disease. <i>The Cochrane Library</i> , 0, , .	1.5	2
883	Differential Outcomes and Clinical Challenges of NAFLD With Extreme Obesity. <i>Hepatology Communications</i> , 2020, 4, 1419-1429.	2.0	5
884	High-Risk Groups for Non-alcoholic Fatty Liver and Non-alcoholic Steatohepatitis Development and Progression. <i>Current Hepatology Reports</i> , 2020, 19, 412-419.	0.4	4
885	Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap. <i>Current Hepatology Reports</i> , 2020, 19, 382-390.	0.4	0

#	ARTICLE	IF	CITATIONS
886	Dietary Intervention Accelerates NASH Resolution Depending on Inflammatory Status with Minor Additive Effects on Hepatic Injury by Vitamin E Supplementation. <i>Antioxidants</i> , 2020, 9, 808.	2.2	6
887	A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD. <i>Obesity</i> , 2020, 28, 1843-1852.	1.5	68
888	Fatty Liver Disease: Metabolic, Genetic, or Both?. <i>Hepatology Communications</i> , 2020, 4, 1239-1241.	2.0	0
889	Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows. <i>Seminars in Liver Disease</i> , 2020, 40, 339-345.	1.8	1
890	Vacuole Segmentation and Quantification in Liver Images of Wistar Rat. , 2020, 2020, 1396-1399.		1
891	Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease. <i>Medicine (United States)</i> , 2020, 99, e21463.	0.4	3
892	New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. <i>Nutrients</i> , 2020, 12, 2762.	1.7	89
893	Exercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2020, 19, 402-411.	0.4	28
894	Racial Disparities in Diagnosis and Prognosis of Nonalcoholic Fatty Liver Disease. <i>Clinical Liver Disease</i> , 2020, 16, 66-72.	1.0	26
895	Estimates of the global reduction in liver disease-related mortality with increased coffee consumption: an analysis of the Global Burden of Disease Dataset. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1195-1203.	1.9	4
896	<p></p>Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 107-116.	1.8	10
898	Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease. <i>Current Gastroenterology Reports</i> , 2020, 22, 52.	1.1	8
899	Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 1141-1157.	1.4	16
900	Lumican in Obese Patients with Nonalcoholic Fatty Liver Disease With or Without Prediabetes. <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 443-448.	0.5	2
901	<p></p>Identifying High-Risk NASH Patients: What We Know so Far</p>. <i>Hepatic Medicine: Evidence and Research</i> , 2020, Volume 12, 125-138.	0.9	18
902	Regulating metabolic inflammation by nutritional modulation. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 706-720.	1.5	42
903	Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. <i>PLoS ONE</i> , 2020, 15, e0236977.	1.1	29
904	Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3842-3853.	1.8	76

#	ARTICLE	IF	CITATIONS
905	History of Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5888.	1.8	74
906	Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease Worsen the Outcome in Acute Pancreatitis: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2698.	1.0	16
907	Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. <i>Cell and Bioscience</i> , 2020, 10, 140.	2.1	26
908	FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. <i>Frontiers in Endocrinology</i> , 2020, 11, 601290.	1.5	111
909	New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. <i>Frontiers in Pediatrics</i> , 2020, 8, 603654.	0.9	23
910	Automated quantification of fibrosis-related parameters using dual-photon microscopy replace diagnosis of pathologists in NAFLD. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 815-816.	0.7	0
911	Nutritional Approaches for the Management of Nonalcoholic Fatty Liver Disease: An Evidence-Based Review. <i>Nutrients</i> , 2020, 12, 3860.	1.7	35
912	Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient. <i>Current Transplantation Reports</i> , 2020, 7, 332-339.	0.9	0
913	Toxic AGEs (TAGE) theory: a new concept for preventing the development of diseases related to lifestyle. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 105.	1.2	28
914	Deregulated Serotonin Pathway in Women with Morbid Obesity and NAFLD. <i>Life</i> , 2020, 10, 245.	1.1	10
915	Cardiovascular risk, Metabolic disease and NASH control for Health Empowerment: Future endeavours. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2020, 32, 206-208.	0.4	1
916	Brown-Algae Polysaccharides as Active Constituents against Nonalcoholic Fatty Liver Disease. <i>Planta Medica</i> , 2022, 88, 9-19.	0.7	15
917	Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882095829.	1.4	17
918	Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2020, 20, 368.	0.8	7
919	DNA Methylation in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8138.	1.8	63
920	Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT. <i>BMC Gastroenterology</i> , 2020, 20, 362.	0.8	1
921	Perspectives on youth-onset nonalcoholic fatty liver disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00184.	1.0	26
922	Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus?. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 239-241.	0.7	9

#	ARTICLE	IF	CITATIONS
923	Oral Recombinant Methioninase Prevents Nonalcoholic Fatty Liver Disease in Mice on a High Fat Diet. <i>In Vivo</i> , 2020, 34, 979-984.	0.6	7
924	Lipid and energy metabolism in Wilson disease. <i>Liver Research</i> , 2020, 4, 5-14.	0.5	17
925	MRI-determined liver fat correlates with risk of metabolic syndrome in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 754-761.	0.8	8
926	The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates. <i>Diabetes</i> , 2020, 69, 1611-1623.	0.3	32
927	Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 739-752.	3.7	481
928	La stÃ©atopathie dysmÃ©tabolique ou NASH: faut-il dÃ©pister les patients Ã haut risque atteints de diabÃ©te de type 2? Nutrition Clinique Et Metabolisme, 2020, 34, 122-129.	0.2	0
929	Ezetimibe Markedly Reduces Hepatic Triglycerides and Cholesterol in Rats Fed on Fish Oil by Increasing the Expression of Cholesterol Efflux Transporters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 374, 175-183.	1.3	11
930	Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. <i>CMAJ Open</i> , 2020, 8, E370-E376.	1.1	20
931	The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods. <i>BioMed Research International</i> , 2020, 2020, 1-7.	0.9	18
932	Hepatic steatosis among people living with HIV in Southern Brazil: prevalence and risk factors. <i>Scientific Reports</i> , 2020, 10, 8282.	1.6	5
933	Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1200-1201.	1.9	0
934	<p>Changes in Serum Nesfatin-1 After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Nonalcoholic Fatty Liver Disease</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 1459-1464.	1.1	4
935	Changed Amino Acids in NAFLD and Liver Fibrosis: A Large Cross-Sectional Study without Influence of Insulin Resistance. <i>Nutrients</i> , 2020, 12, 1450.	1.7	35
936	Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD. <i>Nutrients</i> , 2020, 12, 1316.	1.7	40
937	An Update on the Role of the Microbiome in Non-alcoholic Fatty Liver Disease Pathogenesis, Diagnosis, and Treatment. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 270-280.	0.3	8
938	New aspects of hepatic endothelial cells in physiology and nonalcoholic fatty liver disease. <i>American Journal of Physiology - Cell Physiology</i> , 2020, 318, C1200-C1213.	2.1	27
939	Protective Mechanism of Common Buckwheat (<i>Fagopyrum esculentum</i> Moench.) against Nonalcoholic Fatty Liver Disease Associated with Dyslipidemia in Mice Fed a High-Fat and High-Cholesterol Diet. <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 6530-6543.	2.4	27
940	Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. <i>Gut</i> , 2020, 69, 1877-1884.	6.1	127

#	ARTICLE	IF	CITATIONS
941	Applications and Limitations of Noninvasive Methods for Evaluating Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Liver Disease</i> , 2020, 15, 157-161.	1.0	4
942	Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. <i>Journal of Hepatology</i> , 2020, 73, 896-905.	1.8	119
943	Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. <i>Scientific Reports</i> , 2020, 10, 7440.	1.6	8
944	Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles. <i>Journal of Digestive Diseases</i> , 2020, 21, 372-384.	0.7	34
945	Interface Hepatitis over Grade 2 May Differentiate Chronic Inflammation Associated with CHB from NAFLD in the Early Stage. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-7.	0.7	1
946	6-Amino[1,2,5]oxadiazolo[3,4- <i>b</i>]pyrazin-5-ol Derivatives as Efficacious Mitochondrial Uncouplers in STAM Mouse Model of Nonalcoholic Steatohepatitis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6203-6224.	2.9	13
947	Impact of hepatic steatosis on treatment response in nucleos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. <i>BMC Gastroenterology</i> , 2020, 20, 146.	0.8	14
948	Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1635.	1.0	11
949	Glycyrrhetic acid attenuates disturbed vitamin a metabolism in non-alcoholic fatty liver disease through AKR1B10. <i>European Journal of Pharmacology</i> , 2020, 883, 173167.	1.7	11
950	Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154259.	1.5	42
951	Tissue fat quantification by magnetic resonance imaging: proton density fat fraction in polycystic ovary syndrome. <i>Reproductive BioMedicine Online</i> , 2020, 41, 329-334.	1.1	7
952	Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1149-1159.	1.9	101
954	Cathepsin B deficiency ameliorates liver lipid deposition, inflammatory cell infiltration, and fibrosis after diet-induced nonalcoholic steatohepatitis. <i>Translational Research</i> , 2020, 222, 28-40.	2.2	18
955	Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection. <i>Scientific Reports</i> , 2020, 10, 6736.	1.6	4
956	Hepatic steatosis is associated with abnormal hepatic enzymes, visceral adiposity, altered myocardial glucose uptake measured by 18F-FDG PET/CT. <i>BMC Endocrine Disorders</i> , 2020, 20, 75.	0.9	7
957	Bariatric surgery before, during, and after liver transplantation: a systematic review and meta-analysis. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 1336-1347.	1.0	20
958	Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: Study protocol for a multicenter randomized controlled trial. <i>Trials</i> , 2020, 21, 512.	0.7	15
959	Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?. <i>Clinical Diabetes and Endocrinology</i> , 2020, 6, 9.	1.3	60

#	ARTICLE	IF	CITATIONS
960	Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4039.	1.8	35
961	Correlation between Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease before and after Metabolic Bariatric Surgery. <i>Obesity Surgery</i> , 2020, 30, 3803-3812.	1.1	4
962	Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 81.	2.7	23
964	Decreased Quality of Life Is Significantly Associated With Body Composition in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2980-2988.e4.	2.4	19
965	Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154291.	1.5	20
966	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.	1.8	38
967	Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1637-1649.	0.9	42
968	Metabolic liver disease in diabetes – From mechanisms to clinical trials. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154299.	1.5	90
969	Effect of TSH on Non-Alcoholic Fatty Liver Disease (NAFLD) independent of obesity in children of predominantly Hispanic/Latino ancestry by causal mediation analysis. <i>PLoS ONE</i> , 2020, 15, e0234985.	1.1	5
970	The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3863.	1.8	118
971	Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis. <i>PLoS ONE</i> , 2020, 15, e0234038.	1.1	26
972	Relevance of SIRT1-NF- κ B Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3858.	1.8	90
973	Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. <i>Pharmacological Research</i> , 2020, 159, 104984.	3.1	26
974	Effect of Helicobacter pylori-eradication therapy on hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomized-controlled pilot study. <i>Gastroenterology Report</i> , 2020, 8, 104-110.	0.6	10
975	Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 503-511.	1.1	10
976	Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-9.	0.8	4
977	Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1476-1482.	0.8	16
978	Exercise Training Rapidly Increases Hepatic Insulin Extraction in NAFLD. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 1449-1455.	0.2	9

#	ARTICLE	IF	CITATIONS
979	Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00163.	1.0	34
980	Hepatocellular Carcinoma in a Patient With Hepatic Steatosis. <i>ACG Case Reports Journal</i> , 2020, 7, e00378.	0.2	0
981	Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?. <i>Hepatology</i> , 2020, 72, 794-796.	3.6	7
982	Non-alcoholic fatty liver disease (NAFLD) diagnosis and management—differentiating the essential from the ancillary and the present from the future. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 374-378.	0.7	6
983	Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 401.	1.8	126
984	APOC3 rs2854116 , PNPLA3 rs738409, and TM6SF2 rs58542926 polymorphisms might influence predisposition of NAFLD : A meta-analysis. <i>IUBMB Life</i> , 2020, 72, 1757-1764.	1.5	7
985	Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. <i>Journal of Hepatology</i> , 2020, 73, 516-522.	1.8	78
986	Treatment of Non-Alcoholic Steatosis: Preclinical Study of a New Nutraceutical Multitarget Formulation. <i>Nutrients</i> , 2020, 12, 1819.	1.7	2
987	Effects of low ethanol consumption on nonalcoholic steatohepatitis in mice. <i>Alcohol</i> , 2020, 87, 51-61.	0.8	2
988	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1907.	1.8	42
989	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan. <i>Diagnostics</i> , 2020, 10, 159.	1.3	31
990	Occurrence and clinical management of nonalcoholic fatty liver disease in obesity patients: a literature review. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2020, 33, 579-584.	0.4	7
991	Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 10-10.	1.5	8
992	Nonalcoholic Fatty Liver Disease. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	0.9	6
993	Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part II. <i>Current Urology Reports</i> , 2020, 21, 15.	1.0	3
994	Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. <i>Journal of Internal Medicine</i> , 2020, 287, 711-722.	2.7	50
995	Targeting ferroptosis alleviates methionine-choline deficient (MCD) diet induced NASH by suppressing liver lipotoxicity. <i>Liver International</i> , 2020, 40, 1378-1394.	1.9	135
996	A Potential Linking between Vitamin D and Adipose Metabolic Disorders. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-9.	0.8	17

#	ARTICLE	IF	CITATIONS
997	Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. <i>Free Radical Biology and Medicine</i> , 2020, 152, 116-141.	1.3	574
998	Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. <i>Journal of Hepatology</i> , 2020, 73, 263-276.	1.8	137
999	Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154203.	1.5	88
1000	Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease. <i>Journal of General Internal Medicine</i> , 2020, 35, 1523-1529.	1.3	5
1001	Performance of Noninvasive Liver Fibrosis Scores in the Morbid Obese Patient, Same Scores but Different Thresholds. <i>Obesity Surgery</i> , 2020, 30, 2538-2546.	1.1	13
1002	Overweight and obesity status from the prenatal period to adolescence and its association with non-alcoholic fatty liver disease in young adults: cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1200-1209.	1.1	10
1003	Treatment of non-alcoholic fatty liver disease – Current perspectives. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 22-31.	0.7	18
1004	Non-linear association of serum molybdenum and linear association of serum zinc with nonalcoholic fatty liver disease: Multiple-exposure and Mendelian randomization approach. <i>Science of the Total Environment</i> , 2020, 720, 137655.	3.9	18
1005	Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. <i>Gastroenterology</i> , 2020, 158, 1967-1983.e1.	0.6	75
1006	Cholecystectomy does not worsen progression or outcomes in non-alcoholic fatty liver disease. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 3-3.	1.5	5
1007	Nonalcoholic Steatohepatitis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1175.	3.8	784
1008	Fatty liver as a radiological incidental finding in the emergency department: An opportunity to lessen a growing burden on the health care system. <i>EMA - Emergency Medicine Australasia</i> , 2020, 32, 528-529.	0.5	0
1009	Obeticholic acid for the treatment of nonalcoholic steatohepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 311-321.	1.4	30
1010	Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey. <i>Diabetes Care</i> , 2020, 43, 1227-1233.	4.3	51
1011	Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3238-3243.	1.1	11
1012	Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 28-34.	0.6	0
1013	Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1818.	1.2	42
1014	Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease in Obese Patients Undergoing Bariatric Surgery. <i>Obesity Surgery</i> , 2020, 30, 2572-2578.	1.1	14

#	ARTICLE	IF	CITATIONS
1015	Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1960-1968.	1.4	13
1016	Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. <i>Journal of Gastroenterology</i> , 2020, 55, 701-711.	2.3	16
1017	Are Noninvasive Methods Comparable to Liver Biopsy in Postoperative Patients After Roux-en-Y Gastric Bypass?. <i>Obesity Surgery</i> , 2020, 30, 2566-2571.	1.1	4
1018	Antitumour necrosis factor- α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000349.	1.1	23
1019	Bisphenol-A exposure worsens hepatic steatosis in ovariectomized mice fed on a high-fat diet: Role of endoplasmic reticulum stress and fibrogenic pathways. <i>Life Sciences</i> , 2020, 256, 118012.	2.0	33
1020	Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. <i>Hypertension</i> , 2020, 76, 562-568.	1.3	39
1021	Metformin Ameliorates Testicular Function and Spermatogenesis in Male Mice with High-Fat and High-Cholesterol Diet-Induced Obesity. <i>Nutrients</i> , 2020, 12, 1932.	1.7	21
1022	Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. <i>Current Hepatology Reports</i> , 2020, 19, 315-326.	0.4	11
1023	Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 513-526.	1.9	66
1024	The hepatic lipidome: From basic science to clinical translation. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 180-197.	6.6	37
1025	Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. <i>American Journal of Gastroenterology</i> , 2020, 115, 1007-1018.	0.2	3
1026	Pro-inflammatory HDL in women with obesity and nonalcoholic steatohepatitis. <i>Obesity Research and Clinical Practice</i> , 2020, 14, 333-338.	0.8	3
1027	Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1055-1065.	0.2	177
1028	Risk Prediction for Non-alcoholic Fatty Liver Disease Based on Biochemical and Dietary Variables in a Chinese Han Population. <i>Frontiers in Public Health</i> , 2020, 8, 220.	1.3	11
1029	Ganoderic acid A from <i>Ganoderma lucidum</i> ameliorates lipid metabolism and alters gut microbiota composition in hyperlipidemic mice fed a high-fat diet. <i>Food and Function</i> , 2020, 11, 6818-6833.	2.1	54
1030	Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 36-36.	1.5	5
1031	Efficacy and safety of incretin-based therapies in patients with nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2020, 99, e20695.	0.4	0
1032	Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population. <i>Annals of Hepatology</i> , 2020, 19, 251-257.	0.6	20

#	ARTICLE	IF	CITATIONS
1033	Global epidemiology of lean nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2041-2050.	1.4	67
1034	Epidemiology, Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4337.	1.8	21
1035	High risk of colorectal polyps in men with nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2051-2065.	1.4	11
1036	Role of Androgen in Liver Fat Content in Women: Metabolically Advantageous or Disadvantageous?. <i>Endocrine Practice</i> , 2020, 26, 1003-1016.	1.1	5
1037	Imaging and immunometabolic phenotyping uncover changes in the hepatic immune response in the early phases of NAFLD. <i>JHEP Reports</i> , 2020, 2, 100117.	2.6	10
1038	SHP-1 ameliorates nonalcoholic steatohepatitis by inhibiting proinflammatory cytokine production. <i>FEBS Letters</i> , 2020, 594, 2965-2974.	1.3	12
1039	Spotlight on Impactful Research: Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study. <i>Clinical Liver Disease</i> , 2020, 15, 213-214.	1.0	1
1040	Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 527-547.	1.0	5
1041	Bariatric Surgery is Associated With Decreased Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis. <i>Annals of Surgery</i> , 2020, 272, 32-39.	2.1	40
1042	Review article: prognostic significance of body composition abnormalities in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 600-618.	1.9	45
1043	Mechanisms, screening modalities and treatment options for individuals with nonalcoholic fatty liver disease and type 2 diabetes. <i>Diabetic Medicine</i> , 2020, 37, 1793-1806.	1.2	9
1044	Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 829-838.	3.7	61
1045	Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. <i>SAGE Open Medicine</i> , 2020, 8, 205031212093380.	0.7	12
1046	Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score. <i>Hepatology Communications</i> , 2020, 4, 998-1011.	2.0	7
1047	5-Lipoxygenase Derivatives as Serum Biomarkers of a Successful Dietary Intervention in Patients with NonAlcoholic Fatty Liver Disease. <i>Medicina (Lithuania)</i> , 2020, 56, 58.	0.8	4
1048	The Emerging Epidemic of Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: True, True, and Related?. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1885-1887.	1.1	4
1049	Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 31-31.	1.5	25
1050	Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and noninvasive tests for the diagnosis of advanced liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2020, 50, 682-692.	1.8	32

#	ARTICLE	IF	CITATIONS
1051	The metabolic basis of nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00112.	1.0	64
1052	The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus. <i>Cells</i> , 2020, 9, 481.	1.8	15
1053	Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1525.	1.8	66
1054	Increased Colonic Permeability and Lifestyles as Contributing Factors to Obesity and Liver Steatosis. <i>Nutrients</i> , 2020, 12, 564.	1.7	32
1055	The Patatin-Like Phospholipase Domain Containing Protein 7 Facilitates VLDL Secretion by Modulating ApoE Stability. <i>Hepatology</i> , 2020, 72, 1569-1585.	3.6	19
1056	Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2020, 10, 2565.	1.6	63
1057	Editorial: choosing an appropriate risk stratification tool for nonalcoholic fatty liver disease—“one size does not fit all. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 661-662.	1.9	1
1058	Fatty Liver Disease: Artificial Intelligence Takes on the Challenge. <i>Radiology</i> , 2020, 295, 351-352.	3.6	4
1059	Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients. <i>Metabolism Open</i> , 2020, 5, 100028.	1.4	8
1060	Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. <i>JGH Open</i> , 2020, 4, 497-502.	0.7	22
1061	HAV and HBV vaccination rates among biopsy-confirmed NAFL patients in a free access medical system: How can we improve?. <i>GastroHep</i> , 2020, 2, 31-38.	0.3	0
1063	Rotating night shift work and non-alcoholic fatty liver disease among steelworkers in China: a cross-sectional survey. <i>Occupational and Environmental Medicine</i> , 2020, 77, 333-339.	1.3	31
1064	Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 926.	1.5	9
1065	Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 1279-1301.	1.3	206
1066	Hepatic CD147 knockout modulates liver steatosis and up-regulates autophagy in high-fat-diet-induced NAFLD mice. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 1010-1017.	1.0	9
1067	Development and Validation of a Scoring System, Based on Genetic and Clinical Factors, to Determine Risk of Steatohepatitis in Asian Patients with Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2592-2599.e10.	2.4	32
1068	Nonalcoholic fatty liver disease. <i>Nursing</i> , 2020, 50, 32-39.	0.2	1
1069	Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1094-1101.	2.2	28

#	ARTICLE	IF	CITATIONS
1070	A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. <i>Liver International</i> , 2020, 40, 82-88.	1.9	36
1071	Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p/FGF21 axis. <i>BMC Gastroenterology</i> , 2020, 20, 39.	0.8	28
1072	Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2020, 21, 50.	0.8	8
1073	Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 19-19.	1.5	53
1074	Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 25-44.	1.0	21
1075	Critical Role of microRNA-21 in the Pathogenesis of Liver Diseases. <i>Frontiers in Medicine</i> , 2020, 7, 7.	1.2	95
1076	Burden of Disease due to Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 1-23.	1.0	53
1077	Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 105-121.	1.0	4
1078	Management of nonalcoholic fatty liver disease and the role of bariatric surgery: a brief review for surgeons. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 699-703.	1.0	4
1079	Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions. <i>Seminars in Liver Disease</i> , 2020, 40, 154-162.	1.8	41
1080	Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. <i>Circulation Research</i> , 2020, 126, 679-704.	2.0	121
1081	Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. <i>Frontiers in Endocrinology</i> , 2020, 11, 70.	1.5	29
1083	Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. <i>Hepatology</i> , 2020, 72, 58-71.	3.6	209
1084	Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165753.	1.8	31
1085	A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. <i>JHEP Reports</i> , 2020, 2, 100064.	2.6	29
1086	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.6	1,840
1087	Epidemiology of non-alcoholic and alcoholic fatty liver diseases. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 16-16.	1.5	296
1088	Alterations in the Liver Fat Fraction Features Examined by Magnetic Resonance Imaging Following Bariatric Surgery: a Self-Controlled Observational Study. <i>Obesity Surgery</i> , 2020, 30, 1917-1928.	1.1	7

#	ARTICLE	IF	CITATIONS
1089	Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. <i>Gastroenterology</i> , 2020, 158, 1851-1864.	0.6	710
1090	NAFLD and autoimmune hepatitis: Do not judge a book by its cover. <i>European Journal of Internal Medicine</i> , 2020, 75, 1-9.	1.0	26
1091	Therapeutic Landscape for NAFLD in 2020. <i>Gastroenterology</i> , 2020, 158, 1984-1998.e3.	0.6	136
1092	Acupoint embedding therapy improves nonalcoholic fatty liver disease with abnormal transaminase. <i>Medicine (United States)</i> , 2020, 99, e18775.	0.4	4
1093	New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. <i>Hepatology</i> , 2020, 71, 1831-1844.	3.6	16
1094	Challenges and opportunities in drug development for nonalcoholic steatohepatitis. <i>European Journal of Pharmacology</i> , 2020, 870, 172913.	1.7	12
1095	Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. <i>Metabolism: Clinical and Experimental</i> , 2020, 104, 154144.	1.5	30
1096	Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3868-3880.	2.9	65
1097	Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease. <i>American Journal of Roentgenology</i> , 2020, 214, 786-791.	1.0	20
1098	Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100516.	0.5	11
1099	Limitations of non-invasive tests for assessment of liver fibrosis. <i>JHEP Reports</i> , 2020, 2, 100067.	2.6	133
1100	Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 275-279.	4.3	49
1101	Decreased PEDF Promotes Hepatic Fatty Acid Uptake and Lipid Droplet Formation in the Pathogenesis of NAFLD. <i>Nutrients</i> , 2020, 12, 270.	1.7	7
1102	Nonalcoholic steatohepatitis recurrence after liver transplant. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 24-24.	1.5	22
1103	Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project. <i>Hepatology</i> , 2020, 71, 1106-1116.	3.6	22
1104	OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions. <i>Obesity Facts</i> , 2020, 13, 1-28.	1.6	15
1105	PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 1020-1026.	1.0	32
1106	Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity. <i>Scientific Reports</i> , 2020, 10, 1025.	1.6	9

#	ARTICLE	IF	CITATIONS
1107	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , 2020, 72, 1230-1241.	3.6	59
1108	Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). <i>BMJ Open Gastroenterology</i> , 2020, 7, e000341.	1.1	18
1109	Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis. <i>Cancers</i> , 2020, 12, 286.	1.7	5
1110	Indole Alleviates Diet-Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6-Phosphofructo-2,6-Biphosphatase 3. <i>Hepatology</i> , 2020, 72, 1191-1203.	3.6	67
1111	Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. <i>Molecular Metabolism</i> , 2020, 34, 16-26.	3.0	19
1112	Hesperidin improves insulin resistance via down-regulation of inflammatory responses: Biochemical analysis and in silico validation. <i>PLoS ONE</i> , 2020, 15, e0227637.	1.1	20
1113	Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3292.	1.7	68
1114	Multicenter Validation of Association Between Decline in MRI-PDF and Histologic Response in NASH. <i>Hepatology</i> , 2020, 72, 1219-1229.	3.6	79
1115	NRF-2 and nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2020, 19, 458-465.	0.6	20
1116	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1651-1652.	2.4	1
1117	Fatty liver in pregnancy: a narrative review of two distinct conditions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 127-135.	1.4	17
1119	Epidemiological Features of NAFLD From 1999 to 2018 in China. <i>Hepatology</i> , 2020, 71, 1851-1864.	3.6	341
1120	Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart. <i>Hepatology</i> , 2020, 71, 1867-1869.	3.6	12
1121	Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1019-1026.	1.8	13
1122	Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?. <i>American Journal of Medicine</i> , 2020, 133, 536-543.	0.6	43
1123	Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2073-2080.e7.	2.4	29
1124	Complications, morbidity and mortality of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154170.	1.5	278
1125	AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. <i>Gastroenterology</i> , 2020, 158, 1822-1830.	0.6	202

#	ARTICLE	IF	CITATIONS
1127	Lower eGFR is associated with increased probability of liver fibrosis in Chinese diabetic patients. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3294.	1.7	4
1128	Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. <i>Hepatology</i> , 2020, 72, 1242-1252.	3.6	47
1129	The association of serum total bile acid with non-alcoholic fatty liver disease in Chinese adults: a cross sectional study. <i>Lipids in Health and Disease</i> , 2020, 19, 18.	1.2	11
1130	Role of Exercise in Mitigating Pediatric Nonalcoholic Fatty Liver Disease. <i>Diabetes Care</i> , 2020, 43, 280-282.	4.3	1
1131	Angiotensin-II-Evoked Ca ²⁺ Entry in Murine Cardiac Fibroblasts Does Not Depend on TRPC Channels. <i>Cells</i> , 2020, 9, 322.	1.8	12
1132	Childhood obesity, cardiovascular and liver health: a growing epidemic with age. <i>World Journal of Pediatrics</i> , 2020, 16, 438-445.	0.8	48
1133	Bile Acid Changes Associated With Liver Fibrosis and Steatosis in the Mexican-American Population of South Texas. <i>Hepatology Communications</i> , 2020, 4, 555-568.	2.0	26
1134	Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach. <i>Metabolites</i> , 2020, 10, 168.	1.3	26
1135	Association of the SH2B1 rs7359397 Gene Polymorphism with Steatosis Severity in Subjects with Obesity and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020, 12, 1260.	1.7	11
1136	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. <i>PLoS Medicine</i> , 2020, 17, e1003100.	3.9	205
1137	Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3089.	1.8	7
1138	Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. <i>BMC Gastroenterology</i> , 2020, 20, 88.	0.8	25
1139	Modulation of SIRT1-mediated signaling cascades in the liver contributes to the amelioration of nonalcoholic steatohepatitis in high fat fed middle-aged LDL receptor knockout mice by dihydromyricetin. <i>Biochemical Pharmacology</i> , 2020, 175, 113927.	2.0	29
1140	Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 222, 787-797.	1.9	12
1141	Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease. <i>Atherosclerosis</i> , 2020, 299, 38-44.	0.4	18
1142	Familial non-alcoholic steatohepatitis leading to hepatocellular carcinoma. <i>Chemico-Biological Interactions</i> , 2020, 323, 109054.	1.7	2
1143	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2020, 73, 252-262.	1.8	170
1144	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171

#	ARTICLE	IF	CITATIONS
1145	TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. <i>Cell Death and Disease</i> , 2020, 11, 212.	2.7	90
1146	Current and new pharmacotherapy options for non-alcoholic steatohepatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 953-967.	0.9	28
1147	Survey on screening for paediatric non-alcoholic fatty liver disease in clinical practice in Dutch hospitals. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 2388-2393.	0.7	4
1148	Increased risks of different grades of non-alcoholic fatty liver disease in prediabetic subjects with impaired fasting glucose and glucose tolerance, including the isolated glycosylated hemoglobin levels of 5.7-6.4% in a Chinese population. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1336-1343.	1.1	8
1149	Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001174.	1.2	21
1150	Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1352-1355.	4.3	186
1151	Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. <i>Journal of Gastroenterology</i> , 2020, 55, 722-730.	2.3	13
1152	The <i>PNPLA3</i> rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1160-1168.	1.9	17
1153	Non-invasive diagnosis of non-alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review. <i>Hepatology Research</i> , 2020, 50, 645-655.	1.8	13
1154	Occult hepatitis B virus infection predicts non-alcoholic steatohepatitis in severely obese individuals from Italy. <i>Liver International</i> , 2020, 40, 1601-1609.	1.9	11
1155	Non-obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cutoff to assess fibrosis stages. <i>Journal of Digestive Diseases</i> , 2020, 21, 279-286.	0.7	6
1156	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 904-914.	1.0	17
1157	Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. <i>Journal of Hepatology</i> , 2020, 73, 680-693.	1.8	69
1158	Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, e694-e701.	2.9	27
1159	Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4mg: An Indian Experience. <i>Case Reports in Medicine</i> , 2020, 1-4.	0.3	11
1160	Prospective Comparison of Transient Elastography Using Two Different Devices: Performance of FibroScan and FibroTouch. <i>Hepatic Medicine: Evidence and Research</i> , 2020, Volume 12, 41-48.	0.9	7
1161	Endocan: A Biomarker for Hepatosteatois in Patients with Metabolic Syndrome. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	1.4	11
1162	Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 230-230.	0.7	15

#	ARTICLE	IF	CITATIONS
1163	Modulation of the gut microbiota represents a new management for non-alcoholic fatty liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 223-226.	0.7	4
1164	NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. <i>Gut</i> , 2020, 69, 1691-1705.	6.1	369
1165	The Impact of Bariatric Surgery on Hepatic Function and Predictors of Liver Steatosis and Fibrosis. <i>Obesity Surgery</i> , 2020, 30, 2935-2941.	1.1	10
1166	Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. <i>Hepatology International</i> , 2020, 14, 556-566.	1.9	27
1167	Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD. <i>Annals of Diagnostic Pathology</i> , 2020, 47, 151518.	0.6	37
1168	Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2305-2314.e12.	2.4	38
1169	Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH. <i>Contemporary Clinical Trials Communications</i> , 2020, 18, 100560.	0.5	16
1170	The offspring from rats fed a fatty diet display impairments in the activation of liver peroxisome proliferator activated receptor alpha and features of fatty liver disease. <i>Molecular and Cellular Endocrinology</i> , 2020, 511, 110818.	1.6	7
1171	Primary Liver Cancers. <i>Surgical Clinics of North America</i> , 2020, 100, 535-549.	0.5	54
1172	Pro-inflammatory signalling and gut-liver axis in non-alcoholic and alcoholic steatohepatitis: Differences and similarities along the path. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 5955-5965.	1.6	22
1173	What's in a name? Renaming "NAFLD" to "MAFLD". <i>Liver International</i> , 2020, 40, 1254-1261.	1.9	212
1174	Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2311-2321.	1.8	39
1175	Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00157.	1.3	16
1176	Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Nutrients</i> , 2020, 12, 937.	1.7	35
1177	Addressing the heterogeneity in liver diseases using biological networks. <i>Briefings in Bioinformatics</i> , 2021, 22, 1751-1766.	3.2	9
1178	Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2021, 73, 937-951.	3.6	32
1179	Can Dual-energy CT-based Virtual Monoenergetic Imaging Improve the Assessment of Hypodense Liver Metastases in Patients With Hepatic Steatosis?. <i>Academic Radiology</i> , 2020, 28, 769-777.	1.3	10
1180	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 136-145.e6.	2.4	47

#	ARTICLE	IF	CITATIONS
1181	Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 61-71.e15.	2.4	159
1182	Clinical profile of non-alcoholic fatty liver disease in nonobese patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 257-261.	1.4	7
1183	A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. <i>Annals of Pharmacotherapy</i> , 2021, 55, 65-79.	0.9	54
1184	Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease. <i>Annals of Hepatology</i> , 2021, 21, 100212.	0.6	25
1185	From NAFLD to MAFLD: Implications of a Premature Change in Terminology. <i>Hepatology</i> , 2021, 73, 1194-1198.	3.6	266
1186	Real-World Burden of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1020-1029.e7.	2.4	21
1187	Evolving Role for Pharmacotherapy in NAFLD/NASH. <i>Clinical and Translational Science</i> , 2021, 14, 11-19.	1.5	86
1188	Non-alcoholic fatty liver disease and coronary atherosclerosis-does myocardial glucose metabolism provide the missing link?. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 621-623.	1.4	3
1189	Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. <i>Digestive and Liver Disease</i> , 2021, 53, 79-85.	0.4	36
1190	Hepatokines and adipokines in NASH-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 442-457.	1.8	72
1191	Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 57-64.	3.7	110
1192	Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1670-1678.	1.4	13
1193	Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 947-955.	0.9	45
1194	Simultaneous proton density fat fraction and imaging with water-specific T ₁ mapping (PROFIT ₁): application in liver. <i>Magnetic Resonance in Medicine</i> , 2021, 85, 223-238.	1.9	20
1195	Diagnostic value of MRI-derived liver surface nodularity score for the non-invasive quantification of hepatic fibrosis in non-alcoholic fatty liver disease. <i>European Radiology</i> , 2021, 31, 256-263.	2.3	16
1196	Protective effect of fenofibrate against high-fructose diet induced non-obese NAFLD in rats. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 379-388.	1.0	16
1197	Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2021, 47, 101183.	1.4	59
1198	Technical success rate of MR elastography in a population without known liver disease. <i>Abdominal Radiology</i> , 2021, 46, 590-596.	1.0	7

#	ARTICLE	IF	CITATIONS
1199	The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 893-909.	1.4	13
1200	Inflammatory Diseases and Vitamin E "What Do We Know and Where Do We Go?. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000097.	1.5	27
1201	<scp>NAFLD</scp> in type 2 diabetes mellitus: Still many challenging questions. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3386.	1.7	18
1202	Non-alcoholic fatty liver disease: A review with clinical and pathological correlation. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 68-77.	0.8	24
1203	Associations Between Reproductive and Hormone-Related Factors and Risk of Nonalcoholic Fatty Liver Disease in a Multiethnic Population. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1258-1266.e1.	2.4	23
1204	Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. <i>Digestive and Liver Disease</i> , 2021, 53, 44-51.	0.4	50
1205	A novel model for predicting fatty liver disease by means of an artificial neural network. <i>Gastroenterology Report</i> , 2021, 9, 31-37.	0.6	6
1206	Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. <i>Gut</i> , 2021, 70, 1375-1382.	6.1	307
1207	High-Fat Diet "Induced Adipose Tissue and Liver Inflammation and Steatosis in Mice Are Reduced by Inhibiting Sialidases. <i>American Journal of Pathology</i> , 2021, 191, 131-143.	1.9	22
1208	Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastropasty. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 1110-1118.	0.5	45
1209	The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies. <i>Annals of Hepatology</i> , 2021, 20, 100254.	0.6	46
1210	Methotrexate use does not increase the prevalence of hepatic steatosis: a real-world retrospective nested case-control study. <i>Clinical Rheumatology</i> , 2021, 40, 2037-2045.	1.0	8
1211	The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. <i>American Journal of Medicine</i> , 2021, 134, 23-29.	0.6	14
1212	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 24-39.	8.2	174
1213	Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 125-134.	2.5	3
1214	Association between blood copper and nonalcoholic fatty liver disease according to sex. <i>Clinical Nutrition</i> , 2021, 40, 2045-2052.	2.3	25
1215	DeepLiverNet: a deep transfer learning model for classifying liver stiffness using clinical and T2-weighted magnetic resonance imaging data in children and young adults. <i>Pediatric Radiology</i> , 2021, 51, 392-402.	1.1	10
1216	What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 232-238.	0.4	6

#	ARTICLE	IF	CITATIONS
1217	Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance. <i>Journal of Hepatology</i> , 2021, 74, 1038-1052.	1.8	46
1218	Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 750-761.	1.8	13
1219	The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. <i>Archives of Biochemistry and Biophysics</i> , 2021, 697, 108679.	1.4	12
1220	Metabolic Consequences of Solid Organ Transplantation. <i>Endocrine Reviews</i> , 2021, 42, 171-197.	8.9	16
1221	Clinical Feasibility of Quantitative Ultrasound Imaging for Suspected Hepatic Steatosis: Intra- and Inter-examiner Reliability and Correlation with Controlled Attenuation Parameter. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 438-445.	0.7	19
1222	Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience. <i>Annals of Hepatology</i> , 2021, 22, 100277.	0.6	12
1223	Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Nutrition</i> , 2021, 83, 111092.	1.1	41
1224	A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease. <i>Clinical Nutrition</i> , 2021, 40, 2999-3005.	2.3	10
1225	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021, 160, 1608-1619.e13.	0.6	60
1226	Role of histone deacetylase on nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 353-361.	1.4	5
1227	A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 345-352.	1.4	41
1228	MRI- $\text{Proton Density Fat Fraction}$ Treatment Response Criteria in Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2021, 73, 881-883.	3.6	24
1229	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1113-1124.	13.9	833
1230	A review of non-alcoholic fatty liver disease in non-obese and lean individuals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1497-1507.	1.4	43
1231	INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 354-386.	0.4	3
1232	Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. <i>Hepatology Communications</i> , 2021, 5, 559-572.	2.0	25
1233	Development and Validation of a Predictive Model of Success in Bariatric Surgery. <i>Obesity Surgery</i> , 2021, 31, 1030-1037.	1.1	16
1234	Naringenin alleviates nonalcoholic steatohepatitis in middle-aged ApoE ^{-/-} /A ^{+/+} mice: role of SIRT1. <i>Phytomedicine</i> , 2021, 81, 153412.	2.3	51

#	ARTICLE	IF	CITATIONS
1235	The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 65-72.	3.7	108
1236	Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 144-158.	2.9	38
1237	Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 29-39.	1.3	10
1238	Total-body PET Imaging. <i>PET Clinics</i> , 2021, 16, 75-87.	1.5	7
1239	Addressing Social Determinants of Liver Disease During the COVID-19 Pandemic and Beyond: A Call to Action. <i>Hepatology</i> , 2021, 73, 811-820.	3.6	29
1240	The Changing Liver Transplant Recipient. <i>Clinics in Liver Disease</i> , 2021, 25, 137-155.	1.0	3
1241	Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101568.	0.7	6
1242	NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. <i>Diabetes and Metabolism</i> , 2021, 47, 101215.	1.4	84
1243	Longitudinal plasma protein profiling of newly diagnosed type 2 diabetes. <i>EBioMedicine</i> , 2021, 63, 103147.	2.7	15
1244	Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. <i>Thrombosis Research</i> , 2021, 198, 139-150.	0.8	27
1245	Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. <i>Gastroenterology</i> , 2021, 160, 1620-1633.e13.	0.6	68
1246	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: <i>Standards of Medical Care in Diabetes</i> 2021 </i>. <i>Diabetes Care</i> , 2021, 44, S40-S52.	4.3	179
1247	MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction. <i>Diagnostic and Interventional Radiology</i> , 2021, 27, 7-14.	0.7	16
1248	Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. <i>Pharmacotherapy</i> , 2021, 41, 315-328.	1.2	18
1249	Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. <i>Archives of Medical Research</i> , 2021, 52, 25-37.	1.5	112
1250	Beneficial and deleterious effects of sitagliptin on a methionine/choline-deficient diet-induced steatohepatitis in rats. <i>Biochimie</i> , 2021, 181, 240-248.	1.3	2
1251	Extended-release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 861-865.	2.2	15
1252	MRI Automated T1 Signal Intensity Detection of Diffuse Brain Manganese Accumulation in Cirrhosis. <i>Journal of Neuroimaging</i> , 2021, 31, 186-191.	1.0	1

#	ARTICLE	IF	CITATIONS
1253	Can Baseline Characteristics be Used to Predict Liver Disease Outcomes in Pediatric Nonalcoholic Fatty Liver Disease?. <i>Obesity</i> , 2021, 29, 171-176.	1.5	2
1254	Non-alcoholic fatty liver disease: Not time for an obituary just yet!. <i>Journal of Hepatology</i> , 2021, 74, 972-974.	1.8	24
1255	Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 223-238.	8.2	867
1256	Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1326-1333.	1.4	5
1257	Development and course of diabetes according to genetic factors and diabetes treatment among patients with nonalcoholic fatty liver disease. <i>Nutrition</i> , 2021, 83, 111080.	1.1	5
1258	Adherence to Ideal Cardiovascular Health Metrics Is Associated With Reduced Odds of Hepatic Steatosis. <i>Hepatology Communications</i> , 2021, 5, 74-82.	2.0	7
1259	Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. <i>Hepatology Communications</i> , 2021, 5, 158-167.	2.0	41
1260	NASH-related increases in plasma bile acid levels depend on insulin resistance. <i>JHEP Reports</i> , 2021, 3, 100222.	2.6	24
1261	Are thiazolidinediones a preferred drug treatment for type 2 diabetes?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 131-133.	0.9	14
1262	Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. <i>Hepatology</i> , 2021, 73, 548-559.	3.6	49
1263	Significance of MR/OPN/HMGB1 axis in NAFLD-associated hepatic fibrogenesis. <i>Life Sciences</i> , 2021, 264, 118619.	2.0	11
1264	Angiopoietin-like 8 (ANGPTL8) as a potential predictor of NAFLD in paediatric patients with Prader-Willi Syndrome. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1447-1456.	1.8	5
1265	Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 1623-1631.	1.9	37
1266	Performance of the Attenuation Imaging Technology in the Detection of Liver Steatosis. <i>Journal of Ultrasound in Medicine</i> , 2021, 40, 1325-1332.	0.8	67
1267	Recent advances in the mechanisms underlying the beneficial effects of bariatric and metabolic surgery. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 231-238.	1.0	41
1268	Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 25-40.	1.4	13
1269	Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 27-41.	1.3	24
1270	Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3- β -Glucuronide in Nonalcoholic Steatohepatitis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 676-687.	2.3	17

#	ARTICLE	IF	CITATIONS
1271	Performance of morphologic criteria for the diagnosis of cirrhosis in patients with non-alcoholic steatohepatitis compared to other etiologies of chronic liver disease: effect of level of training and experience. <i>Abdominal Radiology</i> , 2021, 46, 960-968.	1.0	3
1272	Mechanisms of nonalcoholic fatty liver disease and implications for surgery. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 1-17.	0.8	21
1273	Dietary intake of specific amino acids and liver status in subjects with nonalcoholic fatty liver disease: fatty liver in obesity (FLiO) study. <i>European Journal of Nutrition</i> , 2021, 60, 1769-1780.	1.8	15
1274	The association of sex steroid hormone concentrations with non-alcoholic fatty liver disease and liver enzymes in US men. <i>Liver International</i> , 2021, 41, 300-310.	1.9	30
1275	Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls. <i>European Endocrinology</i> , 2021, 1, 33.	0.8	0
1276	Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 2-2.	1.5	46
1277	Evaluating Cerebral Perfusion in Alzheimer Patients and First-Degree Relatives: Lessons from Artemisa Province, Cuba. <i>MEDICC Review</i> , 2021, 23, 55-63.	0.5	0
1278	Posicionamento sobre o Consumo de Gorduras e SaÃºde Cardiovascular â€“ 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 160-212.	0.3	21
1279	Aging Liver and Interpretation of Liver Tests. , 2021, , 1-25.		0
1281	A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4046-4057.	1.1	3
1282	Chinese medicine formulas for nonalcoholic fatty liver disease: Overview of systematic reviews. <i>World Journal of Clinical Cases</i> , 2021, 9, 102-117.	0.3	3
1283	The Prevalence of Metabolic Associated Fatty Liver Disease in The Turkish Population: A Multicenter Study. <i>Hepatology Forum</i> , 2021, , .	0.3	8
1284	Role of chronic inflammation in the pathogenesis of nonalcoholic steatohepatitis: lessons from a unique mouse model using melanocortin receptor-deficient mice. <i>Endocrine Journal</i> , 2021, 68, 743-749.	0.7	2
1285	Lean NAFLD: an underrecognized and challenging disorder in medicine. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 351-366.	2.6	40
1286	Hepatocellular Carcinoma in the Middle East: An Overview. , 2021, , 299-311.		2
1287	Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls. <i>European Endocrinology</i> , 2021, 1, 33.	0.8	1
1288	Aging Liver and Interpretation of Liver Tests. , 2021, , 1329-1352.		0
1289	Pre-transplant portal vein thrombosis in non-alcoholic fatty liver disease patientsâ€™ pathogenesis, risk factors, and implications on management. <i>Translational Gastroenterology and Hepatology</i> , 0, 7, 27-27.	1.5	2

#	ARTICLE	IF	CITATIONS
1290	Non-invasive markers of liver fibrosis and outcome in large vessel occlusion stroke. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110372.	1.5	19
1291	Non-alcoholic fatty liver disease: digest 2021. Russian Journal of Evidence-Based Gastroenterology, 2021, 10, 27.	0.3	4
1292	SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH. Hepatology Communications, 2021, 5, 760-773.	2.0	38
1293	NAFLD-related HCC. Advances in Cancer Research, 2021, 149, 143-169.	1.9	13
1294	Effect of dietary carbohydrate and lipid modification on clinical and anthropometric parameters in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutrition Reviews, 2021, 79, 1321-1337.	2.6	10
1295	Active phase prebiotic feeding alters gut microbiota, induces weight-independent alleviation of hepatic steatosis and serum cholesterol in high-fat diet-fed mice. Computational and Structural Biotechnology Journal, 2021, 19, 448-458.	1.9	16
1296	Effectiveness of dietary interventions on cardio-metabolic risk factors in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Annals of Gastroenterology, 2021, 34, 415-423.	0.4	0
1297	Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. Translational Gastroenterology and Hepatology, 2021, 6, 60-60.	1.5	7
1298	Mitochondrial role in NAFLD as a chronic disease. , 2021, , 155-167.		0
1299	Repeatedly elevated $\hat{\text{I}}^3$ -glutamyltransferase levels are associated with an increased incidence of digestive cancers: A population-based cohort study. World Journal of Gastroenterology, 2021, 27, 176-188.	1.4	5
1300	Nutraceuticals for Non-alcoholic Fatty Liver Disease. Contemporary Cardiology, 2021, , 141-165.	0.0	1
1301	Non-alcoholic fatty liver disease in Asian Indian adolescents and young adults: Prevalence and its associated risk factors. Journal of Diabetology, 2021, 12, 218.	0.1	0
1302	Food insecurity is associated with magnetic resonanceâ€‘determined nonalcoholic fatty liver and liver fibrosis in low-income, middle-aged adults with and without HIV. American Journal of Clinical Nutrition, 2021, 113, 593-601.	2.2	19
1304	Association between obesity profile and non-alcoholic fatty liver by race/ethnicity. Annals of Clinical Endocrinology and Metabolism, 2021, 5, 001-010.	0.3	1
1305	Complementary and alternative therapies for non-alcoholic fatty liver disease. Medicine (United Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50 1.	0.4	0
1306	The Role of Life Style Modifications in Comprehensive Nonâ€‘Alcoholic Fatty Liver Disease Treatment. Clinical Liver Disease, 2021, 17, 11-14.	1.0	12
1307	Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort. Clinical Gastroenterology and Hepatology, 2022, 20, 2393-2395.e4.	2.4	21
1308	Promyelocytic leukemia antigen expression: A histological marker for primary biliary cholangitis diagnosis?. Journal of Translational Internal Medicine, 2021, 9, 43-51.	1.0	6

#	ARTICLE	IF	CITATIONS
1309	Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. <i>Frontiers in Endocrinology</i> , 2020, 11, 617400.	1.5	25
1310	Primary care and referring physician perspectives on non-alcoholic fatty liver disease management: a nationwide survey. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110422.	1.4	8
1311	Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2021, 21, 43.	0.8	12
1312	Effects of Positive Hepatitis B Core Antibody and Metabolic Disorders in Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus. <i>Cancer Control</i> , 2021, 28, 107327482110397.	0.7	0
1313	Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. <i>Antioxidants</i> , 2021, 10, 174.	2.2	192
1314	Tocopheryl quinone improves non-alcoholic steatohepatitis (NASH) associated dysmetabolism of glucose and lipids by upregulating the expression of glucagon-like peptide 1 (GLP-1) <i>via</i> restoring the balance of intestinal flora in rats. <i>Pharmaceutical Biology</i> , 2021, 59, 721-729.	1.3	5
1315	Noninvasive evaluation of liver fibrosis: comparison of the stretched exponential diffusion-weighted model to other diffusion-weighted MRI models and transient elastography. <i>European Radiology</i> , 2021, 31, 4813-4823.	2.3	7
1316	Age, Gender and Geographic Differences in Global Health Burden of Cirrhosis and Liver Cancer due to Nonalcoholic Steatohepatitis. <i>Journal of Cancer</i> , 2021, 12, 2855-2865.	1.2	9
1317	Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. <i>Diagnostics</i> , 2021, 11, 132.	1.3	18
1318	Association of insulin resistance and non-alcoholic fatty liver disease. <i>Diabetes Mellitus</i> , 2021, 23, 412-423.	0.5	0
1319	Herbal Medicines for the Treatment of Nonalcoholic Steatohepatitis. <i>Current Hepatology Reports</i> , 2021, 20, 1-11.	0.4	2
1320	Factors associated with elevated alanine aminotransferase in employees of a German chemical company: results of a large cross-sectional study. <i>BMC Gastroenterology</i> , 2021, 21, 25.	0.8	4
1321	Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110002.	1.4	21
1322	Severe Phenotype of Non-alcoholic Fatty Liver Disease in Pediatric Patients with Subclinical Hypothyroidism: a Retrospective Multicenter Study from Korea. <i>Journal of Korean Medical Science</i> , 2021, 36, e137.	1.1	4
1323	Intragastric Balloon Improves Steatohepatitis and Fibrosis. <i>ACG Case Reports Journal</i> , 2021, 8, e00534.	0.2	0
1324	Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. <i>Biology of Sex Differences</i> , 2021, 12, 1.	1.8	29
1325	Hesperetin ameliorates hepatic oxidative stress and inflammation <i>via</i> the PI3K/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD. <i>Food and Function</i> , 2021, 12, 3898-3918.	2.1	147
1326	Depression and increased risk of non-alcoholic fatty liver disease in individuals with obesity. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e23.	1.8	30

#	ARTICLE	IF	CITATIONS
1327	Short-Term Weight Loss Decreased the Risk of Chronic Kidney Disease in Incident NAFLD Participants: A Prospective Cohort. SSRN Electronic Journal, 0, , .	0.4	0
1328	Combined non-alcoholic fatty liver disease and type 2 diabetes in severely obese patientsâ€”medium term effects of sleeve gastrectomy versus Roux-en-Y-gastric bypass on disease markers. Hepatobiliary Surgery and Nutrition, 2022, 11, 795-807.	0.7	3
1329	Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1519-1539.	2.3	55
1330	Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD). Npj Vaccines, 2021, 6, 9.	2.9	13
1331	Therapeutic approaches for non-alcoholic steatohepatitis. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110343.	1.4	7
1332	Comparative analysis of metabolic risk factors for progression of non-alcoholic fatty liver disease. Clinical and Experimental Hepatology, 2021, 7, 241-247.	0.6	4
1333	SYSTEMATIC REVIEW WITH COMPARATIVE ANALYSIS OF RECOMMENDATIONS FOR THE DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE. , 2021, , 107-112.		0
1334	Hepcidin Levels and Pathological Characteristics in Children with Fatty Liver Disease. Pediatric Gastroenterology, Hepatology and Nutrition, 2021, 24, 295.	0.4	3
1335	Pioglitazone and bariatric surgery are the most effective treatments for nonâ€”alcoholic steatohepatitis: A hierarchical network metaâ€”analysis. Diabetes, Obesity and Metabolism, 2021, 23, 980-990.	2.2	41
1336	Efficacy and Safety of Intra-gastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis. Obesity Surgery, 2021, 31, 1271-1279.	1.1	26
1337	Emerging prevalence of fatty liver disease in HIV. Future Virology, 2021, 16, 59-73.	0.9	1
1338	Impact of bariatric surgery on body composition and metabolism among obese Asian Indians with prediabetes and diabetes. Journal of Diabetology, 2021, 12, 208.	0.1	3
1339	Impact of bariatric surgery on body composition and metabolic profile in obese patients with diabetes: A commentary. Journal of Diabetology, 2021, 12, 111.	0.1	0
1340	Evaluation of subclinical cardiac damage in biopsy-proven nonalcoholic fatty liver disease: a systematic review and meta-analysis. Annals of Gastroenterology, 2021, 34, 424-430.	0.4	3
1341	Non-alcoholic fatty liver disease and lipotoxicity. Clinical and Experimental Hepatology, 2021, 7, 1-6.	0.6	17
1342	Plants of the Spontaneous Flora with Beneficial Action in the Management of Diabetes, Hepatic Disorders, and Cardiovascular Disease. Plants, 2021, 10, 216.	1.6	12
1343	Nonalcoholic Fatty Liver Disease and Obesity. Journal of Postgraduate Medicine Education and Research, 2021, 55, 27-35.	0.1	1
1344	Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no?. Annals of Gastroenterology, 2021, 34, 476-486.	0.4	3

#	ARTICLE	IF	CITATIONS
1345	Significance of Young's Modulus and BMP-7 in the Diagnosis of Different Stages of Diabetic Nephropathy. <i>Advances in Clinical Medicine</i> , 2021, 11, 2781-2787.	0.0	0
1346	Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease. <i>Frontline Gastroenterology</i> , 2021, 12, 578-585.	0.9	17
1347	Pearls and pitfalls in non-alcoholic fatty liver disease: tricky results are common. , 0, , .		1
1348	Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study. <i>European Journal of Nutrition</i> , 2021, 60, 3043-3057.	1.8	5
1349	Clinical Observation on Acupoint Catgut Embedding Combined With Electroacupuncture in the Treatment of Obese Patients with Nonalcoholic Fatty Liver Disease. , 0, 83, .		2
1350	Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized, Open-Label Trial Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1352	Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study. <i>Clinical and Experimental Hepatology</i> , 2021, 7, 172-177.	0.6	15
1354	Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. <i>Hepatology Communications</i> , 2021, 5, 573-588.	2.0	82
1355	Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration. <i>Minerva Gastroenterologica E Dietologica</i> , 2021, 66, 307-320.	2.2	0
1356	Palmitate induces fat accumulation via repressing FoxO1-mediated ATGL-dependent lipolysis in HepG2 hepatocytes. <i>PLoS ONE</i> , 2021, 16, e0243938.	1.1	9
1358	Serum Glycocholic Acid-to-Total Bile Acid Ratio Is Independently Associated with Nonalcoholic Fatty Liver Disease: A Retrospective Cross-Sectional Study. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	1
1359	Transient Elastography-Assessed Hepatic Steatosis and Fibrosis Are Associated With Body Composition in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e808-e830.	2.4	13
1360	Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2021, 8, 637652.	1.2	8
1361	Performance of Ultrasound Techniques and the Potential of Artificial Intelligence in the Evaluation of Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 790.	1.7	14
1362	Treatment potential of LPCN 1144 on liver health and metabolic regulation in a non-genomic, high fat diet induced NASH rabbit model. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2175-2193.	1.8	3
1363	Pyridoxamine and Caloric Restriction Improve Metabolic and Microcirculatory Abnormalities in Rats with Non-Alcoholic Fatty Liver Disease. <i>Journal of Vascular Research</i> , 2021, 58, 121-130.	0.6	3
1364	Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1616.	1.2	9
1365	Nonalcoholic Fatty Liver Disease and Fibrosis Risk in Patients With Obstructive Sleep Apnea: A Retrospective Analysis. <i>Cureus</i> , 2021, 13, e13623.	0.2	1

#	ARTICLE	IF	CITATIONS
1366	Treatments for NAFLD: State of Art. International Journal of Molecular Sciences, 2021, 22, 2350.	1.8	102
1367	The role of recipient myosteatosis in graft and patient survival after deceased donor liver transplantation. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 358-367.	2.9	28
1368	The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories?. Frontiers in Nutrition, 2021, 8, 640557.	1.6	44
1369	Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV. HIV Medicine, 2021, 22, 445-456.	1.0	12
1370	Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?. World Journal of Hepatology, 2021, 13, 233-241.	0.8	8
1371	Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clinical Gastroenterology and Hepatology, 2022, 20, e573-e582.	2.4	84
1372	From NAFLD to MAFLD: Nurse and allied health perspective. Liver International, 2021, 41, 683-691.	1.9	34
1373	Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet. Nutrients, 2021, 13, 604.	1.7	7
1374	The Role of the ATP-Binding Cassette A1 (ABCA1) in Human Disease. International Journal of Molecular Sciences, 2021, 22, 1593.	1.8	73
1375	Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. Endocrinology and Metabolism, 2021, 36, 134-145.	1.3	7
1376	Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease. Antioxidants, 2021, 10, 239.	2.2	3
1377	Coronary artery disease and non-alcoholic fatty liver disease: Clinical correlation using computed tomography coronary calcium scans. JGH Open, 2021, 5, 390-395.	0.7	4
1378	Diagnostic Value of Ultrasound in Fatty Liver Disease. Ultraschall in Der Medizin, 2021, 42, 128-153.	0.8	8
1379	Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. PLoS ONE, 2021, 16, e0245762.	1.1	61
1380	Dietary approaches to managing nonalcoholic fatty liver disease. Nurse Practitioner, 2021, 46, 19-26.	0.2	2
1381	Bariatric surgery and the risk of alcohol-related cirrhosis and alcohol misuse. Liver International, 2021, 41, 1012-1019.	1.9	22
1382	Integrated Analysis of Key Genes and Pathways Involved in Nonalcoholic Steatohepatitis Improvement After Roux-en-Y Gastric Bypass Surgery. Frontiers in Endocrinology, 2020, 11, 611213.	1.5	4
1383	Therapeutic pipeline in nonalcoholic steatohepatitis. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 373-392.	8.2	173

#	ARTICLE	IF	CITATIONS
1384	Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000572.	1.1	19
1385	Screening and identifying hepatobiliary diseases through deep learning using ocular images: a prospective, multicentre study. <i>The Lancet Digital Health</i> , 2021, 3, e88-e97.	5.9	50
1386	Soft drink consumption and risk of nonalcoholic fatty liver disease: results from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIH) cohort study. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1265-1274.	2.2	34
1387	Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. <i>ESC Heart Failure</i> , 2021, 8, 789-798.	1.4	23
1388	Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2021, 31, 2002-2010.	1.1	14
1389	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. <i>Hepatology International</i> , 2021, 15, 366-379.	1.9	71
1390	Metabolic and Hepatic Effects of Energy-Reduced Anti-Inflammatory Diet in Younger Adults with Obesity. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-12.	0.8	16
1391	Gastric Bypass Increases Circulating Bile Acids and Activates Hepatic Farnesoid X Receptor (FXR) but Requires Intact Peroxisome Proliferator Activator Receptor Alpha (PPAR α) Signaling to Significantly Reduce Liver Fat Content. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 871-879.	0.9	10
1392	Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study. <i>World Journal of Gastroenterology</i> , 2021, 27, 523-533.	1.4	7
1393	Efficacy of combining pentoxifylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis: A randomized pilot study. <i>Indian Journal of Gastroenterology</i> , 2021, 40, 41-49.	0.7	10
1394	Valoración bioquímica en la enfermedad hepática grasa asociada a la disfunción metabólica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 209-219.	0.1	1
1395	Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. <i>World Journal of Gastroenterology</i> , 2021, 27, 609-623.	1.4	24
1396	A Novel Nutraceuticals Mixture Improves Liver Steatosis by Preventing Oxidative Stress and Mitochondrial Dysfunction in a NAFLD Model. <i>Nutrients</i> , 2021, 13, 652.	1.7	16
1397	Association Between Non-Alcoholic Fatty Liver Disease and Diabetes-Related Microvascular Complications: A Retrospective Cross-Sectional Study of Hospitalized Patients. <i>Endocrine Practice</i> , 2022, 28, 304-309.	1.1	9
1398	Mesenchymal stromal cells protect hepatocytes from lipotoxicity through alleviation of endoplasmic reticulum stress by restoring SERCA activity. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 2976-2993.	1.6	21
1399	Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	9
1400	The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2020, 11, 601627.	1.5	50
1401	<sc>Nonalcoholic fatty liver disease</sc> as a metabolic disease in humans: A literature review. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1069-1083.	2.2	104

#	ARTICLE	IF	CITATIONS
1402	Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact. International Journal of Molecular Sciences, 2021, 22, 1917.	1.8	25
1403	Sarcopenic Obesity in Non-Alcoholic Fatty Liver Diseaseâ€”The Union of Two Culprits. Life, 2021, 11, 119.	1.1	2
1405	Relationship between Muscle Mass and Non-Alcoholic Fatty Liver Disease. Biology, 2021, 10, 122.	1.3	9
1407	The Impact of Vitamin D in Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Patients with Morbid Obesity. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 487-495.	1.1	14
1408	INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". Obesity and Metabolism, 2021, 18, 5-99.	0.4	49
1409	Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGETâ€”NASH Study. Hepatology Communications, 2021, 5, 938-946.	2.0	21
1410	Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients. Nutrients, 2021, 13, 629.	1.7	15
1411	Pathophysiology of NASH in endocrine diseases. Endocrine Connections, 2021, 10, R52-R65.	0.8	43
1412	An update on drug development for the treatment of nonalcoholic fatty liver disease â€” from ongoing clinical trials to future therapy. Expert Review of Clinical Pharmacology, 2021, 14, 333-340.	1.3	20
1413	3D human nonalcoholic hepatic steatosis and fibrosis models. Bio-Design and Manufacturing, 2021, 4, 157-170.	3.9	20
1414	Fat and fibrosis as confounding cofactors in viscoelastic measurements of the liver. Physics in Medicine and Biology, 2021, 66, 045024.	1.6	13
1415	Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. Frontiers in Endocrinology, 2020, 11, 609135.	1.5	34
1416	Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. BMJ Open Diabetes Research and Care, 2021, 9, e001990.	1.2	53
1417	Advanced Liver Fibrosis Is Associated with Necroinflammatory Grade but Not Hepatic Steatosis in Chronic Hepatitis B Patients. Digestive Diseases and Sciences, 2021, 66, 4492-4500.	1.1	6
1418	Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. Journal of Hypertension, 2021, 39, 961-969.	0.3	10
1419	Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. Journal of Clinical Medicine, 2021, 10, 669.	1.0	11
1420	Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method. Medical Ultrasonography, 2021, 23, 7.	0.4	17
1421	A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science. Journal of the Association of Nurses in AIDS Care, 2021, 32, 322-346.	0.4	15

#	ARTICLE	IF	CITATIONS
1422	Editorial commentary on the Indian Journal of Gastroenterology Januaryâ€“February 2021. Indian Journal of Gastroenterology, 2021, 40, 1-4.	0.7	1
1423	TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation. Frontiers in Immunology, 2020, 11, 609060.	2.2	47
1424	Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. Hepatology Communications, 2021, 5, 786-797.	2.0	12
1425	Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. Antioxidants, 2021, 10, 270.	2.2	104
1426	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. Life, 2021, 11, 143.	1.1	22
1427	National digestive disease specialists survey on cardiovascular risk management in nonâ€“alcoholic fatty liver disease in spanish hospitals. Liver International, 2021, 41, 1243-1253.	1.9	5
1428	EvaluaciÃ³n de fibrosis en pacientes con enfermedad por hÃ¡gado graso no alcohÃ³lico: adherencia a los algoritmos propuestos y barreras para cumplir con ellos. Revista De GastroenterologÃ­a De MÃ©xico, 2021, 87, 4-4.	0.4	0
1429	Comparison of Body Mass Index, Smoking, Vitamin E and Type of Oil Consumed Between Patients Suffering from Non-alcoholic Fatty Liver Disease Versus Non-affected Patients: A Case-Control Study. Jundishapur Journal of Chronic Disease Care, 2021, 10, .	0.1	0
1430	Utility of quantitative ultrasound in community screening for hepatic steatosis. Ultrasonics, 2021, 111, 106329.	2.1	8
1431	Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1235-1241.	2.2	28
1432	Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clinical Therapeutics, 2021, 43, 455-472.	1.1	8
1433	Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General Overview. Biomolecules, 2021, 11, 473.	1.8	10
1434	VCAM-1: closing the gap between lipotoxicity and endothelial dysfunction in nonalcoholic steatohepatitis. Journal of Clinical Investigation, 2021, 131, .	3.9	13
1435	Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut and Liver, 2021, 15, 206-216.	1.4	54
1436	Adipocytokines as Risk Factors for Development of Nonalcoholic Fatty Liver Disease in Children. Journal of Clinical and Experimental Hepatology, 2021, 11, 646-653.	0.4	3
1437	Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions. Clinical Therapeutics, 2021, 43, 500-517.	1.1	16
1438	Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Scientific Reports, 2021, 11, 5637.	1.6	12
1439	Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease. Lipids in Health and Disease, 2021, 20, 27.	1.2	8

#	ARTICLE	IF	CITATIONS
1440	The advantages of using <i>Scutellaria baicalensis</i> and its flavonoids for the management of non-viral hepatocellular carcinoma. <i>Journal of Functional Foods</i> , 2021, 78, 104389.	1.6	5
1441	Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 10-14.	2.8	14
1442	Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13519.	1.7	32
1444	The role of bariatric surgery in the management of nonalcoholic steatohepatitis. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 208-215.	1.0	11
1445	A Positive Relationship between Betel Nut Chewing and Significant Liver Fibrosis in NAFLD Subjects, but Not in Non-NAFLD Ones. <i>Nutrients</i> , 2021, 13, 914.	1.7	6
1446	Efficacy of Intra-gastric Balloons in the Markers of Metabolic Dysfunction-associated Fatty Liver Disease: Results from Meta-analyses. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	2
1448	Emerging Treatment Options for Sarcopenia in Chronic Liver Disease. <i>Life</i> , 2021, 11, 250.	1.1	10
1449	Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?. <i>Hepatology International</i> , 2021, 15, 380-391.	1.9	42
1450	Moderate-Intensity Aerobic vs Resistance Exercise and Dietary Modification in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00316.	1.3	21
1451	The Impact of Dietary Patterns and Nutrition in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2021, 50, 217-241.	1.0	4
1452	Hepatic Steatosis Predicts Higher Incidence of Recurrence in Colorectal Cancer Liver Metastasis Patients. <i>Frontiers in Oncology</i> , 2021, 11, 631943.	1.3	7
1453	Impact of hepatic steatosis on outcomes after left ventricular assist device implantation. <i>Journal of Cardiac Surgery</i> , 2021, 36, 2277-2283.	0.3	0
1454	Adipocyte Fatty Acid-Binding Protein, Cardiovascular Diseases and Mortality. <i>Frontiers in Immunology</i> , 2021, 12, 589206.	2.2	22
1455	Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 1167-1175.	1.1	5
1456	Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. <i>Journal of Clinical Lipidology</i> , 2021, 15, 275-291.	0.6	8
1457	Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1379-1388.	1.1	9
1458	Dietary Oxysterol, 7-Ketocholesterol Accelerates Hepatic Lipid Accumulation and Macrophage Infiltration in Obese Mice. <i>Frontiers in Endocrinology</i> , 2020, 11, 614692.	1.5	11
1459	Non-alcoholic fatty liver disease in polycystic ovary syndrome women. <i>Scientific Reports</i> , 2021, 11, 7085.	1.6	21

#	ARTICLE	IF	CITATIONS
1460	Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use?. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-7.	0.8	22
1461	Prognosis of probable autoimmune hepatitis patients: a single-center study in Japan. Internal and Emergency Medicine, 2021, 16, 2155-2162.	1.0	2
1462	Harnessing brain waves: a review of brain magnetic resonance elastography for clinicians and scientists entering the field. British Journal of Radiology, 2021, 94, 20200265.	1.0	19
1463	Plasma Hemostasis in Patients with Essential Hypertension and Non-alcoholic Fatty Liver Disease Under Conditions of Hypercholesterolemia and Concomitant Statin Therapy. Family Medicine, 2021, , 12-18.	0.1	1
1464	Biochemical assessment of metabolic associated fatty liver disease. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 199-208.	0.1	3
1465	Exploring the Causality Between Hypothyroidism and Non-alcoholic Fatty Liver: A Mendelian Randomization Study. Frontiers in Cell and Developmental Biology, 2021, 9, 643582.	1.8	23
1466	The role of biofactors in the prevention and treatment of age-related diseases. BioFactors, 2021, 47, 522-550.	2.6	15
1467	Elevation of plasma tRNA fragments as a promising biomarker for liver fibrosis in nonalcoholic fatty liver disease. Scientific Reports, 2021, 11, 5886.	1.6	16
1468	Non-alcoholic fatty liver disease and psoriasis – is there a shared proinflammatory network?. JDDG - Journal of the German Society of Dermatology, 2021, 19, 517-528.	0.4	22
1469	Nonalcoholic Fatty Liver Disease: Epidemiology, Assessments, and Interventions Entering 2021. Clinical Therapeutics, 2021, 43, 436-437.	1.1	2
1470	The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. Scientific Reports, 2021, 11, 5195.	1.6	25
1471	Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, 1, 4-52.	0.1	63
1472	Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology Research, 2021, 51, 554-569.	1.8	28
1473	Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. Human and Experimental Toxicology, 2021, 40, 1496-1509.	1.1	16
1475	Caspase-Cleaved Keratin 18 Measurements Identified Ongoing Liver Injury after Bariatric Surgery. Journal of Clinical Medicine, 2021, 10, 1233.	1.0	8
1476	Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease. Digestive and Liver Disease, 2021, 53, 1610-1619.	0.4	8
1477	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. Scientific Reports, 2021, 11, 5416.	1.6	12
1478	Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Liver International, 2021, 41, 1532-1544.	1.9	26

#	ARTICLE	IF	CITATIONS
1479	Is there any useful surrogate to evaluate metabolic fatty liver disease?. Journal of the Chinese Medical Association, 2021, 84, 344-345.	0.6	2
1480	Calcium to magnesium intake ratio and non-alcoholic fatty liver disease development: a case-control study. BMC Endocrine Disorders, 2021, 21, 51.	0.9	7
1481	Natural History of NAFLD. Journal of Clinical Medicine, 2021, 10, 1161.	1.0	23
1482	The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study. Frontiers in Endocrinology, 2021, 12, 638615.	1.5	31
1483	Treatment Candidacy for Pharmacologic Therapies for NASH. Clinical Gastroenterology and Hepatology, 2022, 20, 1209-1217.	2.4	28
1484	Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States. Liver International, 2021, 41, 1832-1840.	1.9	35
1485	Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand. BMC Gastroenterology, 2021, 21, 135.	0.8	8
1486	â€œFocus on diet qualityâ€™: a qualitative study of cliniciansâ€™ perspectives of use of the Mediterranean dietary pattern for non-alcoholic fatty liver disease. British Journal of Nutrition, 2021, , 1-11.	1.2	10
1487	Association of non-alcoholic fatty liver disease with gallstone disease in the United States hospitalized patient population. World Journal of Gastrointestinal Pathophysiology, 2021, 12, 14-24.	0.5	13
1489	Physical activity of Korean cancer survivors is associated with age and sex. Korean Journal of Internal Medicine, 2021, 36, S225-S234.	0.7	5
1490	Nonalcoholic Steatohepatitis: Case-Based Focused on Pediatric and Adult Guidelines. Osteopathic Family Physician, 2021, , 29-37.	0.2	0
1491	Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2022, 20, 511-524.e1.	2.4	35
1492	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. European Journal of Health Economics, 2021, 22, 505-518.	1.4	16
1493	Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study. Expert Opinion on Investigational Drugs, 2021, 30, 579-589.	1.9	3
1494	The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Current Diabetes Reports, 2021, 21, 15.	1.7	78
1495	Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes: A Network Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 649018.	1.5	13
1496	Heroin use is associated with liver fibrosis in the Miami Adult Studies on HIV (MASH) cohort. Drug and Alcohol Dependence, 2021, 220, 108531.	1.6	11
1497	Pharmacological, Endoscopic, Metabolic, and Surgical Procedures for Nonalcoholic Fatty Liver Disease. Clinical Liver Disease, 2021, 17, 209-214.	1.0	2

#	ARTICLE	IF	CITATIONS
1498	Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. <i>Liver International</i> , 2021, 41, 1290-1293.	1.9	134
1499	US-FLI score “ Is it possible to predict the steatosis grade with an ultrasonographic score?. <i>Molecular Genetics and Metabolism</i> , 2021, 132, 204-209.	0.5	15
1500	Nonalcoholic fatty liver disease and cardiovascular concerns: The time for hepatologist and cardiologist close collaboration. <i>World Journal of Meta-analysis</i> , 2021, 9, 164-175.	0.1	2
1501	Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver. <i>PLoS ONE</i> , 2021, 16, e0249556.	1.1	5
1502	Controlled Attenuation Parameter in Healthy Individuals Aged 8–70 Years. <i>Ultrasound International Open</i> , 2021, 07, E6-E13.	0.3	1
1503	Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. <i>Journal of Clinical Medicine</i> , 2021, 10, 1569.	1.0	7
1504	Inhibition of Notch1 signaling reduces hepatocyte injury in nonalcoholic fatty liver disease via autophagy. <i>Biochemical and Biophysical Research Communications</i> , 2021, 547, 131-138.	1.0	12
1506	Elastography—A Bona Fide Non-Invasive Method for Assessing Non-Alcoholic Fatty Liver Disease in Children. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 3240.	1.3	2
1507	Case-finding strategies in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2021, 3, 100219.	2.6	19
1508	Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1877.	1.0	37
1509	Activation of thyroid hormone receptor ^{β2} improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. <i>British Journal of Pharmacology</i> , 2021, 178, 2412-2423.	2.7	47
1510	Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait. <i>Hepatology International</i> , 2021, 15, 912-921.	1.9	12
1511	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 257-269.	4.5	64
1512	Yet more evidence that MAFLD is more than a name change. <i>Journal of Hepatology</i> , 2021, 74, 977-979.	1.8	25
1513	Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2021, 116, 1686-1697.	0.2	20
1514	Deuterium-stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARI ³ Activity. <i>Hepatology Communications</i> , 2021, 5, 1412-1425.	2.0	23
1515	Non-invasive fibrosis assessments of non-alcoholic fatty liver disease associated with low estimated glomerular filtration rate among CKD patients: the Fukuoka Kidney disease Registry Study. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 822-834.	0.7	7
1516	A Canadian survey on knowledge of non-alcoholic fatty liver disease among physicians. <i>Canadian Liver Journal</i> , 2021, 4, 82-92.	0.3	6

#	ARTICLE	IF	CITATIONS
1517	A dietary ketone ester mitigates histological outcomes of NAFLD and markers of fibrosis in high-fat diet fed mice. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G564-G572.	1.6	10
1518	Assessment of the association between body composition and risk of non-alcoholic fatty liver. <i>PLoS ONE</i> , 2021, 16, e0249223.	1.1	12
1519	Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2021, 11, 787.	1.3	12
1520	Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 329-345.	4.5	14
1521	Quantification of Liver Fibrosis, Steatosis, and Viscosity Using Multiparametric Ultrasound in Patients with Non-Alcoholic Liver Disease: A "Real-Life" Cohort Study. <i>Diagnostics</i> , 2021, 11, 783.	1.3	30
1522	Update on cardiovascular risk in nonalcoholic fatty liver disease. <i>Current Opinion in Cardiology</i> , 2021, 36, 478-486.	0.8	5
1523	Weight Change and the Development of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Overweight Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e583-e599.	2.4	9
1524	Integrated Action of Autophagy and Adipose Tissue Triglyceride Lipase Ameliorates Diet-Induced Hepatic Steatosis in Liver-Specific PLIN2 Knockout Mice. <i>Cells</i> , 2021, 10, 1016.	1.8	21
1525	Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 639548.	1.5	35
1527	The Role of the Diabetes Care and Education Specialist in Caring for Diabetes Complications and Common Comorbid Conditions. <i>ADCES in Practice</i> , 2021, 9, 30-52.	0.2	1
1529	Non-alcoholic fatty liver diseases: current challenges and future directions. <i>Annals of Translational Medicine</i> , 2021, 9, 726-726.	0.7	16
1530	Evaluation of clinical efficiency of Decap replacement therapy in patients with type 2 diabetes mellitus and concomitant nonalcoholic fatty liver disease in vitamin D deficiency. <i>MÄ-Ä¾narodnj EndokrinologÄ-Änj Ä½urnal</i> , 2020, 16, 607-615.	0.1	0
1531	Fatty Liver Disease Prediction Model Based on Big Data of Electronic Physical Examination Records. <i>Frontiers in Public Health</i> , 2021, 9, 668351.	1.3	5
1532	Expert Opinion on the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Middle East with a Focus on the Use of Silymarin. <i>Gastroenterology Insights</i> , 2021, 12, 155-165.	0.7	12
1533	Relationship between NAFLD and Periodontal Disease from the View of Clinical and Basic Research, and Immunological Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3728.	1.8	18
1534	Glucose and lipid metabolism disorders in children and adolescents with spinal muscular atrophy types 2 and 3. <i>Neuromuscular Disorders</i> , 2021, 31, 291-299.	0.3	11
1535	Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease. <i>FASEB Journal</i> , 2021, 35, e21567.	0.2	15
1536	Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis. <i>Endocrine</i> , 2021, 73, 52-64.	1.1	17

#	ARTICLE	IF	CITATIONS
1537	Trend for Clinical Use of Metabolic Associated Fatty Liver Disease (MAFLD). , 2021, 4, 99-102.		1
1538	Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. <i>Current Opinion in Lipidology</i> , 2021, 32, 200-206.	1.2	10
1539	Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4459.	1.8	30
1540	Gastric Bypass Compared with Sleeve Gastrectomy for Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis. <i>Obesity Surgery</i> , 2021, 31, 2762-2772.	1.1	35
1541	Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases. <i>Antioxidants</i> , 2021, 10, 660.	2.2	41
1542	Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. <i>Advances in Therapy</i> , 2021, 38, 2130-2158.	1.3	46
1543	Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2021, 12, 609110.	1.5	41
1544	Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)â€”A Condition Associated with Heightened Sympathetic Activation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4241.	1.8	21
1545	Low serum vitamin D concentrations are associated with obese but not lean NAFLD: a cross-sectional study. <i>Nutrition Journal</i> , 2021, 20, 30.	1.5	6
1547	The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease. <i>Genes</i> , 2021, 12, 628.	1.0	8
1548	Meta-analysis of the effect of sodium-glucose cotransporter-2 inhibitors on hepatic fibrosis in patients with type-2 diabetes mellitus complicated with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2021, 51, 641-651.	1.8	10
1549	Hepatic Manifestations of Inflammatory Bowel Disease. <i>Clinical Liver Disease</i> , 2021, 17, 292-296.	1.0	4
1550	The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on COVID-19 Disease Prognosis. <i>Medicina (Lithuania)</i> , 2021, 57, 434.	0.8	11
1551	The effects of dietary intervention on fibrosis and biochemical parameters in metabolic-associated fatty liver disease. <i>Minerva Gastroenterology</i> , 2021, , .	0.3	0
1552	The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. <i>Nutrients</i> , 2021, 13, 1314.	1.7	34
1553	Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 221-235.	4.5	30
1554	Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference. <i>Journal of Clinical Medicine</i> , 2021, 10, 1507.	1.0	9
1555	Liver Fibrosis and Steatosis in Alstr�m Syndrome: A Genetic Model for Metabolic Syndrome. <i>Diagnostics</i> , 2021, 11, 797.	1.3	9

#	ARTICLE	IF	CITATIONS
1556	Measurements of Serum Mac-2-Binding Protein Glycosylation Isomer and Shear Wave Velocity in Health Checkups Are Useful in Screening for Non-Alcoholic Steatohepatitis. <i>Healthcare (Switzerland)</i> , 2021, 9, 523.	1.0	0
1557	Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study. <i>Eating and Weight Disorders</i> , 2021, , 1.	1.2	6
1558	Mining Gut Microbiota From Bariatric Surgery for MAFLD. <i>Frontiers in Endocrinology</i> , 2021, 12, 612946.	1.5	5
1559	Role of Insulin Resistance in MAFLD. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4156.	1.8	131
1560	What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1217-1220.	0.9	4
1561	Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2021, 16, e0249493.	1.1	17
1562	Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 9154.	1.6	9
1563	Nonalcoholic fatty liver disease and cardiovascular concerns: The time for hepatologist and cardiologist close collaboration. <i>World Journal of Meta-analysis</i> , 2021, 9, 163-174.	0.1	0
1564	Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 1751-1761.	1.1	25
1565	Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4495.	1.8	56
1566	Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00337.	1.3	18
1567	NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2856-e2865.	1.8	26
1568	Advanced liver fibrosis and the metabolic syndrome in a primary care setting. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3452.	1.7	10
1569	Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. <i>European Journal of Endocrinology</i> , 2021, 184, 587-596.	1.9	12
1570	Assessment of long-term functional maintenance of primary human hepatocytes to predict drug-induced hepatotoxicity in vitro. <i>Archives of Toxicology</i> , 2021, 95, 2431-2442.	1.9	6
1571	Obesity Primer for the Practicing Gastroenterologist. <i>American Journal of Gastroenterology</i> , 2021, 116, 918-934.	0.2	6
1572	Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. <i>BMC Gastroenterology</i> , 2021, 21, 180.	0.8	5
1573	Noninvasive stratification of nonalcoholic fatty liver disease by whole transcriptome cell-free mRNA characterization. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G439-G449.	1.6	18

#	ARTICLE	IF	CITATIONS
1574	Perfluorooctanesulfonic Acid (PFOS) Thwarts the Beneficial Effects of Calorie Restriction and Metformin. <i>Toxicological Sciences</i> , 2021, 182, 82-95.	1.4	13
1575	Lipotoxic hepatocyte-derived exosomal miR-1297 promotes hepatic stellate cell activation through the PTEN signaling pathway in metabolic-associated fatty liver disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 1419-1434.	1.4	34
1576	Normalization of $\hat{1}^3$ -glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2021, 21, 215.	0.8	9
1577	Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2021, 12, 665987.	1.5	17
1578	Early cardiac electrical and structural changes in patients with non-obese non-alcoholic fatty liver disease. <i>Kardiologiya</i> , 2021, 61, 51-58.	0.3	5
1579	Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, 586-593.	1.1	3
1580	Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. <i>BMC Gastroenterology</i> , 2021, 21, 212.	0.8	54
1581	The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Contemporary Clinical Trials</i> , 2021, 104, 106335.	0.8	38
1582	Low Skeletal Muscle Mass Is a Risk Factor for Subclinical Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2021, 11, 854.	1.3	9
1583	Epigenetics of Hepatic Insulin Resistance. <i>Frontiers in Endocrinology</i> , 2021, 12, 681356.	1.5	23
1584	â€œBioelectrical impedance analysis in managing sarcopenic obesity in NAFLDâ€• <i>Obesity Science and Practice</i> , 2021, 7, 629-645.	1.0	4
1585	Nonalcoholic fatty liver and left ventricular remodelling: now the prospective evidence. <i>Journal of Hypertension</i> , 2021, 39, 864-866.	0.3	1
1586	Prevention of nonâ€œalcoholic steatohepatitis by longâ€œterm exercise via the induction of phenotypic changes in Kupffer cells of hyperphagic obese mice. <i>Physiological Reports</i> , 2021, 9, e14859.	0.7	6
1587	Serum Resistin Levels in Adult Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	7
1588	Elevated levels of urine isocitrate, hydroxymethylglutarate, and formiminoglutamate are associated with arterial stiffness in Korean adults. <i>Scientific Reports</i> , 2021, 11, 10180.	1.6	4
1589	Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 813-822.	1.8	66
1590	Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5462.	1.8	33
1591	Dynamics of Serum Retinol and Alpha-Tocopherol Levels According to Non-Alcoholic Fatty Liver Disease Status. <i>Nutrients</i> , 2021, 13, 1720.	1.7	12

#	ARTICLE	IF	CITATIONS
1592	Association Between Thyroid Hormone Levels and Advanced Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 2399-2406.	1.1	9
1593	Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0252286.	1.1	22
1594	Endogenous vitamin E metabolites mediate allosteric PPAR α activation with unprecedented co-regulatory interactions. <i>Cell Chemical Biology</i> , 2021, 28, 1489-1500.e8.	2.5	19
1595	Sleeve gastrectomy prior to liver transplantation is superior to medical weight loss in reducing posttransplant metabolic complications. <i>American Journal of Transplantation</i> , 2021, 21, 3324-3332.	2.6	8
1596	MRI-Based Quantitation of Hepatic Steatosis Does Not Predict Hypertrophy Rate after Portal Vein Embolization in Patients with Colorectal Liver Metastasis and Normal to Moderately Elevated Fat Fraction. <i>Journal of Clinical Medicine</i> , 2021, 10, 2003.	1.0	3
1597	Abnormal Liver Blood Tests: Primary Care Approach. <i>Digestive Diseases</i> , 2022, 40, 215-222.	0.8	2
1598	Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2638-2640.	2.4	5
1599	Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5227.	1.2	109
1600	Nonalcoholic Fatty Liver Disease after Liver Transplant. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	6
1601	The role of mean platelet volume in nonalcoholic fatty liver disease without cardiovascular comorbidities, obesity and diabetes mellitus. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1222-1228.	0.8	2
1602	Combination of type IV collagen 7S, albumin concentrations, and platelet count predicts prognosis of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2021, 13, 571-583.	0.8	6
1603	Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies. <i>Drugs - Real World Outcomes</i> , 2021, 8, 369-382.	0.7	2
1604	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. <i>Seminars in Liver Disease</i> , 2021, 41, 235-247.	1.8	4
1605	The role of elastography in non-alcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2021, 67, 164-170.	0.3	7
1606	Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5375.	1.8	59
1607	Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. <i>Circulation Research</i> , 2021, 128, 1747-1765.	2.0	49
1608	Importance of non-invasive liver fibrosis scores for mortality and complications development in individuals with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107879.	1.2	10
1609	Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. <i>BMJ Open</i> , 2021, 11, e042843.	0.8	60

#	ARTICLE	IF	CITATIONS
1610	Cut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. <i>Metabolites</i> , 2021, 11, 353.	1.3	19
1611	XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. <i>Nature Medicine</i> , 2021, 27, 1043-1054.	15.2	95
1612	Serum Bile Acid Profiles Improve Clinical Prediction of Nonalcoholic Fatty Liver in T2DM patients. <i>Journal of Proteome Research</i> , 2021, 20, 3814-3825.	1.8	14
1613	Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4807.	1.8	44
1614	Exercise improves lipid droplet metabolism disorder through activation of AMPK-mediated lipophagy in NAFLD. <i>Life Sciences</i> , 2021, 273, 119314.	2.0	29
1615	Brazilian Society of Hepatology and Brazilian College of Radiology practice guidance for the use of elastography in liver diseases. <i>Annals of Hepatology</i> , 2021, 22, 100341.	0.6	4
1616	Association between Sarcopenic Obesity and Nonalcoholic Fatty Liver Disease and Fibrosis detected by Fibroscan. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 227-232.	0.5	8
1617	Constituents, Pharmacokinetics, and Pharmacology of Gegen-Qinlian Decoction. <i>Frontiers in Pharmacology</i> , 2021, 12, 668418.	1.6	29
1618	Comment on: Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, e17.	1.0	0
1619	Serum iron and risk of nonalcoholic fatty liver disease and advanced hepatic fibrosis in US adults. <i>Scientific Reports</i> , 2021, 11, 10387.	1.6	15
1620	Serum Uric Acid Is a Mediator of the Association Between Obesity and Incident Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 657856.	1.5	9
1621	The predictive role of parathyroid hormone for non-alcoholic fatty liver disease based on invasive and non-invasive findings in candidates of bariatric surgery. <i>Eating and Weight Disorders</i> , 2022, 27, 693-700.	1.2	4
1622	Beverages and Non-alcoholic fatty liver disease (NAFLD): Think before you drink. <i>Clinical Nutrition</i> , 2021, 40, 2508-2519.	2.3	25
1623	Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand. <i>Cureus</i> , 2021, 13, e14858.	0.2	4
1624	Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	3
1625	Efficacy and safety of obeticholic acid in liver disease—A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101675.	0.7	19
1626	FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2415.	1.0	24
1627	Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Diabetes Therapy</i> , 2021, 12, 1735-1749.	1.2	16

#	ARTICLE	IF	CITATIONS
1628	Association between ectopic pancreatic and hepatic fat and metabolic risk factors in children with non-alcoholic fatty liver disease. <i>Pediatric Obesity</i> , 2021, 16, e12793.	1.4	6
1629	Nano-encapsulation of hydroxytyrosol into formulated nanogels improves therapeutic effects against hepatic steatosis: An in vitro study. <i>Materials Science and Engineering C</i> , 2021, 124, 112080.	3.8	12
1630	Patients with different types of arthritis may be at risk for major depression: results from the National Health and Nutrition Examination Survey 2007-2018. <i>Annals of Palliative Medicine</i> , 2021, 10, 5280-5288.	0.5	5
1631	Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. <i>World Journal of Gastroenterology</i> , 2021, 27, 1864-1882.	1.4	19
1632	Serum markers for predicting advanced fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2021, 100, e25327.	0.4	3
1633	Reliability of Performing Multiparametric Ultrasound in Adult Livers. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 699-711.	0.8	10
1634	Agents for the treatment of fatty liver disease: focus on essential phospholipids. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 249-264.	0.3	5
1635	Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting. <i>PLoS ONE</i> , 2021, 16, e0251741.	1.1	14
1636	Edmonton Obesity Staging System: an improvement by cardiopulmonary exercise testing. <i>International Journal of Obesity</i> , 2021, 45, 1949-1957.	1.6	5
1637	Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2021, 34, 897-904.	0.4	8
1638	Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1891-1899.	1.6	1
1639	The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 599-612.	8.2	346
1640	US Elastography in Hepatic Fibrosis – Radiology In Training. <i>Radiology</i> , 2021, 299, 264-271.	3.6	8
1641	Abnormal Liver Blood Tests: Hepatologist Approach. <i>Digestive Diseases</i> , 2022, 40, 206-214.	0.8	1
1642	Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study. <i>Obesity Science and Practice</i> , 2021, 7, 497-508.	1.0	2
1643	Exacerbation of liver dysfunction in non-alcoholic steatohepatitis patients during the coronavirus disease 2019 (COVID-19) pandemic. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2021, 68, 243-245.	0.6	2
1644	Î²2-Adrenergic Receptor Agonist Induced Hepatic Steatosis in Mice: Modeling Nonalcoholic Fatty Liver Disease in Hyperadrenergic States. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E90-E104.	1.8	11
1645	The Potential Protective Role of RUNX1 in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5239.	1.8	3

#	ARTICLE	IF	CITATIONS
1646	Synergistic effects of black ginseng and aged garlic extracts for the amelioration of nonalcoholic fatty liver disease (NAFLD) in mice. <i>Food Science and Nutrition</i> , 2021, 9, 3091-3099.	1.5	12
1647	Iron oxide nanoparticles aggravate hepatic steatosis and liver injury in nonalcoholic fatty liver disease through BMP-SMAD-mediated hepatic iron overload. <i>Nanotoxicology</i> , 2021, 15, 761-778.	1.6	16
1648	Association between cumulative childhood blood lead exposure and hepatic steatosis in young Mexican adults. <i>Environmental Research</i> , 2021, 196, 110980.	3.7	16
1649	Mechanisms and disease consequences of nonalcoholic fatty liver disease. <i>Cell</i> , 2021, 184, 2537-2564.	13.5	757
1650	Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5016.	1.8	34
1651	Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications. <i>Diagnostics</i> , 2021, 11, 842.	1.3	16
1652	Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13622.	1.7	63
1653	Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2021, 31, 14-26.	0.2	0
1654	Association of circulating preptin with non-alcoholic fatty liver disease: A case-control study. <i>Journal of Surgery and Medicine</i> , 2021, 5, 628-632.	0.0	2
1655	Cross-sectional pilot study to assess primary healthcare workers's knowledge of nonalcoholic fatty liver disease in a marginalized community in Mexico. <i>Scientific Reports</i> , 2021, 11, 12100.	1.6	1
1656	Synergistic harmful interaction between sustained physical inactivity and hypertension/diabetes mellitus on the risk of all-cause mortality: a retrospective observational cohort study. <i>Journal of Hypertension</i> , 2021, 39, 2058-2066.	0.3	4
1657	Clinical impact of sexual dimorphism in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). <i>Liver International</i> , 2021, 41, 1713-1733.	1.9	58
1658	Estimated insulin sensitivity, cardiovascular risk, and hepatic steatosis after 12 years from the onset of T1D. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, , e3479.	1.7	0
1659	Assessment of Classification Models and Relevant Features on Nonalcoholic Steatohepatitis Using Random Forest. <i>Entropy</i> , 2021, 23, 763.	1.1	12
1660	The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6627.	1.8	18
1661	Association Between the Triglyceride-Glucose Index and Outcomes of Nonalcoholic Fatty Liver Disease: A Large-Scale Health Management Cohort Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 2829-2839.	1.1	10
1662	Deregulation of Secreted Frizzled-Related Protein 5 in Nonalcoholic Fatty Liver Disease Associated with Obesity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6895.	1.8	5
1663	Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease. <i>Hepatology International</i> , 2021, 15, 1148-1159.	1.9	14

#	ARTICLE	IF	CITATIONS
1664	Novel artificial intelligent/neural network system for staging of nonalcoholic steatohepatitis. <i>Hepatology Research</i> , 2021, 51, 1044-1057.	1.8	9
1665	Fructooligosaccharides enhance the therapeutic effect of xiao-zhi-fang on non-alcoholic fatty liver disease via regulating intestinal flora. <i>Liver Research</i> , 2021, 5, 217-223.	0.5	3
1666	Administrative Coding in Electronic Health Care Recordâ€Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021, 74, 474-482.	3.6	102
1667	Bariatric surgery for non-alcoholic fatty liver disease in individuals with obesity (Base-NAFLD): protocol of a prospective multicenter observational follow-up study. <i>BMC Surgery</i> , 2021, 21, 298.	0.6	3
1668	Nonâ€Alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 964-972.	2.9	28
1669	Integrated multiplatform-based metabonomics and network analysis to explore the mechanism of <i>Polygonum cuspidatum</i> on hyperlipidemia. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1176, 122769.	1.2	16
1670	Soyasaponin A₂ Alleviates Steatohepatitis Possibly through Regulating Bile Acids and Gut Microbiota in the Methionine and Cholineâ€Deficient (MCD) Dietâ€Induced Nonalcoholic Steatohepatitis (NASH) Mice. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2100067.	1.5	15
1671	FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitisâ€ Validation in an Indian Cohort. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 440-447.	0.4	9
1672	Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021, 17, 484-495.	4.3	224
1673	Non-alcoholic fatty liver disease. <i>Lancet, The</i> , 2021, 397, 2212-2224.	6.3	1,035
1674	Validation of a twoâ€step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis. <i>JGH Open</i> , 2021, 5, 801-808.	0.7	2
1675	Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD â€ Reconciling the present with the past. <i>JHEP Reports</i> , 2021, 3, 100261.	2.6	31
1676	Dietary Intake of Milk Thistle Seeds as a Source of Silymarin and Its Influence on the Lipid Parameters in Nonalcoholic Fatty Liver Disease Patients. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 5836.	1.3	2
1677	Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation. <i>Scientific Reports</i> , 2021, 11, 13159.	1.6	28
1678	Health Literacy, Knowledge, and Risk Factors for Fatty Liver Disease among Asian American and Pacific Islanders and Latinos in Los Angeles. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1737-1744.	0.5	2
1679	Very-low-calorie ketogenic diet for the management of obesity, overweight and related disorders. <i>Minerva Endocrinology</i> , 2021, 46, 161-167.	0.6	18
1680	High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 2841-2849.	1.1	8
1681	Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations. <i>Seminars in Liver Disease</i> , 2021, 41, 248-262.	1.8	10

#	ARTICLE	IF	CITATIONS
1682	Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study. <i>Diagnostics</i> , 2021, 11, 1083.	1.3	8
1683	Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2910.	1.0	23
1684	Intestinal Dysbiosis and Non-Alcoholic Fatty Liver Disease. <i>Biochemistry</i> , 0, , .	0.8	4
1685	Development and initial validation of the nonalcoholic fatty liver disease self-management questionnaire. <i>Research in Nursing and Health</i> , 2021, 44, 844-853.	0.8	3
1686	Recent advances in nonalcoholic fatty liver disease metabolomics. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 553-559.	4.5	40
1687	Association between Visceral Adipose Tissue and Non-Alcoholic Steatohepatitis Histology in Patients with Known or Suspected Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2565.	1.0	7
1688	Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. <i>Frontiers in Nutrition</i> , 2021, 8, 700058.	1.6	33
1689	Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1438-e1455.	2.4	49
1690	Ten things to know about ten imaging studies: A preventive cardiology perspective (â€œASPC top ten) <i>Tj ETQq0 0 0,rgBT /Overlock 10</i>	1.3	9
1691	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1299-1300.	2.4	2
1692	Genome-wide DNA methylation profiling in nonalcoholic fatty liver reveals predictive aberrant methylation in PRKCE and SEC14L3 promoters. <i>Digestive and Liver Disease</i> , 2022, 54, 521-528.	0.4	9
1693	Nonalcoholic Fatty Liver Diseaseâ€™ A Novel Risk Factor for Recurrent Clostridioides difficile Infection. <i>Antibiotics</i> , 2021, 10, 780.	1.5	9
1694	Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2089-2097.	4.3	27
1695	Alleviating effect of <i>Ficus racemosa</i> in high-fat-high-fructose diet-induced non-alcoholic fatty liver disease. <i>Indian Journal of Physiology and Pharmacology</i> , 0, 65, 12-20.	0.4	2
1696	A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2806.	1.0	11
1697	Non-alcoholic fatty liver disease in type 2 diabetes â€“ A specific entity?. <i>Liver International</i> , 2021, 41, 105-111.	1.9	3
1698	Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. <i>Frontiers in Medicine</i> , 2021, 8, 683250.	1.2	34
1699	Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia. <i>EClinicalMedicine</i> , 2021, 36, 100919.	3.2	14

#	ARTICLE	IF	CITATIONS
1700	Conventional ultrasound for diagnosis of hepatic steatosis is better than believed. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 1235-1248.	0.2	12
1701	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 717-729.	8.2	72
1702	Pediatric nonalcoholic fatty liver disease – a changing diagnostic paradigm. <i>Romanian Journal of Morphology and Embryology</i> , 2021, 61, 1023-1031.	0.4	5
1703	Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. <i>Journal of Personalized Medicine</i> , 2021, 11, 499.	1.1	8
1704	Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. <i>Seminars in Liver Disease</i> , 2021, 41, 225-234.	1.8	37
1705	Current and Evolving Indications for Simultaneous Liver Kidney Transplantation. <i>Seminars in Liver Disease</i> , 2021, 41, 308-320.	1.8	0
1706	TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population. <i>Journal of Clinical Medicine</i> , 2021, 10, 2907.	1.0	12
1707	Circulating branch chain amino acids and improvement in liver fat content in response to exercise interventions in NAFLD. <i>Scientific Reports</i> , 2021, 11, 13415.	1.6	7
1708	The mechanism of increased intestinal palmitic acid absorption and its impact on hepatic stellate cell activation in nonalcoholic steatohepatitis. <i>Scientific Reports</i> , 2021, 11, 13380.	1.6	5
1709	PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS. <i>Arquivos De Gastroenterologia</i> , 2021, 58, 139-144.	0.3	9
1710	Recent Perspective on Thiazolidinedione. <i>Journal of Korean Diabetes</i> , 2021, 22, 97-104.	0.1	1
1711	Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4360-e4371.	1.8	6
1712	Thiamethoxam induces nonalcoholic fatty liver disease in mice via methionine metabolism disturb via nicotinamide N-methyltransferase overexpression. <i>Chemosphere</i> , 2021, 273, 129727.	4.2	16
1713	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2021, 48, 481-487.	0.6	11
1714	Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes. <i>JGH Open</i> , 2021, 5, 915-922.	0.7	8
1715	Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1833-1841.	0.2	15
1716	A clinical model to predict fibrosis on liver biopsy in paediatric subjects with nonalcoholic fatty liver disease. <i>Clinical Obesity</i> , 2021, 11, e12472.	1.1	3
1717	Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2021, 27, 4677-4685.	0.9	7

#	ARTICLE	IF	CITATIONS
1718	Diagnosis and management of secondary causes of steatohepatitis. <i>Journal of Hepatology</i> , 2021, 74, 1455-1471.	1.8	56
1719	Impact of vitamin E on redox biomarkers in non-alcoholic fatty liver disease. <i>Redox Biology</i> , 2021, 42, 101937.	3.9	19
1720	Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes. <i>PLoS ONE</i> , 2021, 16, e0251449.	1.1	11
1721	Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 613389.	1.5	14
1722	Association between Administration of Antithrombotics and Intraoperative Hemorrhage in Patients Undergoing Percutaneous Interventions for Liver Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 2527.	1.0	0
1723	Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-6.	0.6	3
1724	Association between nonalcoholic fatty liver disease and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching. <i>Lipids in Health and Disease</i> , 2021, 20, 59.	1.2	13
1725	Does a high intake of green leafy vegetables protect from NAFLD? Evidence from a large population study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1691-1701.	1.1	15
1726	Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016. <i>Chinese Medical Journal</i> , 2021, 134, 1593-1601.	0.9	28
1727	Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2021, 74, 1220-1233.	3.6	54
1728	Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target. <i>Journal of Personalized Medicine</i> , 2021, 11, 619.	1.1	8
1729	Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3204-3211.	1.4	8
1730	Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1354-1361.e7.	2.4	29
1731	Diagnostic and Treatment Dilemmas in Pediatric NAFLD. <i>Clinical Liver Disease</i> , 2021, 18, 37-39.	1.0	1
1732	Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients. <i>Medicine (United States)</i> , 2021, 100, e26436.	0.4	7
1733	Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. <i>World Journal of Gastroenterology</i> , 2021, 27, 3971-3983.	1.4	18
1734	Usefulness of FibroScan-AST (FAST) score in Japanese patients with non-alcoholic fatty liver disease: A single-center retrospective experience. <i>Acta Hepatologica Japonica</i> , 2021, 62, 393-402.	0.0	0
1735	Anti-diabetic drugs and NASH: from current options to promising perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 813-825.	1.9	16

#	ARTICLE	IF	CITATIONS
1736	Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. <i>Cancers</i> , 2021, 13, 3473.	1.7	12
1737	Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity. <i>Endocrinologia, Diabetes Y Nutrici3n</i> , 2022, 69, 178-188.	0.1	4
1738	Usefulness of Controlled Attenuation Parameter for Identification and Grading of Nonalcoholic Fatty Liver Disease in Adolescents with Obesity. <i>Indian Journal of Pediatrics</i> , 2021, 89, 52.	0.3	1
1739	Assessing Interactions between PNPLA3 and Dietary Intake on Liver Steatosis in Mexican-Origin Adults. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7055.	1.2	4
1740	Ultrasound-Based Quantification of Fibrosis and Steatosis with a New Software Considering Transient Elastography as Reference in Patients with Chronic Liver Diseases. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 1692-1703.	0.7	15
1741	Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 362-371.	0.4	2
1742	2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 461-481.	1.8	146
1743	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	2.4	49
1744	Performance Characteristics, Intra- & Inter-Operator Agreement of Transient Elastography in Pediatric NAFLD. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 74, .	0.9	0
1745	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299.	1.4	37
1746	Differential Effects of Dietary Components on Glucose Intolerance and Non-Alcoholic Steatohepatitis. <i>Nutrients</i> , 2021, 13, 2523.	1.7	6
1747	Body weight gain rather than body weight variability is associated with increased risk of nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 14428.	1.6	4
1748	Effective Treatment of Nonalcoholic Fatty Liver Disease Using a Community-Based Weight Management Program. <i>Cureus</i> , 2021, 13, e16709.	0.2	0
1749	The association between serum liver enzymes and cancer mortality. <i>Clinical and Experimental Medicine</i> , 2022, 22, 75-81.	1.9	7
1750	Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 991.	0.8	12
1751	Extracts of Vine Tea Improve Diet-Induced Non-Alcoholic Steatohepatitis Through AMPK-LXR± Signaling. <i>Frontiers in Pharmacology</i> , 2021, 12, 711763.	1.6	7
1752	Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. Women. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108879.	1.1	8
1753	Risk for hepatic and extrahepatic outcomes in nonalcoholic fatty liver disease. <i>Journal of Internal Medicine</i> , 2022, 292, 177-189.	2.7	11

#	ARTICLE	IF	CITATIONS
1754	Expression of Jejunal Taste Receptors in Women with Morbid Obesity. <i>Nutrients</i> , 2021, 13, 2437.	1.7	4
1755	Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population. <i>Frontiers in Endocrinology</i> , 2021, 12, 711484.	1.5	11
1756	Collagen Î²(1-O) galactosyltransferase 2 deficiency contributes to lipodystrophy and aggravates NAFLD related to HMW adiponectin in mice. <i>Metabolism: Clinical and Experimental</i> , 2021, 120, 154777.	1.5	6
1757	Dietary carbohydrates and fats in nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 770-786.	8.2	108
1758	Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 14639.	1.6	37
1759	Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172.	4.3	30
1760	Identifying Patients at Risk for Fibrosis in a Primary Care NAFLD Cohort. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	3
1761	Reduction of Visceral Adiposity as a Predictor for Resolution of Nonalcoholic Fatty Liver in Potential Living Liver Donors. <i>Liver Transplantation</i> , 2021, 27, 1424-1431.	1.3	4
1762	MAFLD-Epidemiology, Natural History, Outcomes and Prevention. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 12-17.	0.1	1
1764	Delayed Meal Timing, a Breakfast Skipping Model, Increased Hepatic Lipid Accumulation and Adipose Tissue Weight by Disintegrating Circadian Oscillation in Rats Fed a High-Cholesterol Diet. <i>Frontiers in Nutrition</i> , 2021, 8, 681436.	1.6	11
1765	Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2960-2966.	1.4	36
1766	Diagnosis of Nonalcoholic Steatohepatitis. , 0, , .		0
1767	Diabetes Mellitus Increases the Risk of Significant Hepatic Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 409-416.	0.4	4
1768	The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 705485.	2.2	19
1769	Prevalence and risk factors of steatosis and advanced fibrosis using transient elastography in the United Statesâ€™ adolescent population. <i>World Journal of Hepatology</i> , 2021, 13, 790-803.	0.8	1
1770	Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 2258-2269.	0.2	25
1771	Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 578-588.	3.7	206
1772	Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. <i>Foods</i> , 2021, 10, 1719.	1.9	14

#	ARTICLE	IF	CITATIONS
1773	Prehabilitation-Driven Changes in Frailty Metrics Predict Mortality in Patients With Advanced Liver Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2105-2117.	0.2	31
1774	High frequency and long persistency of ballooning hepatocyte were associated with glucose intolerance in patients with severe obesity. <i>Scientific Reports</i> , 2021, 11, 15392.	1.6	7
1775	Sex hormones abnormalities in non-alcoholic fatty liver disease: pathophysiological and clinical implications. <i>Exploration of Medicine</i> , 0, , .	1.5	0
1776	Nonalcoholic Fatty Liver Disease in Children with Obesity: Narrative Review and Research Gaps. <i>Hormone Research in Paediatrics</i> , 2022, 95, 167-176.	0.8	11
1777	Home parenteral nutrition patients on mixed oil lipid emulsion have a higher rate of hospitalizations compare to those on soybean oilâ€” a prospective 2-year cohort study. <i>Clinical Nutrition</i> , 2021, 40, 4616-4623.	2.3	1
1778	Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1181-1189.	1.4	2
1779	The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis. <i>Metabolism: Clinical and Experimental</i> , 2021, 120, 154779.	1.5	23
1780	Alcohol and Metabolic-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	5
1781	Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101755.	0.7	8
1782	Long working hours are associated with a higher risk of non-alcoholic fatty liver disease: A large population-based Korean cohort study. <i>PLoS ONE</i> , 2021, 16, e0255118.	1.1	4
1783	Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. <i>Seminars in Liver Disease</i> , 2021, , .	1.8	2
1784	Prediction of Nonalcoholic Fatty Liver Disease by Anthropometric Indices and Bioelectrical Impedance Analysis in Children. <i>Childhood Obesity</i> , 2021, 17, 551-558.	0.8	3
1785	Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108882.	1.1	9
1786	Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation. <i>International Journal of Biological Macromolecules</i> , 2021, 183, 1379-1392.	3.6	55
1787	Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes. <i>Hepatology</i> , 2021, 74, 1845-1863.	3.6	16
1788	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 363-401.	4.5	152
1789	The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. <i>Scientific Reports</i> , 2021, 11, 13844.	1.6	14
1790	Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results. <i>PLoS ONE</i> , 2021, 16, e0254939.	1.1	7

#	ARTICLE	IF	CITATIONS
1791	Visceral adiposity as a risk factor for lean non-alcoholic fatty liver disease in potential living liver donors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3212-3218.	1.4	16
1792	Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. <i>Hepatology Communications</i> , 2021, 5, 1676-1688.	2.0	38
1793	Assessment of chronic liver disease by multiparametric ultrasound: results from a private practice outpatient facility. <i>Abdominal Radiology</i> , 2021, 46, 5152-5161.	1.0	8
1794	MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. <i>Hepatology Research</i> , 2021, 51, 1115-1128.	1.8	104
1795	Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). <i>Medical Science Monitor</i> , 2021, 27, e933860.	0.5	8
1796	Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. <i>Seminars in Liver Disease</i> , 2021, 41, 421-434.	1.8	55
1797	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1506-1507.	2.4	0
1798	Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101769.	0.7	8
1799	Curcumin and Biochemical Parameters in Metabolic-Associated Fatty Liver Disease (MAFLD)-A Review. <i>Nutrients</i> , 2021, 13, 2654.	1.7	12
1800	Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. <i>Hepatology Communications</i> , 2021, 5, 1833-1847.	2.0	54
1801	Effect of low carbohydrate diets on insulin resistance and the metabolic syndrome. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 463-468.	1.2	8
1802	Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7702.	1.8	18
1803	Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. <i>Gastroenterology</i> , 2021, 161, 171-184.e10.	0.6	78
1804	Saroglitazar, a PPAR α/β Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. <i>Hepatology</i> , 2021, 74, 1809-1824.	3.6	163
1805	Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. <i>Seminars in Liver Disease</i> , 2021, 41, 461-475.	1.8	28
1806	Dose-response relationship between World Trade Center dust exposure and hepatic steatosis. <i>American Journal of Industrial Medicine</i> , 2021, 64, 837-844.	1.0	4
1807	Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. <i>Internal Medicine</i> , 2021, 60, 2167-2174.	0.3	15
1808	The ultrasound-guided attenuation parameter is useful in quantification of hepatic steatosis in non-alcoholic fatty liver disease. <i>JGH Open</i> , 2021, 5, 947-952.	0.7	6

#	ARTICLE	IF	CITATIONS
1809	Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 6-16.	0.7	27
1810	Hepatic steatosis in patients with schizophrenia: a clinical cross-sectional study. <i>Nordic Journal of Psychiatry</i> , 2021, , 1-6.	0.7	3
1811	Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents. <i>Frontiers in Pediatrics</i> , 2021, 9, 667247.	0.9	6
1812	Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 486-498.	4.5	20
1813	Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2021, 120, 154780.	1.5	17
1814	The COP9 Signalosome Variant CSNCSN7A Stabilizes the Deubiquitylating Enzyme CYLD Impeding Hepatic Steatosis. <i>Livers</i> , 2021, 1, 116-131.	0.8	4
1815	Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	8
1816	Deep learning for abdominal ultrasound: A computer-aided diagnostic system for the severity of fatty liver. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 842-850.	0.6	22
1817	Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 2616-2627.	0.6	1
1818	Risks and Rewards of Bariatric Surgery in Advanced Chronic Liver Diseases. <i>Seminars in Liver Disease</i> , 2021, 41, 448-460.	1.8	9
1819	Relationship Between Non-Alcoholic Fatty Liver Disease and Abdominal and Pericardial Adipose Tissue in Middle-Aged and Elderly Subjects. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3439-3444.	0.8	2
1821	Liver Fibrosis is Associated with Ischemic Stroke Risk in Women but not Men: The REGARDS Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105788.	0.7	15
1822	Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. <i>Nature Medicine</i> , 2021, 27, 1262-1271.	15.2	154
1823	Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1451-1458.	0.8	10
1824	Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD). <i>Molecular Metabolism</i> , 2021, 50, 101146.	3.0	16
1825	Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence. <i>World Journal of Hepatology</i> , 2021, 13, 916-925.	0.8	4
1826	Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. <i>Cureus</i> , 2021, 13, e17321.	0.2	3
1827	GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. <i>Frontiers in Endocrinology</i> , 2021, 12, 721135.	1.5	103

#	ARTICLE	IF	CITATIONS
1828	The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021, 13, 2772.	1.7	11
1829	Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. <i>Clinical Nutrition ESPEN</i> , 2021, 44, 61-68.	0.5	13
1830	Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic. , 2021, 32, 466-472.		5
1831	Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154752.	1.5	47
1832	Independent Dose-Response Associations between Fetuin-A and Lean Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021, 13, 2928.	1.7	6
1833	Imaging biomarkers of NAFLD, NASH, and fibrosis. <i>Molecular Metabolism</i> , 2021, 50, 101167.	3.0	83
1834	Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. <i>Chinese Medicine</i> , 2021, 16, 68.	1.6	30
1835	Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2021, 100, e26835.	0.4	21
1836	Associations of Dietary Lipid-Soluble Micronutrients with Hepatic Steatosis among Adults in the United States. <i>Biomedicines</i> , 2021, 9, 1093.	1.4	2
1837	Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin. <i>Journal of Pediatrics</i> , 2021, 239, 161-167.e5.	0.9	8
1838	Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 28-43.	2.2	40
1839	Cancer and hepatic steatosis. <i>ESMO Open</i> , 2021, 6, 100185.	2.0	9
1840	Effects of endoscopic gastric plication on portal pressure gradient in a patient with nonalcoholic steatohepatitis cirrhosis. <i>VideoGIE</i> , 2021, 6, 491-494.	0.3	1
1841	Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis. <i>Periodontology 2000</i> , 2021, 87, 204-240.	6.3	44
1842	GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients: Just a question of weight loss?. <i>Digestive and Liver Disease</i> , 2021, 53, 1673-1674.	0.4	2
1843	Liver frailty and all-cause mortality in the older participants of the Salus in Apulia Study. <i>GeroScience</i> , 2022, 44, 835-845.	2.1	12
1844	Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury. <i>Hepatology International</i> , 2021, 15, 1456-1465.	1.9	10
1845	Independent of Calorie Intake, Short-term Alternate-day Fasting Alleviates NASH, With Modulation of Markers of Lipogenesis, Autophagy, Apoptosis, and Inflammation in Rats. <i>Journal of Histochemistry and Cytochemistry</i> , 2021, 69, 575-596.	1.3	10

#	ARTICLE	IF	CITATIONS
1846	Semaglutide for nonalcoholic steatohepatitis: closer to a solution?. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 541-544.	0.7	4
1847	Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus. <i>Endocrine</i> , 2021, 74, 538-545.	1.1	19
1848	Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2399-2409.	0.2	9
1849	Current-Visit and Next-Visit Prediction for Fatty Liver Disease With a Large-Scale Dataset: Model Development and Performance Comparison. <i>JMIR Medical Informatics</i> , 2021, 9, e26398.	1.3	0
1850	The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 29-38.	1.8	82
1851	First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. <i>Hepatology International</i> , 2021, 15, 1136-1147.	1.9	23
1852	Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 174-179.	0.4	2
1853	Effects of Telemedicine on Obese Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 723790.	1.2	6
1854	Nonalcoholic fatty pancreas disease: An emerging clinical challenge. <i>World Journal of Clinical Cases</i> , 2021, 9, 6624-6638.	0.3	10
1855	Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. <i>PLoS ONE</i> , 2021, 16, e0255822.	1.1	5
1856	Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille?. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	3
1857	Perinatal Risk Factors for Pediatric Nonalcoholic Fatty Liver Disease: Impact of Inborn Errors of Metabolism. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	2
1858	Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis. <i>Life</i> , 2021, 11, 799.	1.1	9
1859	Effect of Luseogliflozin on liver function, BNP and baPWV in diabetics with coronary artery disease. <i>Vascular Failure</i> , 2021, 4, 68-75.	0.2	0
1860	Dysregulation of Components of the Inflammasome Machinery After Bariatric Surgery: Novel Targets for a Chronic Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4917-e4934.	1.8	6
1861	Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1013-1025.	1.9	47
1862	Prevalence and Clinical Significance of Autoantibodies in Children with Overweight and Obesity with Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatrics</i> , 2021, 239, 155-160.	0.9	10
1863	“You Are What You Eat”: The Role of Dietary Macronutrients and Micronutrients in MAFLD. <i>Clinical Liver Disease</i> , 2021, 18, 67-71.	1.0	3

#	ARTICLE	IF	CITATIONS
1864	Systolic Blood Pressure Mediates Body Mass Index and Non-alcoholic Fatty Liver Disease: A Population-Based Study. , 2021, 32, 458-465.		4
1865	The effect of endurance training on non-alcoholic fatty liver disease in mice. <i>Physiological Reports</i> , 2021, 9, e14926.	0.7	2
1866	A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3676-3688.	1.1	11
1867	Inverse Association between Serum 25-hydroxyvitamin D Levels and Risk of Suspected Non-Alcoholic Fatty Liver Disease in Obese Population. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8682.	1.2	4
1868	Development and Validation of a Novel Scoring System for Noninvasive Nonalcoholic Steatohepatitis Detection in Bariatric Patients. <i>Obesity Facts</i> , 2021, 14, 490-500.	1.6	6
1869	Cost-effectiveness of obeticholic acid for the treatment of non-alcoholic steatohepatitis: An early economic evaluation. <i>Canadian Liver Journal</i> , 2021, 4, 360-369.	0.3	2
1870	Non-Alcoholic Steatohepatitis Severity Associates with FGF21 Level and Kidney Glucose Uptake. <i>Metabolic Syndrome and Related Disorders</i> , 2021, 19, 491-497.	0.5	2
1871	NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. <i>Hepatology</i> , 2021, 74, 3330-3344.	3.6	44
1872	Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis. <i>JHEP Reports</i> , 2021, 3, 100317.	2.6	18
1873	NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. <i>Cells</i> , 2021, 10, 2034.	1.8	20
1874	Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis. <i>Radiology</i> , 2021, 300, 361-368.	3.6	11
1875	Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan aspartate aminotransferase score. <i>JGH Open</i> , 2021, 5, 1183-1189.	0.7	21
1876	Hepatocarcinogenesis. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2021, 29, 359-374.	0.6	3
1877	Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. <i>World Journal of Gastroenterology</i> , 2021, 27, 4913-4928.	1.4	16
1878	Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression. <i>Frontiers in Immunology</i> , 2021, 12, 708959.	2.2	37
1879	Awareness, Knowledge, and Misperceptions Related to Nonalcoholic Fatty Liver Disease in a Community Sample of Mexican-Origin Women: A Mixed Methods Study. <i>Frontiers in Public Health</i> , 2021, 9, 626428.	1.3	7
1880	Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies. <i>Nutrients</i> , 2021, 13, 3042.	1.7	24
1881	Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer. <i>Current Oncology</i> , 2021, 28, 3030-3040.	0.9	2

#	ARTICLE	IF	CITATIONS
1882	High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study. <i>Endocrinology and Metabolism</i> , 2021, 36, 800-809.	1.3	5
1883	Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. <i>Hepatology Communications</i> , 2022, 6, 12-35.	2.0	80
1884	Non-alcoholic fatty liver disease: time for changes. <i>Mã¼narodnij Endokrinologã¼nij Å½urnal</i> , 2021, 17, 334-345.	0.1	3
1885	Vibration-controlled Transient Elastography for Assessment of Liver Fibrosis at a USA Academic Medical Center. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	4
1886	Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus. <i>Liver International</i> , 2021, 41, 2892-2902.	1.9	13
1887	Embedding assessment of liver fibrosis into routine diabetic review in primary care. <i>JHEP Reports</i> , 2021, 3, 100293.	2.6	23
1888	Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art. <i>Hepatology</i> , 2021, 74, 2233-2240.	3.6	22
1889	Non-alcoholic fatty liver disease: Update on treatment options and translational implications of sleep disruption. <i>Annals of Clinical Gastroenterology and Hepatology</i> , 2021, 5, 032-038.	0.1	1
1890	Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 566.	0.7	13
1891	microRNA profiles of serum exosomes derived from children with nonalcoholic fatty liver. <i>Genes and Genomics</i> , 2022, 44, 879-888.	0.5	7
1892	Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. <i>Clinical Therapeutics</i> , 2021, 43, 1505-1522.	1.1	6
1893	Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154796.	1.5	3
1894	Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0255535.	1.1	8
1895	Computed Tomography Techniques, Protocols, Advancements, and Future Directions in Liver Diseases. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2021, 29, 305-320.	0.6	14
1896	Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts. <i>Endocrinology and Metabolism</i> , 2021, 36, 823-834.	1.3	1
1897	Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. <i>Journal of Hepatology</i> , 2021, 75, 1284-1291.	1.8	229
1898	Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 3627-3645.	1.1	13
1899	Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412.	1.5	7

#	ARTICLE	IF	CITATIONS
1900	Pediatric vs. adult NAFLD to MAFLD transition: a welcome but tangled path. <i>Exploration of Medicine</i> , 0, , .	1.5	2
1901	In-Hospital Outcomes of Patients With Non-Alcoholic Fatty Liver Disease Who Underwent Percutaneous Coronary Intervention: A Nationwide Inpatient Sample Analysis. <i>Cureus</i> , 2021, 13, e17338.	0.2	1
1902	The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC). <i>Cureus</i> , 2021, 13, e17320.	0.2	3
1903	Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetesâ€”The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 3464-3473.	1.1	14
1904	Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. <i>Clinical Therapeutics</i> , 2021, 43, 1476-1504.	1.1	14
1905	Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 880-889.	1.9	51
1906	Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis. <i>Journal of Integrative Medicine</i> , 2021, 19, 545-554.	1.4	19
1907	The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00400.	1.3	12
1908	Comprehensive Analysis of NAFLD and the Therapeutic Target Identified. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 704704.	1.8	13
1909	Quantification of Liver Fat Content with CT and MRI: State of the Art. <i>Radiology</i> , 2021, 301, 250-262.	3.6	77
1910	Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 52-66.	4.5	11
1911	Consumption of processed red meat and its impact on human health: A review. <i>International Journal of Food Science and Technology</i> , 2021, 56, 6115-6123.	1.3	24
1912	Cyclic GMP in Liver Cirrhosisâ€”Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10372.	1.8	11
1913	Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8.	0.6	58
1914	Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 61-71.	2.2	4
1915	Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. <i>FASEB Journal</i> , 2021, 35, e21871.	0.2	20
1916	Effects of a Fish Oil Rich in Docosahexaenoic Acid on Cardiometabolic Risk Factors and Oxidative Stress in Healthy Rats. <i>Marine Drugs</i> , 2021, 19, 555.	2.2	6
1917	Rational HCC screening approaches for patients with NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 195-201.	1.8	47

#	ARTICLE	IF	CITATIONS
1918	Zonanol Protected Liver from Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease in a Mouse Model. <i>Nutrients</i> , 2021, 13, 3455.	1.7	6
1919	Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates. <i>JHEP Reports</i> , 2021, 3, 100381.	2.6	15
1920	Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 742382.	1.1	22
1921	Retrospective analysis (2009–2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102261.	1.8	2
1922	Accuracy of ultrasound diagnosis of nonalcoholic fatty liver disease in patients with classes II and III obesity: A pathological image study. <i>Obesity Research and Clinical Practice</i> , 2021, 15, 461-465.	0.8	4
1923	Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021, 75, 524-535.	1.8	57
1924	GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH. <i>Frontiers in Endocrinology</i> , 2021, 12, 721198.	1.5	15
1925	Beneficial Effects of Tamarind Trypsin Inhibitor in Chitosan–Whey Protein Nanoparticles on Hepatic Injury Induced High Glycemic Index Diet: A Preclinical Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9968.	1.8	5
1926	NAFLD: Challenges and opportunities to address the public health problem in Latin America. <i>Annals of Hepatology</i> , 2021, 24, 100359.	0.6	20
1927	Fatty Acid Synthase–Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD. <i>Hepatology</i> , 2021, 74, 2508-2525.	3.6	44
1928	Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3997-4009.	2.0	57
1929	Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD. <i>Hepatology</i> , 2021, 74, 3472-3478.	3.6	21
1930	Reply to: “Multiple investigations for a very common disorder: Finding the right balance in NAFLD” <i>Journal of Hepatology</i> , 2021, 75, 1502-1503.	1.8	0
1931	Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1150-1161.	1.9	79
1932	Management of type 2 diabetes without insulin: An update for the PCP. <i>Disease-a-Month</i> , 2021, , 101290.	0.4	0
1934	Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 739-752.	1.8	16
1935	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. <i>Journal of Hepatology</i> , 2021, 75, 659-689.	1.8	676
1936	Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. <i>European Journal of Pharmacology</i> , 2021, 907, 174272.	1.7	14

#	ARTICLE	IF	CITATIONS
1937	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 951-963.	2.3	114
1938	Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1036-1046.	3.7	23
1939	Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. <i>Gut</i> , 2022, 71, 1867-1875.	6.1	105
1940	A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2462-2473.e10.	2.4	59
1941	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 889-902.	3.7	26
1942	Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus. <i>Nutrients</i> , 2021, 13, 3400.	1.7	6
1943	Quantification of liver and muscular fat using contrast-enhanced Dual Source Dual Energy Computed Tomography compared to an established multi-echo Dixon MRI sequence. <i>European Journal of Radiology</i> , 2021, 142, 109845.	1.2	9
1944	Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822.	1.5	25
1945	Diagnostic performance of ultrasound attenuation imaging for assessing low-grade hepatic steatosis. <i>European Radiology</i> , 2022, 32, 2070-2077.	2.3	13
1946	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 743-753.	3.7	60
1947	Non-alcoholic fatty liver disease and hematologic manifestations (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1355.	0.8	4
1948	Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102232.	1.8	3
1949	Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Peripheral Diabetic Polyneuropathy: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4466.	1.0	4
1950	Predictive Modeling of MAFLD Based on Hsp90 α and the Therapeutic Application of Teprenone in a Diet-Induced Mouse Model. <i>Frontiers in Endocrinology</i> , 2021, 12, 743202.	1.5	3
1951	Nonalcoholic steatohepatitis: global impact and clinical consequences. <i>Endocrine Connections</i> , 2021, 10, R240-R247.	0.8	18
1952	Changing clinical management of NAFLD in Asia. <i>Liver International</i> , 2022, 42, 1955-1968.	1.9	18
1953	Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 5753-5763.	1.4	21
1954	The Mitochondrial Trigger in an Animal Model of Nonalcoholic Fatty Liver Disease. <i>Genes</i> , 2021, 12, 1439.	1.0	10

#	ARTICLE	IF	CITATIONS
1955	Fatty liver index as a predictive marker for the development of diabetes: A retrospective cohort study using Japanese health check-up data. <i>PLoS ONE</i> , 2021, 16, e0257352.	1.1	8
1956	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1253-1266.	1.4	9
1957	The role of hepatic lipid composition in obesity-related metabolic disease. <i>Liver International</i> , 2021, 41, 2819-2835.	1.9	23
1958	The role of Sirtuin 2 in sustaining functional integrity of the liver. <i>Life Sciences</i> , 2021, 285, 119997.	2.0	11
1959	Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 4135-4143.	1.1	4
1960	NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. <i>Journal of Hepatology</i> , 2022, 76, 446-457.	1.8	121
1961	Associations of Nutritional, Lifestyle, and Metabolic Factors With Non-alcoholic Fatty Liver Disease: An Umbrella Review With More Than 380,000 Participants. <i>Frontiers in Nutrition</i> , 2021, 8, 642509.	1.6	4
1962	Clinical Relevance of Selenium with Liver Stiffness and Steatosis Detected by Transient Elastography in Adults. <i>Biological Trace Element Research</i> , 2022, 200, 3041-3049.	1.9	5
1963	Sarcopenic obesity at the crossroad of pathogenesis of cardiometabolic diseases. <i>Atherosclerosis</i> , 2021, 335, 84-86.	0.4	3
1964	A Novel Non-invasive Model Based on GPR for the Prediction of Liver Fibrosis in Patients With Chronic Hepatitis B. <i>Frontiers in Medicine</i> , 2021, 8, 727706.	1.2	2
1965	Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. <i>Obesity</i> , 2021, 29, 1950-1960.	1.5	70
1966	Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 747-756.	1.1	2
1967	Strategies to Diagnose Nonalcoholic Steatohepatitis: A Novel Approach to Take Advantage of Pharmacokinetic Alterations. <i>Drug Metabolism and Disposition</i> , 2022, 50, 492-499.	1.7	5
1968	Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2021, 4, e2123923.	2.8	33
1969	Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis. <i>Nutrients</i> , 2021, 13, 3135.	1.7	51
1970	The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population. <i>Annals of Hepatology</i> , 2021, 24, 100336.	0.6	7
1971	Healthcare practitioners' diagnostic and treatment practice patterns of nonalcoholic fatty liver disease in Poland: a cross-sectional survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 426-434.	0.8	4
1972	Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	4

#	ARTICLE	IF	CITATIONS
1973	A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non-specialist needs to know. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 3-14.	2.2	56
1974	Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. <i>Pharmaceuticals</i> , 2021, 14, 995.	1.7	9
1975	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Hepatology Research</i> , 2021, 51, 1013-1025.	1.8	58
1976	Ultra-processed food consumption and the risk of non-alcoholic fatty liver disease in the Tianjin Chronic Low-grade Systemic Inflammation and Health Cohort Study. <i>International Journal of Epidemiology</i> , 2022, 51, 237-249.	0.9	42
1977	A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis. <i>Peptides</i> , 2021, 143, 170597.	1.2	8
1978	Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	23
1979	Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?. <i>World Journal of Diabetes</i> , 2021, 12, 1479-1493.	1.3	13
1980	Management of non-alcoholic fatty liver disease in patients with sarcopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2021, , 1-13.	0.9	0
1981	Activation of the gut microbiota-tyrosine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults. <i>Aging</i> , 2021, 13, 21309-21324.	1.4	10
1982	Mediating Roles of hsCRP, TNF- α and Adiponectin on the Associations between Body Fat and Fatty Liver Disease among Overweight and Obese Adults. <i>Biology</i> , 2021, 10, 895.	1.3	2
1983	Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?. <i>Journal of Hepatology</i> , 2021, 75, 725-726.	1.8	4
1984	Effect of coffee in prevention of non-alcoholic fatty liver disease. <i>International Journal of Community Medicine and Public Health</i> , 2021, 8, 4997.	0.0	0
1985	Bilirubin deficiency renders mice susceptible to hepatic steatosis in the absence of insulin resistance. <i>Redox Biology</i> , 2021, 47, 102152.	3.9	17
1986	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669.	0.6	229
1987	Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107978.	1.2	5
1989	Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 321, G252-G261.	1.6	4
1990	Development of a highly sensitive chemiluminescent enzyme immunoassay for fragmented cytokeratin 18 using new antibodies. <i>Scientific Reports</i> , 2021, 11, 18187.	1.6	3
1991	Screening for nonalcoholic fatty liver disease-when, who and how?. <i>World Journal of Gastroenterology</i> , 2021, 27, 5803-5821.	1.4	18

#	ARTICLE	IF	CITATIONS
1992	Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. <i>Biomedicines</i> , 2021, 9, 1346.	1.4	46
1993	Non-alcoholic fatty liver disease: A patient guideline. <i>JHEP Reports</i> , 2021, 3, 100322.	2.6	109
1994	Fatty liver disease in living liver donors: a single-center experience of 220 donors. <i>Transplant International</i> , 2021, 34, 2238-2246.	0.8	3
1995	Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a cross-sectional study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1927-1934.	0.4	3
1996	Causal Relationship Between Complement C3, C4, and Nonalcoholic Fatty Liver Disease: Bidirectional Mendelian Randomization Analysis. <i>Phenomics</i> , 2021, 1, 211-221.	0.9	7
1998	Pegbelfermin, a PEGylated FGF21 analogue, has pharmacology without bone toxicity after 1-year dosing in skeletally-mature monkeys. <i>Toxicology and Applied Pharmacology</i> , 2021, 428, 115673.	1.3	10
1999	Rotundic acid ameliorates non-alcoholic steatohepatitis via SREBP-1c/ SCD1 signaling pathway and modulating gut microbiota. <i>International Immunopharmacology</i> , 2021, 99, 108065.	1.7	9
2000	Dietary patterns and risk of non-alcoholic fatty liver disease in adults: A prospective cohort study. <i>Clinical Nutrition</i> , 2021, 40, 5373-5382.	2.3	25
2001	Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. <i>Journal of Hepatology</i> , 2021, 75, 795-809.	1.8	94
2002	Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 2803-2820.	0.7	63
2003	The role of bilio-pancreatic limb in nonalcoholic steatohepatitis improvement after duodenal-jejunal bypass in rats. <i>Surgery</i> , 2021, 170, 1006-1013.	1.0	0
2004	Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice. <i>Journal of Pharmacological Sciences</i> , 2021, 147, 176-183.	1.1	6
2005	MAFLD and Cardiovascular Events: What Does the Evidence Show?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2025-2028.	2.4	11
2006	Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Is Associated with Increased Intestinal Inflammation. <i>American Journal of Pathology</i> , 2021, 191, 1743-1753.	1.9	15
2007	Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis. <i>Pharmacological Research</i> , 2021, 172, 105849.	3.1	28
2008	Diabetes and metabolic dysfunction-associated fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154868.	1.5	26
2009	Nonalcoholic Fatty Liver Disease and the Kidney: A Review. <i>Biomedicines</i> , 2021, 9, 1370.	1.4	6
2010	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , 2021, 41, 101145.	3.2	14

#	ARTICLE	IF	CITATIONS
2011	Reduced steatosis and weight as a result of specific diets or the dietitian themselves. JHEP Reports, 2021, 3, 100365.	2.6	2
2012	Blood manganese and nonalcoholic fatty liver disease: A cohort-based case-control study. Chemosphere, 2022, 287, 132316.	4.2	9
2013	Effect of tocotrienol on the primary progression of nonalcoholic steatohepatitis in a mouse model. Journal of Clinical Biochemistry and Nutrition, 2021, 70, 140-146.	0.6	3
2014	Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) – A single arm clinical trial.. Journal of Ayurveda and Integrative Medicine, 2021, 12, 136-142.	0.9	4
2015	Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine. Journal of Medical Systems, 2021, 45, 22.	2.2	10
2016	Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 1041-1051.	2.2	11
2017	LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH. Scientific Reports, 2021, 11, 555.	1.6	33
2018	Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunological Medicine, 2021, 44, 175-186.	1.4	5
2019	Nonalcoholic Fatty Liver Disease and Recent Guideline Updates. Clinical Liver Disease, 2021, 17, 23-28.	1.0	108
2020	Association between Nonalcoholic Fatty Liver Disease and Bone Mineral Density in HIV-Infected Patients Receiving Long-term TDF-Based Antiretroviral Therapy. Current HIV Research, 2021, 19, 40-46.	0.2	2
2021	Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study. Cardiovascular Diabetology, 2021, 20, 27.	2.7	33
2022	A nomogram for predicting metabolic steatohepatitis: The combination of NAMPT, RALGDS, GADD45B, FOSL2, RTP3, and RASD1. Open Medicine (Poland), 2021, 16, 773-785.	0.6	5
2023	Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Annals of Gastroenterology, 2021, 34, 404-414.	0.4	24
2024	Modest alcohol consumption and risk of advanced liver fibrosis in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Annals of Gastroenterology, 2021, 34, 568-574.	0.4	4
2026	Causes of erectile dysfunction in non-alcoholic fatty liver disease. Hepatology Forum, 2021, , .	0.3	1
2027	Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). Methods in Molecular Biology, 2021, 2310, 201-246.	0.4	11
2028	The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: a population-based cross-sectional study. Hepatobiliary Surgery and Nutrition, 2021, 10, 811-824.	0.7	14
2029	The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma. Cancers, 2021, 13, 516.	1.7	15

#	ARTICLE	IF	CITATIONS
2030	Sleeve Gastrectomy in Non-alcoholic Steatohepatitis (NASH) and Liver Cirrhosis. , 2021, , 115-137.		0
2031	Automatic Classification Algorithm for Diffused Liver Diseases Based on Ultrasound Images. IEEE Access, 2021, 9, 5760-5768.	2.6	4
2032	Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping. Journal of Medical Internet Research, 2021, 23, e20491.	2.1	12
2033	Predicting Non-Alcoholic Fatty Liver Disease for Adults Using Practical Clinical Measures: Evidence from the Multi-ethnic Study of Atherosclerosis. Journal of General Internal Medicine, 2021, 36, 2648-2655.	1.3	6
2034	Nonalcoholic Fatty Liver Disease in Children: Spectrum and Consequences. Journal of Postgraduate Medicine Education and Research, 2021, 55, 39-52.	0.1	0
2035	Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. PLoS ONE, 2021, 16, e0244939.	1.1	22
2036	Quantitative ultrasound radiofrequency data analysis for the assessment of hepatic steatosis using the controlled attenuation parameter as a reference standard. Ultrasonography, 2021, 40, 136-146.	1.0	25
2037	Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). , 2021, , 1381-1390.		0
2038	Management of non-alcoholic fatty liver disease. BMJ, The, 2021, 372, m4747.	3.0	99
2039	Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis. Hepatology Communications, 2020, 4, 953-972.	2.0	93
2040	Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. Advances in Experimental Medicine and Biology, 2020, 1307, 417-440.	0.8	21
2041	Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. Journal of Gastroenterology, 2020, 55, 731-741.	2.3	22
2042	Accounting for the Placebo Effect and Optimizing Outcomes in Clinical Trials of Nonalcoholic Steatohepatitis (NASH). Current Hepatology Reports, 2020, 19, 63-69.	0.4	7
2043	NASH in HIV. Current HIV/AIDS Reports, 2020, 17, 601-614.	1.1	23
2044	Work up of fatty liver by primary care physicians, review. Annals of Medicine and Surgery, 2020, 50, 41-48.	0.5	4
2045	The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. Complementary Therapies in Medicine, 2020, 52, 102452.	1.3	30
2046	Serum lactate levels are associated with serum alanine aminotransferase and total bilirubin levels in patients with type 2 diabetes mellitus: A cross-sectional study. Diabetes Research and Clinical Practice, 2019, 149, 1-8.	1.1	10
2047	Ginsenoside Rg1 protects against d-galactose induced fatty liver disease in a mouse model via FOXO1 transcriptional factor. Life Sciences, 2020, 254, 117776.	2.0	26

#	ARTICLE	IF	CITATIONS
2048	Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12748-12772.	2.9	11
2049	Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>Bioscience Reports</i> , 2020, 40, .	1.1	21
2050	Processes exacerbating apoptosis in non-alcoholic steatohepatitis. <i>Clinical Science</i> , 2019, 133, 2245-2264.	1.8	13
2051	ADH1B ^{Δ2} Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption. <i>Gastroenterology</i> , 2020, 159, 929-943.	0.6	18
2053	Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 107-110.	1.9	7
2054	Impact of the Analytical Approach on the Reliability of MRI-Based Assessment of Hepatic Fat Content. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa171.	0.1	2
2055	Metabolic alterations and vulnerabilities in hepatocellular carcinoma. <i>Gastroenterology Report</i> , 2021, 9, 1-13.	0.6	30
2056	MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. <i>Chinese Medical Journal</i> , 2021, 134, 8-19.	0.9	57
2057	Protein and amino acids in nonalcoholic fatty liver disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021, 24, 96-101.	1.3	42
2058	Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 430-435.	0.8	12
2059	A prospective cohort study of the use of the fatty liver index and Fibroscan to determine the prevalence of fatty liver disease in an Irish population. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 200-205.	0.8	2
2060	How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, .	0.5	8
2061	Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1406-1412.	2.1	15
2062	Radiomics, Radiogenomics, and Next-Generation Molecular Imaging to Augment Diagnosis of Hepatocellular Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 108-115.	1.0	12
2068	Predicting Infectious State of Hepatitis C Virus Affected Patient's Applying Machine Learning Methods. , 2020, , .		22
2069	Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1030-1037.	1.9	40
2070	Discrepancies between actual weight, weight perception and weight loss intention amongst persons with NAFLD. <i>Journal of Internal Medicine</i> , 2021, 289, 840-850.	2.7	18
2071	Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. <i>BMJ Case Reports</i> , 2020, 13, e238400.	0.2	3

#	ARTICLE	IF	CITATIONS
2072	Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. <i>Journal of the American Heart Association</i> , 2020, 9, e014279.	1.6	72
2073	Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. <i>Egyptian Liver Journal</i> , 2020, 10, .	0.3	32
2074	Assessment of hepatic fibrosis and steatosis by vibration-controlled transient elastography and controlled attenuation parameter versus non-invasive assessment scores in patients with non-alcoholic fatty liver disease. <i>Egyptian Liver Journal</i> , 2020, 10, .	0.3	8
2075	Amelioration of the Lipogenesis, Oxidative Stress and Apoptosis of Hepatocytes by a Novel Proteoglycan from <i>Ganoderma lucidum</i> . <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 1542-1550.	0.6	7
2077	Efficacy and Safety of Weight Reduction of the Donor in Hepatic Steatosis for Living Donor Liver Transplantation. <i>Annals of Transplantation</i> , 2020, 25, e923211.	0.5	6
2078	Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH). <i>Medical Science Monitor</i> , 2018, 24, 6946-6967.	0.5	25
2079	Recent advances in understanding and managing pediatric nonalcoholic fatty liver disease. <i>F1000Research</i> , 2020, 9, 377.	0.8	14
2080	Metabolic profiling of adolescent non-alcoholic fatty liver disease. <i>Wellcome Open Research</i> , 2018, 3, 166.	0.9	20
2081	Metabolic profiling of adolescent non-alcoholic fatty liver disease. <i>Wellcome Open Research</i> , 2018, 3, 166.	0.9	14
2082	Relationship between non-alcoholic fatty liver disease and coronary heart disease. <i>World Journal of Clinical Cases</i> , 2020, 8, 4688-4699.	0.3	21
2083	Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0240195.	1.1	14
2084	Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. <i>PLoS ONE</i> , 2020, 15, e0241770.	1.1	20
2085	Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-5.	0.7	20
2086	Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-5.	0.7	16
2087	NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 215-221.	0.7	37
2088	Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 000, 1-10.	0.7	13
2089	Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 116-124.	0.2	63
2090	Impact of Body Weight Gain on the Incidence of Nonalcoholic Fatty Liver Disease in Nonobese Japanese Individuals. <i>American Journal of Gastroenterology</i> , 2021, 116, 733-740.	0.2	11

#	ARTICLE	IF	CITATIONS
2091	Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. <i>American Journal of Gastroenterology</i> , 2021, 116, 254-262.	0.2	65
2092	Assessment of liver fibrosis using 2-dimensional shear wave elastography: a prospective study of intra- and inter-observer repeatability and comparison with point shear wave elastography. <i>Ultrasonography</i> , 2020, 39, 52-59.	1.0	21
2093	Steatohepatitic Variant of Hepatocellular Carcinoma: A Focused Review. <i>Gastroenterology Research</i> , 2018, 11, 391-396.	0.4	25
2094	Functional, Diagnostic and Therapeutic Aspects of Gastrointestinal Hormones. <i>Gastroenterology Research</i> , 2019, 12, 233-244.	0.4	11
2095	The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases. <i>Hepatology Forum</i> , 2020, , 8-13.	0.3	27
2096	Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>Asian Biomedicine</i> , 2018, 12, 3-13.	0.2	5
2097	Mice lacking adenosine 2A receptor reveal increased severity of MCD-induced NASH. <i>Journal of Endocrinology</i> , 2019, 243, 199-209.	1.2	16
2098	SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD. <i>Journal of Endocrinology</i> , 2020, 245, 425-437.	1.2	99
2099	Position statement on the diagnosis and management of non-alcoholic fatty liver disease. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2019, 40, 531-540.	0.5	14
2100	BYPASS VS. SLEEVE AND ITS EFFECTS IN NON-ALCOHOLIC FATTY LIVER DISEASE: WHAT IS THE BEST TECHNIQUE?. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2020, 33, e1549.	0.5	6
2101	IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). <i>Arquivos De Gastroenterologia</i> , 2019, 56, 431-439.	0.3	15
2102	Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism. <i>EXCLI Journal</i> , 2020, 19, 620-626.	0.5	11
2103	Psoriasis and fatty liver: a harmful synergy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 314-319.	0.1	13
2104	The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 627-635.	0.1	8
2105	Metabolic syndrome, non-alcoholic fatty liver disease and hepatocarcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 133-138.	0.1	7
2106	Bariatric Surgery for the Treatment of Nonalcoholic Fatty Liver Disease: Is Vertical Sleeve Gastrectomy the Best Future Option?. <i>Journal of Gastroenterology and Hepatology Research</i> , 2016, 5, 1957-1961.	0.2	2
2107	Catalpol induces autophagy and attenuates liver steatosis in ob/ob and high-fat diet-induced obese mice. <i>Aging</i> , 2019, 11, 9461-9477.	1.4	38
2108	Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department. <i>Annals of Gastroenterology</i> , 2019, 32, 283-286.	0.4	11

#	ARTICLE	IF	CITATIONS
2109	Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States. <i>Annals of Gastroenterology</i> , 2019, 32, 504-513.	0.4	15
2110	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center. <i>Archives of Endocrinology and Metabolism</i> , 2020, 64, 235-242.	0.3	10
2111	Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?. <i>Current Pharmaceutical Design</i> , 2020, 26, 1036-1044.	0.9	24
2112	Non-Alcoholic Fatty Liver Disease and Vascular Disease. <i>Current Vascular Pharmacology</i> , 2020, 19, 269-279.	0.8	12
2113	Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. <i>Current Hypertension Reviews</i> , 2021, 17, 94-111.	0.5	9
2114	Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2020, 8, e14802.	1.8	34
2115	The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial. <i>JMIR Research Protocols</i> , 2020, 9, e19189.	0.5	5
2116	Non-alcoholic fatty liver disease: prevalence, etiology, pathogenesis, approaches to the diagnosis and therapy (literature review and own data). <i>MAÅ¼narodnij EndokrinologÅ¼nij Å¼urnal</i> , 2018, 14, 684-693.	0.1	2
2117	Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2020, 30, 28-34.	0.2	4
2118	Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. <i>Diabetes Care</i> , 2021, 44, 399-406.	4.3	173
2119	Aerobic capacity and exercise performance in nonalcoholic fatty liver disease. <i>Journal of Sports Medicine and Physical Fitness</i> , 2019, 59, 1376-1388.	0.4	15
2121	Diet Composition for the Management of Obesity and Obesity-related Disorders. , 2018, 3, 10-25.		21
2122	Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease. <i>Deutsches A&#x0308;rztblatt International</i> , 2020, 117, 719-724.	0.6	21
2123	Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. <i>Yonago Acta Medica</i> , 2020, 63, 188-197.	0.3	15
2124	Recent research trends and updates on nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 1-11.	4.5	74
2125	Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 52-64.	4.5	77
2126	Application of transient elastography in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 128-141.	4.5	70
2127	Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 196-208.	4.5	15

#	ARTICLE	IF	CITATIONS
2128	Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 183-184.	4.5	6
2129	Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 383-400.	4.5	50
2130	Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 430-443.	4.5	38
2131	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. <i>International Journal of Molecular Sciences</i> , 2021, 22, 40.	1.8	8
2132	The Use of Two-Dimensional Shear Wave Elastography in People with Obesity for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 95.	1.0	21
2133	Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021, 13, 15.	1.7	45
2134	The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. <i>Advanced Pharmaceutical Bulletin</i> , 2020, 10, 542-555.	0.6	6
2135	Automated Machine Learning in the Sonographic Diagnosis of Non-alcoholic Fatty Liver Disease. <i>Advanced Ultrasound in Diagnosis and Therapy</i> , 2020, 4, 176.	0.1	7
2136	Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables. <i>World Journal of Gastroenterology</i> , 2018, 24, 4835-4845.	1.4	31
2137	Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients. <i>World Journal of Gastroenterology</i> , 2019, 25, 1741-1752.	1.4	15
2138	Freeze-dried Si-Ni-San powder can ameliorate high fat diet-induced non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 3056-3068.	1.4	20
2139	Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 3664-3668.	1.4	8
2140	Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?. <i>World Journal of Gastroenterology</i> , 2019, 25, 3929-3940.	1.4	29
2141	Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2019, 25, 4959-4969.	1.4	13
2142	Zinc- α 2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor- α . <i>World Journal of Gastroenterology</i> , 2019, 25, 5451-5468.	1.4	19
2143	Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 509-520.	1.4	50
2144	LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway. <i>World Journal of Gastroenterology</i> , 2019, 25, 6607-6618.	1.4	38
2145	Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 1792-1804.	1.4	34

#	ARTICLE	IF	CITATIONS
2146	Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 1993-2011.	1.4	67
2147	Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. <i>World Journal of Gastroenterology</i> , 2020, 26, 2740-2757.	1.4	14
2148	Management of nonalcoholic fatty liver disease in the Middle East. <i>World Journal of Gastroenterology</i> , 2020, 26, 3528-3541.	1.4	14
2149	Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 5919-5943.	1.4	33
2150	Role of gut microbiota via the gut-liver-brain axis in digestive diseases. <i>World Journal of Gastroenterology</i> , 2020, 26, 6141-6162.	1.4	77
2151	Efficacy and safety of anti-hepatic fibrosis drugs. <i>World Journal of Gastroenterology</i> , 2020, 26, 6304-6321.	1.4	22
2152	Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management. <i>World Journal of Gastroenterology</i> , 2020, 26, 6514-6528.	1.4	25
2153	Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. <i>World Journal of Gastroenterology</i> , 2020, 26, 7046-7060.	1.4	18
2154	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. <i>Endocrinology and Metabolism</i> , 2020, 35, 243-259.	1.3	23
2155	Frequency of somatic mutations in promoter, and genes in patients with hepatocellular carcinoma from Southern Italy. <i>Oncology Letters</i> , 2020, 19, 2368-2374.	0.8	16
2156	Preparation and Evaluation of Functional Foods for Prevention of Non-alcoholic Fatty Liver Disease. <i>Pakistan Journal of Biological Sciences</i> , 2018, 21, 454-462.	0.2	4
2157	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 382.	1.8	46
2158	Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 640-657.	1.8	16
2159	Glucose-Lowering Effect of Home-Delivered Therapeutic Meals in Patients with Type 2 Diabetes. <i>Journal of Korean Diabetes</i> , 2020, 21, 46-54.	0.1	1
2160	Nonalcoholic fatty liver disease and Type 2 diabetes mellitus. <i>Indian Journal of Endocrinology and Metabolism</i> , 2018, 22, 421.	0.2	116
2161	Analyzing lipids in the liver & in the red blood cell membrane in liver diseases. <i>Indian Journal of Medical Research</i> , 2018, 147, 334.	0.4	2
2162	Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. <i>World Journal of Hepatology</i> , 2019, 11, 710-718.	0.8	10
2163	Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. <i>World Journal of Hepatology</i> , 2019, 11, 761-772.	0.8	31

#	ARTICLE	IF	CITATIONS
2164	<i>PNPLA3</i> and <i>TM6SF2</i> polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2020, 12, 792-806.	0.8	22
2165	Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. <i>World Journal of Hepatology</i> , 2020, 12, 1168-1181.	0.8	27
2166	Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population. <i>World Journal of Hepatology</i> , 2020, 12, 1228-1238.	0.8	9
2167	High omega arachidonic acid/docosahexaenoic acid ratio induces mitochondrial dysfunction and altered lipid metabolism in human hepatoma cells. <i>World Journal of Hepatology</i> , 2020, 12, 84-98.	0.8	16
2168	Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. <i>World Journal of Hepatology</i> , 2020, 12, 378-388.	0.8	9
2169	Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. <i>World Journal of Hepatology</i> , 2020, 12, 493-505.	0.8	23
2170	Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2020, 14, 486-491.	1.4	51
2171	Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. <i>Gut and Liver</i> , 2020, 14, 537-545.	1.4	38
2172	Non-alcoholic fatty liver disease: A growing public health problem in Turkey. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 865-871.	0.4	30
2173	Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 892-898.	0.4	24
2174	Hepatic Failure After Bariatric Surgery: A Systematic Review. <i>Hepatitis Monthly</i> , 2019, In Press, .	0.1	5
2175	Effect of an Herbal Product on the Serum Level of Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial. <i>Iranian Red Crescent Medical Journal</i> , 2019, 21, .	0.5	5
2176	Comparative Analysis of Nonalcoholic Steatohepatitisâ€“ Versus Viral Hepatitisâ€“ and Alcohol-Related Liver Diseaseâ€“Related Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 322-329.	2.3	38
2177	Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver. <i>ELife</i> , 2020, 9, .	2.8	7
2178	Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH. <i>PeerJ</i> , 2019, 7, e8115.	0.9	11
2179	Association between serum and dietary antioxidant micronutrients and advanced liver fibrosis in non-alcoholic fatty liver disease: an observational study. <i>PeerJ</i> , 2020, 8, e9838.	0.9	23
2180	The Association between Nuts Intake and Non-Alcoholic Fatty Liver Disease (NAFLD) Risk: a Case-Control Study. <i>Clinical Nutrition Research</i> , 2020, 9, 195.	0.5	9
2181	Effect and Signaling Pathways of Nelumbinis Folium in the Treatment of Hyperlipidemia Assessed by Network Pharmacology. <i>World Journal of Traditional Chinese Medicine</i> , 2021, 7, 445.	0.9	10

#	ARTICLE	IF	CITATIONS
2182	Underrecognition of Nonalcoholic Fatty Liver Disease in Poorly Controlled Diabetes: A Call to Action in Diabetes Care. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab155.	0.1	6
2183	Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 405-423.	2.3	10
2185	Editorial to accompany the letter to the Editor entitled "May Silymarin be selectively considered for nonalcoholic fatty liver disease without elevated transaminases?". <i>Nutrition</i> , 2021, , 111510.	1.1	0
2186	Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 10, 128-133.	0.7	5
2189	Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy. <i>Frontiers in Pharmacology</i> , 2021, 12, 768576.	1.6	14
2190	Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1472-1480.	1.9	10
2191	Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA-B Score Among US Adults. <i>Hepatology Communications</i> , 2022, 6, 898-909.	2.0	3
2192	Application of artificial intelligence in liver diseases: From diagnosis to treatment. <i>Artificial Intelligence in Gastroenterology</i> , 2021, 2, 133-140.	0.2	2
2193	Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico. <i>Lipids in Health and Disease</i> , 2021, 20, 136.	1.2	6
2194	Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease. <i>FASEB Journal</i> , 2021, 35, e21976.	0.2	11
2195	ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. <i>Nature Medicine</i> , 2021, 27, 1836-1848.	15.2	97
2196	Changes in Insulin Resistance Index and the Risk of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease without Diabetes: Kangbuk Samsung Health Study. <i>Endocrinology and Metabolism</i> , 2021, 36, 1016-1028.	1.3	6
2197	The liver steatosis severity and lipid characteristics in primary biliary cholangitis. <i>BMC Gastroenterology</i> , 2021, 21, 395.	0.8	12
2198	Green Plant Pigment, Chlorophyllin, Ameliorates Non-alcoholic Fatty Liver Diseases (NAFLDs) Through Modulating Gut Microbiome in Mice. <i>Frontiers in Physiology</i> , 2021, 12, 739174.	1.3	3
2199	Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2021, 20, 97-107.	0.4	2
2200	Stratification by obesity class, rather than age, can identify a higher percent of children at risk for non-alcoholic fatty liver disease and metabolic dysfunction. <i>Pediatric Obesity</i> , 2022, 17, e12862.	1.4	7
2201	Clinically silent LINE 1 insertion in the PNPLA3 gene may impede genotyping of the p.I148M variant. <i>Scientific Reports</i> , 2021, 11, 20924.	1.6	0
2202	Recurrent NASH Post-liver Transplant: Implications and Treatment. <i>Current Hepatology Reports</i> , 2021, 20, 108.	0.4	0

#	ARTICLE	IF	CITATIONS
2203	Impact of bariatric surgery on non-alcoholic fatty liver disease: an integrative review. <i>Research, Society and Development</i> , 2021, 10, e397101321437.	0.0	0
2204	Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study. <i>BMC Gastroenterology</i> , 2021, 21, 394.	0.8	32
2205	Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. <i>Journal of Gastroenterology</i> , 2021, 56, 1022-1032.	2.3	49
2206	Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes. <i>Cureus</i> , 2021, 13, e19046.	0.2	4
2208	Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling. <i>Journal of Hepatology</i> , 2022, 76, 407-419.	1.8	27
2209	Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 329-338.	0.7	49
2210	Comorbidity of non-alcoholic fatty liver disease and cardiovascular disease: focus on ademetionine and ursodeoxycholic acid. <i>Medical Alphabet</i> , 2021, 1, 13-20.	0.0	1
2211	Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. <i>New England Journal of Medicine</i> , 2021, 385, 1559-1569.	13.9	406
2212	Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver. <i>Journal of Clinical Medicine</i> , 2021, 10, 4625.	1.0	6
2213	Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease. <i>Gut and Liver</i> , 2022, 16, 433-442.	1.4	38
2214	Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 60-69.	0.6	3
2215	Novel therapeutic targets for cholestatic and fatty liver disease. <i>Gut</i> , 2022, 71, 194-209.	6.1	84
2216	Association between Muscle Mass Deficits and the Non-Alcoholic Fatty Liver Disease Fibrosis Score in Adults without Central Obesity. <i>Korean Journal of Family Practice</i> , 2021, 11, 345-351.	0.1	1
2217	Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2451-2461.e3.	2.4	37
2218	Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 44-54.	2.2	18
2219	Referral care paths for non-alcoholic fatty liver disease "Gearing up for an ever more prevalent and severe liver disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 903-909.	1.6	8
2220	Non-alcoholic fatty liver disease: modern approaches to diagnosis and treatment. <i>Å¾urnalo-Rossijskij Å¾urnal Terapevtičeskoj Praktiki</i> , 2021, 2, 18-29.	0.1	2
2221	Dietary Approaches for Management of Non-Alcoholic Fatty Liver Disease: A Clinician's Guide. <i>Current Gastroenterology Reports</i> , 2021, 23, 21.	1.1	9

#	ARTICLE	IF	CITATIONS
2241	Clinical Manifestations of Liver Disease in Diabetes Mellitus. <i>Clinical Gastroenterology</i> , 2018, , 275-315.	0.0	0
2242	Diagnostic Approach to Nonalcoholic Steatohepatitis. <i>Korean Journal of Medicine</i> , 2018, 93, 33-37.	0.1	1
2244	Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Bariatric Patients: Tehran Obesity Treatment Study (TOTS). <i>Hepatitis Monthly</i> , 2018, 18, .	0.1	1
2245	Prevalence and characteristics of non-alcoholic steatohepatitis in patients with inflammatory bowel disease in the Novosibirsk region: a cross-sectional, one center study in 245 patients. <i>AlĖ¹manah KliniĖskoj Mediciny</i> , 2018, 46, 464-473.	0.2	0
2246	ÐĖ ³ ŃĖĖµÐ ³ Ð ⁰ Ń†Ð, Ð ³ / ₄ Ð ¹ / ₂ Ð ⁰ Ń•ŃÐ; Ð ³ / ₄ ŃÐ ³ / ₄ Ð±Ð ¹ / ₂ Ð ³ / ₄ ŃŃ, ŃĖ Ń, ŃĖÐ ³ / ₄ Ð ¹ / ₄ Ð±Ð ³ / ₄ Ń†Ð, Ń, Ð ³ / ₄ Ð ² ŃfĖĖ; Ð ⁰ Ń†Ð, Ð, µÐ ¹ / ₂ Ń, Ð ³ / ₄ Ð ² Ń•Ń		
2248	Influence of the intestinal microbiota on the formation and development of non-alcoholic fatty liver disease in children. <i>ZdorovĖ¹e Rebenka</i> , 2018, 13, 776-782.	0.0	0
2249	Clinical Effectiveness of Acupuncture in the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review. <i>The Journal of Internal Korean Medicine</i> , 2018, 39, 1206-1224.	0.0	2
2250	General Care of the Cirrhotic Patient. , 2019, , 165-177.		0
2251	Diagnostic and prognostic biomarkers for the screening of patients with metabolic liver disease risk. <i>Germes</i> , 2018, 8, 175-177.	0.5	0
2252	Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. , 2019, , 75-84.		1
2253	Frontiers and prospects of pharmacotherapy for non-alcoholic fatty liver disease. <i>World Chinese Journal of Digestology</i> , 2019, 27, 73-79.	0.0	1
2254	High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy. <i>Annals of Gastroenterology</i> , 2019, 32, 463-468.	0.4	12
2255	Characterizing specific subgroups in patients with NAFLD: overweight vs obese phenotype. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 253-255.	0.1	1
2256	Liver Cirrhosis with Steatohepatitis: Nonalcoholic Steatohepatitis and Alcoholic Steatohepatitis. , 2019, , 1-21.		0
2257	Evaluation of Liver Biopsy Findings and Comparison with Noninvasive Fibrosis Scores in Patients with Non-Alcoholic Steatohepatitis. <i>Medeniyet Medical Journal</i> , 2019, 34, 354-359.	0.4	0
2258	Non-invasive methods for detection of progressive fibrosis in patients with nonalcoholic fat liver disease. <i>Profilakticheskaya Meditsina</i> , 2019, 22, 82.	0.2	2
2259	Analysis of Mitochondrial 4977-bp Deletion and D-Loop Variation in Iranian Non-Alcoholic Fatty Liver Disease Patients. <i>Hepatitis Monthly</i> , 2019, In Press, .	0.1	0
2260	Results of the observational cross-over PRELID 2 study (2015â€“2016). Part 2. Risk factors of non-alcoholic fatty liver disease and treatment options in patients seeking general practitionersâ€™ and gastroenterologistsâ€™ help in Ukraine. <i>Gastroenterologia</i> , 2019, 53, 106-114.	0.0	0

#	ARTICLE	IF	CITATIONS
2261	Fecal Microbiota Transplantation for the Treatment of Nonalcoholic Fatty Liver Disease. <i>Exploratory Research and Hypothesis in Medicine</i> , 2019, 4, 12-18.	0.1	6
2262	Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An update. <i>Journal of Mind and Medical Sciences</i> , 0, , 52-57.	0.1	0
2265	Vitamin D Supplementation Increases the Aerobic Training Effects on Anthropometric Indices in Elderly Women with Non-Alcoholic Fatty Liver Disease and Vitamin D Deficiency. <i>Modern Care Journal</i> , 2019, 16, .	0.2	3
2267	INFLUENCE OF GASTROINTESTINAL HORMONES ON THE DEVELOPMENT OF OBESITY AND NON-ALCOHOLIC FATTY LIVER DISEASE IN CHILDREN. <i>Problemi Endokrinnoi Patologii</i> , 2019, 69, 128-135.	0.0	0
2268	Non-Alcoholic Fatty Liver Disease. <i>Vnitřni Lekarství</i> , 2019, 65, 571-575.	0.1	4
2269	Evaluation of Thyroid Function in Obese Adults with Non-Alcoholic Fatty Liver Disease Attending Tanta University Hospital. <i>Medical Journal of the University of Cairo Faculty of Medicine</i> , 2019, 87, 3267-3275.	0.0	0
2270	Effect of Non-alcoholic Fatty Liver Disease on Transaminase Levels and Transient Elastography in Patients with Chronic Hepatitis B. <i>Cureus</i> , 2019, 11, e5995.	0.2	3
2271	The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). <i>Gastroenterology & Hepatology (Bartlesville, Okla)</i> , 2019, 10, 262-266.	0.0	2
2272	Diseases of the hepatobiliary system: focus on rational hepatotropic therapy. <i>Gastroenterologia</i> , 2019, 53, 188-195.	0.0	0
2273	Factors Associated with the Severity of Findings on Hepatic Transient Elastography among Persons with Type 2 Diabetes and Fatty Live. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2019, 34, 134-143.	0.1	4
2274	Introductory Chapter: Nonalcoholic Fatty Liver Disease - What Should We Know?. , 0, , .		0
2275	Gaucher's disease and liver involvement: A review and our experience. <i>Annals of Clinical Gastroenterology and Hepatology</i> , 2019, 3, 031-034.	0.1	0
2277	EFFECTIVENESS OF TREATMENT WITH PEGLITAZONE IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND CONCOMITANT METABOLIC SYNDROME DEPENDING ON PRESENCE OF PPAR- α POLYMORPHISM IN GENE PPAR- α . <i>Medical Science of Ukraine (MSU)</i> , 2019, 15, 25-33.	0.0	1
2279	Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. <i>Annals of Gastroenterology</i> , 2020, 33, 603-614.	0.4	13
2281	Intricate interpretation of etiology-specific outcome comparison in patients with hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 238-239.	4.5	1
2283	Is non-alcoholic steatohepatitis caused by alcohol?. <i>Archives of Community Medicine and Public Health</i> , 2020, 6, 081-083.	0.1	0
2284	Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health system. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 424-429.	0.8	2
2285	Non-alcoholic fatty liver disease: modern methods of diagnostics and treatment strategies. <i>Modern Gastroenterology</i> , 2020, .	0.1	1

#	ARTICLE	IF	CITATIONS
2286	Laboratory diagnosis of liver pathology in pregnant women. <i>Aktualnaya Infektologiya</i> , 2020, 8, 20-28.	0.1	0
2288	Effects of empagliflozin and L-ornithine L-aspartate on behavior, cognitive functions, and physical performance in mice with experimentally induced steatohepatitis. <i>Bulletin of Russian State Medical University</i> , 2020, , 49-57.	0.3	3
2289	Association between Cardiorespiratory Fitness, Relative Grip Strength with Non-Alcoholic Fatty Liver Disease. <i>Medical Science Monitor</i> , 2020, 26, e923015.	0.5	6
2290	Nonalcoholic Fatty Liver Disease and the Need for Action. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 139-141.	0.5	3
2292	GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis. <i>Exploration of Medicine</i> , 2020, 1, 108-123.	1.5	3
2296	Role of acetylation in nonalcoholic fatty liver disease: a focus on SIRT1 and SIRT3. <i>Exploration of Medicine</i> , 2020, 1, 248-258.	1.5	4
2297	The diagnostic conundrum in non-alcoholic fatty liver disease. <i>Exploration of Medicine</i> , 2020, 1, .	1.5	6
2298	Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease. <i>ACS Nano</i> , 2021, 15, 17016-17046.	7.3	19
2299	Tumor necrosis factor- α signaling in nonalcoholic steatohepatitis and targeted therapies. <i>Journal of Genetics and Genomics</i> , 2022, 49, 269-278.	1.7	24
2300	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
2301	Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. <i>Frontiers in Endocrinology</i> , 2021, 12, 760860.	1.5	33
2302	A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH). <i>American Journal of Case Reports</i> , 2021, 22, e932961.	0.3	4
2303	Role of vitamin E in the treatment of non-alcoholic steatohepatitis. <i>Free Radical Biology and Medicine</i> , 2021, 177, 391-403.	1.3	12
2304	The combined impact of decabromodiphenyl ether and high fat exposure on non-alcoholic fatty liver disease in vivo and in vitro. <i>Toxicology</i> , 2021, 464, 153015.	2.0	8
2305	High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. <i>Hepatology</i> , 2022, 75, 1491-1506.	3.6	99
2306	Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review. <i>Visceral Medicine</i> , 2022, 38, 126-132.	0.5	11
2307	Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 365-371.	0.8	42
2308	Sex-Dependent Effects of Eicosapentaenoic Acid on Hepatic Steatosis in UCP1 Knockout Mice. <i>Biomedicines</i> , 2021, 9, 1549.	1.4	1

#	ARTICLE	IF	CITATIONS
2309	Association of cardiovascular factors in diabetic patients with non-alcoholic fatty liver disease. <i>Hormones</i> , 2021, , 1.	0.9	4
2310	Magnetic resonance elastography of the liver: everything you need to know to get started. <i>Abdominal Radiology</i> , 2022, 47, 94-114.	1.0	20
2311	Pediatric Nonalcoholic Fatty Liver Disease. <i>Pediatric Clinics of North America</i> , 2021, 68, 1309-1320.	0.9	4
2312	Non-Alcoholic Fatty Liver Disease as a Coronary Heart Disease Severity Predictor. <i>International Journal of Clinical Medicine</i> , 2020, 11, 182-192.	0.1	2
2313	The Association of Hypolipidemia and Hyperlipidemia with Non-Alcoholic Fatty Liver Disease in Obese Children. <i>Turk Pediatri Arsivi</i> , 2020, 55, 263-269.	0.9	4
2314	The Spectrum of NAFLD: From the Organ to the System. , 2020, , 1-10.		0
2315	Detection of NAFLD/NASH in the General Population and in Primary Care Clinics. , 2020, , 11-27.		0
2316	Using intestinal flora to distinguish non-alcoholic steatohepatitis from non-alcoholic fatty liver. <i>Journal of International Medical Research</i> , 2020, 48, 030006052097812.	0.4	12
2317	What Is the Role of Bariatric Surgery in the Treatment of Nonalcoholic Steatohepatitis?. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2021, , 201-211.	0.0	0
2318	Shifts in the Bacterial Community of Supragingival Plaque Associated With Metabolic-Associated Fatty Liver Disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 581888.	1.8	8
2319	Non-Alcoholic Fatty Liver Disease (NAFLD) in overweight and obese children and adolescents. <i>Archives of Clinical Gastroenterology</i> , 2020, , 082-087.	0.1	0
2320	The association of impaired lung function and nonalcoholic fatty liver disease: a systematic review. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 745-751.	0.8	1
2321	Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 000, 1-11.	0.7	30
2322	Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial. <i>JGH Open</i> , 2021, 5, 193-198.	0.7	6
2323	A CD209 ligand and a sialidase inhibitor differentially modulate adipose tissue and liver macrophage populations and steatosis in mice on the Methionine and Choline-Deficient (MCD) diet. <i>PLoS ONE</i> , 2020, 15, e0244762.	1.1	6
2324	Association between APOC3 polymorphisms and non-alcoholic fatty liver disease risk: a meta-analysis. <i>African Health Sciences</i> , 2020, 20, 1800-8.	0.3	6
2325	Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000535.	1.1	14
2326	Comparison of noninvasive scoring systems for the prediction of nonalcoholic fatty liver disease in metabolic syndrome patients. <i>Medicine (United States)</i> , 2020, 99, e23619.	0.4	5

#	ARTICLE	IF	CITATIONS
2327	The roles of autophagy and thyroid hormone in the pathogenesis and treatment of NAFLD. , 2021, 7, 72.		6
2328	OUP accepted manuscript. European Journal of Preventive Cardiology, 2021, , .	0.8	6
2329	Evaluation of liver T1 using MOLLI gradient echo readout under the influence of fat. Magnetic Resonance Imaging, 2022, 85, 57-63.	1.0	3
2331	Steatosis Assessment with Controlled Attenuation Parameter (CAP) in Various Diseases. , 2020, , 441-457.		0
2332	Integrative Proposal for the Use of Biomarkers in Clinical Practice Management of NAFLD/NASH. , 2020, , 225-236.		0
2333	Genes and NAFLD/NASH Progression. , 2020, , 29-47.		0
2334	Machine Learning Technology for Evaluation of Liver Fibrosis, Inflammation Activity and Steatosis (LIVERFAST<sup>TM</sup>). Journal of Intelligent Learning Systems and Applications, 2020, 12, 31-49.	0.4	5
2335	Association between hemoglobin levels and non-alcoholic fatty liver disease in patients with young-onset type 2 diabetes mellitus. Endocrine Journal, 2020, 67, 1139-1146.	0.7	4
2336	Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease. Saudi Journal of Gastroenterology, 2020, 26, 204.	0.5	2
2337	The role of non-invasive scores in determining the liver fibrosis in NAFLD and psoriatic patients. Romanian Journal of Morphology and Embryology, 2020, 61, 503-511.	0.4	4
2338	Noninvasive Diagnostic Approach to NASH: Radiological Diagnostics. , 2020, , 257-269.		0
2339	Bariatric Surgery and NASH: A Feasible Option. , 2020, , 329-342.		0
2340	II. Obesity and Insulin Resistance Drive Hepatic Inflammation. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 19-26.	0.0	0
2341	NAFLD, Diabetes, and Other Endocrine Diseases: Clinical Implications. , 2020, , 147-168.		0
2342	Association between cardiac conduction defect and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Annals of Gastroenterology, 2020, 33, 661-666.	0.4	6
2343	NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications. , 2020, , 169-197.		0
2344	Steatosis Assessment by Controlled Attenuation Parameter (CAP ₃), , 2020, , 413-439.		0
2345	Fibrosis Assessment in Patients with NAFLD. , 2020, , 123-139.		1

#	ARTICLE	IF	CITATIONS
2346	Diagnostic Algorithm for the Identification of NAFLD in Primary Care. , 2020, , 225-234.		0
2347	Histopathology of Nonalcoholic Fatty Liver Disease. , 2020, , 25-47.		1
2348	Hepatocellular Carcinoma: Western Experience. , 2020, , 81-118.		0
2349	Non-alcoholic Fatty Liver Disease: A Global Public Health Issue. , 2020, , 321-333.		2
2350	The health impact of obesity. , 2020, , 73-83.		2
2351	The Clinical and Histological Characteristics of Patients with Biopsy-Proven Non-alcoholic Fatty Liver Disease in the Absence of Insulin Resistance. Hepatology Forum, 2020, , .	0.3	3
2352	Extracellular Vesicles in Non-alcoholic Fatty Liver Disease: Key Players in Disease Pathogenesis and Promising Biomarker Tools. , 2020, , 157-180.		0
2353	Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). , 2020, , 1-10.		0
2354	I. Epidemiology of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 11-18.	0.0	1
2355	VI. Screening High-risk Non-alcoholic Fatty Liver Disease (NAFLD). The Journal of the Japanese Society of Internal Medicine, 2020, 109, 47-55.	0.0	0
2356	Non-viral or Drug-Induced Causes of Acute Liver Failure. , 2020, , 259-279.		0
2357	Enfermedad hepática grasa no alcohólica. Medicine, 2020, 13, 173-181.	0.0	0
2358	Intensity of systemic proteolysis and endotoxemia in patients with non-alcoholic steatohepatitis associated with obesity and comorbid chronic obstructive pulmonary disease in the dynamics of treatment with hepatoprotectors. Gastroenterologia, 2020, 54, 101-106.	0.0	0
2359	Protocolo diagnóstico, terapéutico y de seguimiento del paciente con enfermedad hepática grasa no alcohólica. Medicine, 2020, 13, 215-219.	0.0	0
2360	Biochemical Parameters in Obese Egyptian Patients as a Non-Invasive Marker for Disease Screening in Early Diagnosis of Non-Alcoholic Fatty Liver Disease. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 105-112.	0.1	0
2361	Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them. Revista De Gastroenterología De México (English) Tj ETQq1 1 00784314 r0BT /Over		
2362	Identification of a 17-gene-signature in Non-alcoholic Steatohepatitis and Its Relationship with Immune Cell Infiltration. Hepatitis Monthly, 2021, 21, .	0.1	0
2363	Policosanol alleviates hepatic lipid accumulation by regulating bile acids metabolism in C57BL6/mice through AMPK-FXR-TGR5 cross-talk. Journal of Food Science, 2021, 86, 5466-5478.	1.5	14

#	ARTICLE	IF	CITATIONS
2364	Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2022, 126, 154925.	1.5	134
2365	A Step Closer to the “Fourth 90”: A Practical Narrative Review of Diagnosis and Management of Nutritional Issues of People Living with HIV. <i>Diagnostics</i> , 2021, 11, 2047.	1.3	4
2366	The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 671-683.	0.9	58
2367	Editorial: statin use in patients with NAFLD—safety concerns, decreased awareness or both?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1499-1500.	1.9	1
2368	Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. <i>Biomedicines</i> , 2021, 9, 1639.	1.4	84
2369	Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. <i>Obesity Reviews</i> , 2022, 23, e13367.	3.1	7
2370	Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11905.	1.8	34
2371	Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease. <i>Gut and Liver</i> , 2022, 16, 589-598.	1.4	11
2372	Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. <i>Hepatology Research</i> , 2022, 52, 176-186.	1.8	8
2373	Lipid-induced DRAM recruits STOM to lysosomes and induces LMP to promote exosome release from hepatocytes in NAFLD. <i>Science Advances</i> , 2021, 7, eabh1541.	4.7	17
2374	A Pre-Release Algorithm With a Confidence Map for Estimating the Attenuation Coefficient for Liver Fat Quantification. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 1939-1948.	0.8	3
2375	Ultrasound Image Computerized Analysis for Non-invasive Quantitative Evaluation of Hepatic Fibrosis. <i>Journal of Ultrasound in Medicine</i> , 2021, 32, 888-895.		1
2376	Screening for Non-alcoholic Fatty Liver Disease in Current Practice. <i>Current Hepatology Reports</i> , 2021, 20, 128-134.	0.4	0
2377	Obesity and Nonalcoholic Fatty Liver Disease. <i>Nursing Clinics of North America</i> , 2021, 56, 543-552.	0.7	6
2378	The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. <i>Exploration of Medicine</i> , 2020, 1, 170-183.	1.5	4
2379	Assessment of non-alcoholic fatty liver disease by non-invasive methods: present and future perspectives. <i>Revista Médica Del Hospital General De México</i> , 2020, 83, .	0.0	0
2380	Hydrogen inhalation alleviates nonalcoholic fatty liver disease in metabolic syndrome rats. <i>Molecular Medicine Reports</i> , 2020, 22, 2860-2868.	1.1	10
2381	Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. <i>World Journal of Hepatology</i> , 2020, 12, 379-389.	0.8	0

#	ARTICLE	IF	CITATIONS
2382	Pre-assessment for Hepato-Pancreato-Biliary and Liver Transplant Surgery. , 2021, , 111-136.		0
2383	Advances in the treatment of nonalcoholic steatohepatitis. World Journal of Pharmacology, 2020, 9, 1-12.	1.3	1
2384	Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!. World Journal of Hepatology, 2020, 12, 709-721.	0.8	5
2385	Diagnostic Assessment of Nonalcoholic Fatty Liver Disease. Korean Journal of Medicine, 2020, 95, 299-307.	0.1	0
2386	The miR-21 potential of serving as a biomarker for liver diseases in clinical practice. Biochemical Society Transactions, 2020, 48, 2295-2305.	1.6	10
2387	Bariatric surgery proves long-term benefit in patients with cirrhosis. Gastroenterology Report, 2021, 9, 252-256.	0.6	5
2388	Genetic variations of three important antioxidative enzymes SOD2, CAT, and GPX1 in nonalcoholic steatohepatitis. Journal of the Chinese Medical Association, 2021, 84, 14-18.	0.6	8
2389	CHANGES IN CARBOHYDRATE METABOLISM AND ADIPOCYTOKINES UNDER THE INFLUENCE OF TREATMENT OF PATIENTS WITH ALCOHOLIC CIRRHOSIS OF THE LIVER IN COMBINATION WITH OBESITY USING ADAMETHIONINUM AND ARGININE GLUTAMATE. Medical and Clinical Chemistry, 2020, , 17-25.	0.1	1
2390	New Drugs on the Block – Emerging Treatments for Nonalcoholic Steatohepatitis. Journal of Clinical and Translational Hepatology, 2020, 000, 1-9.	0.7	3
2391	Parallels between non-alcoholic fatty liver disease and non-alcoholic fatty pancreatic disease: looking for points of contact or regard through the lens of metabolic syndrome. Eksperimental'naya i Klinicheskaya Gastroenterologiya, 2020, 183, 80-101.	0.1	0
2392	Role of Etiology Therapy in Management of Variceal Hemorrhage in Liver Cirrhosis. , 2021, , 41-51.		0
2393	Obstructive sleep apnea and severity of nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2021, 33, 1104-1109.	0.8	9
2394	Risk of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis. Gastroenterology and Hepatology, 2018, 14, 247-249.	0.2	3
2395	Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology and Hepatology, 2018, 14, 407-414.	0.2	8
2396	NASH: The Emerging Most Common Form of Chronic Liver Disease. Missouri Medicine, 2018, 115, 225-229.	0.3	21
2397	Omega-3 for nonalcoholic fatty liver disease in children. Canadian Family Physician, 2019, 65, 34-38.	0.1	1
2398	Identifying and Treating Nonalcoholic Fatty Liver Disease. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, 20-29.	0.6	1
2399	Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients. AMIA ... Annual Symposium proceedings, 2018, 2018, 430-439.	0.2	20

#	ARTICLE	IF	CITATIONS
2400	Pharmacologic Management of Nonalcoholic Steatohepatitis. <i>Gastroenterology and Hepatology</i> , 2018, 14, 582-589.	0.2	4
2401	Population Management of Nonalcoholic Fatty Liver Disease. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, 72-82.	0.6	2
2402	Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, 64-71.	0.6	19
2403	Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Gastroenterology and Hepatology</i> , 2019, 15, 83-89.	0.2	9
2404	Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic. <i>Gastroenterology and Hepatology</i> , 2019, 15, 357-365.	0.2	10
2405	Implications of Nonalcoholic Fatty Liver Disease on Pregnancy and Maternal and Child Outcomes. <i>Gastroenterology and Hepatology</i> , 2019, 15, 221-228.	0.2	3
2406	The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2019, 12, 267-277.	0.6	8
2407	Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i. <i>Hawai'i Journal of Health & Social Welfare</i> , 2020, 79, 180-186.	0.2	0
2408	Prevalence and Clinical Characteristics of NAFLD in Chronic Liver Disease Patients from King Abdulaziz University Hospital, Jeddah. <i>Saudi Journal of Medicine and Medical Sciences</i> , 2020, 8, 118-124.	0.3	1
2409	Changes and roles of intestinal fungal microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 3445-3460.	0.0	2
2410	Effect of soy consumption on liver enzymes, lipid profile, anthropometry indices, and oxidative stress in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. <i>Iranian Journal of Basic Medical Sciences</i> , 2020, 23, 1245-1250.	1.0	0
2411	Lifestyle Interventions Beyond Diet and Exercise for Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology and Hepatology</i> , 2020, 16, 119-130.	0.2	1
2412	Role of Noninvasive Biomarkers in the Diagnosis of Nonalcoholic Steatohepatitis With Stage 2 or 3 Fibrosis. <i>Gastroenterology and Hepatology</i> , 2020, 16, 139-141.	0.2	0
2413	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00417.	1.3	1
2414	The uprising of metabolic dysfunction-associated fatty liver disease (MAFLD) in acute-on-chronic liver failure (ACLF). <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 857-859.	0.7	7
2415	Polycystic ovary syndrome and nonalcoholic fatty liver disease. , 2022, , 187-216.		1
2416	SP-1154, a novel synthetic TGF- β 2 inhibitor, alleviates obesity and hepatic steatosis in high-fat diet-induced mice. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112441.	2.5	4
2417	CLINICAL FEATURES AND LABORATORY PARAMETERS IN PREGNANT WOMEN WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND OBESITY. <i>Zbŕnik Naukovih PracĀ AsocĀ-acĀ-ĀĀ ĀkuĀjerĀ-v-gĀ-nekologĀ-v UkraĀni</i> , 2021, 5-13. 0	0.1	0

#	ARTICLE	IF	CITATIONS
2418	Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2023, 48, .	0.6	2
2419	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00417.	1.3	13
2420	Advances in Liver Rehabilitation. <i>The Japanese Journal of Rehabilitation Medicine</i> , 2021, 58, 1120-1127.	0.0	0
2421	Prognostic Value of Inflammatory Indicators in Chronic Hepatitis B Patients With Significant Liver Fibrosis: A Multicenter Study in China. <i>Frontiers in Pharmacology</i> , 2021, 12, 653751.	1.6	1
2422	Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-14.	1.0	0
2423	The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 792667.	1.6	11
2424	Approach to Pediatric Obesity and Nonalcoholic Fatty Liver Disease. <i>Pediatric Annals</i> , 2021, 50, e474-e477.	0.3	1
2425	Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients. <i>Dermatologic Therapy</i> , 2022, 35, e15203.	0.8	4
2426	Non-Alcoholic Fatty Liver Disease (NAFLD) and Nutrition. <i>Nutrition Today</i> , 2021, 56, 296-305.	0.6	0
2427	Nonalcoholic Fatty Liver Disease Underdiagnosis in Primary Care: What Are We Missing?. <i>Journal of General Internal Medicine</i> , 2022, 37, 2587-2590.	1.3	5
2428	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548.	1.8	66
2429	Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis. <i>JHEP Reports</i> , 2022, 4, 100392.	2.6	10
2430	Increased Serum Pentraxin 3 Is Associated with Prediabetes and Type 2 Diabetes in Obese Patients with Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , 2022, 20, 132-136.	0.5	4
2431	Development, validation, qualification, and dissemination of quantitative MR methods: Overview and recommendations by the ISMRM quantitative MR study group. <i>Magnetic Resonance in Medicine</i> , 2022, 87, 1184-1206.	1.9	21
2432	PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD. <i>BMC Gastroenterology</i> , 2021, 21, 434.	0.8	8
2433	The Neglected Role of Bile Duct Epithelial Cells in NASH. <i>Seminars in Liver Disease</i> , 2022, 42, 034-047.	1.8	8
2434	Immunoglobulin G in non-alcoholic steatohepatitis predicts clinical outcome: A prospective multi-centre cohort study. <i>World Journal of Gastroenterology</i> , 2021, 27, 7563-7571.	1.4	8
2435	Y-box binding protein 1 regulates liver lipid metabolism by regulating the Wnt/ β -catenin signaling pathway. <i>Annals of Translational Medicine</i> , 2021, 9, 1693-1693.	0.7	3

#	ARTICLE	IF	CITATIONS
2436	Translational Control in Liver Disease. <i>Frontiers in Physiology</i> , 2021, 12, 795298.	1.3	2
2437	Transdermal Drug Delivery Systems and Their Use in Obesity Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12754.	1.8	16
2438	Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial. <i>Trials</i> , 2021, 22, 801.	0.7	9
2439	Controversies surrounding peripheral cannabinoid receptor 1 in fatty liver disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	1
2440	Potential relation between non-alcoholic fatty liver disease and glycemic and metabolic parameters in subjects without diabetes. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	2
2441	Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up. <i>International Journal of Colorectal Disease</i> , 2022, 37, 349-356.	1.0	5
2442	Evaluation of fibrosis in patients with nonalcoholic fatty liver disease. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2021, 87, 1-1.	0.1	0
2444	ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis. <i>Surgery for Obesity and Related Diseases</i> , 2022, 18, 314-325.	1.0	8
2445	Emerging Role of Interleukins for the Assessment and Treatment of Liver Diseases. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 371-382.	0.6	3
2446	Fatty Liver Disease: Diagnosis and Stratification. <i>Annual Review of Medicine</i> , 2022, 73, 529-544.	5.0	17
2447	Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. <i>Nature Reviews Endocrinology</i> , 2022, 18, 55-66.	4.3	82
2448	Statins in Non-alcoholic Steatohepatitis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 777131.	1.1	15
2449	Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. <i>Journal of Controlled Release</i> , 2022, 341, 457-474.	4.8	8
2450	Comparison of diagnostic performance between FIBâ€4 and NFS in metabolicâ€associated fatty liver disease era. <i>Hepatology Research</i> , 2022, 52, 247-254.	1.8	14
2451	Pathophysiology of type 2 diabetes and the impact of altered metabolic interorgan crosstalk. <i>FEBS Journal</i> , 2023, 290, 620-648.	2.2	22
2452	Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE). <i>PLoS ONE</i> , 2021, 16, e0260320.	1.1	10
2453	The Dietary Inflammatory Index and hepatic health in the US adult population. <i>Journal of Human Nutrition and Dietetics</i> , 2022, 35, 968-979.	1.3	9
2454	Abnormal liver enzymes: A review for clinicians. <i>World Journal of Hepatology</i> , 2021, 13, 1688-1698.	0.8	47

#	ARTICLE	IF	CITATIONS
2455	Roles of Î ^α B kinases and TANK-binding kinase 1 in hepatic lipid metabolism and nonalcoholic fatty liver disease. <i>Experimental and Molecular Medicine</i> , 2021, 53, 1697-1705.	3.2	13
2456	Inverse Association of Serum Adipsin with the Remission of Nonalcoholic Fatty-Liver Disease: A 3-Year Community-Based Cohort Study. <i>Annals of Nutrition and Metabolism</i> , 2022, 78, 21-32.	1.0	8
2457	Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 691556.	1.5	7
2458	Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients. <i>Biomedicines</i> , 2021, 9, 1751.	1.4	4
2459	Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study. <i>PLoS ONE</i> , 2021, 16, e0260477.	1.1	2
2460	Acoustic radiation force impulse elastography and liver fibrosis risk scores in severe obesity. <i>Archives of Endocrinology and Metabolism</i> , 2021, 65, .	0.3	3
2461	Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study. <i>Endoscopy International Open</i> , 2021, 09, E1792-E1800.	0.9	5
2463	Beyond the Liver Function Tests: A Radiologist's Guide to the Liver Blood Tests. <i>Radiographics</i> , 2022, 42, 125-142.	1.4	5
2464	Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions. <i>JHEP Reports</i> , 2022, 4, 100411.	2.6	24
2465	Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage. <i>Oncology</i> , 2022, 100, 31-38.	0.9	5
2466	Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. <i>Diagnostics</i> , 2021, 11, 2236.	1.3	16
2467	Statistical Machine Learning Approaches to Liver Disease Prediction. <i>Livers</i> , 2021, 1, 294-312.	0.8	16
2468	Serum copper, ceruloplasmin, and their relations to metabolic factors in nonalcoholic fatty liver disease: a cross-sectional study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 443-448.	0.8	4
2469	Ruthenium 360 and mitoxantrone inhibit mitochondrial calcium uniporter channel to prevent liver steatosis induced by high-fat diet. <i>British Journal of Pharmacology</i> , 2022, 179, 2678-2696.	2.7	20
2470	Non-alcoholic fatty liver disease: Current therapeutic options. <i>Current Opinion in Pharmacology</i> , 2021, 61, 98-105.	1.7	15
2471	Fatty Liver and the Coronavirus Disease 2019 Pandemic: Health Behaviors, Social Factors, and Telemedicine Satisfaction in Vulnerable Populations. <i>Hepatology Communications</i> , 2022, 6, 1045-1055.	2.0	13
2472	An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 619-629.e7.	2.4	90
2473	Current and Potential Therapies Targeting Inflammation in NASH. <i>Frontiers in Endocrinology</i> , 2021, 12, 767314.	1.5	20

#	ARTICLE	IF	CITATIONS
2474	Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of U.S. adults using NHANES 2017â€“2018.. Preventive Medicine, 2022, 154, 106903.	1.6	21
2475	Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. European Radiology, 2022, 32, 2457-2469.	2.3	19
2476	Relationships among N,N-dimethylformamide exposure, CYP2E1 and TM6SF2 genes, and non-alcoholic fatty liver disease. Ecotoxicology and Environmental Safety, 2021, 228, 112986.	2.9	3
2477	The association between NAFLD and risk of chronic kidney disease: a cross-sectional study. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110486.	1.1	17
2478	Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry. Laboratory Medicine, 2022, 53, 360-368.	0.8	0
2479	Serum Metabolome Alterations in Patients With Nonalcoholic Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0
2481	Gut microbiome profiling in nonalcoholic fatty liver disease and healthy individuals in Indonesian population. Journal of Medical Sciences (Taiwan), 2022, 42, 166.	0.1	1
2482	Glucose-lowering agents and reduced risk of incident non-alcoholic fatty liver disease: new insights. Hepatobiliary Surgery and Nutrition, 2022, 11, 156-160.	0.7	1
2483	NAFLD in type 1 diabetes: overrated or underappreciated?. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110555.	1.4	14
2484	Prevalence of non alcoholic fatty liver disease and associated factors?. Annals of Hepatology, 2022, 27, 100659.	0.6	0
2485	The use of very lowâ€“calorie diets in subjects with obesity complicated with nonalcoholic fatty liver disease: A scoping review. Obesity Science and Practice, 2022, 8, 510-524.	1.0	5
2486	Stratifying individuals into non-alcoholic fatty liver disease risk levels using time series machine learning models. Journal of Biomedical Informatics, 2022, 126, 103986.	2.5	7
2487	Diagnostic Value of Neutrophil to Lymphocyte Ratio in Non-Alcoholic Fatty Liver Disease Evaluated Using Transient Elastography (TE) with Controlled Attenuated Parameter (CAP). Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 15-22.	1.1	5
2488	The advantages of physical exercise as a preventive strategy against NAFLD in postmenopausal women. European Journal of Clinical Investigation, 2022, 52, e13731.	1.7	8
2489	OUP accepted manuscript. Journal of Nutrition, 2022, , .	1.3	1
2490	Characteristics of peripheral blood Gamma-glutamyl transferase in different liver diseases. Medicine (United States), 2022, 101, e28443.	0.4	6
2491	Adherence to the dietary approaches to stop hypertension diet and nonâ€“alcoholic fatty liver disease. Liver International, 2022, 42, 809-819.	1.9	14
2492	Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD. BMJ Open Gastroenterology, 2022, 9, e000798.	1.1	3

#	ARTICLE	IF	CITATIONS
2493	The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 15-27.	2.2	24
2494	Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. <i>Cureus</i> , 2022, 14, e21110.	0.2	1
2495	Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 180-191.	1.2	46
2496	Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: Evidence from mediation analysis. <i>Clinical Nutrition</i> , 2022, 41, 356-364.	2.3	20
2497	Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]. <i>Metabolism Open</i> , 2022, 13, 100158.	1.4	8
2498	Highland barley <i>Monascus purpureus</i> Went extract ameliorates high-fat, high-fructose, high-cholesterol diet induced nonalcoholic fatty liver disease by regulating lipid metabolism in golden hamsters. <i>Journal of Ethnopharmacology</i> , 2022, 286, 114922.	2.0	11
2499	Adiponectin alleviates nonalcoholic fatty liver injury via regulating oxidative stress in liver cells. <i>Minerva Medica</i> , 2020, , .	0.3	2
2500	RELATION OF LACTOBACILLI ACIDOPHILUS TO NON-ALCOHOLIC FATTY LIVER IN A SAMPLE OF EGYPTIAN POPULATION. <i>Ain Shams Medical Journal</i> , 2020, 71, 681-688.	0.0	0
2501	Relationship between Hepatic Artery Resistive Index and Liver Fibrosis Score in Non-Alcoholic Fatty Liver Disease Patient. <i>The Egyptian Journal of Hospital Medicine</i> , 2020, 81, 2093-2098.	0.0	0
2502	Deep Learning based NAS Score and Fibrosis Stage Prediction from CT and Pathology Data. , 2020, , .		6
2503	Possibilities of non-pharmacological correction of intestinal microbiota in patients with non-alcoholic fatty liver disease. <i>Modern Gastroenterology</i> , 2020, .	0.1	1
2504	Analysis of Metabolic Biomarkers in Non-Alcoholic Fatty Liver Disease (NAFLD); A Comprehensive Review. <i>Advanced Journal of Graduate Research</i> , 2020, 9, 46-58.	0.5	1
2505	The prognostic factors for effectiveness of the treatment of non-alcoholic fatty liver disease against the obesity background. <i>Modern Gastroenterology</i> , 2020, .	0.1	0
2506	Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and metanalysis. <i>Przegląd Gastroenterologiczny</i> , 2022, 17, 288-300.	0.3	2
2507	INSULIN RESISTANCE AS AN INDICATOR OF DIFFERENTIATION FOR THE FORMATION OF RISK GROUPS FOR NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITHOUT TYPE 2 DIABETES MELLITUS, AS A PART OF ONTOLOGICAL MODEL OF NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Wiadomości Lekarskie</i> , 2021, 74, 2593-2598.	0.1	0
2508	Non-invasive diagnosis of liver fibrosis associated with nonalcoholic steatohepatitis. <i>Russian Journal of Evidence-Based Gastroenterology</i> , 2021, 10, 75.	0.3	0
2509	Management of Obesity in Children and Young People. , 2022, , 1846-1851.		0
2510	An algorithm for the management of non-alcoholic fatty liver disease in primary care. <i>Gastroenterology & Hepatology (Bartlesville, Okla)</i> , 2021, 12, 114-122.	0.0	0

#	ARTICLE	IF	CITATIONS
2511	Non-alcoholic steatohepatitis in patients with endocrine pathology. Review. <i>Clinical Endocrinology and Endocrine Surgery</i> , 2021, , 82-93.	0.1	0
2512	An Observational Study to Determine Severity and Complications Associated with Non-Alcoholic Fatty Liver Disease with Special Emphasis on Riskfactors. <i>Research Journal of Pharmacy and Technology</i> , 2021, , 5498-5502.	0.2	0
2513	A New Machine Learning-Based Complementary Approach for Screening of NAFLD (Hepatic Steatosis). , 2021, 2021, 2343-2346.		2
2514	Clinical predictive score for detecting nonalcoholic fatty liver disease with significant fibrosis in patients with metabolic syndrome. <i>Medicine (United States)</i> , 2021, 100, e27640.	0.4	1
2515	Focal fatty sparing as an indicator of higher-grade fatty liver assessed by attenuation imaging: a prospective clinical study in NAFLD population. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 1483-1489.	0.2	2
2516	Polymorphisms 677Câ€†â€†T and 1298Aâ€†â€†C in the MTHFR gene and homocysteine levels in patients with non-alcoholic fatty liver disease as a component of the ontological model. <i>Modern Gastroenterology</i> , 2021, , .	0.1	0
2517	Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. <i>Journal of Clinical Medicine</i> , 2021, 10, 5755.	1.0	9
2518	Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 940-946.	1.2	8
2519	Features of the hemostasis system in patients with non-alcoholic fatty liver disease. <i>Gastroenterologia</i> , 2021, 55, 235-238.	0.0	0
2520	The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care. <i>Journal of General Internal Medicine</i> , 2022, 37, 3266-3274.	1.3	3
2521	The Prediction Model of Fatty Liver Established by Blood Biochemical Indexes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2522	Portrait of Regional Trends in Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. <i>American Journal of Gastroenterology</i> , 2022, 117, 433-444.	0.2	10
2523	The Role of Sarcopenia and Myosteatosis in Short- and Long-Term Outcomes Following Curative-Intent Surgery for Hepatocellular Carcinoma in a European Cohort. <i>Cancers</i> , 2022, 14, 720.	1.7	23
2524	Future pharmacotherapy for non-alcoholic steatohepatitis. <i>The National Medical Journal of India</i> , 2022, 34, 225-227.	0.1	0
2525	Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review. <i>Hepatology International</i> , 2022, 16, 27-37.	1.9	7
2526	Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. <i>Biomedicines</i> , 2022, 10, 274.	1.4	22
2527	Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. <i>Frontiers in Oncology</i> , 2021, 11, 783339.	1.3	4
2528	Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. <i>European Journal of Endocrinology</i> , 2022, 186, 367-377.	1.9	12

#	ARTICLE	IF	CITATIONS
2529	NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH. <i>Hepatology</i> , 2022, 76, 172-185.	3.6	24
2530	Dyspepsia and Gut Microbiota in Female Patients with Postcholecystectomy Syndrome. <i>International Journal of Women's Health</i> , 2022, Volume 14, 41-56.	1.1	8
2531	Associations among FT₄ level, FT₃/FT₄ ratio, and non-alcoholic fatty liver disease in Chinese patients with hypopituitarism. <i>Endocrine Journal</i> , 2022, 69, 659-667.	0.7	1
2532	Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. <i>World Journal of Gastroenterology</i> , 2022, 28, 310-331.	1.4	29
2533	An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care. <i>Diabetic Medicine</i> , 2022, 39, e14799.	1.2	8
2534	Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the U.S.. <i>Ethnicity and Health</i> , 2023, 28, 299-312.	1.5	10
2535	Adherence to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Bulletin of Siberian Medicine</i> , 2022, 20, 112-122.	0.1	0
2536	Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 143-152.e3.	2.4	14
2537	Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. <i>Acta Diabetologica</i> , 2022, 59, 519-533.	1.2	10
2538	Electrophilic thymol isobutyrate from <i>Inula nervosa</i> Wall. (Xiaoheiyao) ameliorates steatosis in HepG2 cells via Nrf2 activation. <i>Journal of Functional Foods</i> , 2022, 88, 104895.	1.6	4
2539	Serum cadmium is associated with hepatic steatosis and fibrosis. <i>Medicine (United States)</i> , 2022, 101, e28559.	0.4	11
2540	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. <i>Journal of Hepatology</i> , 2022, 76, 1013-1020.	1.8	66
2541	Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2022, 117, 453-461.	0.2	28
2542	NASH and the Gut Microbiome: Implications for New Therapies. <i>Clinical Liver Disease</i> , 2022, 19, 97-100.	1.0	8
2543	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041.	1.8	74
2544	Inflammation: The Straw That Broke the NAFLD Liver!. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1273-1274.	2.3	2
2545	NASH: regulatory considerations for clinical drug development and U.S. FDA approval. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1210-1214.	2.8	11
2546	Hepatocellular carcinoma diagnosis using a novel electrochemiluminescence immunoassay targeting serum IgM-free AIM. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 41-51.	0.4	6

#	ARTICLE	IF	CITATIONS
2547	Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 356-362.	0.7	6
2549	Transgenic overexpression of CTRP3 does not prevent alcohol induced hepatic steatosis in female mice. <i>PLoS ONE</i> , 2022, 17, e0258557.	1.1	0
2550	Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , 2022, 20, 166-173.	0.5	15
2551	The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24225.	0.9	14
2552	Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease. <i>Journal of Personalized Medicine</i> , 2022, 12, 92.	1.1	6
2553	Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease. <i>Journal of Medical Economics</i> , 2022, 25, 347-355.	1.0	10
2554	Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 367-378.	3.7	92
2555	A sequential approach using the age-adjusted fibrosis index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 994-1007.	1.9	2
2556	High prevalence of functional dyspepsia in nonalcoholic fatty liver disease: a cross-sectional study. <i>Sao Paulo Medical Journal</i> , 2022, 140, 199-206.	0.4	3
2557	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1-16.	1.1	15
2558	The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States. <i>Quality of Life Research</i> , 2022, 31, 2481-2491.	1.5	6
2559	The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival. <i>Clinical Therapeutics</i> , 2022, 44, 257-268.	1.1	4
2560	Nonalcoholic Fatty Liver Disease and Associated Risk Factors in a Community-Based Sample of Mexican-Origin Adults. <i>Hepatology Communications</i> , 2022, 6, 1322-1335.	2.0	11
2561	Non-alcoholic fatty liver disease and type-2 diabetes: An update. <i>Journal of Diabetes Investigation</i> , 2022, 13, 930-940.	1.1	25
2562	Berberine Depresses Hepatocellular Lipogenesis Via Targeting to Methyltransferase SETD2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2563	Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States. <i>Obesity Surgery</i> , 2022, 32, 712-719.	1.1	4
2564	Biyopsi tanımlanan nonalkolik steatohepatit hastalarında fibrozis evrelerine göre metabolik sendrom komponentlerinin sıklıklarının kararlaştırılması: Metabolik bozukluk sayısındaki artışı fibrozis progresyonunda etkili mi?. <i>Akademik Gastroenteroloji Dergisi</i> , 0, , .		0
2565	Magnetic Resonance Imaging-Proton Density Fat Fraction vs. Transient Elastography-Controlled Attenuation Parameter in Diagnosing Non-alcoholic Fatty Liver Disease in Children and Adolescents: A Meta-Analysis of Diagnostic Accuracy. <i>Frontiers in Pediatrics</i> , 2021, 9, 784221.	0.9	14

#	ARTICLE	IF	CITATIONS
2566	Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost. <i>Journal of Translational Medicine</i> , 2022, 20, 2.	1.8	12
2567	From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. <i>Biomedicines</i> , 2022, 10, 161.	1.4	4
2568	The Worldwide Burden of NAFLD: A Systematic Review and Meta-Analysis of Prevalence and Incidence. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2569	The effect of hydroxy citric acid supplementation with calorie-restricted diet on metabolic, atherogenic and inflammatory biomarkers in women with non-alcoholic fatty liver disease: a randomized controlled clinical trial. <i>Food and Function</i> , 2022, 13, 5124-5134.	2.1	11
2570	Inhibition of 11 β -Hydroxysteroid dehydrogenase α 1 with <i>AZD4017</i> in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 881-890.	2.2	16
2571	Peripheral immune cells in NAFLD patients: A spynhole to disease progression. <i>EBioMedicine</i> , 2022, 75, 103768.	2.7	13
2572	Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 712-724.	1.9	4
2573	US Attenuation for Liver Fat Quantification: An AIUM-RSNA QIBA Pulse-Echo Quantitative Ultrasound Initiative. <i>Radiology</i> , 2022, 302, 495-506.	3.6	60
2574	Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. <i>Hepatology</i> , 2022, 76, 492-501.	3.6	26
2575	Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD. <i>Hepatology</i> , 2022, 76, 1452-1465.	3.6	75
2576	The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Saudi Journal of Gastroenterology</i> , 2022, 28, 3.	0.5	12
2577	Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 481-482.	1.9	0
2578	Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 388-397.e10.	2.4	29
2579	Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2022, 31, 16-24.	0.2	0
2580	Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement. <i>Frontiers in Endocrinology</i> , 2021, 12, 739875.	1.5	11
2581	Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, , 1-11.	1.4	8
2582	Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 339-355.	0.7	16
2583	Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (<i>EDICT</i>). <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 899-907.	2.2	15

#	ARTICLE	IF	CITATIONS
2584	Sex-specific Cutoff Values of Visceral Fat Area for Lean vs. Overweight/Obese Nonalcoholic Fatty Liver Disease in Asians. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
2585	Lifestyle changes during the coronavirus disease 2019 pandemic impact metabolic dysfunction-associated fatty liver disease. <i>Liver International</i> , 2022, , .	1.9	12
2586	Liver fibrosis quantification. <i>Abdominal Radiology</i> , 2022, 47, 1032-1052.	1.0	11
2587	Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?. <i>World Journal of Hepatology</i> , 2022, 14, 158-167.	0.8	5
2588	Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention. <i>Hepatology</i> , 2022, 76, 12-14.	3.6	0
2589	LifeStyle versus Ezetimibe plus lifestyle in patients with biopsy-proven Non-alcoholic steatohepatitis (LISTEN): a double-blind randomised placebo-controlled trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	1.1	3
2590	Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 154-161.	0.6	24
2591	Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 370-379.	2.4	30
2592	The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C. <i>Journal of Digestive Diseases</i> , 2022, 23, 33-43.	0.7	12
2593	Vibration-controlled transient elastography for noninvasive evaluation of liver steatosis. <i>Medical Physics</i> , 2022, , .	1.6	2
2594	Subclinical hepatic fibrosis is associated with coronary microvascular dysfunction by myocardial perfusion reserve index: a retrospective cohort study. <i>International Journal of Cardiovascular Imaging</i> , 2022, , 1.	0.7	0
2595	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
2596	Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 380-387.e3.	2.4	10
2597	Relationship Between Serum Uric Acid-to-Creatinine Ratio and the Risk of Metabolic-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 257-267.	1.1	6
2598	Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis. <i>Endocrine Practice</i> , 2022, 28, 204-213.	1.1	16
2599	Oxidative Stress in Non-Alcoholic Fatty Liver Disease. <i>Livers</i> , 2022, 2, 30-76.	0.8	21
2600	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Digestive and Liver Disease</i> , 2022, 54, 170-182.	0.4	12
2601	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022, 5, 61-90.	0.3	7

#	ARTICLE	IF	CITATIONS
2602	Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 406-414.e7.	2.4	23
2603	Tetrahydrocurcumin protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis. <i>Journal of Functional Foods</i> , 2022, 89, 104957.	1.6	6
2604	Single Point Insulin Sensitivity Estimator in Pediatric Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2022, 13, 830012.	1.5	3
2605	Chronic lead exposure induces fatty liver disease associated with the variations of gut microbiota. <i>Ecotoxicology and Environmental Safety</i> , 2022, 232, 113257.	2.9	33
2606	Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors. <i>Annals of Hepatology</i> , 2022, 27, 100670.	0.6	3
2607	Endothelial group IVA phospholipase A2 promotes hepatic fibrosis with sinusoidal capillarization in the early stage of non-alcoholic steatohepatitis in mice. <i>Life Sciences</i> , 2022, 294, 120355.	2.0	3
2608	Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Ethnopharmacology</i> , 2022, 288, 114999.	2.0	5
2609	The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials. <i>Metabolism: Clinical and Experimental</i> , 2022, 129, 155136.	1.5	19
2610	Randomized placebo-controlled trial of losartan for pediatric NAFLD. <i>Hepatology</i> , 2022, 76, 429-444.	3.6	9
2611	Effect of Aerobic Exercise Alone or in Conjunction With Diet on Liver Function, Insulin Resistance and Lipids in Non-Alcoholic Fatty Liver Disease. <i>Biological Research for Nursing</i> , 2022, 24, 259-276.	1.0	6
2612	A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study. <i>Scientific Reports</i> , 2022, 12, 1956.	1.6	6
2613	Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. <i>Diagnostics</i> , 2022, 12, 407.	1.3	22
2614	A Network Pharmacology Study on the Active Components and Targets of the Radix Ginseng and Radix Bupleuri Herb Pair for Treating Nonalcoholic Fatty Liver Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-18.	0.5	2
2615	Clinical evaluation of grayscale and linear scale hepatorenal indices for fatty liver quantification: a prospective study of a native Chinese population. <i>Abdominal Radiology</i> , 2022, 47, 1321.	1.0	1
2616	Perturbation of Wnt/ β -catenin signaling and sexual dimorphism in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 433-448.	1.8	2
2617	TCF7L2 transcriptionally regulates <i>Fgf15</i> to maintain bile acid and lipid homeostasis through gut-liver crosstalk. <i>FASEB Journal</i> , 2022, 36, e22185.	0.2	3
2618	Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. <i>Hepatology Communications</i> , 2022, 6, 1336-1349.	2.0	22
2619	Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 703-714.	0.7	5

#	ARTICLE	IF	CITATIONS
2620	Dysregulation of S-adenosylmethionine Metabolism in Nonalcoholic Steatohepatitis Leads to Polyamine Flux and Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1986.	1.8	13
2621	The paradigm shift from <sc>NAFLD</sc> to <sc>MAFLD</sc>: A global primary care viewpoint. <i>Liver International</i> , 2022, 42, 1259-1267.	1.9	15
2622	Association of Nonalcoholic Fatty Liver Disease With COVID-19 Severity and Pulmonary Thrombosis: CovidFAT, a Prospective, Observational Cohort Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac073.	0.4	22
2623	NAFLD and vitamin D: Evidence for intersection of microRNA-regulated pathways. <i>Nutrition Research Reviews</i> , 2021, , 1-20.	2.1	11
2624	The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13219.	1.8	24
2625	Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. <i>Diabetologia</i> , 2022, 65, 518-527.	2.9	12
2626	2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2809-2817.e28.	2.4	255
2627	Skipping breakfast is associated with an increased long-term cardiovascular mortality in metabolic dysfunction-associated fatty liver disease (MAFLD) but not MAFLD-free individuals. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 212-224.	1.9	8
2628	A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. <i>Science Translational Medicine</i> , 2021, 13, eabg8116.	5.8	30
2629	FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. <i>BMC Gastroenterology</i> , 2021, 21, 453.	0.8	33
2630	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: <i>Standards of Medical Care in Diabetes</i>. <i>Diabetes Care</i> , 2022, 45, S46-S59.	4.3	99
2632	Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. <i>Biomolecules</i> , 2022, 12, 56.	1.8	98
2633	Intestinal Barrier and Permeability in Health, Obesity and NAFLD. <i>Biomedicines</i> , 2022, 10, 83.	1.4	71
2634	Tagging incidental finding of fatty liver on ultrasound: A novel intervention to improve early detection of liver fibrosis. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 641-647.	0.3	0
2636	Positive Pattern Recognition System Using Alanine Aminotransferase, Type IV Collagen 7s, and E Value (Liver Stiffness) for the Diagnosis of Nonalcoholic Steatohepatitis Based on Natural History. <i>JMA Journal</i> , 2022, 5, .	0.6	1
2637	Role of Serum Hyaluronic Acid in Predicting Necroinflammatory Activity of Non-Alcoholic Fatty Liver Disease. <i>Hepatology Forum</i> , 2022, , .	0.3	0
2638	Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH). <i>Methods in Molecular Biology</i> , 2022, 2455, 1-18.	0.4	5
2639	Metabolic Syndrome Severity Predicts Mortality in Nonalcoholic Fatty Liver Disease. , 2022, 1, 445-456.		6

#	ARTICLE	IF	CITATIONS
2640	Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease. <i>Methods in Molecular Biology</i> , 2022, 2455, 19-30.	0.4	4
2641	Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 39-49.	0.4	0
2643	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 216-253.	0.2	19
2644	Novel insights into the effect of Xiaoyao san on corticosterone-induced hepatic steatosis: inhibition of glucocorticoid receptor/perilipin-2 signaling pathway. , 2022, 2, 49-57.		5
2645	The Concept of Indeterminable NASH Induced by Preoperative Diet and Metabolic Surgery: Analyses of Histopathological and Clinical Features. <i>Biomedicines</i> , 2022, 10, 453.	1.4	2
2646	A robust gene expression signature for NASH in liver expression data. <i>Scientific Reports</i> , 2022, 12, 2571.	1.6	11
2647	The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101896.	0.7	2
2648	The Effect of Berberine on Lipid Profile, Liver Enzymes, and Fasting Blood Glucose in Patients with Non-alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial. <i>Medical Journal of the Islamic Republic of Iran</i> , 0, , .	0.9	5
2649	Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1812-1824.	1.8	32
2650	Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2022, 13, 836455.	1.5	11
2651	Association between Metabolic Dysfunction-associated Fatty Liver Disease and Cognitive Impairment. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	5
2652	Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease. <i>PPAR Research</i> , 2022, 2022, 1-7.	1.1	11
2653	Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease. <i>BMC Endocrine Disorders</i> , 2022, 22, 49.	0.9	14
2654	Therapeutic developments in metabolic dysfunction-associated fatty liver disease. <i>Chinese Medical Journal</i> , 2022, Publish Ahead of Print, .	0.9	2
2655	Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico. <i>Clinical Liver Disease</i> , 2022, 19, 68-72.	1.0	3
2656	Approach to the Patient With Moderate Hypertriglyceridemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1686-1697.	1.8	5
2657	Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. <i>Bioengineered</i> , 2022, 13, 5091-5102.	1.4	14
2658	Organ meat consumption and risk of nonalcoholic fatty liver disease: the TCLSIIH study. <i>British Journal of Nutrition</i> , 2022, , 1-21.	1.2	0

#	ARTICLE	IF	CITATIONS
2659	Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0263931.	1.1	39
2660	Association between serum uric acid level and non-alcoholic fatty liver disease in Koreans. <i>Asian Biomedicine</i> , 2022, 16, 15-22.	0.2	1
2661	Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5300-5308.	1.1	7
2662	Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory Analysis. <i>Metabolites</i> , 2022, 12, 192.	1.3	3
2663	Novel Approach of Multistate Markov Chains to Evaluate Progression in the Expanded Model of Non-alcoholic Fatty Liver Disease. <i>Frontiers in Applied Mathematics and Statistics</i> , 2022, 7, .	0.7	2
2664	A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2022, 13, 821689.	1.5	12
2665	Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2636.	1.8	11
2666	Comparative efficacy of an optimal exam between ultrasound versus abbreviated <i>scp</i> MRI for <i>scp</i> HCC screening in <i>scp</i> NAFLD cirrhosis: A prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 820-827.	1.9	30
2667	Hepatocyte nuclear factor 4 α in the pathogenesis of non-alcoholic fatty liver disease. <i>Chinese Medical Journal</i> , 2022, 135, 1172-1181.	0.9	13
2668	Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. <i>World Journal of Hepatology</i> , 2022, 14, 319-337.	0.8	3
2669	Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention. <i>Current Diabetes Reports</i> , 2022, 22, 129-136.	1.7	5
2670	Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis. <i>Healthcare (Switzerland)</i> , 2022, 10, 374.	1.0	0
2671	Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1103-1119.	2.8	31
2672	Histological assessment based on liver biopsy: the value and challenges in NASH drug development. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1200-1209.	2.8	9
2673	Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
2674	Endoscopic Bariatric and Metabolic Therapies for Liver Disease: Mechanisms, Benefits, and Associated Risks. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	0
2675	The impact of clinical pharmacist-led health education on the disease course of non-alcoholic fatty liver disease patients: an interventional study. <i>F1000Research</i> , 0, 11, 234.	0.8	0
2676	Liver biopsy for assessment of chronic liver diseases: a synopsis. <i>Clinical and Experimental Medicine</i> , 2023, 23, 273-285.	1.9	23

#	ARTICLE	IF	CITATIONS
2677	Water Specific ^{MRI T1} Mapping for Evaluating Liver Inflammation Activity Grades in Rats With ^{Methionine&Choline&Deficient} Diet&Induced Nonalcoholic Fatty Liver Disease. Journal of Magnetic Resonance Imaging, 2022, 56, 1429-1436.	1.9	1
2678	Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy. Medicina (Lithuania), 2022, 58, 290.	0.8	6
2679	Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?. World Journal of Hepatology, 2022, 14, 354-371.	0.8	4
2680	Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. Biomedicines, 2022, 10, 451.	1.4	4
2681	Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial). Cancers, 2022, 14, 1183.	1.7	1
2682	Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. Journal of Clinical Medicine, 2022, 11, 968.	1.0	20
2683	Increasing prevalence of obesity and diabetes among patients evaluated for liver transplantation in a Swiss tertiary referral center: a 10-year retrospective analysis. , 2022, 152, w30138.		0
2684	Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank. Hepatology International, 2022, 16, 325-336.	1.9	9
2685	Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children. Epigenetics, 2022, 17, 1446-1461.	1.3	4
2686	A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study. PeerJ, 2022, 10, e13022.	0.9	5
2687	Metabolic Syndrome: A Warning Sign of Liver Fibrosis. Journal of Obesity and Metabolic Syndrome, 2022, 31, 1-3.	1.5	2
2688	Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH). BMJ Health and Care Informatics, 2022, 29, e100510.	1.4	3
2689	Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. Clinical and Molecular Hepatology, 2022, 28, 725-738.	4.5	10
2690	Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. Clinical and Molecular Hepatology, 2022, 28, 483-496.	4.5	49
2691	Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease. Hepatology Communications, 2022, 6, 1598-1610.	2.0	6
2692	Antiplatelet therapy associated with lower prevalence of advanced liver fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Indian Journal of Gastroenterology, 2022, 41, 119-126.	0.7	6
2693	Association Between Non-alcoholic Fatty Liver Disease and Risk of Stroke: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 812030.	1.1	14
2694	The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Journal of Clinical Medicine, 2022, 11, 1375.	1.0	20

#	ARTICLE	IF	CITATIONS
2695	SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3107.	1.8	49
2696	Associations of Urinary Phytoestrogen Concentrations with Nonalcoholic Fatty Liver Disease among Adults. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-13.	1.1	4
2697	Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 241-247.	0.6	6
2698	Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1061-1071.	2.2	15
2699	NAFLD in normal weight individuals. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, 45.	1.2	20
2700	Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD. <i>Hepatology Communications</i> , 2022, 6, 1516-1526.	2.0	7
2701	A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2022, 9, 862879.	1.2	2
2702	Editorial Comment: Is Quantitative CT Fat Fraction Ready for Prime Time?. <i>American Journal of Roentgenology</i> , 2021, , 13-13.	1.0	0
2703	Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review. <i>Metabolites</i> , 2022, 12, 298.	1.3	19
2704	Review article: current and emerging therapies for the management of cirrhosis and its complications. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1099-1115.	1.9	20
2705	Non-Alcoholic Steatohepatitis (NASH): An Update. <i>International Journal of Research in Pharmaceutical Sciences</i> , 2022, 13, 1-4.	0.0	0
2707	Diabetes medications and risk of HCC. <i>Hepatology</i> , 2022, 76, 1880-1897.	3.6	39
2708	Bidirectional Association between Hypertension and NAFLD: A Systematic Review and Meta-Analysis of Observational Studies. <i>International Journal of Endocrinology</i> , 2022, 2022, 1-10.	0.6	20
2709	Sex-related association of nonalcoholic fatty liver disease and liver fibrosis with body fat distribution in the general US population. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1528-1534.	2.2	34
2710	Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease. <i>Hepatology International</i> , 2022, 16, 412-422.	1.9	2
2711	A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3076-e3077.	1.8	1
2712	Explainability Analysis of Black Box SVM models for Hepatic Steatosis Screening. , 2022, , .		1
2714	Impact of a Mediterranean diet on hepatic and metabolic outcomes in <sc>nonalcoholic</sc> fatty liver disease: The <sc>MEDINA</sc> randomised controlled trial. <i>Liver International</i> , 2022, 42, 1308-1322.	1.9	20

#	ARTICLE	IF	CITATIONS
2715	May Silymarin be selectively considered for nonalcoholic fatty liver disease without elevated transaminases?. <i>Nutrition</i> , 2022, , 111648.	1.1	2
2716	Liver stiffness measurement identifies subclinical myocardial dysfunction in non-advanced non-alcoholic fatty liver disease patients without overt heart disease. <i>Internal and Emergency Medicine</i> , 2022, 17, 1425-1438.	1.0	3
2717	Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?. <i>Renal Failure</i> , 2022, 44, 434-449.	0.8	5
2718	Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 497-507.	1.8	26
2719	Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3357.	1.8	3
2720	Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 944-959.	1.9	17
2721	Elevated Serum Regulator of Calcineurin 2 is Associated With an Increased Risk of Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2022, 13, 840764.	1.6	1
2722	Association between non-alcoholic fatty liver disease and the risk of dementia: A nationwide cohort study. <i>Liver International</i> , 2022, 42, 1027-1036.	1.9	23
2723	Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from <i>Curcuma longa</i> in Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 368-390.	0.6	10
2724	Ginsenoside Rg1 exerts anti-apoptotic effects on non-alcoholic fatty liver cells by downregulating the expression of SGLP1. <i>Molecular Medicine Reports</i> , 2022, 25, .	1.1	5
2725	Relationship Between Thyroid Hormone and Liver Steatosis Analysis Parameter in Obese Participants: A Case-Control Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 887-896.	1.1	1
2726	Visceral Fat Area Is an Independent Risk Factor for Overweight or Obese Nonalcoholic Fatty Liver Disease in Potential Living Liver Donors. <i>Transplantation Proceedings</i> , 2022, 54, 702-705.	0.3	3
2727	Qinggan Huoxue Recipe Alleviates Alcoholic Liver Injury by Suppressing Endoplasmic Reticulum Stress Through LXR-LPCAT3. <i>Frontiers in Pharmacology</i> , 2022, 13, 824185.	1.6	4
2728	Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic) Tj ETQq1 1 0.784314rgBT /Overlock 101	0.8	18
2729	Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development. <i>Cancers</i> , 2022, 14, 1442.	1.7	6
2730	Utility of sonic hedgehog and keratin 8/18 immunohistochemistry for detecting ballooned hepatocytes. <i>Histopathology</i> , 2022, 80, 974-981.	1.6	2
2732	SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3668.	1.8	14
2733	Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. <i>Hepatology International</i> , 2022, 16, 269-281.	1.9	23

#	ARTICLE	IF	CITATIONS
2734	Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study. <i>Diagnostics</i> , 2022, 12, 663.	1.3	7
2735	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología y Hepatología</i> , 2022, 45, 724-734.	0.2	3
2736	Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. <i>Journal of Obesity and Metabolic Syndrome</i> , 2022, 31, 17-27.	1.5	39
2737	<i>PNPLA3 rs 738409</i> and Other Nongenetic Factors Associated with Hepatic Steatosis Estimated by Magnetic Resonance Imaging Proton Density Fat Fraction in Adult Greek Subjects with Type 2 Diabetes Mellitus. <i>Metabolic Syndrome and Related Disorders</i> , 2022, 20, 124-131.	0.5	2
2738	MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2022, 16, 316-324.	1.9	5
2739	Empirically-Derived Dietary Patterns in Relation to Non-Alcoholic Fatty Liver Diseases Among Adult Participants in Amol, Northern Iran: A Structural Equation Modeling Approach. <i>Frontiers in Nutrition</i> , 2022, 9, 821544.	1.6	4
2740	Nonalcoholic fatty liver disease: opinions, population served, and management from a sample of French hepato(gastroentero)logists (PERSEPT study). <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 791-800.	0.8	1
2741	Long or Irregular Menstrual Cycles and Risk of Prevalent and Incident Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2309-e2317.	1.8	6
2742	Clinical and Laboratory Characteristics of Normal Weight and Obese Individuals with Non-Alcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2022, 12, 801.	1.3	4
2743	Role of liver biopsy in management of liver diseases without hepatic nodules following end of the interferon era: experience of a tertiary referral center. <i>Clinical and Experimental Medicine</i> , 2022, , 1.	1.9	0
2744	Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity. <i>Internal and Emergency Medicine</i> , 2022, 17, 1609-1616.	1.0	3
2745	Fibromax and inflammatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2022, 68, .	0.3	5
2746	Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study. <i>Diabetes and Metabolism</i> , 2022, 48, 101344.	1.4	15
2747	Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2022, 9, 864570.	1.2	5
2748	Combination Effects of Metformin and a Mixture of Lemon Balm and Dandelion on High-Fat Diet-Induced Metabolic Alterations in Mice. <i>Antioxidants</i> , 2022, 11, 580.	2.2	2
2749	Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109791.	1.1	10
2750	Effect of rosemary leaf powder with weight loss diet on lipid profile, glycemic status, and liver enzymes in patients with nonalcoholic fatty liver disease: A randomized, double-blind clinical trial. <i>Phytotherapy Research</i> , 2022, 36, 2186-2196.	2.8	2
2751	Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102446.	1.8	3

#	ARTICLE	IF	CITATIONS
2752	The role of microbiota in nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13768.	1.7	22
2753	Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity. <i>Endocrinología y Nutrición (English Ed)</i> , 2022, 69, 178-188.	0.1	0
2754	Relationship between growth hormone deficiency and nonalcoholic fatty liver disease in patients with pituitary stalk interruption syndrome. <i>Clinical Endocrinology</i> , 2022, 97, 612-621.	1.2	2
2755	Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 1409-1422.	3.6	24
2756	EUS imaging for the diagnosis of nonalcoholic fatty liver disease. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 711-716.	0.5	5
2757	Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. <i>Hepatology Communications</i> , 2022, 6, 1537-1548.	2.0	33
2758	Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia. <i>Liver International</i> , 2022, 42, 1981-1990.	1.9	13
2759	Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, 5695.	1.6	6
2760	Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXR β /PCSK9 pathway. <i>Scientific Reports</i> , 2022, 12, 5639.	1.6	10
2761	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
2762	Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101876.	0.7	10
2763	Diabetes and Fatty Liver. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, , .	0.6	0
2764	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	3.6	15
2765	Bariatric Surgery Improves Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. <i>Obesity Surgery</i> , 2022, 32, 1872-1883.	1.1	19
2766	The longitudinal associations between sweet potato intake and the risk of non-alcoholic fatty liver disease: the TCLSIH cohort study. <i>International Journal of Food Sciences and Nutrition</i> , 2022, , 1-12.	1.3	2
2767	Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109827.	1.1	8
2768	Integrating metabolomics and network pharmacology to reveal the mechanisms of Delphinium brunonianum extract against nonalcoholic steatohepatitis. <i>Journal of Ethnopharmacology</i> , 2022, 293, 115268.	2.0	4
2769	Clinical Utility of Ultrasound-Guided Attenuation Parameter for the Detection and Quantification of Hepatic Steatosis in Patients with Fatty Liver Diagnosed by Computed Tomography. <i>Ultrasound in Medicine and Biology</i> , 2022, 48, 1282-1289.	0.7	1

#	ARTICLE	IF	CITATIONS
2770	Proteomic analysis reveals exercise training induced remodelling of hepatokine secretion and uncovers syndecan-4 as a regulator of hepatic lipid metabolism. <i>Molecular Metabolism</i> , 2022, 60, 101491.	3.0	12
2771	A global view of the interplay between non-alcoholic fatty liver disease and diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 284-296.	5.5	232
2772	Dihydroflavonoids as Bioactive Components of <i>Penthorum chinense</i> , a Miao Ethnomedicine, against NAFLD through Bile Acid Metabolism Pathway. <i>Chemistry and Biodiversity</i> , 2022, , .	1.0	2
2774	The Role of Hydrogen Sulfide Regulation of Autophagy in Liver Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4035.	1.8	9
2775	Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. <i>PLoS ONE</i> , 2022, 17, e0265153.	1.1	18
2776	The impact of MAFLD on the prognosis of HCC patients with radical resection. <i>CRediT authorship contribution statement. Hepatobiliary and Pancreatic Diseases International</i> , 2022, , .	0.6	4
2777	Effect of physical activity on the development and the resolution of nonalcoholic fatty liver in relation to body mass index. <i>BMC Public Health</i> , 2022, 22, 655.	1.2	4
2778	Bioinformatics study of the potential therapeutic effects of ginsenoside Rf in reversing nonalcoholic fatty liver disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112879.	2.5	2
2779	Serum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF- κ B signaling pathway. <i>Molecular Metabolism</i> , 2022, 59, 101462.	3.0	19
2780	Transcriptomic analysis reveals a novel regulatory factor of ECHDC1 involved in lipid metabolism of non-alcoholic fatty liver disease. <i>Biochemical and Biophysical Research Communications</i> , 2022, 605, 1-8.	1.0	2
2781	Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. <i>Thrombosis Research</i> , 2022, 213, 9-15.	0.8	6
2782	New insights into NAFLD based on preclinical MRI studies. <i>Chemistry and Physics of Lipids</i> , 2022, 244, 105192.	1.5	0
2783	Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1. <i>Carbohydrate Polymers</i> , 2022, 288, 119388.	5.1	7
2784	Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2022, 27, 100699.	0.6	2
2785	A Qualitative Analysis of Mexican-Origin Men's Knowledge and Cultural Attitudes Toward Non-Alcoholic Fatty Liver Disease and Interest in Risk Reduction. <i>American Journal of Men's Health</i> , 2021, 15, 155798832110633.	0.7	4
2786	Research progress of artificial intelligence in the diagnosis of fatty liver. , 2021, , .		1
2787	A Specifically Tailored Multistrain Probiotic and Micronutrient Mixture Affects Nonalcoholic Fatty Liver Disease-Related Markers in Patients with Obesity after Mini Gastric Bypass Surgery. <i>Journal of Nutrition</i> , 2022, 152, 408-418.	1.3	5
2788	Remnant Lipoprotein Cholesterol as a Factor Related to Adult Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1598-e1609.	1.8	6

#	ARTICLE	IF	CITATIONS
2789	Lactobacillus plantarum MA2 Ameliorates Methionine and Choline-Deficient Diet Induced Non-Alcoholic Fatty Liver Disease in Rats by Improving the Intestinal Microecology and Mucosal Barrier. <i>Foods</i> , 2021, 10, 3126.	1.9	12
2790	Association Between Helicobacter Pylori Infection and Non-alcoholic Fatty Liver Disease, Hepatic Adipose Deposition and Stiffness in Southwest China. <i>Frontiers in Medicine</i> , 2021, 8, 764472.	1.2	8
2791	The promising role of CCL2 as a noninvasive marker for nonalcoholic steatohepatitis diagnosis in Egyptian populations. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e954-e960.	0.8	3
2792	Coffee Consumption and Non-alcoholic Fatty Liver Disease: An Umbrella Review and a Systematic Review and Meta-analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 786596.	1.6	15
2793	Fibrosisâ€4 Index as an Independent Predictor of Mortality and Liverâ€Related Outcomes in NAFLD. <i>Hepatology Communications</i> , 2022, 6, 765-779.	2.0	26
2794	Serine palmitoyltransferase long chain subunit 3 is associated with hepatocellular carcinoma in patients with NAFLD. <i>Molecular and Clinical Oncology</i> , 2021, 16, 55.	0.4	4
2795	Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. <i>Biomedicines</i> , 2022, 10, 55.	1.4	4
2796	Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 796207.	1.6	20
2797	Vitamin C Deficiency May Delay Diet-Induced NASH Regression in the Guinea Pig. <i>Antioxidants</i> , 2022, 11, 69.	2.2	5
2798	Lycium barbarum Polysaccharides Promotes Mitochondrial Biogenesis and Energy Balance in a NAFLD Cell Model. <i>Chinese Journal of Integrative Medicine</i> , 2022, 28, 975-982.	0.7	6
2799	Artificial Intelligence in hepatology, liver surgery and transplantation: Emerging applications and frontiers of research. <i>World Journal of Hepatology</i> , 2021, 13, 1977-1990.	0.8	10
2800	Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD). <i>Cureus</i> , 2021, 13, e20776.	0.2	6
2801	Histological impact at 5 years after the start of sodium-glucose cotransporter 2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus. <i>Acta Hepatologica Japonica</i> , 2021, 62, 820-822.	0.0	0
2802	Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. <i>Frontiers in Pharmacology</i> , 2021, 12, 788558.	1.6	34
2803	Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up. <i>Diagnostics</i> , 2021, 11, 2316.	1.3	8
2804	Prevalence of Hepatic Steatosis and Fibrosis in the United States. <i>Metabolic Syndrome and Related Disorders</i> , 2022, 20, 141-147.	0.5	3
2805	Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1401-1409.	1.4	12
2806	Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e986-e991.	0.8	6

#	ARTICLE	IF	CITATIONS
2807	The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students. <i>Diagnostics</i> , 2021, 11, 2341.	1.3	6
2808	Î2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development. <i>Science Translational Medicine</i> , 2021, 13, eabk2267.	5.8	23
2809	De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation. <i>World Journal of Hepatology</i> , 2021, 13, 1991-2004.	0.8	3
2810	Changes in rat liver fatty acid profile in experimental non-alcoholic steatohepatitis. <i>Drug Development and Registration</i> , 2021, 10, 206-214.	0.2	0
2811	Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2021, 9, 1920.	1.4	21
2812	Metabolic Associated Fatty Liver Disease in Children—From Atomistic to Holistic. <i>Biomedicines</i> , 2021, 9, 1866.	1.4	3
2813	Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. <i>Acta Pharmacologica Sinica</i> , 2021, , .	2.8	9
2814	Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 752-756.	2.2	5
2815	Dietary Composition and Its Association with Newly Diagnosed Nonalcoholic Fatty Liver Disease and Insulin Resistance. <i>Nutrients</i> , 2021, 13, 4438.	1.7	12
2816	Associations between serum total bilirubin, obesity and type 2 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 143.	1.2	12
2817	Effect of Different Types of Intermittent Fasting on Biochemical and Anthropometric Parameters among Patients with Metabolic-Associated Fatty Liver Disease (MAFLD)—A Systematic Review. <i>Nutrients</i> , 2022, 14, 91.	1.7	13
2818	Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States. <i>Medicine (United States)</i> , 2021, 100, e28165.	0.4	3
2819	Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. <i>Frontiers in Endocrinology</i> , 2021, 12, 777075.	1.5	8
2820	Association of Serum Bilirubin and Functional Variants of Heme Oxygenase 1 and Bilirubin UDP-Glucuronosyl Transferase Genes in Czech Adult Patients with Non-Alcoholic Fatty Liver Disease. <i>Antioxidants</i> , 2021, 10, 2000.	2.2	6
2821	Fasting, Nutrition and Weight Loss: An Approach to Refine Non-Alcoholic Fatty Liver Disease. <i>Journal of Nutritional Science and Vitaminology</i> , 2021, 67, 366-374.	0.2	1
2822	Effectiveness and safety of Shugan Jianpi (SGJP) formula in the treatment of nonalcoholic steatohepatitis (NASH). <i>Medicine (United States)</i> , 2021, 100, e28366.	0.4	1
2823	Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study. <i>World Journal of Hepatology</i> , 2021, 13, 2179-2191.	0.8	3
2824	A family history of type 2 diabetes as a predictor of fatty liver disease in diabetes-free individuals with excessive body weight. <i>Scientific Reports</i> , 2021, 11, 24084.	1.6	9

#	ARTICLE	IF	CITATIONS
2825	Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. <i>Nutrients</i> , 2022, 14, 103.	1.7	40
2826	Polyunsaturated fatty acids: omega-3 and omega-6 and nonalcoholic fatty liver disease. <i>Pediatric Consilium Medicum</i> , 2021, , 335-340.	0.1	0
2827	2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea. <i>Journal of Korean Diabetes</i> , 2021, 22, 244-249.	0.1	8
2828	Machine learning enables new insights into genetic contributions to liver fat accumulation. <i>Cell Genomics</i> , 2021, 1, 100066.	3.0	34
2829	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. <i>Biomedicines</i> , 2022, 10, 46.	1.4	10
2830	Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. <i>Emergency and Critical Care Medicine</i> , 2022, 2, 12-22.	0.1	2
2831	Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System. <i>Frontiers in Medicine</i> , 2021, 8, 781567.	1.2	16
2832	Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection. <i>Diagnostics</i> , 2022, 12, 14.	1.3	3
2833	Endoscopic sleeve gastropasty — minimally invasive treatment for non-alcoholic fatty liver disease and obesity. <i>Indian Journal of Gastroenterology</i> , 2021, 40, 572-579.	0.7	14
2835	Quantitative evaluation of hepatic steatosis using novel ultrasound technology normalized local variance (NLV) and its standard deviation with different ROIs in patients with metabolic-associated fatty liver disease: a pilot study. <i>Abdominal Radiology</i> , 2022, 47, 693-703.	1.0	5
2836	Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. <i>Liver International</i> , 2022, 42, 374-383.	1.9	14
2837	Clinical Profiles of Asians with NAFLD: A Systematic Review and Meta-Analysis. <i>Digestive Diseases</i> , 2022, 40, 734-744.	0.8	10
2838	Fibrogenesis Marker PRO-C3 Is Higher in Advanced Liver Fibrosis and Improves in Patients Undergoing Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1356-e1366.	1.8	6
2839	Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 938-946.	0.8	52
2840	The effects of Mediterranean diet on hepatic steatosis, oxidative stress, and inflammation in adolescents with non-alcoholic fatty liver disease: A randomized controlled trial. <i>Pediatric Obesity</i> , 2022, 17, e12872.	1.4	22
2841	The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 368-379.	1.9	5
2842	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Eating and Weight Disorders</i> , 2022, 27, 1603-1619.	1.2	9
2843	Cilofexor for the Treatment of Nonalcoholic Steatohepatitis. <i>Current Vascular Pharmacology</i> , 2022, 20, 111-113.	0.8	3

#	ARTICLE	IF	CITATIONS
2844	Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. <i>Frontiers in Endocrinology</i> , 2021, 12, 768850.	1.5	11
2846	Advances in liver US, CT, and MRI: moving toward the future. <i>European Radiology Experimental</i> , 2021, 5, 52.	1.7	25
2847	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2008-e2020.	1.8	27
2848	Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 5721.	1.0	24
2849	III. Non-alcoholic Fatty Liver Disease (NAFLD) /Non-alcoholic Steatohepatitis (NASH). <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 729-737.	0.0	0
2850	Association between Non-Alcoholic Fatty Liver Disease and the Risk of Colorectal Polyp. <i>Advances in Clinical Medicine</i> , 2022, 12, 2996-3004.	0.0	0
2851	Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis. <i>Annals of Gastroenterology</i> , 2022, , .	0.4	4
2852	DNA Methylation Patterns According to Fatty Liver Index and Longitudinal Changes from the Korean Genome and Epidemiology Study (KoGES). <i>Current Issues in Molecular Biology</i> , 2022, 44, 1149-1168.	1.0	4
2853	The Association Between Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease Diagnosis Varies by Race. <i>Metabolic Syndrome and Related Disorders</i> , 2022, , .	0.5	2
2854	Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes. <i>Clinical Diabetes</i> , 0, , .	1.2	0
2855	Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD. <i>Radiology</i> , 2022, , 211131.	3.6	12
2856	PROBIOTIC, PREBIOTIC OR SYMBIOTIC SUPPLEMENTATION IMPACTS ON INTESTINAL MICROBIOTA IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW. <i>Arquivos De Gastroenterologia</i> , 2022, 59, 123-128.	0.3	1
2857	Ä°n Vitro Lipopolisakkarit UyarÄ±mlÄ± KaraciÄŸer YangÄ± Modelinde Alfa-TerpineolÄ±n EtkinliÄŸinin AraÅŸtırÄ±lmasÄ±. <i>Etlık Veteriner Mikrobiyoloji Dergisi</i> , 0, , .	0.2	0
2858	The impact of health status, diet and lifestyle on <sc>nonÄ±alcoholic</sc> fatty liver disease: Narrative review. <i>Clinical Obesity</i> , 2022, 12, e12525.	1.1	9
2859	Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-Î²1 axis. <i>Chemico-Biological Interactions</i> , 2022, 361, 109953.	1.7	8
2860	Association of Thyroid Autoimmunity with Nonalcoholic Fatty Liver Disease in Euthyroid MiddleÄ±ged Subjects: A PopulationÄ±Based Study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	1.4	3
2861	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 101161ATV0000000000000153.	1.1	167
2862	PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4305.	1.8	28

#	ARTICLE	IF	CITATIONS
2863	A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers. <i>Panminerva Medica</i> , 2022, 64, .	0.2	5
2864	Liver Fibrosis Marker and Postoperative Mortality in Patients Without Overt Liver Disease. <i>Anesthesia and Analgesia</i> , 2022, 135, 957-966.	1.1	2
2865	Epigallocatechin-3-gallate ameliorates hepatic damages by relieve FGF21 resistance and promotion of FGF21-AMPK pathway in mice fed a high fat diet. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, 53.	1.2	8
2866	Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2022, 28, 1563-1573.	1.4	4
2867	Validation of the accuracy of the FAST-1 score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. <i>PLoS ONE</i> , 2022, 17, e0266859.	1.1	20
2868	Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials. <i>BMC Endocrine Disorders</i> , 2022, 22, 95.	0.9	5
2869	Liver biopsy implementation rate for diagnosis of NASH in Japan -analysis of big data of health insurance claims-. <i>Acta Hepatologica Japonica</i> , 2022, 63, 211-213.	0.0	0
2870	Left ventricular strain predicts subclinical atherosclerosis in nonadvanced nonalcoholic fatty liver disease patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, Publish Ahead of Print, .	0.8	1
2871	The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 552-559.	3.7	25
2872	Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review. <i>Frontiers in Nutrition</i> , 2022, 9, 844374.	1.6	5
2873	Lipoprotein Levels in Early Adulthood and NAFLD in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. <i>Journal of Nutrition and Metabolism</i> , 2022, 2022, 1-9.	0.7	0
2874	Potential Therapeutic Targets and Promising Agents for Combating NAFLD. <i>Biomedicines</i> , 2022, 10, 901.	1.4	6
2875	Special Considerations on Hyperandrogenism and Insulin Resistance in Nonobese Polycystic Ovaries Syndrome. , 0, , .		1
2876	L-theanine prevents progression of nonalcoholic hepatic steatosis by regulating hepatocyte lipid metabolic pathways via the CaMKK1 ² -AMPK signaling pathway. <i>Nutrition and Metabolism</i> , 2022, 19, 29.	1.3	7
2877	Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. <i>Journal of Hepatology</i> , 2022, 77, 607-618.	1.8	79
2878	Racial Disparities in Associations of Alcohol Consumption with Liver Disease Mortality in a Predominantly Low-Income Population: A Report from the Southern Community Cohort Study (SCCS). <i>American Journal of Gastroenterology</i> , 2022, Publish Ahead of Print, .	0.2	2
2879	Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1523-1532.e1.	2.4	31
2880	Endothelial-immune crosstalk contributes to vasculopathy in nonalcoholic fatty liver disease. <i>EMBO Reports</i> , 2022, 23, e54271.	2.0	7

#	ARTICLE	IF	CITATIONS
2881	Impact of cardiac dysfunction on morbidity and mortality in liver transplant candidates. <i>Clinical Transplantation</i> , 2022, 36, e14682.	0.8	3
2882	Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis. <i>Redox Biology</i> , 2022, 52, 102313.	3.9	15
2906	Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents. <i>Hepatology Communications</i> , 2022, 6, 2070-2078.	2.0	12
2907	CAQ Corner: Disease recurrence after liver transplantation. <i>Liver Transplantation</i> , 2023, 29, 768-776.	1.3	0
2908	Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach. <i>Frontiers of Medicine</i> , 2022, 16, 745-759.	1.5	12
2909	Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis. <i>Thyroid</i> , 2022, 32, 725-738.	2.4	30
2910	MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1080-1089.	1.9	19
2911	Gamma-glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1624-1632.	1.4	6
2913	Naoxintong Capsule Alternates Gut Microbiota and Prevents Hyperlipidemia in High-Fat-Diet Fed Rats. <i>Frontiers in Pharmacology</i> , 2022, 13, 843409.	1.6	6
2914	Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1756.	1.0	5
2915	Peripheral Artery Disease and Risk of Fibrosis Deterioration in Nonalcoholic Fatty Liver Disease: A Prospective Investigation. <i>Biomedical and Environmental Sciences</i> , 2020, 33, 217-226.	0.2	4
2916	Prevalence and clinical characteristics of NAFLD in chronic liver disease patients from King Abdulaziz University Hospital, Jeddah. <i>Saudi Journal of Medicine and Medical Sciences</i> , 2020, 8, 118.	0.3	4
2917	A predictive model for the diagnosis of non-alcoholic fatty liver disease based on an integrated machine learning method.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 12704-12713.	0.0	0
2919	NAFLD-related hepatocellular carcinoma: The growing challenge. <i>Hepatology</i> , 2023, 77, 323-338.	3.6	62
2920	Liver Fibrosis-4 index indicates atrial fibrillation in acute ischemic stroke. <i>European Journal of Neurology</i> , 2022, 29, 2283-2288.	1.7	5
2921	Diosgenin Ameliorates Non-alcoholic Fatty Liver Disease by Modulating the Gut Microbiota and Related Lipid/Amino Acid Metabolism in High Fat Diet-Fed Rats. <i>Frontiers in Pharmacology</i> , 2022, 13, 854790.	1.6	9
2922	Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations. <i>World Journal of Hepatology</i> , 2022, 14, 754-765.	0.8	8
2923	Invited Perspective: PFAS and Liver Disease: Bringing All the Evidence Together. <i>Environmental Health Perspectives</i> , 2022, 130, 41303.	2.8	11

#	ARTICLE	IF	CITATIONS
2924	Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. <i>Cells</i> , 2022, 11, 1475.	1.8	16
2925	Identification of Hub Genes Associated With Non-alcoholic Steatohepatitis Using Integrated Bioinformatics Analysis. <i>Frontiers in Genetics</i> , 2022, 13, 872518.	1.1	7
2926	Prevention of Higher Triglycerides, Malondialdehyde, And Fatty Liver Disease Using the Ethanolic Extract of Sea Lettuce (<i>Ulva lactuca</i>) in Male Wistar Rats (<i>Rattus Norvegicus</i>). <i>Current Research in Nutrition and Food Science</i> , 2022, 10, 287-294.	0.3	0
2927	Higher hepatic advanced glycation end products and liver damage markers are associated with nonalcoholic steatohepatitis. <i>Nutrition Research</i> , 2022, 104, 71-81.	1.3	4
2928	Reduced and more appropriate referrals of patients with type 2 diabetes using liver stiffness measurement compared to FIB-4. <i>Irish Journal of Medical Science</i> , 2022, , 1.	0.8	1
2929	Diabetes-Associated Comorbidities. <i>Primary Care - Clinics in Office Practice</i> , 2022, 49, 275-286.	0.7	18
2930	Effect of a Six-Month Lifestyle Intervention on the Physical Activity and Fitness Status of Adults with NAFLD and Metabolic Syndrome. <i>Nutrients</i> , 2022, 14, 1813.	1.7	19
2931	The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care. <i>Hepatology</i> , 2023, 77, 256-267.	3.6	18
2932	ABORDAJE PREVENTIVO EN LA ENFERMEDAD POR HĀGADO GRASO NO ALCOHĀLICO. <i>Epistemus</i> , 2022, 16, .	0.0	0
2933	Twenty-year trends in heart failure among U.S. adults, 1999-2018: The growing impact of obesity and diabetes. <i>International Journal of Cardiology</i> , 2022, 362, 104-109.	0.8	7
2934	Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 2445.	1.0	0
2935	Label-free Assessment of the Nascent State of Rat Non-alcoholic Fatty Liver Disease Using Spontaneous Raman Microscopy. <i>Acta Histochemica Et Cytochemica</i> , 2022, 55, 57-66.	0.8	6
2936	Effect of a High Protein, Low Glycemic Index Dietary Intervention on Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial. <i>Frontiers in Nutrition</i> , 2022, 9, 863834.	1.6	6
2937	Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 755-769.	3.7	34
2938	Burden and Predictors of Non-Alcoholic Fatty Liver Disease in a Retrospective Cohort of Patients With Crohn's Disease. <i>Gastroenterology Research</i> , 2022, 15, 82-90.	0.4	6
2939	A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis. <i>Hepatology Communications</i> , 2022, 6, 1987-1999.	2.0	7
2940	Phospholipids in non-alcoholic fatty liver disease. <i>Meditinskiy Sovet</i> , 2022, , 92-99.	0.1	0
2941	Using Telehealth for Diagnosis and Management of Non-Alcoholic Fatty Liver Disease. <i>Clinical Liver Disease</i> , 2022, 19, 171-175.	1.0	2

#	ARTICLE	IF	CITATIONS
2942	Selenium-Enriched Probiotic Alleviates Western Diet-Induced Non-alcoholic Fatty Liver Disease in Rats via Modulation of Autophagy Through AMPK/SIRT-1 Pathway. <i>Biological Trace Element Research</i> , 2023, 201, 1344-1357.	1.9	13
2943	Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD. <i>Hepatology</i> , 2022, 76, 1811-1824.	3.6	30
2944	The transition from NAFLD to MAFLD: One size still does not fit all—Time for a tailored approach?. <i>Hepatology</i> , 2022, 76, 1243-1245.	3.6	8
2945	The macrophage-associated microRNA-4715-3p / Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: evidence from transcriptome and biological data. <i>Bioengineered</i> , 2022, 13, 11740-11751.	1.4	2
2946	Indole supplementation ameliorates MCD-induced NASH in mice. <i>Journal of Nutritional Biochemistry</i> , 2022, 107, 109041.	1.9	8
2947	Liver Stiffness Measurements by 2D Shear-Wave Elastography: Effect of Steatosis on Fibrosis Evaluation. <i>American Journal of Roentgenology</i> , 2022, , .	1.0	2
2948	Ramulus Mori (Sangzhi) Alkaloids Alleviate High-Fat Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease in Mice. <i>Antioxidants</i> , 2022, 11, 905.	2.2	14
2949	Early life programming of nonalcoholic fatty liver disease in children. <i>Early Human Development</i> , 2022, 168, 105578.	0.8	2
2950	Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. <i>Hepatology Communications</i> , 2022, 6, 2238-2252.	2.0	11
2951	Association of Low Skeletal Muscle Mass with the Phenotype of Lean Non-Alcoholic Fatty Liver Disease. <i>Healthcare (Switzerland)</i> , 2022, 10, 850.	1.0	1
2952	Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults. <i>Diagnostics</i> , 2022, 12, 1199.	1.3	0
2953	Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5146.	1.8	22
2954	Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2022, 117, 897-911.	0.5	6
2955	Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	4
2956	Chronic ethanol consumption plus an atherogenic diet cause metabolic steatohepatitis with advanced liver fibrosis in apolipoprotein E/low-density lipoprotein receptor double-knockout mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 1192-1203.	1.4	1
2957	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. <i>Endocrine Practice</i> , 2022, 28, 528-562.	1.1	323
2958	Endoscopic Bariatric and Metabolic Therapies and Their Effects on Metabolic Syndrome and Non-alcoholic Fatty Liver Disease - A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	3
2959	High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	7

#	ARTICLE	IF	CITATIONS
2960	Liver Stiffness by Transient Elastography Correlates With Degree of Portal Hypertension in Common Variable Immunodeficiency Patients With Nodular Regenerative Hyperplasia. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
2961	Current Evidence Concerning Effects of Ketogenic Diet and Intermittent Fasting in Patients with Nonalcoholic Fatty Liver. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 730-739.	0.7	7
2962	Prevalence of non-alcoholic fatty liver disease in the Russian Ural Eye and Medical Study and the Ural Very Old Study. <i>Scientific Reports</i> , 2022, 12, 7842.	1.6	5
2963	Official health communications are failing PFAS-contaminated communities. <i>Environmental Health</i> , 2022, 21, 51.	1.7	7
2964	Body composition and the skeletal muscle compartment in liver transplantation: Turning challenges into opportunities. <i>American Journal of Transplantation</i> , 2022, 22, 1943-1957.	2.6	10
2965	Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. <i>Current Atherosclerosis Reports</i> , 2022, 24, 533-546.	2.0	19
2966	Hepatic Steatosis and Fibrosis in Chronic Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 2623.	1.0	6
2967	Human Immunodeficiency Virus Is Associated With Elevated FibroScan® Aspartate Aminotransferase (FAST) Score. <i>Clinical Infectious Diseases</i> , 2022, 75, 2119-2127.	2.9	8
2968	Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2022, 24, 515-532.	2.0	18
2969	Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 790-801.	4.5	40
2970	Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation. <i>Redox Biology</i> , 2022, 52, 102322.	3.9	32
2971	Methyltransferase SETD2 mediates hepatoprotection of berberine against steatosis. <i>Annals of Translational Medicine</i> , 2022, 10, 552-552.	0.7	2
2972	Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease. <i>Acta Clinica Croatica</i> , 2021, 60, 36-52.	0.1	0
2973	Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, .	0.7	1
2974	Association between body mass index and liver stiffness measurement using transient elastography in patients with non-alcoholic fatty liver disease in a hepatology clinic: a cross sectional study. <i>Translational Gastroenterology and Hepatology</i> , 0, 8, 10-10.	1.5	1
2976	Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. <i>Frontiers in Medicine</i> , 2022, 9, 892495.	1.2	2
2977	Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups. <i>BMC Gastroenterology</i> , 2022, 22, 241.	0.8	13
2978	Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations. , 2022, 1, 882-893.		1

#	ARTICLE	IF	CITATIONS
2979	<sc>FIB</sc> and incident severe liver outcomes in patients with undiagnosed chronic liver disease: A <sc>Fineâ€Gray</sc> competing risk analysis. <i>Liver International</i> , 2023, 43, 170-179.	1.9	9
2980	Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	6
2981	Lipocalinâ€2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in highâ€fat dietâ€fed Ob/Ob mice. <i>Hepatology</i> , 2023, 77, 888-901.	3.6	21
2982	Periodontal disease could be a potential risk factor for non-alcoholic fatty liver disease: An 11-year retrospective follow-up study. <i>Clinical Oral Investigations</i> , 2022, 26, 5503-5514.	1.4	5
2983	Nonalcoholic Fatty Liver Disease Among Obese Patients in Oman. <i>Revista Bionatura</i> , 2022, 7, 1-5.	0.1	0
2984	MAFLD Versus NAFLD: Which Better Predicts the Risk of Atherosclerotic Cardiovascular Disease?. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4606-4608.	1.1	1
2985	MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4919-4928.	1.1	26
2986	Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. <i>Hepatology Communications</i> , 2022, 6, 2273-2285.	2.0	17
2987	Hyperferritinemia Correlates to Metabolic Dysregulation and Steatosis in Chinese Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 1543-1552.	1.1	9
2988	Impact of non-invasive biomarkers on hepatology practice: Past, present and future. <i>Journal of Hepatology</i> , 2022, 76, 1362-1378.	1.8	78
2989	Differential fat accumulation in early adulthood according to adolescentâ€BMI and heavy metal exposure. <i>New Directions for Child and Adolescent Development</i> , 2022, 2022, 37-51.	1.3	6
2990	Favorable impact of longâ€term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5â€year followâ€up study. <i>Hepatology Communications</i> , 2022, 6, 2286-2297.	2.0	20
2991	Renaming from nonalcoholic fatty liver disease to metabolism dysfunction associated fatty liver disease: Pros and cons. <i>Hepatology Research</i> , 2022, 52, 415-416.	1.8	0
2992	A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease. <i>Journal of Nanobiotechnology</i> , 2022, 20, 237.	4.2	9
2993	Clinical Application of Quantitative MR Imaging in Nonalcoholic Fatty Liver Disease. <i>Magnetic Resonance in Medical Sciences</i> , 2023, 22, 435-445.	1.1	2
2994	The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 565-574.	4.5	39
2995	Probiotic Therapy With VSL#3Â® in Patients With NAFLD: A Randomized Clinical Trial. <i>Frontiers in Nutrition</i> , 2022, 9, .	1.6	13
2996	Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2022, 10, 1232.	1.4	3

#	ARTICLE	IF	CITATIONS
2997	Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 955-964.	0.7	9
2999	Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena. <i>Liver Research</i> , 2022, 6, 72-83.	0.5	10
3000	Nutrition as Therapy in Liver Disease. <i>Clinical Therapeutics</i> , 2022, 44, 682-696.	1.1	13
3001	Vitaminler ve Non Alkolik Yağlı Karaciğer Hastalıkları. <i>Adnan Menderes Üniversitesi Sağık Bilimleri Fakültesi Dergisi</i> , 0, , .	0.4	0
3002	The improvement of nonalcoholic steatohepatitis by <i>Poria cocos</i> polysaccharides associated with gut microbiota and NF- κ B/CCL3/CCR1 axis. <i>Phytomedicine</i> , 2022, 103, 154208.	2.3	15
3003	Association between non-alcoholic fatty liver disease and bone turnover markers in southwest China. <i>Journal of Bone and Mineral Metabolism</i> , 0, , .	1.3	2
3004	Vitamin E for people with non-alcoholic fatty liver disease. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
3005	Distinct Cytokine Profiles in Severe COVID-19 and Non-Alcoholic Fatty Liver Disease. <i>Life</i> , 2022, 12, 795.	1.1	9
3007	Does Hepatic Steatosis Influence the Virological Response with Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir Disoproxil Fumarate?. , 2022, 33, 587-595.		0
3008	Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. <i>Annals of Medicine</i> , 2022, 54, 1548-1560.	1.5	39
3009	Relationship between Liver Stiffness and Steatosis in Obesity Conditions: In Vivo and In Vitro Studies. <i>Biomolecules</i> , 2022, 12, 733.	1.8	6
3010	Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: An international physician needs assessment. <i>Liver International</i> , 2022, 42, 1772-1782.	1.9	7
3011	Patients with type 2 diabetes and elevated fibrosis are under-referred to hepatology and have unrecognized hepatic decompensation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 0, , .	1.4	2
3012	Intra-individual Comparisons of the Ultrasound-Guided Attenuation Parameter and the Magnetic Resonance Imaging-Based Proton Density Fat Fraction Using Bias and Precision Statistics. <i>Ultrasound in Medicine and Biology</i> , 2022, 48, 1537-1546.	0.7	2
3013	The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	3
3014	Inulin may prevent steatosis by suppressing cannabinoid receptor-1 and patatin-like phospholipase-3 expression in liver. <i>Nutrition</i> , 2022, 103-104, 111742.	1.1	2
3015	Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function. <i>BMC Endocrine Disorders</i> , 2022, 22, .	0.9	7
3016	Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 391-401.	1.8	9

#	ARTICLE	IF	CITATIONS
3017	A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. <i>PLoS ONE</i> , 2022, 17, e0269265.	1.1	10
3018	Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 965-971.	0.7	2
3019	Vanadium(IV)-Chlorodipicolinate Protects against Hepatic Steatosis by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammation. <i>Antioxidants</i> , 2022, 11, 1093.	2.2	3
3020	Pregnancy and Metabolic-associated Fatty Liver Disease: A Clinical Update. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 947-954.	0.7	7
3021	Contribution of a genetic risk score to ethnic differences in fatty liver disease. <i>Liver International</i> , 2022, 42, 2227-2236.	1.9	16
3022	Mechanisms behind the Role of SIBO in Non-Alcoholic Fatty Liver Disease: An Interplay between Liver, Gut Microbiota and Nutrition. <i>Current Nutrition and Food Science</i> , 2022, 18, .	0.3	0
3023	Associations of Sex Steroids and Sex Hormone-Binding Globulin with Non-Alcoholic Fatty Liver Disease: A Population-Based Study and Meta-Analysis. <i>Genes</i> , 2022, 13, 966.	1.0	7
3024	Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Nutrition</i> , 2022, 9, .	1.6	7
3025	Effect of Dietary and Lifestyle Interventions on the Amelioration of NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study. <i>Nutrients</i> , 2022, 14, 2223.	1.7	22
3026	Differential Effects of Dietary versus Exercise Intervention on Intrahepatic MAIT Cells and Histological Features of NAFLD. <i>Nutrients</i> , 2022, 14, 2198.	1.7	10
3027	Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. <i>Cureus</i> , 2022, , .	0.2	7
3028	Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1013-1022.e6.	2.4	12
3029	Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases. <i>Metabolites</i> , 2022, 12, 514.	1.3	33
3030	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> , 2022, 54, 761-771.	9.4	68
3031	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. <i>Hormones</i> , 2022, 21, 349-368.	0.9	12
3032	Ferroptosis in Chronic Liver Diseases: Opportunities and Challenges. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	12
3033	Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial. <i>Trials</i> , 2022, 23, .	0.7	0
3034	Decision-Making Scoring System for the Repetition of Conventional Transarterial Chemoembolization in Patients with Inoperable Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.3	0

#	ARTICLE	IF	CITATIONS
3035	The Role of Autophagy and Pyroptosis in Liver Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6208.	1.8	16
3036	Serum Biomarkers for Autoimmune Hepatitis Type 1: the Case for CD48 and a Review of the Literature. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 342-356.	2.9	3
3037	Low AST/ALT ratio is a predictor of diabetes incidence in Japanese people: Population-based Panasonic cohort study 5. <i>Diabetes/Metabolism Research and Reviews</i> , 0, , .	1.7	2
3038	Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108226.	1.2	5
3039	Tanshinone IIA regulates the TGF β 1/Smad signaling pathway to ameliorate non-alcoholic steatohepatitis-related fibrosis. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	2
3040	Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	27
3041	Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6270.	1.8	4
3042	Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	16
3043	Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 477-496.	1.8	13
3044	The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population: A Review. <i>Life</i> , 2022, 12, 839.	1.1	3
3045	Relationship between the consumption of wholegrain and nonalcoholic fatty liver disease: The TCLSIH cohort study. <i>Clinical Nutrition</i> , 2022, 41, 1483-1490.	2.3	4
3046	Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Neoplasia</i> , 2022, 30, 100809.	2.3	18
3047	Curcumin as adjuvant treatment in patients with non-alcoholic fatty liver (NAFLD) disease: A systematic review and meta-analysis. <i>Complementary Therapies in Medicine</i> , 2022, 68, 102843.	1.3	18
3048	Probiotics for liver disease prevention and treatment. , 2022, , 579-588.		0
3049	Ultrasound diagnosis of fatty liver disease. <i>Choonpa Igaku</i> , 2022, , .	0.0	0
3051	Fatty Liver Disease. , 2022, , 265-298.		0
3052	A Case Report of Nonalcoholic Fatty Liver Disease with Obesity and Dyslipidemia. <i>The Journal of Internal Korean Medicine</i> , 2022, 43, 184-190.	0.0	3
3053	Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids. <i>Seminars in Liver Disease</i> , 2022, 42, 122-137.	1.8	3

#	ARTICLE	IF	CITATIONS
3054	La esteatohepatitis no alcohólica: una causa emergente de cirrosis en Colombia. Revista Colombiana De Gastroenterología, 2022, 37, 136-144.	0.1	0
3055	Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Science Translational Medicine, 2022, 14, .	5.8	40
3056	Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. Hepatology, 2023, 77, 558-572.	3.6	17
3057	Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis. Obesity Surgery, 2022, 32, 2495-2503.	1.1	6
3058	Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. Seminars in Liver Disease, 2022, 42, 379-400.	1.8	17
3059	Liver Fibrosis in Primary Sjögren's Syndrome. Frontiers in Immunology, 0, 13, .	2.2	4
3060	Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens. Open Forum Infectious Diseases, 2022, 9, .	0.4	8
3061	Impact of Physical Activity Differences Due to COVID-19 Pandemic Lockdown on Non-Alcoholic Fatty Liver Parameters in Adults with Metabolic Syndrome. Nutrients, 2022, 14, 2370.	1.7	5
3062	Risk factors associated with nonalcoholic fatty liver disease evaluated by elastography in patients with type 2 diabetes. Archives of Endocrinology and Metabolism, 2022, , .	0.3	1
3063	The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018. Endocrinology and Metabolism, 2022, 37, 455-465.	1.3	9
3064	A Freshwater Fish-Based Diet Alleviates Liver Steatosis by Modulating Gut Microbiota and Metabolites: A Clinical Randomized Controlled Trial in Chinese Participants With Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2022, 117, 1621-1631.	0.2	11
3065	Gallstone Disease and Bacterial Metabolic Performance of Gut Microbiota in Middle-Aged and Older Patients. International Journal of General Medicine, 0, Volume 15, 5513-5531.	0.8	11
3066	Associations of Uric Acid With Liver Steatosis and Fibrosis Applying Vibration Controlled Transient Elastography in the United States: A Nationwide Cross-Section Study. Frontiers in Endocrinology, 0, 13, .	1.5	11
3067	Chrysin Attenuates Fructose-Induced Nonalcoholic Fatty Liver in Rats via Antioxidant and Anti-Inflammatory Effects: The Role of Angiotensin-Converting Enzyme 2/Angiotensin (1-7)/Mas Receptor Axis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-14.	1.9	7
3068	Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 638-651.	8.2	69
3069	Mechanistic study of regulation of iron homeostasis by N. sativa seeds and P. ovata husks on high fat/high sucrose diet induced non-alcoholic fatty liver disease. Molecular Biology Reports, 0, , .	1.0	0
3070	Shear wave elastography in evaluation of carotid elasticity in the type 2 diabetes mellitus patients with nonalcoholic fatty liver disease. International Journal of Diabetes in Developing Countries, 2023, 43, 191-198.	0.3	1
3071	Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes. Diabetes and Metabolism, 2022, 48, 101363.	1.4	11

#	ARTICLE	IF	CITATIONS
3072	How Mexicansâ€™ Emotional Responses to Non-Alcoholic Fatty Liver Disease Can Help Inform Culturally Congruent Health Care. <i>Journal of Transcultural Nursing</i> , 0, , 104365962211019.	0.6	2
3073	Serum Ferritin and NAFLD in Patients Undergoing Bariatric Surgery. <i>Obesity Surgery</i> , 2022, 32, 2658-2663.	1.1	2
3074	Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. <i>Obesity Reviews</i> , 2022, 23, .	3.1	7
3075	Machine-Learning Algorithm for Predicting Fatty Liver Disease in a Taiwanese Population. <i>Journal of Personalized Medicine</i> , 2022, 12, 1026.	1.1	5
3076	A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
3077	Licoglitazone for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. <i>Nature Medicine</i> , 2022, 28, 1432-1438.	15.2	23
3078	Plaque progression at coronary CT angiography links non-alcoholic fatty liver disease and cardiovascular events: a prospective single-center study. <i>European Radiology</i> , 2022, 32, 8111-8121.	2.3	2
3079	Liposomal Form of 2,4-Dinitrophenol Lipophilic Derivatives as a Promising Therapeutic Agent for ATP Synthesis Inhibition. <i>Nanomaterials</i> , 2022, 12, 2162.	1.9	0
3080	Short-term weight loss decreased the risk of chronic kidney disease in men with incident nonalcoholic fatty liver disease. <i>Obesity</i> , 2022, 30, 1495-1506.	1.5	3
3081	The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. <i>JHEP Reports</i> , 2022, 4, 100525.	2.6	23
3082	Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. <i>JGH Open</i> , 2022, 6, 503-511.	0.7	10
3083	Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
3084	Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 2493.	1.7	7
3085	The Benefit of Bariatric Surgery on Histological Features of Metabolic Associated Fatty Liver Disease Assessed Through Noninvasive Methods. <i>Obesity Surgery</i> , 2022, 32, 2682-2695.	1.1	3
3086	Prognostic value of pericoronary adipose tissue attenuation in patients with non-alcoholic fatty liver disease with suspected coronary artery disease. <i>Heart and Vessels</i> , 0, , .	0.5	1
3087	Waitlist and posttransplantation outcomes of lean individuals with nonalcoholic fatty liver disease. <i>Liver Transplantation</i> , 2023, 29, 145-156.	1.3	3
3088	Evaluation of [18F]F-TZ3108 for PET Imaging of Metabolic-Associated Fatty Liver Disease. <i>Molecular Imaging and Biology</i> , 0, , .	1.3	0
3089	NAFLD: Mechanisms, Treatments, and Biomarkers. <i>Biomolecules</i> , 2022, 12, 824.	1.8	86

#	ARTICLE	IF	CITATIONS
3090	The potential role of FNDC5/irisin in various liver diseases: awakening the sleeping beauties. <i>Expert Reviews in Molecular Medicine</i> , 0, , 1-42.	1.6	3
3091	Effects of chemical mixtures on liver function biomarkers in the Korean adult population: thresholds and molecular mechanisms for non-alcoholic fatty liver disease involved. <i>Environmental Science and Pollution Research</i> , 2022, 29, 78555-78587.	2.7	13
3092	When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. <i>Journal of Clinical Medicine</i> , 2022, 11, 3286.	1.0	8
3093	The isoxazole based flavonoid derivative 1 ameliorates non-alcoholic fatty liver disease in high-fat diet-induced obese mice by regulating lipid metabolism and inflammatory responses. <i>Phytochemistry Letters</i> , 2022, 50, 112-117.	0.6	0
3094	Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF- κ B/NLRP3 signaling pathway. <i>Phytomedicine</i> , 2022, 104, 154241.	2.3	12
3095	Impact of metabolic and bariatric surgery on liver diseases: Current evidence. , 2022, .		0
3096	MORPHOLOGICAL FEATURES OF THE LIVER PARENCHYMA IN THE EXPERIMENTAL SUPPLEMENTATION OF RATION WITH THE FOOD ADDITIVES. <i>Wiadomości Lekarskie</i> , 2022, 75, 1525-1528.	0.1	2
3097	Assessing strategies to target screening for advanced liver fibrosis among overweight and obese patients. , 2022, 2, 11.		4
3098	Obesity and its impact on gastrointestinal health. , 2022, , 1-11.		0
3099	Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7280.	1.8	38
3100	The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. <i>Journal of Clinical Medicine</i> , 2022, 11, 3649.	1.0	19
3101	Genetic Factors Associated with Response to Vitamin E Treatment in NAFLD. <i>Antioxidants</i> , 2022, 11, 1284.	2.2	3
3102	The influence and therapeutic effect of dietary pattern on liver diseases in the United State. , 0, 2, 54-62.		0
3103	Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study. <i>BMJ Open</i> , 2022, 12, e054891.	0.8	6
3104	Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	4
3105	Triglyceride and glucose index is a simple and easy to calculate marker associated with nonalcoholic fatty liver disease. <i>Obesity</i> , 2022, 30, 1279-1288.	1.5	7
3106	Machine learning approaches using blood biomarkers in non-alcoholic fatty liver diseases. <i>Artificial Intelligence in Gastroenterology</i> , 2022, 3, 80-87.	0.2	1
3107	Role of NAFLD on the Health Related QoL Response to Lifestyle in Patients With Metabolic Syndrome: The PREDIMED Plus Cohort. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	7

#	ARTICLE	IF	CITATIONS
3108	Risk assessment with gut microbiome and metabolite markers in NAFLD development. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	50
3109	Transient Elastography Measures of Hepatic Steatosis and Fibrosis Are Associated With Body Composition Among US Adolescents. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 75, 497-505.	0.9	2
3110	A Greater Improvement of Intrahepatic Fat Contents after 6 Months of Lifestyle Intervention Is Related to a Better Oxidative Stress and Inflammatory Status in Non-Alcoholic Fatty Liver Disease. <i>Antioxidants</i> , 2022, 11, 1266.	2.2	5
3111	The importance of glycemic control in non-alcoholic fatty liver disease. <i>Clinical Endocrinology and Endocrine Surgery</i> , 2022, , 20-26.	0.1	0
3112	The Benefit of Probiotics in Pediatric Nonalcoholic Fatty Liver Disease: A Meta-analysis of Randomized Control Trials. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 75, e31-e37.	0.9	7
3113	The diagnosis and management of nonalcoholic fatty liver disease: A patientâ€friendly summary of the 2018 AASLD guidelines. <i>Clinical Liver Disease</i> , 2022, 19, 222-226.	1.0	4
3114	PRO: Should patients with nonalcoholic steatohepatitis fibrosis undergo bariatric surgery as primary treatment?. <i>Clinical Liver Disease</i> , 2022, 20, 5-8.	1.0	1
3115	Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. <i>Nature Reviews Endocrinology</i> , 2022, 18, 638-650.	4.3	18
3116	Amelioration of Non-Alcoholic Steatohepatitis by Atractylodes macrocephala Polysaccharide, Chlorogenic Acid, and Geniposide Combination Is Associated With Reducing Endotoxin Gut Leakage. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	6
3117	Diagnosing Pediatric NAFLD. , 2022, 1, 13-20.		0
3118	Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1380-1395.	1.4	0
3119	GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	14
3120	The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease. <i>Clinical and Translational Science</i> , 0, , .	1.5	1
3121	Crosstalk between dietary patterns, obesity and nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2022, 28, 3314-3333.	1.4	9
3122	Discovery of (<i>E</i>)-3-(3-((2-Cyano-4â€dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9974-10000.	2.9	5
3123	Association of Previous Gastric Bypass Surgery and Patient Outcomes in Alcohol-Associated Cirrhosis Hospitalizations. <i>Digestive Diseases and Sciences</i> , 2023, 68, 1026-1034.	1.1	3
3124	Artificial Neural Networks Analysis of the Risk Factors for Aneurysm in the Population of the Setif Region in Algeria. <i>WSEAS Transactions on Biology and Biomedicine</i> , 2022, 19, 163-167.	0.3	1
3125	Interobserver Variability in Ultrasoundâ€Based Liver Fat Quantification. <i>Journal of Ultrasound in Medicine</i> , 2023, 42, 833-841.	0.8	7

#	ARTICLE	IF	CITATIONS
3126	Association of circulating vaspin levels and patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , 2022, 21, .	1.2	0
3127	The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review. <i>Pharmacoeconomics</i> , 2022, 40, 751-776.	1.7	16
3128	Current treatment of non-alcoholic fatty liver disease. <i>Journal of Internal Medicine</i> , 2022, 292, 190-204.	2.7	56
3129	A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
3130	The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
3131	Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	10
3132	Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	63
3133	The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 851-861.	3.7	566
3134	One-hour post-load glucose is associated with severity of hepatic fibrosis risk. <i>Diabetes Research and Clinical Practice</i> , 2022, 189, 109977.	1.1	9
3135	Noninvasive Algorithms for the Case Finding of "At-Risk" Patients with NAFLD. <i>Seminars in Liver Disease</i> , 2022, 42, 313-326.	1.8	7
3136	Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study. <i>Hormones</i> , 2022, 21, 477-486.	0.9	5
3137	AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. <i>Gastroenterology</i> , 2022, 163, 764-774.e1.	0.6	92
3138	Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD. <i>Hepatology</i> , 2023, 77, 920-930.	3.6	14
3139	Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. <i>Gastroenterology</i> , 2022, 163, 1079-1089.e5.	0.6	52
3140	Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
3141	Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	4
3142	Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States. <i>Journal of Clinical Laboratory Analysis</i> , 0, , .	0.9	6
3143	Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease. <i>Liver Cancer</i> , 2023, 12, 19-31.	4.2	5

#	ARTICLE	IF	CITATIONS
3144	Bone metabolism discrepancy in type 2 diabetes mellitus patients with and without non-alcoholic fatty liver disease. <i>Journal of Clinical Densitometry</i> , 2022, , .	0.5	0
3145	Postprandial glucose is correlated with an increasing risk of liver fibrosis in Chinese patients with nonalcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , 2022, 48, 101377.	1.4	5
3146	Performance of Imaging Techniques in Non-invasive Diagnosis of Non-alcoholic Fatty Liver Disease in Children: A Systematic Review and Meta-Analysis. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	3
3147	Accuracy of steatosis and fibrosis NAFLD scores in relation to vibration controlled transient elastography: An NHANES analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101997.	0.7	7
3148	Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 3, 100027.		8
3149	Î²BÎ¶ regulates the development of nonalcoholic fatty liver disease through the attenuation of hepatic steatosis in mice. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
3150	Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 425-472.	4.5	14
3152	Combination Therapies for Nonalcoholic Fatty Liver Disease. <i>Journal of Personalized Medicine</i> , 2022, 12, 1166.	1.1	18
3153	Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials. <i>Annals of Hepatology</i> , 2022, 27, 100738.	0.6	8
3154	Evidence-based management of patients with nonalcoholic fatty liver disease. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2022, Published Ahead of Print, .	0.1	1
3155	Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. <i>Pharmacological Research</i> , 2022, 182, 106348.	3.1	29
3156	Hydroxynonenal Causes Hepatocyte Death by Disrupting Lysosomal Integrity in Nonalcoholic Steatohepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, , .	2.3	9
3157	Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. <i>World Journal of Clinical Cases</i> , 2022, 10, 6759-6768.	0.3	3
3158	New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7442.	1.8	7
3159	Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7734.	1.8	16
3160	Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives. <i>Biochemical Pharmacology</i> , 2022, 202, 115157.	2.0	19
3161	Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes. <i>Current Opinion in Pediatrics</i> , 2022, 34, 414-422.	1.0	1
3162	Cadmium, lead, and mercury mixtures interact with non-alcoholic fatty liver diseases. <i>Environmental Pollution</i> , 2022, 309, 119780.	3.7	36

#	ARTICLE	IF	CITATIONS
3163	The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study. <i>Annals of Hepatology</i> , 2022, 27, 100727.	0.6	22
3164	Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. <i>Metabolism: Clinical and Experimental</i> , 2022, 134, 155264.	1.5	12
3165	An overview of ferroptosis in non-alcoholic fatty liver disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113374.	2.5	22
3166	Recent advances in lean NAFLD. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113331.	2.5	34
3167	The hypolipidemic, anti-inflammatory and antioxidant effect of Kavol [®] aqueous extract, a mixture of <i>Brassica oleracea</i> leaves, in a rat model of NAFLD. <i>Food and Chemical Toxicology</i> , 2022, 167, 113261.	1.8	2
3168	Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD). <i>Metabolism: Clinical and Experimental</i> , 2022, 134, 155246.	1.5	12
3169	Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2022, 51, 101547.	3.2	28
3170	Macrophage-specific MyD88 deletion and pharmacological inhibition prevents liver damage in non-alcoholic fatty liver disease via reducing inflammatory response. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166480.	1.8	6
3171	Redox-Unlockable Nanoparticle-Based MST1 Delivery System to Attenuate Hepatic Steatosis via the AMPK/SREBP-1c Signaling Axis. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 34328-34341.	4.0	4
3172	Conditional GANs based system for fibrosis detection and quantification in Hematoxylin and Eosin whole slide images. <i>Medical Image Analysis</i> , 2022, 81, 102537.	7.0	4
3173	Polycystic ovary syndrome is associated with nonalcoholic steatohepatitis in women of reproductive age. <i>Hepatology Communications</i> , 2022, 6, 2634-2639.	2.0	7
3174	Improvement in nonalcoholic fatty liver disease through bariatric surgery. <i>Clinical Liver Disease</i> , 2022, 20, 13-17.	1.0	2
3175	The Effect of Low Glycemic Index Mediterranean Diet and Combined Exercise Program on Metabolic-Associated Fatty Liver Disease: A Joint Modeling Approach. <i>Journal of Clinical Medicine</i> , 2022, 11, 4339.	1.0	5
3176	Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia. <i>Biomedicines</i> , 2022, 10, 1770.	1.4	7
3177	Effects of oily fish and its fatty acid intake on non-alcoholic fatty liver disease development among South Korean adults. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	3
3178	IRX3 plays an important role in the pathogenesis of metabolic-associated fatty liver disease by regulating hepatic lipid metabolism. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
3179	Glycated albumin is associated with all-cause and cardiovascular mortality among U.S. adults with and without diabetes: A retrospective cohort study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 2375-2382.	1.1	2
3180	Association of Serum Bilirubin With Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6

#	ARTICLE	IF	CITATIONS
3181	Endoplasmic reticulum stress in innate immune cells -A significant contribution to non-alcoholic fatty liver disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
3182	Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 942-956.	1.9	88
3183	Clinical Factors Associated with Non-Obese Nonalcoholic Fatty Liver Disease Detected among US Adults in the NHANES 2017-2018. <i>Journal of Clinical Medicine</i> , 2022, 11, 4260.	1.0	0
3184	Diagnosis and Therapy of Non-alcoholic Steatohepatitis (NASH). <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 1670-1676.	0.0	0
3185	Advances in ultrasound elastography for nonalcoholic fatty liver disease. <i>Choonpa Igaku</i> , 2022, , .	0.0	0
3186	Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. <i>Choonpa Igaku</i> , 2022, , .	0.0	0
3187	Association of serum creatinine with hepatic steatosis and fibrosis: a cross-sectional study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	2
3188	Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4. <i>Journal of Clinical Medicine</i> , 2022, 11, 4394.	1.0	3
3189	Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. <i>Diabetes Care</i> , 2022, 45, 2064-2075.	4.3	31
3190	Xanthine oxidoreductase activity is correlated with hepatic steatosis. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
3191	Gut microbiome is associated with metabolic syndrome accompanied by elevated gamma-glutamyl transpeptidase in men. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	18
3192	Correlation between T-Lymphocyte Subsets, Regulatory T Cells, and Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-8.	0.5	5
3193	Best Practices in Liver Biopsy Histologic Assessment for Nonalcoholic Steatohepatitis Clinical Trials: Expert Opinion. <i>GastroHep</i> , 2022, 2022, 1-11.	0.3	4
3194	Severity of Nonalcoholic Fatty Liver Disease is Associated With Cardiovascular Outcomes in Patients With Prehypertension or Hypertension: A Community-Based Cohort Study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
3195	Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2022, 2022, 1-12.	0.6	1
3196	A Recent Update on the Epigenetic Repertoire and Chromatin Modifying Therapy in Diabetes Mellitus: A Comprehensive Review. <i>Current Medicinal Chemistry</i> , 2023, 30, 2020-2038.	1.2	0
3197	Modifications decrease hepatic steatosis in Taiwanese with metabolic-associated fatty liver disease. <i>Kaohsiung Journal of Medical Sciences</i> , 0, , .	0.8	1
3198	Sex-specific differences in prevalence of nonalcoholic fatty liver disease in subjects with prediabetes and type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 190, 110027.	1.1	11

#	ARTICLE	IF	CITATIONS
3199	Sex-Dependent Hepatoprotective Role of IL-22 Receptor Signaling in Non-Alcoholic Fatty Liver Disease-Related Fibrosis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 1269-1294.	2.3	6
3200	Effect of obeticholic acid in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) patients: a systematic review and meta-analysis. , 2022, 1, .		2
3201	Voluntary physical activity in early life attenuates markers of fatty liver disease in adult male rats fed a high-fat diet. <i>British Journal of Nutrition</i> , 2023, 129, 1667-1676.	1.2	1
3202	The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study. <i>Hepatology</i> , 2023, 77, 949-964.	3.6	58
3203	Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4051.	1.7	11
3204	Primary-like Human Hepatocytes Genetically Engineered to Obtain Proliferation Competence as a Capable Application for Energy Metabolism Experiments in In Vitro Oncologic Liver Models. <i>Biology</i> , 2022, 11, 1195.	1.3	2
3205	Statins™ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Clinical Nutrition</i> , 2022, 41, 2195-2206.	2.3	11
3206	<scp>D</scp>â€œLimonene for regulating metabolismâ€œassociated fatty liver disease (MAFLD) and analysis of the TCM constitution: A protocol for an exploratory, randomized, doubleâ€œblind, placeboâ€œcontrolled trial (DLâ€œMAFLDâ€œTCM). <i>Food Frontiers</i> , 2022, 3, 550-559.	3.7	2
3207	Demographic, clinical and laboratory predictors of hepatic steatosis and fibrosis by elastography. <i>Akademik Gastroenteroloji Dergisi</i> , 0, , .	0.0	0
3208	Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 4627.	1.0	2
3209	The biological clock enhancer nobiletin ameliorates steatosis in genetically obese mice by restoring aberrant hepatic circadian rhythm. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, G387-G400.	1.6	9
3210	Complete alcohol abstinence increases the risk of NAFLD but not severity. A population analysis with transient elastography. <i>Scandinavian Journal of Gastroenterology</i> , 0, , 1-7.	0.6	0
3211	Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 3224.	1.7	6
3212	Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	90
3213	Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2022, 12, S51-S58.	0.1	3
3214	Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2022, 12, S46-S50.	0.1	4
3215	Needle-free Nonalcoholic Fatty Liver Disease Prognostication: Moving One Step Closer. <i>Gastroenterology</i> , 2022, 163, 819-822.	0.6	1
3216	Chitosan reduces inflammation and protects against oxidative stress in a hyperlipidemic rat model: relevance to nonalcoholic fatty liver disease. <i>Molecular Biology Reports</i> , 0, , .	1.0	2

#	ARTICLE	IF	CITATIONS
3217	Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3. <i>Hepatology Communications</i> , 2022, 6, 2676-2688.	2.0	4
3218	A vegan diet improves insulin resistance in individuals with obesity: a systematic review and meta-analysis. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	3
3219	Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
3220	Bicyclol alleviates high-fat diet-induced hepatic ER stress- and autophagy-associated non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in mice. <i>Drug Development and Industrial Pharmacy</i> , 2022, 48, 247-254.	0.9	4
3221	Fatty Liver Change in Korean Adults in a Systematic Social Distancing System Amid the COVID-19 Pandemic: A Multicenter Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10444.	1.2	3
3222	Berberine in Non-Alcoholic Fatty Liver Disease—A Review. <i>Nutrients</i> , 2022, 14, 3459.	1.7	8
3223	Association between grip strength and non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
3224	Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease. <i>World Journal of Hepatology</i> , 2022, 14, 1633-1642.	0.8	3
3225	Identification of hub genes and small molecule therapeutic drugs related to simple steatosis with secondary analysis of existing microarray data. <i>International Journal of Transgender Health</i> , 2022, 15, 921-932.	1.1	0
3226	Historical Changes in Weight Classes and the Influence of NAFLD Prevalence: A Population Analysis of 34,486 Individuals. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 9935.	1.2	12
3227	Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
3228	Supplementation of Lycium barbarum Polysaccharide Combined with Aerobic Exercise Ameliorates High-Fat-Induced Nonalcoholic Steatohepatitis via AMPK/PPAR α /PGC-1 α Pathway. <i>Nutrients</i> , 2022, 14, 3247.	1.7	5
3229	Radiological Features of Microvascular Invasion of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. <i>Gastroenterology Insights</i> , 2022, 13, 275-285.	0.7	2
3230	Fibroblast growth factor receptor 1/Klotho β agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial. <i>Hepatology</i> , 2023, 78, 847-862.	3.6	10
3231	Transient Elastography and Serum-Based Tests for Diagnosis of Fatty Liver and Advanced Fibrosis in a Community Cohort: A Cross-Sectional Analysis. <i>Digestive Diseases</i> , 2023, 41, 767-779.	0.8	4
3232	Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	6
3233	Work-up for Incidentally Detected NAFLD: How Far is It Worth?. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2022, 12, S26-S36.	0.1	0
3234	A novel model for detecting advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, .	1.7	3

#	ARTICLE	IF	CITATIONS
3253	Vibration-controlled Transient Elastography in NAFLD: Review Study. Euroasian Journal of Hepato-gastroenterology, 2022, 12, S41-S45.	0.1	1
3255	The effects of the voglibose on non-alcoholic fatty liver disease in mice model. Scientific Reports, 2022, 12, .	1.6	5
3256	A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Reports, 2023, 5, 100563.	2.6	15
3257	How to select the quantitative magnetic resonance technique for subjects with fatty liver: A systematic review. World Journal of Clinical Cases, 2022, 10, 8906-8921.	0.3	0
3258	A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPAR α) and farnesoid X receptor (FXR). Biomedicine and Pharmacotherapy, 2022, 154, 113577.	2.5	17
3259	Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial. Complementary Therapies in Medicine, 2022, 70, 102866.	1.3	9
3260	Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159209.	1.2	11
3262	The evolving view of thermogenic fat and its implications in cancer and metabolic diseases. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	15
3263	The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population. Journal of Translational Medicine, 2022, 20, .	1.8	16
3264	Evaluation of nonalcoholic fatty liver disease in Japanese patients with psoriasis: Chest <sc>CT</sc> imaging for screening purposes. Journal of Dermatology, 2022, 49, 1263-1267.	0.6	1
3265	Associations between serum biomarkers and non-alcoholic liver disease: Results of a clinical study of Mediterranean patients with obesity. Frontiers in Nutrition, 0, 9, .	1.6	6
3266	Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial Based on the Theory of Planned Behavior. BioMed Research International, 2022, 2022, 1-10.	0.9	9
3267	Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China. Frontiers in Endocrinology, 0, 13, .	1.5	10
3268	Non-alcoholic fatty liver disease (NAFLD) in lean individuals – Single centre large cohort clinicopathologic and immunophenotypic study. Pathology Research and Practice, 2022, 238, 154112.	1.0	1
3269	Emerging role of carboxylesterases in nonalcoholic fatty liver disease. Biochemical Pharmacology, 2022, 205, 115250.	2.0	1
3270	The spectrum of magnetic resonance imaging proton density fat fraction (MRI-PDFF), magnetic resonance spectroscopy (MRS), and two different histopathologic methods (artificial intelligence vs.) Tj ETQq1 1 0.784314 rgBT /Ove 5251-5262.	1.1	1
3271	MicroRNA targeted therapy in hepatitis. , 2022, , 549-561.		0
3272	Non-Alcoholic Fatty Liver Disease and Steatohepatitis. , 2023, , 610-621.		2

#	ARTICLE	IF	CITATIONS
3273	Nicht-alkoholische Fettlebererkrankung und Alkoholkonsum. , 2022, , 367-373.		0
3274	Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. , 2022, , 211-225.		0
3275	Diagnostik: Elastometrie. , 2022, , 125-135.		0
3276	Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series. Clinics, 2022, 77, 100097.	0.6	0
3277	Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211001.	1.4	5
3278	Pathophysiologie: Genetik. , 2022, , 75-92.		0
3279	Therapie: Bewegung. , 2022, , 189-199.		0
3280	Most Cases of Cryptogenic Cirrhosis May Be Nonobese Nonalcoholic Steatohepatitis - Risk Factors of Liver Steatosis After Liver Transplantation for Cryptogenic Cirrhosis: A Retrospective Study. Internal Medicine, 2023, 62, 1415-1423.	0.3	1
3281	Metabolic Syndrome and Liver Cancer. , 2022, , 87-104.		0
3282	Diagnostik: Algorithmus und Leberbiopsie. , 2022, , 167-179.		0
3283	Therapie: Diät. , 2022, , 201-209.		0
3284	Potential role of gut microbiota-LCA-INSR axis in high fat-diet-induced non-alcoholic fatty liver dysfunction: From perspective of radiation variation. Current Research in Food Science, 2022, 5, 1685-1700.	2.7	3
3285	Intestinal microbiomics and liver metabolomics insights into the preventive effects of chromium (III)-enriched yeast on hyperlipidemia and hyperglycemia induced by high-fat and high-fructose diet. Current Research in Food Science, 2022, 5, 1365-1378.	2.7	2
3286	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. Choonpa Igaku, 2022, 49, 385-396.	0.0	0
3287	Diagnostik: Blutbasierte Marker. , 2022, , 149-155.		0
3289	Ein Ausblick in die Zukunft. , 2022, , 409-416.		0
3290	Progress in the Treatment of Metabolism-Related Fatty Liver Disease. Advances in Clinical Medicine, 2022, 12, 8647-8654.	0.0	0
3291	Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective. , 2022, , 81-111.		0

#	ARTICLE	IF	CITATIONS
3292	Spezifische Therapie â€œ neue Medikamente. , 2022, , 227-255.		0
3293	Pathologie. , 2022, , 21-28.		0
3294	The NAFLDâ€™MAFLD debate through the lens of the Arab world. Saudi Journal of Gastroenterology, 2022, .	0.5	1
3295	Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211224.	1.1	8
3296	Prevalence of non-Alcoholic Fatty Liver Disease and Associated Factors in Patients with Moderate or Severe Hemophilia: A Multicenter-Based Study. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211282.	0.7	2
3297	A retrospective study on the relationship between fibrosisâ€™4 index and allâ€™cause mortality in patients with acute myocardial infarction. Experimental and Therapeutic Medicine, 2022, 24, .	0.8	2
3298	Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. Acta Pharmaceutica Sinica B, 2023, 13, 1-28.	5.7	5
3299	Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Biomedicines, 2022, 10, 2101.	1.4	4
3300	Antifibrotic effect and longâ€™term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatology Communications, 2022, 6, 3073-3082.	2.0	14
3301	Association of glycated hemoglobin with non-alcoholic fatty liver disease patients and the severity of liver steatosis and fibrosis measured by transient elastography in adults without diabetes. BMC Endocrine Disorders, 2022, 22, .	0.9	6
3302	Liver cirrhosis in children â€œ the role of imaging in the diagnostic pathway. Pediatric Radiology, 2023, 53, 714-726.	1.1	1
3303	Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment. , 0, , .		1
3304	Constitution of mucosaâ€™associated microbiota in the lower digestive tract does not change in early stage of nonâ€™alcoholic fatty liver disease with fecal dysbiosis. JGH Open, 2022, 6, 677-684.	0.7	1
3305	Effect of theaflavin-3,3â€™-digallate on leptin-deficient induced nonalcoholic fatty liver disease might be related to lipid metabolism regulated by the Fads1/PPARÎ³/Fabp4 axis and gut microbiota. Frontiers in Pharmacology, 0, 13, .	1.6	3
3306	Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitusâ€™From Prevalence to Diagnostic Approach and Treatment Strategies. Journal of Clinical Medicine, 2022, 11, 5144.	1.0	8
3307	The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2022, 16, 835-849.	1.4	1
3308	Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis. PharmacoEconomics - Open, 2023, 7, 93-110.	0.9	3
3309	Association of Inflammatory and Metabolic Biomarkers with Mitral Annular Calcification in Type 2 Diabetes Patients. Journal of Personalized Medicine, 2022, 12, 1484.	1.1	5

#	ARTICLE	IF	CITATIONS
3310	Analysis of time-dependent changes in the FIB4 index in patients with obesity receiving weight reduction therapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
3311	Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes. <i>Biomedicines</i> , 2022, 10, 2375.	1.4	5
3312	Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States. <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	2
3313	A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD). <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
3314	Trajectory of NAFLD characteristics after Roux-en-Y gastric bypass: a five-year historical cohort study. <i>Sao Paulo Medical Journal</i> , 2022, 140, 739-746.	0.4	6
3315	Worldwide long-term trends in the incidence of nonalcoholic fatty liver disease during 1990â€“2019: A joinpoint and age-period-cohort analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	11
3316	Systematic Review and Meta-Analysis of the Usefulness of Epicardial Fat Thickness as a Non-Invasive Marker of the Presence and Severity of Nonalcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2022, 10, 2204.	1.4	2
3317	Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?. <i>Nutrients</i> , 2022, 14, 3875.	1.7	3
3318	Food and Gut Microbiota-Derived Metabolites in Nonalcoholic Fatty Liver Disease. <i>Foods</i> , 2022, 11, 2703.	1.9	3
3319	High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study. <i>Hepatology Communications</i> , 2022, 6, 3212-3222.	2.0	3
3320	Advances in metformin for the treatment of non-alcoholic fatty liver disease in children. <i>Expert Review of Gastroenterology and Hepatology</i> , 0, , 1-15.	1.4	1
3321	The Impact of Bariatric-Surgery-Induced Weight Loss on Patients Undergoing Liver Transplant: A Focus on Metabolism, Pathophysiological Changes, and Outcome in Obese Patients Suffering NAFLD-Related Cirrhosis. <i>Journal of Clinical Medicine</i> , 2022, 11, 5293.	1.0	3
3322	Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice. <i>JHEP Reports</i> , 2023, 5, 100596.	2.6	12
3323	Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization. <i>Radiology</i> , 2022, 305, 265-276.	3.6	9
3325	Geographical similarity and differences in the burden and genetic predisposition of NAFLD. <i>Hepatology</i> , 2023, 77, 1404-1427.	3.6	43
3326	Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives. <i>ClinicoEconomics and Outcomes Research</i> , 0, Volume 14, 607-618.	0.7	1
3327	Racial and ethnic differences in diet quality and food insecurity among adults with fatty liver and significant fibrosis: a U.S. populationâ€“based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 1383-1393.	1.9	9
3328	Liver blood marker testing in UK primary care: a UK wide cohort study, 2004â€“2016. <i>BMJ Open</i> , 2022, 12, e058967.	0.8	1

#	ARTICLE	IF	CITATIONS
3329	The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	12
3330	Effects of Maternal Gut Microbiota-Targeted Therapy on the Programming of Nonalcoholic Fatty Liver Disease in Dams and Fetuses, Related to a Prenatal High-Fat Diet. <i>Nutrients</i> , 2022, 14, 4004.	1.7	5
3331	The correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with nonalcoholic fatty liver disease: a cross-sectional study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 1158-1164.	0.8	9
3332	Liver Inflammation Is Common and Linked to Metabolic Derangements in Persons With Treated Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2023, 76, e571-e579.	2.9	4
3333	Association of Statin Adherence With the Development of Nonalcoholic Fatty Liver Disease: A Nested Case-Control Study Using a Japanese Claims Database. <i>Annals of Pharmacotherapy</i> , 2023, 57, 637-645.	0.9	2
3334	Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease. <i>Pharmaceutical Biology</i> , 2022, 60, 1819-1838.	1.3	1
3335	Clinical and laboratory predictors of hepatic steatosis formation in adolescent boys with hypoandrogenism. <i>ZdorovĚie Rebenka</i> , 2022, 17, 121-127.	0.0	0
3336	Therapies for non-alcoholic fatty liver disease: A 2022 update. <i>World Journal of Hepatology</i> , 0, 14, 1718-1729.	0.8	4
3337	A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	3
3338	Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1700-1716.	1.4	17
3339	Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. <i>Clinical Science</i> , 2022, 136, 1347-1366.	1.8	56
3340	Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
3341	(Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis. <i>FASEB Journal</i> , 2022, 36, .	0.2	3
3342	Primary Care Providers and Nonalcoholic Fatty Liver Disease: A Needs Assessment Survey. <i>Digestive Diseases and Sciences</i> , 2023, 68, 434-438.	1.1	7
3343	MAFLD was more easily diagnosed than NAFLD in liver transplant recipients with abnormal liver function. , 2022, 1, 194-198.		0
3344	Relation of retinol binding protein4, visfatin and vitamin a in obese and non obese Iraqi patients with non alcoholic fatty liver disease. <i>International Journal of Health Sciences</i> , 0, , 11315-11325.	0.0	0
3345	Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?. <i>World Journal of Hepatology</i> , 0, 14, 1704-1717.	0.8	1
3346	Essential phospholipids decrease apoptosis and increase membrane transport in human hepatocyte cell lines. <i>Lipids in Health and Disease</i> , 2022, 21, .	1.2	4

#	ARTICLE	IF	CITATIONS
3347	Hepatic Fat Quantification With Novel Ultrasound Based Techniques: A Diagnostic Performance Study Using Magnetic Resonance Imaging Proton Density Fat Fraction as Reference Standard. Canadian Association of Radiologists Journal, 0, , 084653712211236.	1.1	5
3349	Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial. Hepatology, 2023, 78, 863-877.	3.6	9
3350	Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease – a survey in a university hospital in Brazil. Archives of Endocrinology and Metabolism, 2022, , .	0.3	0
3351	Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression. Nature Communications, 2022, 13, .	5.8	20
3352	Accuracy of Ultrasound Elastography and Fibrosis-4 Index (FIB-4) in Ruling Out Cirrhosis in Obese Non-Alcoholic Fatty Liver Disease (NAFLD) Patients. Cureus, 2022, , .	0.2	0
3353	Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients – A Retrospective Observational Study. Cancers, 2022, 14, 4422.	1.7	4
3354	Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality. Frontiers in Microbiology, 0, 13, .	1.5	16
3355	Fatty liver disease reverses the obesity paradox in chronic kidney disease stages 3 – 5: A follow-up study of NHANES III. Hepatology Communications, 2022, 6, 3132-3139.	2.0	1
3356	The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches. International Journal of Molecular Sciences, 2022, 23, 10616.	1.8	12
3357	The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications. Journal of Biomedical Science, 2022, 29, .	2.6	7
3358	Evaluation of Six Noninvasive Methods for the Detection of Fibrosis in Chinese Patients with Obesity and Nonalcoholic Fatty Liver Disease. Obesity Surgery, 0, , .	1.1	0
3359	Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. World Journal of Gastroenterology, 2022, 28, 5129-5140.	1.4	4
3360	Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study. European Journal of Gastroenterology and Hepatology, 2022, 34, 1172-1177.	0.8	0
3361	Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis. Alimentary Pharmacology and Therapeutics, 0, , .	1.9	3
3362	Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals. Expert Review of Gastroenterology and Hepatology, 2022, 16, 895-901.	1.4	7
3363	Differences in HDL-Bound Apolipoproteins in Patients With Advanced Liver Fibrosis Due to Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 108, 42-51.	1.8	3
3364	Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection – a population-based study. Alimentary Pharmacology and Therapeutics, 2022, 56, 1581-1590.	1.9	8
3365	The development of the Metabolic-associated Fatty Liver Disease during pharmacotherapy of mental disorders - a review. Current Problems of Psychiatry, 2022, 23, 128-143.	0.1	0

#	ARTICLE	IF	CITATIONS
3366	Waist-to-Hip Ratio and Inflammatory Parameters Are Associated with Risk of Non-Alcoholic Fatty Liver Disease in Patients with Morbid Obesity. <i>Biomedicines</i> , 2022, 10, 2416.	1.4	5
3367	Evaluate the elasticity of carotid artery in the type 2 diabetes mellitus patients with nonalcoholic fatty liver disease by two-dimensional strain imaging. <i>Medicine (United States)</i> , 2022, 101, e30738.	0.4	1
3368	Tangible Resources for Multidisciplinary Treatment of Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2023, 118, 389-393.	0.2	2
3370	Serum metabolome alterations in patients with early nonalcoholic fatty liver disease. <i>Bioscience Reports</i> , 2022, 42, .	1.1	4
3371	Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysis. , 2022, 240, 108294.		7
3373	Diabetes Mellitus is Associated With Higher Serum Neurofilament Light Chain Levels in the General US Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 361-367.	1.8	14
3374	The impact of fatigue on mortality of patients with nonâ€œalcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005â€œ2010 and 2017â€œ2018. <i>Liver International</i> , 2022, 42, 2646-2661.	1.9	8
3375	Dietary and nutrition considerations in caring for patients with nonalcoholic fatty liver disease: Updates for the practicing clinician. <i>Nutrition in Clinical Practice</i> , 2023, 38, 70-79.	1.1	0
3376	Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons. <i>Journal of Hepatology</i> , 2023, 78, 442-447.	1.8	9
3377	Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
3378	Correlation between Liver Fat Indices and Ultrasonography to Determine Non-alcoholic Fatty Liver Disease among Diabetic Patients in Sri Lanka. , 0, 17, 15.		0
3379	Validation and Comparison of Two Dietary Indexes for Predicting Nonalcoholic Fatty Liver Disease in US Adults. <i>Journal of Nutrition</i> , 2022, 152, 2865-2876.	1.3	7
3380	Inhibition on XBP1s-driven lipogenesis by Qushi Huayu Decoction contributes to amelioration of hepatic steatosis induced by fructose. <i>Journal of Ethnopharmacology</i> , 2023, 301, 115806.	2.0	2
3381	The role of oxidized lipid species in insulin resistance and NASH in children. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
3382	Glutaminase 1 blockade alleviates nonalcoholic steatohepatitis via promoting proline metabolism. <i>Biochemical and Biophysical Research Communications</i> , 2022, 634, 1-9.	1.0	0
3383	Incidence and Predictors of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 37-47.	0.4	3
3384	Association of Bariatric Surgery With Cardiovascular Outcomes in Adults With Severe Obesity and Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2022, 5, e2235003.	2.8	13
3385	Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study. <i>Annals of Hepatology</i> , 2023, 28, 100769.	0.6	7

#	ARTICLE	IF	CITATIONS
3386	Discovery of novel AdipoRon analogues as potent anti-inflammatory agents against nonalcoholic steatohepatitis. <i>European Journal of Medicinal Chemistry</i> , 2022, 244, 114800.	2.6	5
3387	The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e34809.	1.2	12
3388	Influence of changes in the intestinal microbiome on the course and progression of metabolically associated fatty liver disease. , 0, , 38-44.		1
3389	Genetic variants in promoter region of <i>TFR2</i> is associated with the risk of non-alcoholic fatty liver disease in a Chinese Han population: a case-control study. <i>Gastroenterology Report</i> , 2022, 10, .	0.6	6
3390	Correlation between shift work and non-alcoholic fatty liver disease among male workers in the steel manufacturing company of Korea: a cross-sectional study. <i>Annals of Occupational and Environmental Medicine</i> , 2022, 34, .	0.3	4
3391	The Challenging Ethical Landscape of Non-alcoholic Fatty Liver Disease. <i>European Medical Journal Hepatology</i> , 0, , .	1.0	2
3392	A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség. <i>Orvosi Hetilap</i> , 2022, 163, 855-862.	0.1	2
3393	Salidroside in the Treatment of NAFLD/NASH. <i>Chemistry and Biodiversity</i> , 2022, 19, .	1.0	6
3394	Cardiovascular and hepatic disease associations by magnetic resonance imaging: A retrospective cohort study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
3395	Risk factors for cardiovascular disease among individuals with hepatic steatosis. <i>Hepatology Communications</i> , 2022, 6, 3406-3420.	2.0	2
3397	Mendelian randomization prioritizes abdominal adiposity as an independent causal factor for liver fat accumulation and cardiometabolic diseases. <i>Communications Medicine</i> , 2022, 2, .	1.9	8
3398	Nonalcoholic fatty liver disease in children with obesity—observations from one clinical centre in the Western Pomerania region. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
3399	Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD). <i>Livers</i> , 2022, 2, 264-282.	0.8	3
3400	NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?. <i>Seminars in Liver Disease</i> , 2022, 42, 465-474.	1.8	8
3402	The Relationship between Visceral Adiposity and Nonalcoholic Fatty Liver Disease Diagnosed by Controlled Attenuation Parameter in People with HIV: A Pilot Study. <i>Diagnostics</i> , 2022, 12, 2590.	1.3	1
3403	Regulation of Iron Metabolism in NAFLD/NASH. , 0, , .		0
3404	Higher Adherence to Healthy Lifestyle Score Is Associated with Lower Odds of Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 4462.	1.7	3
3405	The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2022, 4, 132-141.	0.0	0

#	ARTICLE	IF	CITATIONS
3406	Association of non-alcoholic fatty liver disease with left ventricular changes in treatment-naive patients with uncomplicated hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	5
3408	Apnoea-hypopnoea index of 5 as a metabolomic threshold in patients with sleep complaintsâ€™. <i>ERJ Open Research</i> , 0, , 00325-2022.	1.1	0
3409	Emerging trends and hotspots in the links between the gut microbiota and MAFLD from 2002 to 2021: A bibliometric analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
3410	Combined hepatoprotective pharmacotherapy for liver disease. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2022, , 5-20.	0.1	2
3411	Dietary Quality and Relationships with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among United States Adults, Results from NHANES 2017â€™2018. <i>Nutrients</i> , 2022, 14, 4505.	1.7	20
3412	Role of Oxidative Stress in Liver Disorders. <i>Livers</i> , 2022, 2, 283-314.	0.8	22
3413	Current Research on the Pathogenesis of NAFLD/NASH and the Gutâ€™Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11689.	1.8	21
3414	Association of non-alcoholic fatty liver disease with cardiovascular disease according to autopsy data. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2022, , 38-44.	0.1	0
3415	A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity. <i>PLoS ONE</i> , 2022, 17, e0275901.	1.1	3
3418	Associations of serum folate and vitamin C levels with metabolic dysfunction-associated fatty liver disease in US adults: A nationwide cross-sectional study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
3419	Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China. <i>Hepatology Communications</i> , 2022, 6, 3393-3405.	2.0	14
3420	Approach to the Patient With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 483-495.	1.8	5
3421	The association of nonâ€™alcoholic fatty liver disease between parents and adolescent children. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 245-252.	1.9	8
3422	Comparison of non-invasive imaging methods and laboratory findings on non-alcoholic fatty liver disease (NAFLD) in childhood. <i>Journal of Health Sciences and Medicine</i> , 2022, 5, 1541-1546.	0.0	0
3424	Study on the protective mechanism of dexmedetomidine on the liver of perioperative diabetic patients: A randomized controlled trial. <i>Medicine (United States)</i> , 2022, 101, e30899.	0.4	0
3426	Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis. <i>Journal of Clinical Gastroenterology</i> , 0, Publish Ahead of Print, .	1.1	1
3427	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 77-98.	4.5	27
3428	Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8

#	ARTICLE	IF	CITATIONS
3429	Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter. <i>Journal of Clinical Medicine</i> , 2022, 11, 5959.	1.0	1
3430	Potential hepatoprotective effects of <i>Cistanche deserticola</i> Y.C. Ma: Integrated phytochemical analysis using UPLC-Q-TOF-MS/MS, target network analysis, and experimental assessment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
3431	Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study. <i>Obesity Science and Practice</i> , 2023, 9, 218-225.	1.0	1
3433	Hepatic Fat Quantification with the Multi-Material Decomposition Algorithm by Using Low-Dose Non-Contrast Material-Enhanced Dual-Energy Computed Tomography in a Prospectively Enrolled Cohort. <i>Medicina (Lithuania)</i> , 2022, 58, 1459.	0.8	2
3434	The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
3435	Incidence and Impact of Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent. <i>World Journal of Surgery</i> , 2023, 47, 227-235.	0.8	0
3436	Multiomics study of nonalcoholic fatty liver disease. <i>Nature Genetics</i> , 2022, 54, 1652-1663.	9.4	53
3437	TM6SF2 rs58542926 is related to hepatic steatosis, fibrosis and serum lipids both in adults and children: A meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	7
3438	The role of noninvasive scoring systems for predicting cardiovascular disease risk in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 1277-1284.	0.8	2
3439	Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies. <i>Diagnostics</i> , 2022, 12, 2608.	1.3	2
3440	Aging of Liver in Its Different Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13085.	1.8	13
3441	Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
3442	Critical Overview of Hepatic Factors That Link Non-Alcoholic Fatty Liver Disease and Acute Kidney Injury: Physiology and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12464.	1.8	2
3444	Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy. <i>Biomedicines</i> , 2022, 10, 2652.	1.4	3
3445	Effects of a 12-week whole-grain or refined wheat intervention on plasma acylcarnitines, bile acids and signaling lipids, and association with liver fat: A post-hoc metabolomics study of a randomized controlled trial. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	0
3446	Prevalence and risk factors of nonalcoholic fatty liver disease in a general population, the HUNT study. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 505-511.	0.6	1
3447	Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
3448	Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	13

#	ARTICLE	IF	CITATIONS
3450	Mouse models of nonalcoholic steatohepatitis and their application to new drug development. Archives of Pharmacal Research, 2022, 45, 761-794.	2.7	5
3451	Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. Frontiers in Pharmacology, 0, 13, .	1.6	12
3452	Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature. Journal of Gastroenterology and Hepatology (Australia), 2023, 38, 269-273.	1.4	11
3453	Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation, 2022, 132, .	3.9	18
3454	Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. Journal of Comparative Effectiveness Research, 2022, 11, 1349-1363.	0.6	1
3455	Therapeutic strategies for liver diseases based on redox control systems. Biomedicine and Pharmacotherapy, 2022, 156, 113764.	2.5	1
3456	Modulation of gut microbiota by glycyrrhizic acid may contribute to its anti-NAFLD effect in rats fed a high-fat diet. Life Sciences, 2022, 310, 121110.	2.0	4
3457	Quantitative imaging tests for non-alcoholic fatty liver disease: which, when and why. Translational Gastroenterology and Hepatology, 0, 8, 1-1.	1.5	1
3458	Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage. Vitamins and Hormones, 2023, , 271-292.	0.7	0
3459	Liver disorders: nutritional management. , 2022, , .		0
3460	Metabolically associated fatty liver disease – a disease of the 21st century: A review. Consilium Medicum, 2022, 24, 325-332.	0.1	3
3461	Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD. Biomedicines, 2022, 10, 2806.	1.4	1
3462	Rejuvenation: Turning Back Time by Enhancing CISD2. International Journal of Molecular Sciences, 2022, 23, 14014.	1.8	6
3463	The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study. Journal of Clinical and Experimental Hepatology, 2023, 13, 233-240.	0.4	3
3464	Advances in responsive liquid metal composites for cancer therapy. Materials Today Nano, 2023, 21, 100285.	2.3	5
3465	Development and validation of a nonalcoholic fatty liver disease-based self-diagnosis tool for diabetes. Annals of Translational Medicine, 2022, 10, 1158-1158.	0.7	0
3466	Management of non-alcoholic fatty liver disease patients with sleep apnea syndrome. World Journal of Gastroenterology, 0, 28, 6099-6108.	1.4	0
3467	Sodium Alginate Prevents Non-Alcoholic Fatty Liver Disease by Modulating the Gut-Liver Axis in High-Fat Diet-Fed Rats. Nutrients, 2022, 14, 4846.	1.7	14

#	ARTICLE	IF	CITATIONS
3468	Non-invasive 3D Photoacoustic Tomography of Angiographic Anatomy and Hemodynamics of Fatty Livers in Rats. <i>Advanced Science</i> , 2023, 10, .	5.6	6
3469	Non-alcoholic fatty liver disease: the pathologist's perspective. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S302-S318.	4.5	4
3470	The effects of fasting diets on nonalcoholic fatty liver disease. <i>Nutrition Reviews</i> , 2023, 81, 857-868.	2.6	2
3471	Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography. <i>Hepatology Research</i> , 2023, 53, 208-218.	1.8	3
3472	Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 20-30.	3.7	89
3473	Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	3
3474	Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-18.	0.8	0
3475	Mulberry Leaf (<i>Morus alba</i> L.) Extracts and Its Chlorogenic Acid Isomer Component Improve Glucolipotoxicity-Induced Hepatic Lipid Accumulation via Downregulating miR-34a and Decreased Inflammation. <i>Nutrients</i> , 2022, 14, 4808.	1.7	9
3476	Mesenchymal stem cells-derived exosomal miR-24-3p ameliorates non-alcohol fatty liver disease by targeting Keap-1. <i>Biochemical and Biophysical Research Communications</i> , 2022, 637, 331-340.	1.0	5
3477	In vivo grading of lipids in fatty liver by near-infrared autofluorescence and reflectance. <i>Journal of Biophotonics</i> , 2023, 16, .	1.1	0
3478	Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: Systematic review and meta-analysis. <i>Annals of Hepatology</i> , 2023, 28, 100873.	0.6	14
3479	Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis. <i>JHEP Reports</i> , 2023, 5, 100627.	2.6	11
3480	NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	9
3481	Therapeutic Approach to NAFLD-NASH. , 0, , .		0
3482	Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 215-223.	1.9	8
3483	Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH). <i>International Journal of Molecular Sciences</i> , 2022, 23, 13501.	1.8	4
3484	Plasma phospholipid arachidonic acid in relation to non-alcoholic fatty liver disease: Mendelian randomization study. <i>Nutrition</i> , 2023, 106, 111910.	1.1	5
3485	Review article: the role of <i>HSD17B13</i> on global epidemiology, natural history, pathogenesis and treatment of NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 37-51.	1.9	17

#	ARTICLE	IF	CITATIONS
3486	A meta-analysis of the diagnostic accuracy of serum type IV collagen 7S concentration for the staging of liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 0, , .	1.8	0
3487	Association between <i>Porphyromonas Gingivalis</i> and systemic diseases: Focus on T cells-mediated adaptive immunity. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	9
3488	Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	4
3489	Nonalcoholic Fatty Liver Disease—A Concise Review of Noninvasive Tests and Biomarkers. <i>Metabolites</i> , 2022, 12, 1073.	1.3	1
3490	Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 1192-1201.	1.8	11
3491	Bioelectrical Impedance Analysis Can Be an Effective Tool for Screening Fatty Liver in Patients with Suspected Liver Disease. <i>Healthcare (Switzerland)</i> , 2022, 10, 2268.	1.0	3
3492	Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	22
3493	The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review. <i>Nutrients</i> , 2022, 14, 4655.	1.7	11
3494	Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2023, 78, 238-246.	1.8	14
3495	NAFLD as the metabolic hallmark of obesity. <i>Internal and Emergency Medicine</i> , 2023, 18, 31-41.	1.0	5
3496	MAFLD is associated with increased all-cause mortality in low cardiovascular-risk individuals but not in intermediate to high-risk individuals. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, 33, 376-384.	1.1	3
3498	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. <i>Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). Gastroenterology Y Hepatología (English Edition)</i> , 2022, 45, 724-734.	0.0	0
3499	Polymeric nanomedicines for the treatment of hepatic diseases. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	10
3500	A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	4
3501	Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102053.	0.7	5
3502	Research trends analysis of chronic hepatitis C versus nonalcoholic fatty liver disease: A literature review text-mining analysis of publications. <i>Health Science Reports</i> , 2022, 5, .	0.6	1
3503	A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. <i>Journal of Hepatology</i> , 2023, 78, 471-478.	1.8	55
3504	A nem alkoholos zsÃ¡jbetegsÃ©g Ã©s a 2-es tÃ¡pusÃ© cukorbetegsÃ©g. <i>Orvosi Hetilap</i> , 2022, 163, 815-825. 0.1		4

#	ARTICLE	IF	CITATIONS
3505	Emerging pharmacological treatment options for MAFLD. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882211424.	1.4	4
3506	Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882211396.	1.4	8
3507	Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842211463.	1.0	15
3508	Fibrosis-4 stage of liver fibrosis predicts cardiovascular outcomes in acute coronary syndrome patients with and without type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2023, 195, 110206.	1.1	3
3509	Luteolin ameliorates palmitate-induced lipotoxicity in hepatocytes by mediating endoplasmic reticulum stress and autophagy. <i>Food and Chemical Toxicology</i> , 2023, 171, 113554.	1.8	4
3510	Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 1-14.	0.8	5
3511	Hepatic fat as a novel marker for high-risk coronary atherosclerotic plaque features in familial hypercholesterolaemia. <i>Metabolism: Clinical and Experimental</i> , 2023, 139, 155370.	1.5	2
3512	Use of a combined transient elastography and biochemical strategy to determine liver fibrosis in pediatric intestinal failure. <i>Clinical Nutrition</i> , 2023, 42, 136-142.	2.3	1
3513	Setting up of a machine learning algorithm for the identification of severe liver fibrosis profile in the general US population cohort. <i>International Journal of Medical Informatics</i> , 2023, 170, 104932.	1.6	5
3514	Non-Invasive Imaging Modalities in Nonalcoholic Fatty Liver Disease: Where Do We Stand?. <i>European Medical Journal Hepatology</i> , 0, , 80-85.	1.0	0
3515	Noninvasive Imaging Modalities in Nonalcoholic Fatty Liver Disease: Where Do We Stand?. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 57-62.	3.0	2
3516	Update on the role of elastography in liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211406.	1.4	12
3517	Non-invasive assessment of metabolic dysfunction-associated fatty liver disease. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882211396.	1.4	0
3518	Health associations of liver enzymes and inflammatory scores with urinary citrus flavonoid metabolites. <i>Food and Function</i> , 0, , .	2.1	0
3519	Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2022, 32, 104-140.	0.2	17
3520	Implementation of a Whole Food Plant Based Diet in a Food as Prevention Program in a Resource Constrained Environment. <i>Journal of Lifestyle Medicine</i> , 2022, 12, 148-152.	0.3	1
3521	SoundAI: Improved Imaging with Learned Sound Speed Maps. , 2022, , .		0
3522	Cardiac abnormalities in patients with nonalcoholic fatty liver disease. <i>Revista Da Associação Médica Brasileira</i> , 2022, 68, 1394-1399.	0.3	0

#	ARTICLE	IF	CITATIONS
3523	Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma. <i>Oncogene</i> , 2023, 42, 308-321.	2.6	1
3524	Urinary neutrophil gelatinase-associated lipocalin: A novel biomarker for predicting chronic kidney disease in patients with nonalcoholic fatty liver disease. , 2022, 1, 157-166.		0
3525	Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
3526	Bariatric endoscopic-surgical therapies for NAFLD. Should they be considered viable options among current treatments?. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
3527	MAFLD: How is it different from NAFLD?. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S17-S31.	4.5	52
3528	Aqueous extract of <i>Artemisia capillaris</i> improves non-alcoholic fatty liver and obesity in mice induced by high-fat diet. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
3529	Age patterns of nonalcoholic fatty liver disease incidence: heterogeneous associations with metabolic changes. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	9
3530	Associations of phthalates with NAFLD and liver fibrosis: A nationally representative cross-sectional study from NHANES 2017 to 2018. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	5
3531	Effect of aerobic exercise on GRP78 and ATF6 expressions in mice with non-alcoholic fatty liver disease. <i>Sports Medicine and Health Science</i> , 2022, , .	0.7	1
3532	Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 419.	0.8	5
3533	Duodenal mucosal resurfacing for nonalcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2022, 20, 166-169.	1.0	2
3534	Do Semaphorins Play a Role in Development of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease?. <i>Biomedicines</i> , 2022, 10, 3014.	1.4	1
3535	Fat mass index as a screening tool for the assessment of non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
3537	Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 686-694.	0.2	2
3538	Screening strategy for non-alcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S103-S122.	4.5	16
3539	Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S43-S57.	4.5	13
3540	Mediators of dietary diversity score (DDS) on NAFLD in Iranian adults: a structural equation modeling study. <i>European Journal of Clinical Nutrition</i> , 2023, 77, 370-379.	1.3	3
3541	PPAR α in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?. <i>Biomedicines</i> , 2022, 10, 3041.	1.4	5

#	ARTICLE	IF	CITATIONS
3542	TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination. <i>Human Cell</i> , 2023, 36, 209-222.	1.2	12
3543	Nonalcoholic fatty liver disease (NAFLD) among older adults. , 2022, 1, 184-191.		0
3544	Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling. <i>Nutrients</i> , 2022, 14, 4950.	1.7	17
3545	HÃgado graso: una epidemia silente. , 2022, 44, 386-395.		0
3546	Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
3547	Integration of Lipidomics and Transcriptomics Reveals the Efficacy and Mechanism of Qige Decoction on NAFLD. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-13.	0.5	1
3548	Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation in vitro and in vivo. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
3549	Efeitos do uso da suplementaÃÃo de probiÃ³ticos na doenÃ§a hepÃtica gordurosa nÃo alcoÃlica. <i>Brazilian Journal of Health Review</i> , 2022, 5, 23437-23456.	0.0	0
3550	IdentifiedÃn blood diet-related methylation changes stratify liver biopsies of NAFLD patients according to fibrosis grade. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	5
3551	Effect of Two Different Dietary Weight Loss Strategies on Risk Factors for Urinary Stone Formation and Cardiometabolic Risk Profile in Overweight Women. <i>Nutrients</i> , 2022, 14, 5054.	1.7	3
3552	Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III. <i>BMJ Open</i> , 2022, 12, e067203.	0.8	5
3553	Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2496-2507.e5.	2.4	17
3554	Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 521-533.	0.6	0
3555	Association of non-Alcoholic Fatty Liver Disease with Urolithiasis detected on non-Contrast Computed Tomography. , 2022, 7, 87-92.		0
3556	Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2023, 78, 693-703.	1.8	9
3557	Implementing Screening for Nonalcoholic Fatty Liver Disease in Endocrinology Clinics. <i>Journal for Nurse Practitioners</i> , 2022, , .	0.4	0
3558	Nonheavy Alcohol Use Associates With Liver Fibrosis and Nonalcoholic Steatohepatitis in the Framingham Heart Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2854-2863.e2.	2.4	9
3560	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetesâ”2023 </i>. <i>Diabetes Care</i> , 2023, 46, s49-s67.2.	4.3	58

#	ARTICLE	IF	CITATIONS
3561	Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration. <i>Nutrients</i> , 2022, 14, 5340.	1.7	0
3562	The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	6
3563	Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
3564	Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16063.	1.8	0
3565	Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study. <i>Cancers</i> , 2022, 14, 6234.	1.7	10
3566	SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. <i>Journal of Gastroenterology</i> , 2023, 58, 79-97.	2.3	6
3567	Liver Fibrosis and Hearing Loss in an Older Mediterranean Population: Results from the Salus in Apulia Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 7213.	1.0	1
3568	Biomarkers reflecting pericellular fibrosis improve together with liver histology after bariatric surgery in early non-alcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2023, 113, 29-35.	0.8	2
3569	Trends in prevalence of probable fibrotic nonalcoholic steatohepatitis in the United States, 1999–2016. <i>Liver International</i> , 2023, 43, 340-344.	1.9	6
3570	Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. <i>Cell Metabolism</i> , 2023, 35, 56-70.e3.	7.2	38
3571	The Influence of Plum (<i>Prunus salicina</i> Lindl) Extract to Liver MDA Levels in Rats Induced by High Fat Diet. , 2023, , 134-138.		0
3572	Effects of metabolic traits, lifestyle factors, and pharmacological interventions on liver fat: mendelian randomisation study. , 2022, 1, e000277.		2
3573	Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1112-1116.	2.2	2
3574	Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study. <i>PLoS ONE</i> , 2022, 17, e0277729.	1.1	5
3576	Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S123-S135.	4.5	6
3577	Triglyceride to high-density lipoprotein cholesterol ratio is an independent predictor of liver fibrosis among pediatrics non-alcoholic fatty liver disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
3578	Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: Multicenter study. <i>Hepatology Research</i> , 2023, 53, 312-321.	1.8	5
3579	Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity. <i>Revista Clínica Espanola</i> , 2023, 223, 134-143.	0.3	3

#	ARTICLE	IF	CITATIONS
3580	Hepato-Protective Effects of Delta-Tocotrienol and Alpha-Tocopherol in Patients with Non-Alcoholic Fatty Liver Disease: Regulation of Circulating MicroRNA Expression. <i>International Journal of Molecular Sciences</i> , 2023, 24, 79.	1.8	4
3581	Metabolic associated liver disease. <i>Panminerva Medica</i> , 2022, 64, .	0.2	1
3582	The Growing Economic and Clinical Burden of Nonalcoholic Steatohepatitis (NASH) in the United States. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 454-467.	0.4	9
3583	NAFLD in Indians: A Myopic Yet Alarming Perspective. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, , .	0.4	0
3584	Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease. <i>World Journal of Gastroenterology</i> , 0, 28, 6909-6921.	1.4	18
3585	Diagnostic Value of Non-invasive Liver Function Tests in Liver Fibrosis and Changes in These Parameters Post-metabolic Surgery. <i>Obesity Surgery</i> , 0, , .	1.1	0
3586	Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	39
3589	A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of α -06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 992-1001.	2.2	6
3590	Global incidence and prevalence of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S32-S42.	4.5	67
3591	Exosomal RBP4 potentiated hepatic lipid accumulation and inflammation in high-fat-diet-fed mice by promoting M1 polarization of Kupffer cells. <i>Free Radical Biology and Medicine</i> , 2023, 195, 58-73.	1.3	14
3592	Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities. <i>Journal of Diabetes Investigation</i> , 2023, 14, 463-478.	1.1	3
3593	Reliability of Non-invasive Liver Fibrosis Assessment Tools Versus Biopsy in Pre- and Post-bariatric Surgery Patients with Non-alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 0, , .	1.1	0
3594	Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease. <i>Gut</i> , 2023, 72, 573-580.	6.1	9
3595	The correlation between triiodothyronine and the severity of liver fibrosis. <i>BMC Endocrine Disorders</i> , 2022, 22, .	0.9	1
3596	The surveillance of progression and assessment of treatment endpoint for nonalcoholic steatohepatitis. <i>Clinical and Molecular Hepatology</i> , 0, , .	4.5	0
3597	The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study. <i>Diabetes Research and Clinical Practice</i> , 2022, 194, 110191.	1.1	4
3598	Ideal Cardiovascular Health Metrics Are Associated with Reduced Severity of Hepatic Steatosis and Liver Fibrosis Detected by Transient Elastography. <i>Nutrients</i> , 2022, 14, 5344.	1.7	2
3599	Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S268-S275.	4.5	10

#	ARTICLE	IF	CITATIONS
3600	Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis. <i>Gut and Liver</i> , 2023, 17, 130-138.	1.4	9
3601	Efficacy and safety of Yinchenwuling Powder for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis of randomized controlled trials. <i>Medicine (United States)</i> , 2022, 101, e32088.	0.4	0
3602	The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. <i>Pharmaceuticals</i> , 2022, 15, 1516.	1.7	7
3603	Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 273-302.	0.4	16
3604	The associations of total testosterone with probable nonalcoholic steatohepatitis and nonalcoholic fatty liver disease fibrotic progression in men with type 2 diabetes: a cross-sectional study. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	3
3605	The effects of moderate alcohol consumption on non-alcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S261-S267.	4.5	4
3606	Preoperative circulating peroxiredoxin 1 levels as a predictor of non-alcoholic fatty liver disease remission after laparoscopic bariatric surgery. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
3607	Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S276-S285.	4.5	4
3608	Incidental finding of non-alcoholic steatohepatitis-cirrhosis. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2022, 2022, .	0.2	0
3610	Effect of exercise-based interventions in nonalcoholic fatty liver disease: A systematic review with meta-analysis. <i>Digestive and Liver Disease</i> , 2023, 55, 1178-1186.	0.4	5
3611	Diet Modulates Gut Microbiome and Metabolites in Non-alcoholic Fatty Liver Diseases. , 2023, , 131-146.		0
3612	Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	30
3613	Management of metabolic-associated fatty liver disease: The diabetology perspective. <i>World Journal of Gastroenterology</i> , 0, 29, 126-143.	1.4	12
3614	Psychiatric Aspects of Obesity in Transplantation. , 2022, , 65-72.		0
3615	VI. Diagnosis and Treatment of Cirrhosis with Non-alcoholic Steatohepatitis (NASH). <i>The Journal of the Japanese Society of Internal Medicine</i> , 2022, 111, 43-49.	0.0	0
3616	Prognostic value of liver fibrosis assessed by the FIB-4 index in patients with acute coronary syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2023, 76, 618-625.	0.4	1
3617	Increased Hepatic ATG7 mRNA and ATG7 Protein Expression in Nonalcoholic Steatohepatitis Associated with Obesity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1324.	1.8	1
3618	Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis. <i>Gut</i> , 2023, 72, 1399-1409.	6.1	17

#	ARTICLE	IF	CITATIONS
3619	Abdominal obesity and dysglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5
3620	Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1708-1722.	2.4	15
3621	Unique genetic variants of lean nonalcoholic fatty liver disease: a retrospective cohort study. <i>BMC Endocrine Disorders</i> , 2023, 23, .	0.9	2
3622	Therapeutic Potential of Herbal medicine against Non-alcoholic Fatty Liver Disease. <i>Current Drug Targets</i> , 2023, 24, .	1.0	0
3623	Impact of physical exercise on metabolic dysfunction-associated fatty liver disease (MAFLD). <i>Brazilian Journal of Development</i> , 2023, 9, 735-755.	0.0	0
3624	Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan. <i>Hepatology Forum</i> , 2023, , .	0.3	0
3625	Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	2
3626	On the relationship between metabolic capacities and in vivo viscoelastic properties of the liver. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	1
3627	Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
3628	Therapeutic modulation of V Set and Ig domain-containing 4 (VSIG4) signaling in immune and inflammatory diseases. <i>Cytotherapy</i> , 2023, 25, 561-572.	0.3	1
3629	Ghost messages: cell death signals spread. <i>Cell Communication and Signaling</i> , 2023, 21, .	2.7	8
3630	We are what we eat: The role of lipids in metabolic diseases. <i>Advances in Food and Nutrition Research</i> , 2023, , 173-219.	1.5	1
3631	Regression of Hepatic Fibrosis After Endoscopic Gastric Plication in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2023, 118, 983-990.	0.2	5
3632	Dietary weight loss strategies for kidney stone patients. <i>World Journal of Urology</i> , 2023, 41, 1221-1228.	1.2	3
3633	Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. <i>World Journal of Gastroenterology</i> , 0, 29, 343-356.	1.4	4
3635	The diagnostic value of novel ultrasound attenuation analysis in detecting liver steatosis identified by the controlled attenuation parameter: a diagnostic accuracy study. <i>Annals of Translational Medicine</i> , 2023, 11, 38-38.	0.7	3
3636	Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2023, 37, 108389.	1.2	7
3638	Circulating miRNAs associated with nonalcoholic fatty liver disease. <i>American Journal of Physiology - Cell Physiology</i> , 2023, 324, C588-C602.	2.1	14

#	ARTICLE	IF	CITATIONS
3639	CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population. <i>Hepatology</i> , 2023, 77, 1241-1252.	3.6	9
3640	Healthy Eating Index-2015 in relation to risk of metabolic dysfunction-associated fatty liver disease among US population: National Health and Nutrition Examination Survey 2017-2018. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	3
3641	Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 286-309.	1.4	2
3642	Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
3643	A multistakeholder approach to innovations in NAFLD care. <i>Communications Medicine</i> , 2023, 3, .	1.9	10
3644	Do Ultrasound Based Quantitative Hepatic Fat Content Measurements Have Differences Between Respiratory Phases?. <i>Academic Radiology</i> , 2023, 30, 1832-1837.	1.3	0
3645	Communicating PNPLA3 genetic risk status for NAFLD among Mexican-origin men. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
3646	Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. <i>JHEP Reports</i> , 2023, 5, 100661.	2.6	7
3647	Examining the interim proposal for name change to steatotic liver disease in the US population. <i>Hepatology</i> , 2023, 77, 1712-1721.	3.6	5
3648	Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice. <i>Free Radical Biology and Medicine</i> , 2023, 195, 199-218.	1.3	7
3649	5-Methoxyflavone ameliorates non-alcoholic fatty liver disease through targeting the cytochrome P450 1A1. <i>Free Radical Biology and Medicine</i> , 2023, 195, 178-191.	1.3	4
3650	Extraction, characterization, and anti-non-alcoholic steatohepatitis activity of a (1,3) (1,6)- β -D-glucan from the <i>Polyporus umbellatus</i> (Pers.) Fries. <i>International Journal of Biological Macromolecules</i> , 2023, 230, 123252.	3.6	4
3651	Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2023, 49, 101416.	1.4	3
3652	Hígado graso (parte 1): aspectos generales, epidemiología, fisiopatología e historia natural. <i>Revista Colombiana De Gastroenterología</i> , 2022, 37, 420-433.	0.1	1
3653	A Comparative Study of Ultrasound Attenuation Imaging, Controlled Attenuation Parameters, and Magnetic Resonance Spectroscopy for the Detection of Hepatic Steatosis. <i>Journal of Ultrasound in Medicine</i> , 2023, 42, 1481-1489.	0.8	3
3654	Clinical features and management issues of NAFLD-related HCC: what we know so far. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 31-43.	1.4	4
3655	Self-Management and Associated Factors among Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 667.	1.2	0
3656	Factores asociados a la masa y la fuerza muscular en pacientes con cirrosis hepática: un estudio transversal. <i>Revista Colombiana De Gastroenterología</i> , 2022, 37, 410-419.	0.1	1

#	ARTICLE	IF	CITATIONS
3657	Liver fibrosis for the dermatologist: a review. <i>Clinical and Experimental Dermatology</i> , 0, , .	0.6	1
3658	Exercise-Induced ADAR2 Protects against Nonalcoholic Fatty Liver Disease through miR-34a. <i>Nutrients</i> , 2023, 15, 121.	1.7	0
3659	Non-alcoholic fatty liver disease: Definition and subtypes. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S5-S16.	4.5	21
3660	Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S286-S301.	4.5	10
3661	Validation of the Hepamet fibrosis score in a multi-ethnic Asian population. <i>Annals of Hepatology</i> , 2023, 28, 100888.	0.6	2
3662	Cranberry Proanthocyanidins as a Therapeutic Strategy to Curb Metabolic Syndrome and Fatty Liver-Associated Disorders. <i>Antioxidants</i> , 2023, 12, 90.	2.2	4
3664	NAFLD and type 2 diabetes: A practical guide for the joint management. <i>Gastroenterolog&Aa Y Hepatolog&Aa</i> , 2023, 46, 815-825.	0.2	4
3665	The improvement of treatment and prevention of non-alcoholic fatty liver disease progression against the background of metabolic disorders. <i>Modern Gastroenterology</i> , 2022, , 17-23.	0.1	0
3666	The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes. <i>Life</i> , 2023, 13, 36.	1.1	3
3667	A Retrospective Study On Liver Function Tests & Urine Protein in Presumptive Non-Alcoholic Fatty Liver Cases Performed in A Local Private Laboratory Service. <i>Trends in Undergraduate Research</i> , 2022, 5, i1-8.	0.1	0
3668	Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?. <i>Diagnostics</i> , 2023, 13, 91.	1.3	8
3669	Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. <i>Hepatology International</i> , 2023, 17, 606-614.	1.9	8
3670	Association of energy intake with handgrip strength in Korean adults with non-alcoholic fatty liver disease. <i>Journal of Nutrition and Health</i> , 2022, 55, 684.	0.2	0
3671	Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses. <i>Hypertension Research</i> , 2023, 46, 1110-1121.	1.5	8
3672	Increased Serum Adipsin Correlates with MAFLD and Metabolic Risk Abnormalities. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 16, 187-200.	1.1	1
3673	Nutrition Literacy Is Not Sufficient to Induce Needed Dietary Changes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2023, 118, 1381-1387.	0.2	1
3674	Effect of Metabolic Surgery on Non-Alcoholic Steatohepatitis. , 2023, , 1005-1011.		0
3676	Cost and value in liver disease guidelines: 2011–2022. <i>Hepatology Communications</i> , 2023, 7, e0001-e0001.	2.0	2

#	ARTICLE	IF	CITATIONS
3677	Screening for MAFLD: who, when and how?. Therapeutic Advances in Endocrinology and Metabolism, 2023, 14, 204201882211456.	1.4	5
3678	The prognostic value of including non-alcoholic fatty liver disease in the definition of metabolic syndrome. Alimentary Pharmacology and Therapeutics, 2023, 57, 979-987.	1.9	9
3679	Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist. Journal of Clinical Pharmacology, 2023, 63, 560-568.	1.0	4
3680	Laparoscopic One Anastomosis Gastric Bypass (OAGB)/Mini Gastric Bypass (MGB): Co-morbidity Outcomes. , 2023, , 627-639.		0
3681	Exploiting the Potential of Photon-Counting CT in Abdominal Imaging. Investigative Radiology, 2023, 58, 488-498.	3.5	4
3682	Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin Therapy: A 6-Year Retrospective Study. Diagnostics, 2023, 13, 503.	1.3	2
3683	Associations of different serum folate forms with indices of nonalcoholic fatty liver disease and advanced fibrosis. Obesity Research and Clinical Practice, 2023, 17, 58-65.	0.8	10
3684	Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients, 2023, 15, 687.	1.7	12
3685	PPAR α activation partially drives NAFLD development in liver-specific <i>Hnf4a</i> -null mice. Journal of Biochemistry, 0, , .	0.9	4
3686	Dietary inflammatory index and risk of non-alcoholic fatty liver disease and advanced hepatic fibrosis in US adults. Frontiers in Nutrition, 0, 10, .	1.6	2
3687	Overall, abdominal, and visceral obesity in men and women: an introduction. , 2023, , 3-18.		0
3688	A natural history study of paediatric non-alcoholic fatty liver disease over 10 years. JHEP Reports, 2023, 5, 100685.	2.6	4
3689	Significant fibrosis assessed by liver biopsy among Chinese bariatric surgery patients: A prospective cross-sectional study. Frontiers in Endocrinology, 0, 14, .	1.5	2
3690	Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement. Cancers, 2023, 15, 637.	1.7	1
3691	Geographic Variation in NAFLD Prevalence and Subspecialty Care Utilization Among Insured Adults in the United States. Clinical Gastroenterology and Hepatology, 2023, 21, 3440-3443.e2.	2.4	0
3692	Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population. Journal of Translational Medicine, 2023, 21, .	1.8	2
3693	Two Cases of Rapidly Progressive Fatty Liver Disease due to Pancreatic Exocrine Insufficiency without a History of Surgery. Internal Medicine, 2023, 62, 2667-2673.	0.3	0
3694	Will noninvasive screening for fibrosis/steatosis open Pandora's box? Sharing the healthcare burden of state-of-the-art hepatology practice. Hepatology, 2023, 77, 1085-1087.	3.6	0

#	ARTICLE	IF	CITATIONS
3695	Combination of the effect of ginger and anti-inflammatory diet on children with obesity with nonalcoholic fatty liver disease: A randomized clinical trial. <i>Food Science and Nutrition</i> , 0, , .	1.5	3
3696	AI-based opportunistic CT screening of incidental cardiovascular disease, osteoporosis, and sarcopenia: cost-effectiveness analysis. <i>Abdominal Radiology</i> , 0, , .	1.0	5
3697	Nonalcoholic fatty liver disease and cardiovascular disease. , 2023, , 11-16.		0
3698	Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	5
3700	Metabolic-associated Fatty Liver Disease regulation through Nutri Epigenetic Methylation. <i>Mini-Reviews in Medicinal Chemistry</i> , 2023, 23, .	1.1	0
3701	Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling. <i>Hepatology Communications</i> , 2023, 7, e0039-e0039.	2.0	1
3702	Circulating chemerin level and the risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Journal of Diabetes and Metabolic Disorders</i> , 0, , .	0.8	0
3703	Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2023, 53, 391-400.	1.8	3
3704	Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 104-117.	1.8	6
3705	Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	7
3706	Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology. <i>Clinical Therapeutics</i> , 2023, 45, 55-70.	1.1	9
3708	Plasma proteomic signature of fatty liver disease: The Rotterdam Study. <i>Hepatology</i> , 2023, 78, 284-294.	3.6	5
3709	AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2023, 77, 1797-1835.	3.6	358
3710	Hsp70.1 carbonylation induces lysosomal cell death for lifestyle-related diseases. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
3711	Association of plasma metabolites and diagnostic imaging findings with hepatic lipidosis in bearded dragons (<i>Pogona vitticeps</i>) and effects of gemfibrozil therapy. <i>PLoS ONE</i> , 2023, 18, e0274060.	1.1	1
3712	Association of PNPLA3 SNP With the Development of HBV-related Hepatocellular Carcinoma. <i>In Vivo</i> , 2023, 37, 763-770.	0.6	0
3713	Liver Disease and Heart Failure. , 2023, , 237-255.		0
3714	Metabolic-associated fatty liver disease: pharmacological management. , 2023, , 319-341.		0

#	ARTICLE	IF	CITATIONS
3715	Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis. <i>Medicine (United States)</i> , 2023, 102, e32734.	0.4	12
3716	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. <i>Choonpa Igaku</i> , 2023, , .	0.0	0
3717	Nonalcoholic Fatty Liver Disease Is a Risk Factor for Thiopurine Hepatotoxicity in Crohn's & Colitis 360, 2023, 5, .	0.5	0
3718	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular disease. , 2023, , 137-173.		0
3719	A bibliometric analysis and visualization of nonalcoholic fatty liver disease from 2012 to 2021. <i>Clinical and Experimental Medicine</i> , 2023, 23, 1961-1971.	1.9	2
3720	Analysis of Diagnosis and Treatment Aimed at Improving the Prognosis of Non-viral Liver Disease. <i>Kitakanto Medical Journal</i> , 2023, 73, 113-114.	0.0	0
3721	Significance of MiRNA-34a and MiRNA-192 as a risk factor for nonalcoholic fatty liver disease. <i>Journal of Genetic Engineering and Biotechnology</i> , 2023, 21, 13.	1.5	0
3722	Characterization of lipid composition and localization at different stages of nonalcoholic fatty liver disease using stimulated Raman scattering microscopy. , 2023, , .		1
3723	Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria. <i>Journal of Clinical Medicine</i> , 2023, 12, 2126.	1.0	3
3724	The Effect of Obesity on Gastrointestinal Disease. <i>Gastroenterology Clinics of North America</i> , 2023, 52, 403-415.	1.0	2
3725	<i>Lycium barbarum</i> Oligosaccharides Alleviate Hepatic Steatosis by Modulating Gut Microbiota in C57BL/6J Mice Fed a High-Fat Diet. <i>Foods</i> , 2023, 12, 1617.	1.9	3
3726	Multidisciplinary intensive lifestyle intervention improves markers of Nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes and obesity: a retrospective matched-cohort study. <i>Clinical Diabetes and Endocrinology</i> , 2023, 9, .	1.3	1
3727	Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis. <i>Journal of Affective Disorders</i> , 2023, 329, 184-191.	2.0	2
3728	Hydrogen inhalation ameliorates hepatic inflammation and modulates gut microbiota in rats with high-fat diet-induced non-alcoholic fatty liver disease. <i>European Journal of Pharmacology</i> , 2023, 947, 175698.	1.7	3
3729	Monte Carlo modeling of hepatic steatosis based on stereology and spatial distribution of fat droplets. <i>Computer Methods and Programs in Biomedicine</i> , 2023, 233, 107494.	2.6	0
3730	Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2023, 27, 373-395.	1.0	3
3731	Evaluation of PXL065 deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1). <i>Journal of Hepatology</i> , 2023, 78, 914-925.	1.8	13
3732	Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2023, 27, 211-223.	1.0	6

#	ARTICLE	IF	CITATIONS
3733	Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102111.	0.7	6
3734	Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2023, 27, 187-210.	1.0	9
3735	The Role Bariatric Surgery and Endobariatric Therapies in Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2023, 27, 413-427.	1.0	2
3736	Special Population. <i>Clinics in Liver Disease</i> , 2023, 27, 471-482.	1.0	0
3737	Role of Liver Biopsy in Clinical Trials and Clinical Management of Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2023, 27, 353-362.	1.0	1
3739	Chemogenetic stimulation of the parasympathetic nervous system lowers hepatic lipid accumulation and inflammation in a nonalcoholic steatohepatitis mouse model. <i>Life Sciences</i> , 2023, 321, 121533.	2.0	6
3740	A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease. <i>Life Sciences</i> , 2023, 322, 121626.	2.0	1
3741	Clonal haematopoiesis and risk of chronic liver disease. <i>Nature</i> , 2023, 616, 747-754.	13.7	40
3743	Mitochondrial cholesterol: Metabolism and impact on redox biology and disease. <i>Redox Biology</i> , 2023, 61, 102643.	3.9	14
3744	Liver diseases: Perspective from the Philippines. <i>Annals of Hepatology</i> , 2023, 28, 101085.	0.6	4
3745	PPAR- δ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets. , 2023, 245, 108391.		18
3748	Association of subclinical hypothyroidism with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A cross-sectional study. <i>Advanced Biomedical Research</i> , 2022, 11, 124.	0.2	1
3750	Non-invasive multispectral optoacoustic tomography resolves intrahepatic lipids in patients with hepatic steatosis. <i>Photoacoustics</i> , 2023, 29, 100454.	4.4	7
3751	The Phytochemical Synergistic Properties of Combination of Bergamot Polyphenolic Fraction and <i>Cynara cardunculus</i> Extract in Non-Alcoholic Fatty Liver Disease. <i>Agriculture (Switzerland)</i> , 2023, 13, 249.	1.4	2
3752	Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 273-282.	1.4	6
3753	Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness. <i>Digestive Diseases and Sciences</i> , 2023, 68, 2695-2703.	1.1	3
3754	Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S150-S156.	4.5	7
3755	The association between liver fibrosis and depression in patients after ischemic stroke. <i>BMC Neurology</i> , 2023, 23, .	0.8	0

#	ARTICLE	IF	CITATIONS
3756	Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases. <i>Crohn's & Colitis</i> 360, 2023, 5, .	0.5	2
3758	<i>Helicobacter pylori</i> infection increases the risk of nonalcoholic fatty liver disease in diabetic population. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	1
3760	The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance. <i>Hepatology Communications</i> , 2023, 7, e0033-e0033.	2.0	2
3761	Effect of Dietary Intervention, with or without Cointerventions, on Inflammatory Markers in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Advances in Nutrition</i> , 2023, 14, 475-499.	2.9	4
3762	The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease. <i>Life</i> , 2023, 13, 419.	1.1	8
3763	Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 0, Publish Ahead of Print, .	1.1	1
3764	Identifying High-Risk Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 0, Publish Ahead of Print, .	1.1	0
3765	Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist. <i>Nutrients</i> , 2023, 15, 748.	1.7	2
3766	Evolution of pretransplant cardiac risk factor burden and major adverse cardiovascular events in liver transplant recipients over time. <i>Liver Transplantation</i> , 2023, 29, 581-590.	1.3	4
3767	Postprandial triglycerides and fibroblast growth factor 19 as potential screening tools for paediatric nonalcoholic fatty liver disease. <i>Pediatric Obesity</i> , 2023, 18, .	1.4	0
3768	Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 783-793.	0.4	3
3769	The Effects of Eight Weeksâ€™ Very Low-Calorie Ketogenic Diet (VLCKD) on Liver Health in Subjects Affected by Overweight and Obesity. <i>Nutrients</i> , 2023, 15, 825.	1.7	10
3770	Liver stiffness is associated with excess mortality in the general population driven by heart failure: The Rotterdam Study. <i>Liver International</i> , 2023, 43, 1000-1007.	1.9	3
3771	Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. <i>Biomedicines</i> , 2023, 11, 468.	1.4	13
3772	Adipose-targeted SWELL1 deletion exacerbates obesity- and age-related nonalcoholic fatty liver disease. <i>JCI Insight</i> , 2023, 8, .	2.3	2
3773	PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis. <i>Gastroenterology</i> , 2023, 164, 966-977.e17.	0.6	18
3774	Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with nonalcoholic fatty liver disease: A prospective randomized study. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1576-1588.	2.2	9
3775	Association Between Hypertension and New-Onset Non-Alcoholic Fatty Liver Disease in Chinese Non-Obese People: A Longitudinal Cohort Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 16, 345-363.	1.1	3

#	ARTICLE	IF	CITATIONS
3777	Long-term weight changes are associated with initial weight changes after nonalcoholic fatty liver disease diagnosis. <i>Hepatology Communications</i> , 2023, 7, e0044-e0044.	2.0	1
3778	Non-alcoholic fatty liver disease-related hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2023, 23, 127-142.	0.3	5
3779	Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals. <i>Hepatology Communications</i> , 2023, 7, e0005-e0005.	2.0	9
3780	Liver fat quantification in photon counting CT in head to head comparison with clinical MRI – First experience. <i>European Journal of Radiology</i> , 2023, 161, 110734.	1.2	10
3781	Association between Dietary Fatty Acid Intake and Liver Steatosis and Fibrosis in a Sample of Mexican-Origin Hispanic Adults with Overweight or Obesity. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 3103.	1.2	1
3782	Non-alcoholic fatty liver disease is not associated with impairment in health-related quality of life in virally suppressed persons with human immune deficiency virus. <i>PLoS ONE</i> , 2023, 18, e0279685.	1.1	2
3783	Benzyl isothiocyanate attenuates activation of the NLRP3 inflammasome in Kupffer cells and improves diet-induced steatohepatitis. <i>Toxicology and Applied Pharmacology</i> , 2023, 462, 116424.	1.3	3
3784	Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 13-26.	2.2	8
3785	The effect of DASH diet on glycemic response, meta-inflammation and serum LPS in obese patients with NAFLD: a double-blind controlled randomized clinical trial. <i>Nutrition and Metabolism</i> , 2023, 20, .	1.3	3
3786	Nonalcoholic fatty liver disease from a primary care perspective. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1421-1433.	2.2	5
3787	Stationary Trend in Elevated Serum Alpha-Fetoprotein Level in Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2023, 15, 1222.	1.7	2
3788	The association between perceived stress, acculturation, and non-alcoholic fatty liver disease in Mexican-origin adults in Southern Arizona. <i>Preventive Medicine Reports</i> , 2023, 32, 102147.	0.8	0
3789	Adiponectin/leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance. <i>Annals of Medicine</i> , 2023, 55, 634-642.	1.5	4
3790	The Association between Coffee Consumption and Non-Alcoholic Fatty Liver Disease: Is there a Protective Role?. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2023, 11, 54-59.	0.1	0
3791	Impact of multiple different high-fat diets on metabolism, inflammatory markers, dysbiosis, and liver histology: study on NASH rat model induced diet. <i>F1000Research</i> , 0, 12, 180.	0.8	0
3793	Effects of lifestyle intervention on adults with metabolic associated fatty liver disease: A systematic review and meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	12
3794	Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial. <i>Nature Medicine</i> , 2023, 29, 392-400.	15.2	42
3795	Prevalence and Influence Factors for Non-Alcoholic Fatty Liver Disease in Long-Term Hospitalized Patients with Schizophrenia: A Cross-Sectional Retrospective Study. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 19, 379-389.	1.0	1

#	ARTICLE	IF	CITATIONS
3796	Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 0, .	1.4	0
3797	Discovery of Highly Potent and Selective Thyroid Hormone Receptor β Agonists for the Treatment of Nonalcoholic Steatohepatitis. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3284-3300.	2.9	9
3798	Significant Dose-Response Association of Physical Activity and Diet Quality With Mortality in Adults With Suspected NAFLD in a Population Study. <i>American Journal of Gastroenterology</i> , 2023, 118, 1576-1591.	0.2	5
3799	Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes. <i>Gut and Liver</i> , 2023, 17, 610-619.	1.4	4
3800	Correlation of multiple lipid and lipoprotein ratios with nonalcoholic fatty liver disease in patients with newly diagnosed type 2 diabetic mellitus: A retrospective study. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
3801	NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. <i>Internal and Emergency Medicine</i> , 2023, 18, 993-1006.	1.0	10
3802	Comparison of strain elastography and shear wave elastography in diagnosis of fibrosis in nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2023, 50, 187-195.	0.6	1
3803	Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience. <i>JGH Open</i> , 2023, 7, 215-220.	0.7	8
3804	Collagen matrix scaffolds: Future perspectives for the management of chronic liver diseases. <i>World Journal of Clinical Cases</i> , 0, 11, 1224-1235.	0.3	0
3805	Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study. <i>Hepatology</i> , 2023, 78, 578-591.	3.6	5
3806	Five-year Weight Loss Maintenance With Obesity Pharmacotherapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, e832-e841.	1.8	2
3807	Filamin A is overexpressed in non-alcoholic steatohepatitis and contributes to the progression of inflammation and fibrosis. <i>Biochemical and Biophysical Research Communications</i> , 2023, 653, 93-101.	1.0	0
3810	Low 25 (OH) vitamin D levels are associated with increased prevalence of nonalcoholic fatty liver disease and significant liver fibrosis. <i>Diabetes/Metabolism Research and Reviews</i> , 2023, 39, .	1.7	7
3811	Metabonomics application on screening serum biomarkers of golden hamsters with nonalcoholic steatohepatitis induced by high-fat diet. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2023, 26, .	0.6	0
3812	Therapeutic Physical Exercise Programs in the Context of NASH Cirrhosis and Liver Transplantation: A Systematic Review. <i>Metabolites</i> , 2023, 13, 330.	1.3	4
3813	Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2021, 21, 194-203.	1.1	1
3814	Weight change across adulthood is related to the presence of NAFLD: results from NHANES III. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	4
3816	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	1

#	ARTICLE	IF	CITATIONS
3817	Patients with High Cardiovascular Risk in the Practice of a Primary Care Physician. , 2022, , 56-62.		0
3818	Prevalence of non-alcoholic fatty liver disease in patients with nephrotic syndrome: A population-based study. <i>World Journal of Hepatology</i> , 0, 15, 265-273.	0.8	2
3819	Validity of fatty liver prediction scores for diagnosis of fatty liver by Fibroscan. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2023, , .	0.6	1
3820	Electro-acupuncture reduced steatosis on MRI-PDFF in patients with non-alcoholic steatohepatitis: a randomized controlled pilot clinical trial. <i>Chinese Medicine</i> , 2023, 18, .	1.6	0
3821	Alignment of Physician-Stated vs Clinically Derived Reference Fibrosis Score in Patients with Non-Alcoholic Steatohepatitis: A Real-World European Survey. <i>Journal of Pragmatic and Observational Research</i> , 0, Volume 14, 13-27.	1.1	0
3822	Sarcopenia Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Is Associated With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2876-2888.e5.	2.4	9
3823	Lipid Disorders and Metabolic-Associated Fatty Liver Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2023, 52, 445-457.	1.2	3
3824	A Bidirectional Association Between Obstructive Sleep Apnea and Metabolic-Associated Fatty Liver Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2023, 52, 509-520.	1.2	2
3825	New insights into the inter-organ crosstalk mediated by ChREBP. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	2
3826	Non-pharmacological treatment approach in patients with metabolic dysfunction-associated liver disease. , 2023, , 343-367.		0
3827	Comparison of portal vein hemodynamics with ultrasound-based elastography for the prediction of liver fibrosis in patients with chronic liver disease. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
3828	Meta-Analysis of Exploring the Effect of Curcumin Supplementation with or without Other Advice on Biochemical and Anthropometric Parameters in Patients with Metabolic-Associated Fatty Liver Disease (MAFLD). <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4266.	1.2	1
3829	Assessing Liver Fibrosis Using 2D-SWE Liver Ultrasound Elastography and Dynamic Liver Scintigraphy with ^{99m} Tc-mebrofenin: A Comparative Prospective Single-Center Study. <i>Medicina (Lithuania)</i> , 2023, 59, 479.	0.8	1
3830	The Prevalence of Advanced Liver Fibrosis among Patients with Type 2 Diabetes Mellitus: A Single-Centre Experience in Penang, Malaysia. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2023, 38, 52-61.	0.1	1
3831	Types of Physical Activity in Nonalcoholic Fatty Liver Disease and All-Cause and Cardiovascular Mortality. <i>Journal of Clinical Medicine</i> , 2023, 12, 1923.	1.0	2
3832	The utility of non-invasive tests to assess advanced fibrosis in Asian subjects with chronic hepatitis B and concomitant hepatic steatosis. <i>Liver International</i> , 2023, 43, 1008-1014.	1.9	1
3833	A cross-sectional analysis of the association between testosterone and biopsy-proven non-alcoholic fatty liver disease in men with obesity. <i>Endocrine</i> , 2023, 80, 54-63.	1.1	1
3834	The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 414-416.	4.5	0

#	ARTICLE	IF	CITATIONS
3835	Correlation between CT Abdominal Anthropometric Measurements and Liver Density in Individuals with Non-Alcoholic Fatty Liver Disease. <i>Medicina (Lithuania)</i> , 2023, 59, 500.	0.8	1
3836	Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK/MAPK in mice. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	6
3837	Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis. <i>Journal of Medical Economics</i> , 2023, 26, 348-356.	1.0	1
3838	The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis. <i>Liver International</i> , 2023, 43, 964-974.	1.9	8
3839	Imaging of pregnancy-related liver diseases. , 2023, 2, 56-66.		0
3840	Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2789-2796.	2.4	7
3841	Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003-2018. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	12
3842	Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review. <i>Nutrients</i> , 2023, 15, 1269.	1.7	2
3843	Associations of urinary organophosphate esters metabolites and diet quality with nonalcoholic/metabolic dysfunction-associated fatty liver diseases in adults. <i>Ecotoxicology and Environmental Safety</i> , 2023, 254, 114720.	2.9	4
3844	Initial outcomes of a dedicated multidisciplinary non-alcoholic fatty liver disease clinic: a retrospective cohort study. <i>Internal Medicine Journal</i> , 2023, 53, 2065-2072.	0.5	1
3845	The growing burden of non-alcoholic fatty liver disease on mortality. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 374-376.	4.5	0
3846	Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023?. <i>Nutrients</i> , 2023, 15, 1323.	1.7	6
3847	Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 413-428.	1.8	10
3848	Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints. <i>PLoS ONE</i> , 2023, 18, e0281674.	1.1	1
3849	Challenges and opportunities in NASH drug development. <i>Nature Medicine</i> , 2023, 29, 562-573.	15.2	51
3850	Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors. <i>Hepatology Research</i> , 2023, 53, 607-617.	1.8	2
3851	Association Between Serum Trace Heavy Metals and Liver Function Among Adolescents. <i>Journal of Occupational and Environmental Medicine</i> , 2023, 65, e155-e160.	0.9	0
3852	Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology. <i>Cancers</i> , 2023, 15, 1687.	1.7	1

#	ARTICLE	IF	CITATIONS
3853	Comparison of Animal Models for the Study of Nonalcoholic Fatty Liver Disease. <i>Laboratory Investigation</i> , 2023, 103, 100129.	1.7	2
3855	Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	10
3856	Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 693-704.	4.5	3
3857	Azonal steatosis correlates with disease severity and poor outcome of nonalcoholic fatty liver disease. <i>Journal of Digestive Diseases</i> , 0, , .	0.7	0
3858	Nonalcoholic Fatty Liver Disease and MicroRNAs: A Weighty Consideration. <i>Biomedical and Biotechnology Research Journal</i> , 2023, 7, 1.	0.3	1
3859	Non-alcoholic fatty liver disease as an emerging risk factor and potential intervention target for atherosclerotic cardiovascular diseases. <i>Journal of Cardiovascular Pharmacology</i> , 2023, Publish Ahead of Print, .	0.8	2
3860	Alternate-Day Fasting Combined with Exercise: Effect on Sleep in Adults with Obesity and NAFLD. <i>Nutrients</i> , 2023, 15, 1398.	1.7	4
3861	From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications. <i>Biomedicines</i> , 2023, 11, 883.	1.4	14
3862	Association of nonalcoholic fatty liver disease and liver fibrosis detected by transient elastography with serum retinol in American adults. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	0
3863	Integrative network-based analysis on multiple Gene Expression Omnibus datasets identifies novel immune molecular markers implicated in non-alcoholic steatohepatitis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	6
3864	Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 511-522.	3.7	83
3865	A greater ratio of thigh subcutaneous fat to abdominal fat is associated with protection against non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2023, 5, 100730.	2.6	0
3867	Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 198-200.	1.8	0
3868	Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 1143-1150.	1.9	4
3869	CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	1
3870	Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2023, 6, e233513.	2.8	22
3871	Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 487-503.	8.2	55
3872	Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. <i>Nature Communications</i> , 2023, 14, .	5.8	10

#	ARTICLE	IF	CITATIONS
3873	Mobile health lifestyle intervention program leads to clinically significant loss of body weight in patients with NASH. <i>Hepatology Communications</i> , 2023, 7, .	2.0	5
3875	The association between sleep duration, quality, and nonalcoholic fatty liver disease: A cross-sectional study. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	2
3876	History of Gestational Diabetes and Incident Nonalcoholic Fatty Liver Disease: The Kangbuk Samsung Health Study. <i>American Journal of Gastroenterology</i> , 2023, 118, 1980-1988.	0.2	2
3877	Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis. <i>Nutrients</i> , 2023, 15, 1481.	1.7	3
3878	BIOCHEMICAL MARKERS FOR STEATOSIS: A NECESSITY. BUT FOR NOW, BE SATISFIED WITH THE BIOPSY. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 0, 36, .	0.5	0
3879	Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification. <i>Metabolites</i> , 2023, 13, 444.	1.3	1
3880	Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	3
3881	Clinical-radiomic analysis for non-invasive prediction of liver steatosis on non-contrast CT: A pilot study. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
3882	Emerging targets for therapy in ALD: lessons from NASH. <i>Hepatology</i> , 0, Publish Ahead of Print, .	3.6	1
3883	Different Dietary Approaches, Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: A Literature Review. <i>Nutrients</i> , 2023, 15, 1483.	1.7	3
3884	Prediction of Fatty Liver Disease in a Chinese Population Using Machine-Learning Algorithms. <i>Diagnostics</i> , 2023, 13, 1168.	1.3	2
3885	Characterization of hepatic fatty acids using magnetic resonance spectroscopy for the assessment of treatment response to metformin in an eNOS ^{+/+} mouse model of metabolic nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>NMR in Biomedicine</i> , 2023, 36, .	1.6	0
3886	Non-pharmacological management options for MAFLD: a practical guide. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2023, 14, 204201882311603.	1.4	4
3887	Approaches in the Nutritional Management of Non Alcoholic Fatty Liver Disease. <i>International Journal of Advanced Research in Science, Communication and Technology</i> , 0, , 145-157.	0.0	0
3888	Racial difference in the association between non-alcoholic fatty liver disease and incident type 2 diabetes: findings from the CARDIA study. <i>Diabetologia</i> , 2023, 66, 1235-1246.	2.9	3
3889	Clinical and diagnostic characteristics of non-alcoholic fatty liver disease among Egyptian children and adolescents with type1 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	1.2	0
3890	To scan or not to scan: Use of transient elastography in an integrated health system. <i>World Journal of Hepatology</i> , 0, 15, 419-430.	0.8	0
3891	The Association between Advanced Liver Fibrosis and Mortality Is Modified by Dietary Quality among Korean Adults: Results from the Korea National Health and Nutrition Examination Survey with Mortality Data. <i>Nutrients</i> , 2023, 15, 1501.	1.7	0

#	ARTICLE	IF	CITATIONS
3892	Endocrine disrupting chemicals: A promoter of non-alcoholic fatty liver disease. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	4
3893	Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2023, 14, 204201882311603.	1.4	3
3894	Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2023, 68, 2757-2767.	1.1	3
3895	Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	4
3896	Mouse strain-dependent variation in metabolic associated fatty liver disease (MAFLD): a comprehensive resource tool for pre-clinical studies. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
3897	Perirenal fat thickness and liver fat fraction are independent predictors of MetS in adults with overweight and obesity suspected with NAFLD: a retrospective study. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	1.2	1
3898	Development and implementation of a continuing medical education program on non-alcoholic fatty liver disease for primary care practitioners in Europe. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2
3899	Integrated-gut-liver-on-a-chip platform as an in vitro human model of non-alcoholic fatty liver disease. <i>Communications Biology</i> , 2023, 6, .	2.0	14
3900	Associations of physical activity domains and muscle strength exercise with non-alcoholic fatty liver disease: a nation-wide cohort study. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
3901	Discovery of FXR/PPAR β dual partial agonist. <i>Bioorganic and Medicinal Chemistry</i> , 2023, 85, 117238.	1.4	1
3902	Development and validation of machine learning models for nonalcoholic fatty liver disease. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2023, 22, 615-621.	0.6	1
3903	Risk of subclinical atherosclerosis across metabolic transition in individuals with or without fatty liver disease: a prospective cohort study. <i>Nutrition and Metabolism</i> , 2023, 20, .	1.3	0
3904	Liver Ultrasound Elastography in Non-Alcoholic Fatty Liver Disease: A State-of-the-Art Summary. <i>Diagnostics</i> , 2023, 13, 1236.	1.3	3
3905	Comparison of survival rates as predicted by total tumor volume or tumor burden score in patients with hepatocellular carcinoma concurrent with fatty liver disease and hepatitis B virus. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 499-507.	1.4	2
3907	Mediterranean Diet Improves Plasma Biomarkers Related to Oxidative Stress and Inflammatory Process in Patients with Non-Alcoholic Fatty Liver Disease. <i>Antioxidants</i> , 2023, 12, 833.	2.2	4
3908	HÃgado graso (parte 2): enfoque clÃnico y tratamiento. <i>Revista Colombiana De Gastroenterologia</i> , 2023, 38, 46-58.	0.1	0
3909	Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	2
3910	An ethical analysis of obesity as a contraindication to pediatric liver transplant candidacy. <i>American Journal of Transplantation</i> , 2023, 23, 736-743.	2.6	0

#	ARTICLE	IF	CITATIONS
3911	Intermittent fasting for the management of NAFLD: Is there enough evidence?. Acta Marisiensis - Seria Medica, 2023, 69, 3-10.	0.2	0
3912	Unravelling the role of obesity and lipids during tumor progression. Frontiers in Pharmacology, 0, 14, .	1.6	1
3913	ABDA Score: A Non-invasive Model to Identify Subjects with Fibrotic Non-alcoholic Steatohepatitis in the Community. Journal of Clinical and Experimental Hepatology, 2023, 13, 742-752.	0.4	0
3914	American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease. Hepatology Communications, 2023, 7, .	2.0	9
3915	Effects of Genistein on Lipid Metabolism, Antioxidant Activity, and Immunity of Common Carp (Cyprinus carpio L.) Fed with High-Carbohydrate and High-Fat Diets. Aquaculture Nutrition, 2023, 2023, 1-16.	1.1	2
3916	Complex metabolicâ€“endocrine syndromes: associations with cardiovascular disease. , 2023, , 39-81.		1
3917	Development and validation of a novel non-invasive test for diagnosing nonalcoholic fatty liver disease in Chinese children. World Journal of Pediatrics, 0, , .	0.8	2
3918	Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo. Frontiers in Pharmacology, 0, 14, .	1.6	0
3919	Fibroscan-aspartate aminotransferase (FAST) score predicts liver-related outcomes, but not extra-hepatic events, in a multicenter cohort of people with HIV. Clinical Infectious Diseases, 0, , .	2.9	0
3920	A Healthy Diet is Associated with a Lower Risk of Hepatic Fibrosis. Journal of Nutrition, 2023, 153, 1587-1596.	1.3	3
3921	Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes. Metabolites, 2023, 13, 517.	1.3	2
3923	A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis â€“ Study design and rationale of HM-TRIA-201 study. Contemporary Clinical Trials, 2023, 130, 107176.	0.8	5
3924	Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis. Hepatology, 2023, 77, 1702-1711.	3.6	10
3925	Silymarin for treatment of adults with nonalcoholic fatty liver disease. The Cochrane Library, 2023, .	1.5	0
3926	Macrophage-derived Osteopontin (SPP1) Protects From Nonalcoholic Steatohepatitis. Gastroenterology, 2023, 165, 201-217.	0.6	16
3927	NASHmap: clinical utility of a machine learning model to identify patients at risk of NASH in real-world settings. Scientific Reports, 2023, 13, .	1.6	3
3928	Serum Cardiotrophin-1 Concentration Is Negatively Associated with Controlled Attenuation Parameters in Subjects with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2023, 12, 2741.	1.0	0
3929	Polycystic ovary syndrome and nonalcoholic fatty liver disease. , 2024, , 92-99.		0

#	ARTICLE	IF	CITATIONS
3930	Comorbidities and Malignancy among NAFLD Patients Compared to the General Population, A Nation-Based Study. <i>Biomedicines</i> , 2023, 11, 1110.	1.4	1
3931	Noninvasive assessment of liver steatosis with ultrasound techniques. , 2024, , 177-198.		0
3932	Dietary cholesterol drives the development of nonalcoholic steatohepatitis by altering gut microbiota mediated bile acid metabolism in high-fat diet fed mice. <i>Journal of Nutritional Biochemistry</i> , 2023, 117, 109347.	1.9	4
3933	Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes. <i>JHEP Reports</i> , 2023, 5, 100753.	2.6	5
3934	Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. <i>Journal of Hepatology</i> , 2023, 79, 287-295.	1.8	43
3935	Therapeutic potential of bioactive phytoconstituents found in fruits in the treatment of non-alcoholic fatty liver disease: A comprehensive review. <i>Heliyon</i> , 2023, 9, e15347.	1.4	2
3936	DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates. <i>Cell Metabolism</i> , 2023, 35, 742-757.e10.	7.2	10
3937	An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
3938	Clinical Trial Landscape in NASH. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2001-2014.	2.4	21
3939	Dihydro sphingolipids are associated with steatosis and increased fibrosis damage in non-alcoholic fatty liver disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2023, , 159318.	1.2	1
3940	The role of ChREBP in carbohydrate sensing and NAFLD development. <i>Nature Reviews Endocrinology</i> , 2023, 19, 336-349.	4.3	9
3941	Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study. <i>Clinical Gastroenterology and Hepatology</i> , 2024, 22, 124-134.e1.	2.4	17
3942	Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy. <i>Biomedicines</i> , 2023, 11, 1166.	1.4	6
3943	Reduction of portosystemic gradient during transjugular intrahepatic portosystemic shunt achieves good outcome and reduces complications. <i>World Journal of Gastroenterology</i> , 0, 29, 2336-2348.	1.4	0
3944	EFFICACY OF COMPREHENSIVE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH PREDIABETES. <i>Wiadomości Lekarskie</i> , 2023, 76, 581-585.	0.1	0
3945	High Prevalence of Severe Hepatic Fibrosis in Type 2 Diabetic Outpatients Screened for Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 2858.	1.0	1
3946	The relationship between vitamin K and metabolic dysfunction-associated fatty liver disease among the United States population: National Health and Nutrition Examination Survey 2017â€“2018. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	2
3947	Perspectives in weight control in diabetes â€“ SGLT2 inhibitors and GLP-1â€“glucagon dual agonism. <i>Diabetes Research and Clinical Practice</i> , 2023, 199, 110669.	1.1	1

#	ARTICLE	IF	CITATIONS
3948	Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease. <i>Hepatology International</i> , 2023, 17, 626-635.	1.9	2
3949	Liver lipidomics analysis reveals the anti-obesity and lipid-lowering effects of gynosides from heat-processed <i>Gynostemma pentaphyllum</i> in high-fat diet fed mice. <i>Phytomedicine</i> , 2023, 115, 154834.	2.3	4
3950	Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH. <i>Cell Reports Medicine</i> , 2023, 4, 101016.	3.3	2
3951	Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7454.	1.8	1
3952	Metabolic Reprogramming of HCC: A New Microenvironment for Immune Responses. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7463.	1.8	9
3953	Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial. <i>BMC Complementary Medicine and Therapies</i> , 2023, 23, .	1.2	2
3954	Feasibility and acceptability of an evidence-informed digital intervention to support self-management in people with non-alcoholic fatty liver disease: protocol for a non-randomised feasibility study (VITALISE). <i>Pilot and Feasibility Studies</i> , 2023, 9, .	0.5	1
3955	Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
3956	Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes. <i>World Journal of Hepatology</i> , 0, 15, 477-496.	0.8	2
3957	Association between hypertension and the prevalence of liver steatosis and fibrosis. <i>BMC Endocrine Disorders</i> , 2023, 23, .	0.9	1
3958	Associations of Serum Iron Status with MAFLD and Liver Fibrosis in the USA: a Nationwide Cross-Section Study. <i>Biological Trace Element Research</i> , 2024, 202, 87-98.	1.9	2
3959	Sugar-sweetened beverages, low/no-calorie beverages, fruit juice and non-alcoholic fatty liver disease defined by fatty liver index: the SWEET project. <i>Nutrition and Diabetes</i> , 2023, 13, .	1.5	7
3960	Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective. <i>Nutrients</i> , 2023, 15, 1992.	1.7	3
3961	Serum neurofilament light chain levels are associated with all-cause mortality in the general US population. <i>Journal of Neurology</i> , 2023, 270, 3830-3838.	1.8	2
3962	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease. <i>Pharmaceuticals</i> , 2023, 16, 623.	1.7	0
3963	Peroxisome Proliferator-Activated Receptor- β as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease. <i>Cells</i> , 2023, 12, 1205.	1.8	5
3964	Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States. <i>Diabetes Research and Clinical Practice</i> , 2023, 199, 110679.	1.1	0
3965	Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2023, 5, 100778.	2.6	2

#	ARTICLE	IF	CITATIONS
4035	Detection of Steatosis Disease using Region Based Segmentation of Growcut Algorithm and Comparing with Random Walker Algorithm to Enhance the Accuracy. , 2023, , .		0
4063	Endocrine. , 2023, , 107-203.		0
4093	Meta-analysis of the association between major foods with added fructose and non-alcoholic fatty liver disease. Food and Function, 2023, 14, 5551-5561.	2.1	1
4146	The possible role of Helicobacter pylori in liver diseases. Archives of Microbiology, 2023, 205, .	1.0	2
4168	Impact of tofogliflozin on hepatic outcomes: a systematic review. European Journal of Clinical Pharmacology, 2023, 79, 1281-1290.	0.8	3
4191	Comparing the direct assessment of steatosis in liver explants with mid- and near-infrared vibrational spectroscopy, prior to organ transplantation. Analyst, The, 2023, 148, 3986-3991.	1.7	2
4212	Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis. Obesity Surgery, 2023, 33, 2917-2926.	1.1	2
4219	Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatology International, 2023, 17, 1082-1097.	1.9	4
4223	Prediction of Possible Outcomes using Big Data Analysis and Machine Learning. , 2023, , .		0
4224	Nonalcoholic Fatty Liver Disease Within Other Causes of Chronic Liver Diseases. , 2023, , 133-147.		0
4225	Natural History of Nonalcoholic Fatty Liver Disease. , 2023, , 19-43.		0
4226	The Place of Transabdominal Liver Biopsy in Nonalcoholic Fatty Liver Disease. , 2023, , 73-79.		0
4255	The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. European Journal of Pediatrics, 0, , .	1.3	1
4282	Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia. Sports Medicine, 2023, 53, 2347-2371.	3.1	2
4292	Unraveling the link between insulin resistance and Non-alcoholic fatty liver disease (or metabolic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Disorders, 2023, 22, 1083-1094.	0.8	2
4299	How non-alcoholic fatty liver disease and cirrhosis affect the heart. Hepatology International, 2023, 17, 1333-1349.	1.9	2
4305	Mechanisms Behind NAFLD: a System Genetics Perspective. Current Atherosclerosis Reports, 2023, 25, 869-878.	2.0	1
4332	Psychological Burden of NAFLD and Psychiatric Disorders as Extrahepatic Manifestations. , 2023, , 203-215.		0

#	ARTICLE	IF	CITATIONS
4333	Practical Clinical Cases in Nonalcoholic Fatty Liver Disease. , 2023, , 255-267.		0
4393	Non-alcoholic Fatty Liver Disease. , 2023, , 1-17.		0
4421	Non-alcoholic Fatty Liver Disease in Pediatric Obesity. , 2023, , 305-324.		0
4468	Leptin and Obesity: Understanding the Impact on Dyslipidemia. , 0, , .		0
4524	22.ÂChronic Liver Disease. , 2023, , .		0
4561	Pharmacologic therapies in metabolic syndrome with special reference to non-alcoholic fatty liver disease. , 2024, , 383-391.		0
4597	Endocrine disruptors in the pathogenesis of metabolic syndrome. , 2024, , 235-248.		0
4619	Non-alcoholic Fatty Liver Disease. , 2023, , 567-583.		0
4624	Association of chronic liver disease with bone diseases and muscle weakness. Journal of Bone and Mineral Metabolism, 0, , .	1.3	0
4641	ĐŸŃ€Đ,ĐŸĐ,Đ·Đ½ĐμĐ½Đ½Đ½Đ¾Đμ ĐŸĐ¾Đ½Đ¾Đ¾Ń€ŃŃ,Đ²Đ¾ Ń,Ń€Đ°Đ¾Đ¾Đ½Đ½Đ¾Đ² Đ;ĐμŃ†ĐμĐ½Đ, ĐĐμĐ°Đ¾Đ¾Đ¾Đ½Đ		0
4646	Surveillance of the liver in type 2 diabetes: important but unfeasible?. Diabetologia, 0, , .	2.9	0
4667	Liver: From Biochemistry to Clinical Biochemistry. , 2023, , 95-123.		0
4671	Accurate Prediction of Stage of Hepatitis C Virus Through a Stacking Ensemble. Lecture Notes in Networks and Systems, 2024, , 485-494.	0.5	0
4679	Treatment of MASLD. , 2023, , 309-318.		0